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Introduction 
 
Despite the progress achieved in modern medicine and treatment methods, human 
malignant tumor diseases still threaten human life expectancy. According to the International 
Agency for Research on Cancer,i about 14.1 million new cancer cases and 8.2 million cancer-
related deaths occurred in 2012. Additionally, the number of new cancer cases per year is 
predicted to increase to 19.3 million by 2025. So, in the last decades, massive research efforts 
have been focused on early diagnosis and efficient treatment.  
To diagnose accurately the disease stage, numerous imaging techniques have been 
applied, including X-ray radiography, Magnetic Resonance Imaging (MRI), ultrasound and 
nuclear medicine imaging that uses specific radiotracers so-called radiopharmaceuticals.ii A 
huge advantage of the latter imaging modality is that it can easily be adapted to therapeutic 
purposes. Whereas the radionuclides used for nuclear medicine imaging emit gamma rays, 
which can penetrate deeply into the body and consequently give a whole-body image, the 
radionuclides used for targeted therapy must emit radiation with a relatively short path length 
(E- or D emitter) in order to only irradiate the cancer cells. Among the radioisotopes that can be 
used, technetium-99m (J-emitter) and rhenium-188 (β--emitter) represent an interesting pair of 
radionuclides for diagnosis and therapy, the technetium being the most widely used for medical 
applications. Both compounds belong to the group 7 of the Periodic Table and have very similar 
coordination behaviors. Moreover, non-radioactive rhenium complexes have drawn a lot of 
attention due to their rich photophysical and photochemical properties that make them attractive 
luminescent imaging probes and photoactive agents for the controlled generation of carbon 
monoxide (PhotoCORMs). Therefore, a number of research groups, including ours, have been 
committed to the development of new rhenium complexes as a new class of imaging/therapeutic 
agents. 
 
Among the many oxidation states of rhenium (ranging from –I to VII), Re(I) and Re(V) 
have been the most extensively investigated, in particular the [Re(CO)3]+ and [ReO]3+ cores, 
respectively. Until now, a large number of Tc/Re-specific chelators for the stabilization of both 
 
i  GLOBOCAN 2012 project: Estimated Cancer Incidence, Mortality and Prevalence worldwide in 2012 (see 
http://globocan.iarc.fr/Default.aspx). 
 
ii Radiopharmaceuticals have been defined as radioactive drugs that, when used for the purpose of diagnosis or 
therapy, typically elicit no physiological response from the patient (definition from the Nuclear Medicine 
Radiochemistry society). 
Introduction 
 
 3
cores have been described. Their structure, their denticity and the nature of the donor atoms 
depend on the considered rhenium cores. Among the plethora of synthetic strategies reported 
for the preparation of such chelators, the “Click-to-Chelate” concept, developed in 2006 by 
Schibli’s groupiii has especially attracted our attention. This group has showed that the 1,4-
disubstitued 1,2,3-triazole obtained by click chemistry was an efficient chelator for the 
[Re(CO)3]+ core. Following this result, we developed several ligands including a triazole ring 
in the chelating cavity for the development of imaging and therapeutic agents based on 
tricarbonyltechnetium-99m and tricarbonylrhenium cores, respectively.iv  
 
The present work is a continuation of our group’s investigations about Tc/Re-
complexes. Based on the “Click-to-Chelate” or the analogous “Chelate, then Click” approach, 
our objective is to design a new series of click ligands for [Re(CO)3]+ and [ReO]3+ cores, and 
to assess their potential as imaging/therapeutic probes. 
 
 Before detailing our results, the first chapter presents a bibliographic state of the art 
related to our research project. In a first part, we outline the interest of rhenium complexes and 
provide a quick overview of their use as radiopharmaceuticals and a detailed review on their 
photophysical behavior. Focusing on the [ReO]3+ and [Re(CO)3]+ cores, we give many 
examples of applications as imaging and therapeutic agents in the biomedical field. The main 
emphasis is placed on identifying the characteristic features that make the most efficient 
compounds. In a second part, particular attention is paid to synthesis and to the advantages of 
the copper(I)-catalyzed azide-alkyne cycloaddition so-called CuAAC reaction, including the 
elegant “Click-to-Chelate” or Chelate, then Click approaches for the conception of Re/Tc-
specific click ligands. 
 
 The second chapter is focused on the design of new radiopharmaceuticals and it is an 
extension of previous works based on a semi-rigid N2O scaffold that have been carried out in 
the group.v Two different routes are investigated (i) the preparation of potentially tetradentate 
click ligands in order to develop original click chelators to stabilize the [188ReO]3+ core; (ii) the 
development of targeted 99mTc-imaging probes by combining the semi-rigid N2O framework 
 
iii See Ref 96, Chapter I. 
iv See Ref 124 and 126, Chapter I. 
v See Ref 126c, Chapter I. 
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with metronidazole or nitrophenyl groups, 99mTc-complexes provided with an appended nitro 
moiety being potential hypoxia imaging agents. Interestingly, an original dinuclear rhenium 
complex including for the first time one 1,2,3-triazole group as a bridging ligand is also 
reported, the starting click chelator resulting from an unexpected reaction which occurred 
during the preparation of our tetradentate chelating species. 
 
The third chapter deals with the solid-state emission properties of new tricarbonyl 
rhenium(I) complexes, based on the pyridine-triazole frameworkvi (so called pyta), an analog 
to the bipyridine bidentate ligand. The photophysical properties of such complexes in solution 
have been extensively studied in the literature, but curiously, the study of their solid-state 
emission properties is still in its early stages. Thus, the main objective of this chapter was to 
design highly emissive rhenium(I) luminescent probes. To do so, an organic fluorophore which 
displays excellent optical properties has been combined with the pyta unit. Different structural 
combinations were achieved and the photophysical properties of these hybrid systems 
(containing an organic scaffold plus a coordination complex) have been thoroughly studied in 
solutions and in the solid state. Results were supported by electrochemical data, and preliminary 
imaging test have been achieved. We try to explain how the emission properties are linked to 
the geometry of the complexes and we show the appearance of a phenomenon called 
aggregation-induced emission (or AIE), which has rarely been reported for Re complexes. 
 
 In both chapters II and III, a combined experimental and theoretical study was 
performed in most of the investigations. Finally, we conclude by briefly foregrounding the most 
pertinent results of this work, and giving the directions for future research that stem from the 
project. 
 
 
vi See ref. 45 and 124, Chapter I. 
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The Group 7 element rhenium covers various oxidation states from –I to VII. This 
chemical diversity contributes to a number of corresponding complexes whose applications 
have been widely investigated, particularly as catalysts, imaging agents and 
radiopharmaceuticals. From a chemical point of view, the rhenium cores which lead to stable 
complexes involve either the higher oxidation states, such as [ReO]3+, [ReO2]+, [ReN]2+ and 
[ReNR]3+ cores, or the lower oxidation states, especially the [Re(CO)3]+ core. The former cores 
are usually stabilized by strong π-donors like oxide, nitride or halide, whereas the latter requires 
π-acceptors such as carbonyls, phosphines and cyanide.[1] Among all the oxidation states, 
rhenium(V) and rhenium(I) complexes have been extensively developed and studied in 
bioinorganic chemistry due to their great stability under physiological conditions. For instance, 
radioactive 186/188Re-complexes have been emerged as promising therapeutic 
radiopharmaceuticals. In addition, the attractive photophysical and photochemical properties of 
non-radioactive rhenium(I) complexes make them ideal candidates as imaging/therapeutic 
agents.  
 
In this chapter, only Re(V) and Re(I) complexes will be considered. In the first two 
sections of this chapter, a brief overview on rhenium radiopharmaceuticals and a more detailed 
presentation of photoactive tricarbonyl rhenium complexes for applications in imaging and 
therapy will be given. In these parts, some important criteria for the design of efficient rhenium 
complexes for biomedical applications will be illustrated. Then, an exhaustive focus on two 
elegant chemical strategies, “Click-to-Chelate” and Click, then Chelate approaches, that allow 
the rapid development of rhenium complexes will be presented before listing the objectives of 
this work. 
 
1. Radioactive rhenium complexes as radiopharmaceuticals 
1.1. Rhenium (and technetium) radiolabeling  
In nuclear medicine, radioisotopes of technetium and to a lesser extent rhenium have 
attracted increasing interests as diagnostic or therapeutic radiopharmaceuticals.[2] Despite the 
fact that technetium has no stable isotopes, metastable isotope 99mTc has been widely explored. 
This radionuclide is the “workhorse” of nuclear medicine, and some of 99mTc-complexes were 
currently used as diagnostic imaging agents in the clinic. However, 186Re (t1/2 = 89.2 h) and 
Chapter I 
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188Re (t1/2 = 17.0 h) radionuclides have not acquire equal success, no matter in diagnosis and 
therapy.[3] This is probably due to their less stability under biological relevant conditions and 
low specific activity compared to the common therapeutic isotopes of 90Y and 177Lu.[ 4 ] 
Furthermore, the radioactive rhenium and technetium are usually available as perrhenate or 
pertechnetate ions, they must be reduced before coordinated to the ligand systems. But 
unfortunately 186/188ReO4- is usually more difficult to reduce and easier to oxidize under 
chemical or biological relevant conditions than 99mTcO4-, which also makes rhenium not as 
popular as technetium. In spite of these drawbacks, radioactive isotopes of rhenium still remain 
as a promising radionuclide for nuclear medicine with two principal reasons: (a) excellent 
penetration ability into solid tumors by high emission energy of β--emitter (1.069 MeV for 186Re 
and 2.12 MeV for 188Re); (b) recognizable J-emitter energy (137 eV for 186Re and 155 eV for 
188Re) during radiotherapy in most hospitals. These make 186/188Re potential usage as 
radiopharmaceuticals for radiotherapeutics and single photon emission computed tomography 
(SPECT) imaging agents (theranostic probes).[5]  
 
Additionally, as 99mTc, 188Re are readily available and inexpensive.[6] The preparation 
of the short half-life radionuclide 99mTc (t1/2 = 6 h, J-emission of 140 keV) is generated by a β--
emitter 99Mo (t1/2 = 66 h). This 99Mo/99mTc-generator can almost continuously provide eluted 
99mTcO4- solutions from an alumina chromatography column, which contains MoO42– ions. 
Similarly, 188Re is produced from the 188W/188Re-generator. The half-life of 188W is 69.4 days, 
making it possible to generate 188Re during a period of 6-12 months (depending on rated activity 
of generator).[7] 
 
As mentioned before, to prepare the final 99mTc or 186/188Re radiopharmaceuticals, the 
negative permetallate ions have to be reduced and coordinated with ligand systems. The ligands 
should coordinate and stabilize the reduced metal cores, such as M(I) or M(V) cores (M = 99mTc 
or 186/188Re). Furthermore, the ligands must be designed elaborately in order to have the specific 
targeting properties or biological distribution patterns. For the reducing agents, one common 
strategy is by using so-called “instant kits”. This procedure consists to use a commercial set 
containing the prefabricated ligands, reductants (e.g. Sn2+ ion or boranocarbonate) and some 
other related reagents, in which an appropriate amount of the radioactive 99mTcO4– or 
186/188ReO4– solutions is added. As prerequisites for pharmaceuticals, the resulting radiolabeled 
complexes should be in high yields and purities and do not need further purification steps. So 
the reaction conditions must be optimized so as to obtain the readily injected pharmaceuticals. 
Chapter I 
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Based on these, a great progress has been achieved in the 99mTc and 186/188Re containing 
diagnostic and therapeutic radiopharmaceuticals nowadays. The best example is certainly the 
development of the Isolink KitTM by the Paul Scherrer Institute.[8] This fully aqueous-based kit 
allowing the preparation of the organometallic technetium precursor [99mTc(H2O)3(CO)3]+ 
under mild reaction conditions. Similarly, The optimized preparation of the corresponding 
rhenium precursor [188Re(H2O)3(CO)3]+, was also developed by the same authors.[8b] 
 
1.2. Design of Re-based radiopharmaceuticals 
The formation of a radiopharmaceutical showing high chemical stability and inertness 
under physiological conditions is the sine qua none condition for its industrial development. 
For example, a large variety of 99mTc-based radiopharmaceuticals have been developed for 
assessing disease stages and determining organ functions, and some of them have been 
approved by Food and Drug Administration (FDA), including 99mTc bicisate (Neurolite), 99mTc 
disofenin (Hepatolite), 99mTc exametazine (Ceretec), 99mTc mebrofenin (Choletec), 99mTc 
medronate (MDP-25, MDP Multidose), 99mTc mertiatide (Technescan MAG3™), 99mTc 
oxidronate (Technescan™ HDP), 99mTc red blood cells (UltraTag™), 99mTc tetrofosmin 
(Myoview™), 99mTc sestamibi (Cardiolite)[9] and so on. 
 
 With the fact tha rhenium and technetium elements are located in Group 7 of the 
Periodic Table, they exhibits very similar coordination behaviors. So it is expected to see 
parallel coordination chemistry and labelling results between technetium and rhenium. Besides, 
non-radioactive rhenium complexes were often used as surrogates for technetium-99m in order 
to indirectly confirm the structures of analogous 99mTc-compounds (by HPLC comparison with 
the corresponding non-radioactive rhenium complex). So the methods originally developed for 
99mTc-radiochemistry should be proper for 188Re-radiochemistry. 
Based on this strategy, some 186/188Re radiopharmaceuticals started to be tested in 
preclinical investigations, with some moved to clinic.[10] Specifically, for malignant gliomas, 
the 188Re-labelled humanized monoclonal antibody Nimotuzumab has been evaluated in the 
locoregional treatment.[10b] 188Re–tin colloid has been used to improve magnetic resonance 
imaging (MRI) in refractory rheumatoid arthritis patients.[10c] 188Re-Lipiodol was investigated 
in the treatment of inoperable hepatocellular carcinoma (HCC).[10d] 188Re-HEDP complexes 
have been used in palliative therapeutics of bone metastases.[11]  
Chapter I 
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As mentioned in the beginning of this part, a high in vivo stability is required for such 
compounds. So it is necessary to design suitable coordinated ligands for the stabilization of Re 
cores. Depending on the oxidation states of rhenium, while different approaches and chelating 
systems have been developed, here we only focus on the two most stable oxidation states, Re(I) 
and Re(V) complexes. 
 
1.2.1. Re(V) complexes as potential radiopharmaceuticals 
The coordination chemistry of rhenium(V) complexes often presents a five- or six-
coordination arrangement, the molecular geometry ranging from tetrahedral to distorted 
octahedral. As illustrated above, a large number of π-donor systems for Re(V) complexes have 
been chosen to develop new chelating agents, especially for [ReN]2+ and [ReO]3+ cores. 
Based on these two prerequisites, many interesting compounds have been reported by 
changing the functional groups that coordinated the rhenium center. 
 
- [ReO]3+ ([ReO2]+) core 
According to Pearson theory,[12] a plethoria of systems including “soft” and “borderline” 
ligand classes was developed. Thus, ligands with N, O and S chelating atoms are well reported 
due to their high donating properties. For example, several 188Re complexes with S and N 
donors have been used as potential drugs to treat hepatocellular carcinoma (Figure 1, 
compounds a, b, c).[13]  
In these multidentate ligand systems, tetradentate ligands (Figure 1, compounds c, d, e) 
represent the most developed and appropriate chelators for Re(V) cores. Even though the design 
of such ligand requires multi-step synthesis, the corresponding rhenium complexes exhibit 
generally a better in vivo stability than those based on tridentate or bidentate ligands. As 
examples, the tetradentate N3S ligands for stable oxorhenium complexes have been used as 
interesting scaffolds for radiolabeled antibodies (Figure 1, compound e).[14] Another interesting 
alternative, so-called “3+1” mixed-ligand system, which combines different functionalized 
groups was also reported (Figure 1, compound b).[13b] In this case, the tripodal SNS-type ligand 
is generally commercially available or readily synthetized and the fourth coordination site is 
occupied by a monodentate ligand. The latter monodentate ligand usually bears either a 
functional group or a biomolecule directed toward a biological target (target-specific 
Chapter I 
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radiopharmaceuticals). Finally, some pentadentate Re(V) complexes were applied in the 
labeling of proteins with both 186/188Re radioisotopes (Figure 1, compound e).[15] 
 
Figure 1. Representative [186/188ReO] tracers based on different chelating systems that have been used as potential 
radiopharmaceuticals: (a) S4 donors with DMSA or DMSA derivatives;[13a] (b) “3+1” mixed-ligand system with 
NS2/S donors;[13b] (c) N2S2 ligand with amine and amidodithiolato donors;[13c] (d) S4 ligands from meso-
dimercaptosuccinic acid; [13d] (e) N3S donors; [14] (f) pentadentate N2O3 ligands.[15] 
 
More recently, the framework of N-heterocyclic carbene (NHC) has been applied to the 
coordination of 186/188Re. Wagner et al. synthesized with a high radiochemical purity (>98%), 
a radioactive dioxocomplex in which four NHC units chelate the metal (Scheme 1).[16] Although 
the final dioxorhenium(V) complex was not stable under physiological conditions, it paved a 
new way to design this kind of 188Re complexes. 
Scheme 1. Synthetic pathway of NHC-based 188Re complexes (Scheme extracted from 
reference [16]). 
 
-With [ReN]2+ core 
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The rhenium(V) nitride, [Re≡N]2+constitutes a characteristic functional moiety in which 
the Re5+ ion is multiply bonded to a nitride nitrogen atom (N3-).[17] It represents one of the most 
stable chemical scaffolds in all the rhenium(technetium) complexes and exhibits inertness 
toward oxidation and reduction reactions. With the [Re≡N]2+ core, numerous 186/188Re 
complexes were designed by the fine tuning of chelating ligands to various biomolecules. Using 
the “3+2” mixed-ligand system, the groups of Tisato then Refosco developed a series of 
phosphinoamine ligands (PNP) which were used for the development of [188ReN]2+-based 
target-specific radiopharmaceuticals. Different [Re(N)(PNP)]2+ mixed-ligand systems were 
described in Figure 2.[18]  
 
Figure 2. Several examples of [188ReN]2+ complexes by the “3+2” strategy (Figure extracted from reference 
[112]). 
In the same manner, by using the “3+1” approach, a new class of 188Re-diagnostic and 
therapeutic agents was described recently.[ 19 ] This includes the mixed-ligand 
[M(N)(SNS)(PPh3)] complexes (M = Tc, Re) with a tridentate π-donor and one monodentate 
π-acceptor (PPh3) (Figure 3, compound a).[20] A similar structure with triphenylphosphine as 
monodentate chelating site and a tridentate NOS ligand which acted as the π-donor system, was 
synthesized by the same group (Figure 3, compound b).[21] 
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Figure 3. Two “3+1” mixed-ligand systems for [Re≡N]2+ core 
 
1.2.2. Re(I) complexes as potential radiopharmaceuticals 
Over the past two decades, the coordination chemistry of tricarbonyl technetium(I) and 
tricarbonyl rhenium(I) cores has been intensively studied, mainly due to the easy production of 
the hydrophilic air-stable fac-[M(CO)3(H2O)3]+ precursor from the corresponding permetallates 
MO4- (M = 99mTc or 186/188Re). From a chemical point of view, as reviewed by R. Schibli and 
P. A. Schubiger,[8a] the fac-[M(CO)3]+ core (M = Tc, Re) is very compact and the metal center 
is hidden by the chelating system plus the three carbonyl groups which form a shield around 
the metal, protecting it against further ligand attack or re-oxidation (fac-octahedral geometry). 
In contrast, in an oxorhenium (or oxotechnetium) complex, the [MO]3+ (M = Tc, Re) core is not 
completely protected by the chelating system and thence to decompose. Consequently, the 
chelating systems required for the stabilization of the Re(I) core are easier to develop than those 
for Re(V) cores. With all these reasons, one of the major challenges facing coordination 
chemists today is the synthesis of low-oxidation-state rhenium (or technetium) complexes that 
exhibit high in vivo inertness. 
 
Various chelating systems for the [M(CO)3]+ core (M = 99mTc and 188Re) were developed 
as described above (Figure 4). Some of the rhenium-188 compounds gave promising results as 
targeted radiopharmaceuticals.[ 22 ] The vast majority of these ligands concern bidentate or 
tridentate systems which contain nitrogen and oxygen donor atoms. For nitrogen atoms, N-
heterocycles are generally favoured. Moreover, as shown by Schibli, 99mTc- and 188Re-
complexes based on tridentate ligands were more in vitro and in vivo stable than those based on 
bidentate ones.[8a] 
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Figure 4. Representative examples of bidentate and tridentate chelators for technetium- and rhenium-tricarbonyl 
cores (Figure extracted from reference [8a]). 
 
The possibility of obtaining high specific activity for 188Re, as well as the fact that this 
radionuclide is readily available (generator) and possesses both J and E- emissions, make it ideal 
for applications in nuclear medicine. While the preparation of 188Re-radiopharmaceuticals 
requires improvement (optimize the reduction step of the [ReO4]-), the simple and versatile 
synthetic strategies for the design of new chelating systems, in particular for the tricarbonyl 
rhenium core, are still in progress.  
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2. Design of photoactive tricarbonyl rhenium complexes for applications in 
imaging and therapy 
 
2.1. Rhenium(I) complexes  
Non-radioactive rhenium(I) complexes have very attractive features that make them 
ideal candidates for applications in the biological and biomedical fields. Most of them are air 
and water stable so that they can be easily handled. The cytotoxicity of the Re(I) core is 
generally very low, although toxicity may be associated with certain ligands.[ 23 ] The 
coordination sphere lends itself to multiple modifications that impact the physical and 
biological properties of the complexes. Functionalization may be carried out in a stepwise 
manner, allowing a number of physical features to be tuned independently, and then combined 
with one another, until the desired properties are reached. Since the pioneering work of 
Wrighton and Morse in the 1970s,[24] these complexes have been known as light emitters. 
Thereafter, they have been widely studied as luminophores that allow detection in the visible 
range, in particular for application in live cell imaging through fluorescence microscopy which 
is a very powerful tool in modern biology and medicinal science. The chemical analogy of Re 
with 99mTc allows obtaining non-radioactive probes that mimic the behavior of “hot” probes 
within the cells and enable their localization by luminescence imaging. The Re(I) complexes 
also absorb strongly in the middle infrared where light penetration in tissues is optimal, hence 
their potential use for multimodal bioimaging. Finally, these compounds are also photoactive 
and can be used in the frame of phototherapy. A quick overview of these multiple applications 
will be given in the following parts. 
 
2.2. As imaging agents 
2.2.1. Photophysical properties of Re(I) complexes 
Before we go any further, it is important to briefly describe the photophysical behavior 
of Re(I) complexes, which is well documented.[ 25 ] From a general point of view, the 
photophysics of transition metal complexes is dominated by a strong metal-induced spin-orbit 
coupling, which results in fast intersystem crossing processes. Consequently, the singlet state 
S1 that is initially formed after absorption of a photon passes non-radiatively to the lowest triplet 
state T1 after a very short period of time. Transition from T1 to the singlet ground state S0 is also 
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partially allowed. These processes lead to long-lived phosphorescence (i.e. light emission from 
the triplet state) that is often observable at room temperature. This explains why transition metal 
complexes present distinct advantages for imaging with respect to conventional organic dyes. 
Phosphorescence spectra being strongly red-shifted with respect to the excitation wavelength, 
there is no re-absorption effect. Quite high concentrations of complexes can be used without 
self-quenching and detection is facilitated by wavelength filtering.  
 
Many luminescent transition metal complexes show good photostability and allow 
prolonged or repeated illumination by the microscope beam. Since phosphorescence is 
characterized by lifetimes up to the microsecond scale, interferences with cell autofluorescence 
(in the nanosecond scale) can be avoided using time-gated detection. Although time resolved 
microscopy is not as widely available as standard confocal fluorescence microscopy, the 
sensitivity of phosphorescence lifetime imaging microscopy (PLIM) is very high.[ 26 ] One 
drawback of these complexes is their sensitivity to the presence of oxygen that quenches the 
emission of phosphorescence. 
 
Like other physical properties, the spectroscopic and photophysical properties of Re(I) 
complexes closely depend on the coordination sphere. As an example, we may consider 
tricarbonyl Re(I) complexes, whose photophysics is particularly rich and has been well studied 
for a long time.[25] The [Re(CO)3]+ core possesses three facial positions available for 
substitution by various organic ligands. According to the nature of these ligands, a clear 
progression in the photophysical properties of the complexes can be distinguished. 
 
The simplest complexes are based on 2-2’-bipyridine, pyridyl-triazole and pyridyl-
imidazole ligands (Figure 5).[27] Phosphorescence generally appears around 550 nm, and it is 
characterized by its very low emission efficiency in solutions (10-4-10-3), which does not hinder 
applications as bioimaging agents. It is noteworthy that in the structures presented in Figure 5, 
the R group on the monodentate ligand is frequently used to attach a recognition moiety directed 
toward a biological target. 
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Figure 5. Examples of Re(I) complexes based on simple ligands derived from bipyridine or analog. 
 
Extending the π-conjugated system of the chelating groups is a very popular strategy for 
enhancing the photophysical properties of the complexes.[ 28 ] They generally contain 
polypyridyl ligands (e.g. phenanthroline and dipyridophenazine derivatives) and conjugated 
pyridyl groups (Figure 6). Very variable emission efficiencies are reported in solutions, the 
photoluminescence quantum yield often being in the 10-2 range. The quantum yield may also 
be drastically reduced due to quenching by energy transfer from 3MLCT to 3IL, as occurs in 
compound (viii). 
 
 
Figure 6. Examples Re(I) complexes based on ligands with extended electron systems. 
 
Complexes that incorporate an organic fluorophore non-conjugated to the chelating 
ligands are still quite rare (Figure 7). In this case, chelation with ReI has no direct impact on the 
electron system of the fluorophores. The excitation energy can be shifted to long wavelengths. 
Emission wavelength, Stokes shift and lifetime depend on the relative energy levels. With 
fluorophores that absorb at short wavelengths and emit poorly,[29] the optical properties are 
close to those of the compounds above. In contrast, with properly-chosen fluorophores, 
quenching by the 3MLCT state is prevented. Emission is therefore fluorescence, arising from 
the organic fluorophore, i.e. naphthalimide in the case of compound (xi). The position of the 
emission spectrum depends totally on the nature of the fluorophore, the quantum yield may be 
(i) (ii) (iii) (iv)
(v) (vi) (vii) (viii)
R = CH2-COOCH3 
or CH2-Ph-COOH
R = alkyl
R = C4H9 or C10H21
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very high, and there is no quenching by oxygen.[30] In this case, advantage is not taken from the 
intrinsic emission properties of the rhenium center. These compounds have been originally 
designed to mimic the behavior of 99mTc radioactive probes and study their behavior and 
localization in biological medium. 
 
Figure 7. Examples of Re(I) complexes incorporating an organic fluorophore moiety. 
 
2.2.2. Unconjugated complexes for imaging applications 
Whatever their emission properties, Re(I) complexes are often biocompatible. They 
have been tested on various types of cells, including yeasts[31] and parasitic flagellates.[23,30b] It 
appeared that they are particularly well uptaken by mammalian cells and, most interestingly, 
by cancer cells.[28,29] However, non-specific staining of the cytoplasm is not ideal for imaging 
applications. In a review article, Balasingham et al. have tried to understand the factors 
governing the cell uptake and localization of various metal complexes.[32] Regarding Re(I), a 
systematic study from Fernández-Moreira et al. allows some basic principles to be identified.[31] 
This study compares various complexes of type (iii) in which the bipyridyl group is responsible 
for the spectroscopic properties, while the ancillary pyridyl ligand is used for varying charges 
and lipophilicities. This allows the behavior of the complexes in living medium to be controlled, 
in particular for membrane permeability, cell uptake and localization in cell components, with 
minor interferences with the photophysical properties. It appears, with a few exceptions, that 
cationic species are taken up well by passive diffusion. Highly lipophilic complexes are easily 
incorporated into dead cells, while the other species require a healthy membrane potential to 
facilitate uptake. Simple cationic lipophilic complexes are highly membrane permeable, they 
localize in the cytoplasmic membrane and in the lipophilic sites of organelles.[31,33] However, 
when lipophilicity becomes very high, for example after incorporation of a fluorous chain in 
(vi), the compound tends to self-aggregate in aqueous solutions and shows low cellular uptake 
(ix) (x) (xi)
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efficiency.[28b] Electrophilic complexes localize in the mitochondria. Anionic polar species 
associate with the outer face of the plasma membrane, while anionic lipophilic species show no 
or little uptake.[28,33] Neutral complexes such as (v) also exhibit good cellular uptake by live 
cancer cells and non-specific perinuclear localization.[28a] Finally, when the ligand incorporates 
a large planar aromatic system like dipyridophenazine, the resulting complex easily intercalates 
between two DNA bases.[28f,34] 
 
2.2.3. Bioconjugated complexes  
Cell localization may be markedly improved by biological targeting. As recently 
reviewed by Lo whose research group has done a lot of work in the field, bioconjugated 
complexes become efficient biological sensors and precise imaging reagents.[35] Most often, 
conjugation with a biomolecule is achieved on the pyridinyl group, so that the photophysical 
properties are affected as little as possible. It is classically made via a functional group, i.e. 
isothiocyanate and aldehyde that can react on primary amines, or maleimide and iodoacetamide 
that react with the sulfhydryl groups of biomolecules. For instance, Re(I) complexes have been 
directly used in solid-phase peptide synthesis to afford labeled neurotensin.[28d] They have been 
used to tag gluthathione and proteins like bovine serum albumin (BSA), with successful results 
in imaging (Figure 8).[28b] Luminescent biotin complexes [Re(NN)(CO)3(py-biotin)]+ have 
been developed.[35c] Contrary to classical organic biotin-fluorophores that suffer from self-
quenching, they show an increase of the emission intensity and elongation of the lifetime upon 
binding to avidin, the natural receptor of biotin. They have therefore been very useful to study 
the recognition processes between these two biologically important molecules. The 
luminescence properties of Re(I) complexes conjugated with estradiol have also been exploited 
for imaging of hormone-dependent breast cancer cells.[35d] Similarly, Re(I) complexes 
conjugated to glucose have been imagined to study the uptake and transportation of glucose in 
cancer cells, that generally overexpress the sugar receptors.[36] Actually, the fructose conjugates 
have shown enhanced uptake by breast cancer cells.[ 37 ] Complexes of the type 
[Re(NN)(CO)3(py-indole)]+ have been developed to study the interactions with indole-
binding proteins such as BSA and lysozyme.[38] Chromone derivatives such as complexes (ix) 
have been designed to recognize regulatory enzymes engaged in the biochemical signal 
transduction pathways.[29]  
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Figure 8. False-color fluorescence (left), differential interference contrast (middle), and overlaid (right) laser-
scanning confocal microscopy images of HeLa cells incubated with the BSA conjugate of complex (vi) (10 μM) 
at 37 °C for 2 h, λex = 405 nm. (Figures are extracted from reference [28b]) 
 
2.2.4. Sensing 
Re(I) probes have also been used as biochemical sensors. For example, Re(I) complexes 
appended to a dipicolylamine unit displayed enhanced emission and elongation of the 
phosphorescence lifetime in the presence of zinc(II) and cadmium (II) ions. These compounds 
have been shown to be potentially useful for monitoring the intracellular concentration of these 
ions, although the ion-concentration range where they can be used in their present form is very 
narrow.[28c] It is also noteworthy that some probes have been successfully developed for the 
sensing of nitric oxide (NO), a small endogenously-produced molecule that has recently been 
recognized as a major signaling agent whose unregulated production leads to diseases of the 
immune, cardiovascular and nervous.[39] 
 
2.2.5. Correlations with radioimaging studies  
As already mentioned above, Re(I) probes are often used for correlations with 
radioimaging techniques, whose main modalities are single photon emission computed 
tomography (SPECT) and positron emission tomography (PET). As mentioned previously, 
since Re is the closest chemical analog of Tc, non-radioactive isotope of Re allow the 
development of complexes adapted to biological applications. Moreover, the luminescence 
properties allow the identification of cellular targets using confocal fluorescence microscopy, 
whereas the insufficient resolution of radioimaging techniques does not permit access to this 
crucial information.  
In this field, we must underline the effort made by the group of Valliant and Zubieta to 
develop a library of metallopeptides that can be used in the preparation of a variety of 
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bioconjugates.[40] It is curious to note that very few probes developed in this aim exploit the 
intrinsic luminescence properties of Re(I).[27b,30a] They are often associated to organic 
fluorophores, i.e. naphthalimide in the case of compound (xi)[30b]  and 2-phenylbenzothiazole 
in complexes designed as potential imaging probes for the β-amyloid plaques that are formed 
in the course of Alzheimer’s disease.[ 41 ] In the latter case, both techniques are well 
complementary, since confocal fluorescence imaging has been used to detect β-amyloid plaques 
at the cellular level, while in vitro autoradiography provided images of their distribution in large 
brain sections.  
 
2.2.6. Bimodal infrared and luminescence imaging 
When rhenium complexes incorporate carbonyl ligands, the unique vibrational signature 
of the CO group enables detection by infrared and Raman spectroscopies. These vibrational 
spectroscopies are of particular interest for bio-imaging because radiations in the infrared cause 
little damage to living tissues, contrary to excitation in the UV and visible range. The problem 
of fluorophore photobleaching does not arise. Resolution reached the subcellular level.[42] As 
recently reviewed by Clède and Policar,[43] Re-carbonyl probes are very attractive candidates 
for these spectroscopies, especially because they absorb in the middle-infrared, a wavelength 
range comprised between 2200 and 1800 cm-1 where the biological medium is almost 
transparent.  
IR-imaging at the sub-cellular level has first been made using synchrotron radiation 
FTIR spectromicroscopy (SR-FTIR SM) and Re-carbonyl probes that contain a 
cyclopentadienyl group linked to a tamoxifen moiety.[ 44 ] Thereafter, vibrational and 
luminescence spectroscopies have been combined, taking advantage of the intrinsic 
luminescence properties of the Re(I) core. Using a pytavii-based Re(I) complexes, provided with 
various alkyl chains that enhance cell uptake by cancer cells, the authors have shown a good 
correlation between IR mappings and fluorescence imaging at the cell level.[27b, 45 ] 
Bioconjugation with an estrogen analog allowed visualization by both techniques of estrogen-
dependent breast cancer cells.[45b] 
 
vii Pyta means 2-pyridyl-1,2,3-triazole entity. This term was used first by Obata in 2008 (see M. Obata et al., Dalton 
Trans. 25 (2008) 3292-3300. 
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To our knowledge, no rhenium probes have been used for bimodal imaging using 
Raman spectroscopy, contrary to Mn probes,[46] probably because this powerful non-invasive 
method is still in its early stages. 
 
2.3. From photoactivity to the use as phototherapeutic agents 
2.3.1. Photocytotoxicity and generation of active oxygen species 
 During imaging studies using Re(I) complexes, two interesting features have emerged. 
The first one is the slow photobleaching of these complexes with respect to common organic 
dyes, although remarkable exceptions have been reported. The second one is their 
photocytotoxic action.[35,37] It results in membrane blebbing that appears after multiple image 
collection under the confocal fluorescence microscope, and leads to cell death. The origin of 
photocytoxicity has rarely been investigated, although the photochemistry of Re(I) complexes 
has been thoroughly investigated.[25a,25c] It is well known that these complexes are quenched by 
molecular oxygen and may generate highly reactive oxygen species such as singlet oxygen 
1O2.[ 47 ] In the case of dipyridophenazine Re(I) complexes intercalated in DNA, the 
photocleavage of DNA would be rather due to direct oxidation by the photoexcited complex, 
or to the photoproduction of superoxide (O2-) and hydroxyl (OH.) radicals, depending on the 
ligand structure.[34] The easy uptake of Re(I) complexes by cancer cells combined with their 
phototoxic activity suggests that they could be used for theranostics that is the combination of 
diagnosis and therapeutics.  
 
2.3.2. Photogeneration of carbon monoxide  
Besides, a characteristic feature of Re(I) complexes is their ability to release carbon 
monoxide (CO) photochemically. They could therefore serve as new agents for the delivery of 
CO to biological targets or in the frame of a therapy based on the use of this gas, namely CO-
therapy.  
 
2.3.2.1. From CORMS to photoCORMs in CO-therapy 
The toxic nature of carbon monoxide has been well known for a long time. This small 
molecule, often referred to as the “silent killer”, strongly binds to hemoglobin, thus reducing 
the oxygen-carrying capacity of the blood and impairing respiration. The salutary effects of CO 
have only recently been recognized.[48] Much like its toxic twin nitric oxide, CO has been 
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identified as an important endogenously-generated signaling molecule that participates in a 
variety of physiological processes. It is now well established that CO plays a crucial role in 
immune and anti-inflammatory responses, as well as in vaso-relaxation. Most spectacular of 
the CO-mediated effects is its capacity to promote graft survival during organ transplantation. 
CO also helps treating cardiovascular disease, promotes wound-healing and apoptosis of cancer 
tissues, and has antibacterial activity. Exogenously applied CO gas is thus increasingly 
considered as a therapeutic agent. According to the desired therapeutic effect, low doses (100-
250 ppm) or moderate doses (> 250 ppm) may be used. Unfortunately, the implementation of 
CO gas in hospital setting raises technical and safety-related issues. These issues have prompted 
the quest for exogenous CO-releasing molecules (CORMs) to deliver controlled amounts of 
CO to biological targets. But, controlling when and where the CO is released is also of major 
importance. In these regards, triggering by light has rapidly appeared as an excellent strategy, 
because it allows fine temporal and spatial control of CO release. This led to the concept of 
light-triggered CORMs (PhotoCORMs), the development of which has expanded significantly 
in the last half-decade, as recently reviewed.[49] 
 
Like CORMs, the majority of photoCORMs are based around metal carbonyl 
complexes, which offer a direct route to the release of CO. The photochemical reaction induces 
the release of at least one CO molecule that is replaced by a solvent molecule, e.g. water, in the 
coordination sphere. The first photoCORMs have been reported by Motterlini et al. in 2002.[50] 
They were simple metal carbonyls, i.e. Fe(CO)5 and Mn2(CO)10, and were not truly suitable for 
biological use because their required excitation in the ultraviolet (UV) that damages living cells. 
Since then, a lot of systems have been explored and the design of photoCORMs has been 
markedly improved. The ideal photoCORM is stable in the dark under ambient conditions, 
soluble in water and non-toxic before and after CO-release. It releases CO efficiently under 
illumination by visible light, preferentially red light that has the best penetration of the living 
tissues. Organometallic complexes have therefore been developed to meet these specifications. 
Various metal d6 centers such as Mn(I), Re(I), Fe(II) and Ru(II) that ensure overall stability of 
the carbonyl complexes have been investigated, with particular attention to Mn(I). Collectively, 
experimental and theoretical works have allowed several principles to emerge regarding the 
choice of ligands and their disposition in the coordination sphere.[51] It has been shown that CO 
release is favored in complexes in which electron transfer from electron-rich metals to π* 
orbitals of the ligand (metal-to-ligand charge transfer, MLCT) is easy. In other words, low-
lying orbitals on the ligand system, hence strong MLCT absorption in the visible or near 
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infrared, should be associated to good CO dissociation. For example, when the 2-2’-bipyridine 
ligand of a Mn complex is replaced by a ligand with increased π-electron system, the excitation 
wavelength passes from 350-450 nm to 520 nm, with increased photolability of CO.[ 52 ] 
Auxillary ligands also modulate the energy of the occupied orbitals depending on their electron-
donating abilities. A small number of CO ligands in the complexes also favors good 
photochemical activity.  
 
2.3.2.2. Design of Re(I)-based photoCORMs 
As specifically concerns rhenium complexes, interest in these compounds has grown 
considerably in recent years. Their stability and biocompatibility are attractive. Since these 
complexes were already known for their photoluminescence properties, the idea was also to 
take advantage of both their imaging and therapeutic abilities. However, the use of Re salts as 
photoCORMs raises three important issues concerning photoreactivity, as well as the 
optimization of photoluminescence properties and excitation wavelength.  
 
First of all, many Re complexes are not very photoreactive. Complexes of the type fac-
[ReCO3(X)(bpy)] (bpy = 2,2’-bipyridine; X= Cl or Br) and fac-[ReCO2(X2bpy)(py)]+ (py = 
pyridine, X = H, CF3), based on either V-donating or moderately π-accepting ancillary ligands, 
are relatively photoinert, unless highly energetic irradiation by UV-B light is used.[53] Koike et 
al. have thoroughly studied the mechanisms of photochemical ligand substitution in this series 
of complexes and they have explained the reason for this photostability. Most interestingly, 
they have also shown that the introduction of a strongly π-acidic ancillary ligand, such as a 
phosphine, makes the axial CO photolabile with low-energy UV-A light (Figure 9).[53] For 
instance, complexes of type (xii) undergo photorelease of one CO molecule upon irradiation in 
the near-UV, and substitution by a molecule of organic solvent. Complexes of type (xiii), 
derived from 1,10-phenanthroline, readily delivered CO under illumination by light. Four of 
them could even be excited by low-power UV light and liberate none, one or all three molecules 
of CO depending on the nature of an ancillary ligand.[54] Complexes (xiv) and (xv) derived from 
2-(2-pyridyl)-benzothiazole also undergo rapid release of CO under low-power UV 
illumination (Figure 9).[55]  
 
It is interesting to notice that in these complexes built on a large S-conjugated ligand, a 
phosphine ligand is no longer compulsory to observe CO-photorelease. Photoreactivity 
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therefore depends totally on the proper choice of the ligands. Compared to Mn complexes, Re 
complexes such as (xvi), (xvii), (xviii) and (xix) (Figure 9) are moderately photoreactive.[51,56, 
57] The presence of the bromide ligand in (xix) leads to facile intersystem crossing to 3MLCT 
excited state due to spin-orbit coupling, i.e. heavy atom effect, and this prevents the dissociation 
of the metal-CO bond.  
 
 
 
 
Figure 9. Chemical structure of some photoCORMs. 
 
Rhenium photoCORMs may indeed be used as photoluminescent trackers and generally 
show good internalization by cells. For example, several type (xiii) complexes, as well as 
complex (xvi) have been used to show the uptake of this type of compounds by human breast 
cancer cells.[54,56] Ideally, it should be possible to take advantage of the photoluminescence 
properties to monitor the release of CO. The pioneering work of Ford and co-workers has paved 
the way for this.[58] As seen above, phosphine complexes are well photoreactive. But, they are 
often poorly soluble in water. Owing to the P(CH2OH)3 ligand, complex (xx) is water-soluble 
and releases CO efficiently. This complex was readily internalized by human prostatic cancer 
cells with no apparent cytotoxicity and could be used to visualize cell uptake using a 
(xii) (xiii)
(xiv)
(xv)
(xvi) (xvii)
(xviii)
(xix)
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fluorescence microscope. Interestingly, the starting compound emitted in the green while the 
photoproduct emitted in the blue inside the cells (Figure 10). This color change suggested the 
possibility to track both the localization of the compounds and the release of CO. However, the 
spectral overlap between the two emission bands hampers this simultaneous detection. 
Thereafter, significant contributions have been made by the Mascharak group, with the aim to 
make the luminescence signals as distinct as possible. Complexes (xiv) and (xv) have been 
shown to release CO under low-power UV illumination. Both complexes are photoluminescent 
in the orange. In (xv), the loss of one CO molecule results in complete extinction of the 
luminescence signal. The delivery process was then monitored through the decrease of 
photoluminescence.[55b] In contrast, in (xiv), the CO release is accompanied by a change in 
photoluminescence from orange to deep blue. This compound was used successfully to track in 
vitro the uptake into cancer cells and the end of CO delivery within the target.[55a] 
 
 
Figure 10. Top: Chemical structure and photoreactivity of a photoCORM. Bottom: Confocal fluorescence 
microscopy images of PPC-1 cells that were incubated for 60 min with 50 μM of (xx). The top image (in blue, λem 
= 465−495 nm) was collected with minimal photolysis from the 405 nm excitation source and indicates the 
incorporation of (xx) into the cellular cytosol. The bottom image (in green, λem > 660 nm) was collected after 405 
nm photolysis for 15 min and indicates the transformation of (xx) to its photoproduct. (Figures extracted from 
reference [58]). 
 
(xx)
a b
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Finally, the biggest challenge in the field of Re-photoCORMs remains to shift the 
excitation wavelength to the biocompatible range (500 nm – 900 nm).[49] Complexes of type 
(xii), as well as (xvi) and (xvii) were efficiently excited around 360 nm.[56,58]  Complex (xx) 
was excited around 405 nm.[58] Curiously, contrary to their Mn analogs, complexes of type (xiii) 
and complexes (xiv), (xv), (xviii) and (xix) released CO only with illumination by low-power 
UV light, and were insensitive to visible light despite the presence of a MLCT band in the 
visible.[54,55a,57] This shows that the presence of a strong MLCT band in the visible region is not 
sufficient to insure good photolability of the CO ligands.[51] At the moment, the reported 
complexes must be excited in the near-UV or, at the best, at the edge of the visible range. 
Excitation at these wavelengths allows in vitro cell experiments, but it would be highly 
desirable to move the excitation wavelength to the red for in vivo applications. Only a small 
number of complexes have been explored to date and a lot of developments can still be made 
in this direction. In any event, these systems can be very finely tuned and obviously constitute 
very attractive candidates for theranostics. 
 
2.3.2.3. Vectorization 
Very few examples of incorporation of photoCORMs in nanoparticles can be found in 
the literature. To our knowledge, Rhenium photoCORMs have only been used once in 
nanoparticles. Complex (xv) incorporated in the mesoporous silica nanoparticles has been 
shown to be well endocytosed in vitro by human breast cancer cells, leading to their rapid 
eradication.[55b] According to the exciting results obtained with Mn-based photoCORMs 
incorporated in mesoporous silica nanoparticles and phospholipid-functionalized 
poly(ethyleneglycol) (PEG) layers,[59] many developments with Re(I) probes can be expected 
in this field in a near future.  
 
The most important thing to remember is that Re(I) complexes allow to play on many 
fields at a time. Not only the versatility of the ligand structure allows precise targeting to be 
achieved, but multimodal imaging and theranostic can also be envisaged. Consequently, a 
rational design of the complexes is absolutely necessary so that the various functionalities can 
be harmoniously combined. Additionally, the simplicity and modularity of using different 
bifunctional chelators and radiometals facilitate the creation of a wide variety of imaging 
agents. To do so, it is obvious that the use of general synthetic approaches allowing the readily 
preparation of a large family of rhenium-specific chelates is also crucial. Among modular and 
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versatile chemistry reactions, in our opinion, the Copper(I)-catalyzed azide-alkyne 
cycloaddition seems the more suitable approach. 
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3. Click chemistry, “Click-to-Chelate” concept, Click, then Chelate approach 
 
3.1. Copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC reaction) 
Click chemistry, a term coined in 1998 and reported in 2001 by Sharpless et al., is a 
particular useful synthetic method for the formation of carbon-heteroatom bonds by joining 
small molecular building blocks in a rapid, facile, and selective reaction.[60] According to 
Sharpless’ criteria, click transformations are usually performed under mild aqueous conditions 
and with readily available starting materials and reagents, in high yields and exhibited high 
atom economy and generated little or no byproducts. Among these click reactions, viii  the 
copper(I)-catalyzed azide-alkyne cycloaddition so-called CuAAC reaction, reported 
independently in 2002 by the groups of Sharpless and Fokin[61] and Meldal,[62] has emerged as 
the perfect example of click chemistry. Compared to non-catalyzed azide/alkyne reaction first 
described by Michael[63] and later investigated by Huisgen[64] which lead to a mixture of two 
isomers (1,5-disubstituted and 1,4-disubstituted 1,2,3-triazoles), the CuAAC reaction of 
terminal alkynes proceeds selectively in the formation of the 1,4-disubstituted 1,2,3-triazole 
and does not require high temperature and/or harsh conditions (Scheme 2).  
 
Scheme 2. Synthesis of 1,2,3-triazole via Huisgen 1,3-dipolar cycloaddition and CuAAC. 
 
 
 
viii Non exhaustive list of click chemistry reactions: nucleophilic ring opening reactions of epoxides and aziridines, 
non-aldol type carbonyl reactions such as formation of hydrazones, Diels-Alder and inverse electron demand 
Diels-Alder reactions, Michael addition…[61] 
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Due to the intense research interests focused on CuAAC, numerous papers involving 
some reviews have been reported.[65] The CuAAC reaction has become ubiquitous since Fokin 
and Sharpless publication in 2002. The reasons for this success are mainly due to the versatility 
of this “click” reaction which is easy to perform and appropriate in a wide range of conditions. 
It may be conducted in aqueous solution at room temperature, using a large variety of 
catalytically Cu(I) species and exhibited a high functional group tolerance. In addition, 
numerous applications of the CuAAC reaction have been reported. This modular synthetic 
approach was used in distinct scientific disciplines such as drug discovery,[66] biochemistry,[67] 
dendrimer,[68] polymer materials[69] and so on. The CuAAC reaction was currently considered 
as the “cream of the crop” of click reactions and more than 3000 publications with “click 
chemistry” in the title have come out in a decade and a half.[70] 
 
As mentioned above, the CuAAC reaction is an extraordinarily robust reaction, which 
could be performed under a wide variety of conditions and almost any copper source can be 
used as a pre-catalyst.[ 71 ] Before detailing the mechanism of this reaction, different used 
catalytic copper systems will be briefly discussed. 
 
3.1.1. Copper catalystsix 
- Cu(II) salts 
If Cu(II) ion is the most thermodynamically stable among the three most common states 
of copper (0, +1, and +2), its reduction is required to be used as copper catalyst in the CuAAC 
reaction. In 2002, Fokin and co-workers introduced sodium ascorbate as a convenient reductant 
for Cu(II) ion.[61] Its combination with a copper(II) salt, such as the stable and commercial 
available CuSO4.5H2O or Cu(OAc)2.H2O, constituted the method of choice for the preparation 
of 1,2,3-triazoles, the main advantage of this protocol being its compatibility with oxygen and 
water, allowing the application of CuAAC in biological media. Classically, this reaction is 
carried out with two to ten equivalents of the Cu(II) species in a mixture of water and organic 
solvent, the most commonly used being aqueous alcohol, THF or DMSO to ensure the solubility 
of hydrophobic reactants.  
 
ix Only examples of “molecular” catalytic systems will be presented in this section. For catalytic nanoreactors (like 
dendrimers or zeolite) or copper-based nanoparticules, see C. Deraedt et al., J. Am. Chem. Soc. 136 (2014) 12092-
12098 or S. Chassaing et al., Org. Lett. 9 (2007) 883-886 or F. Alonso et al., Acc. Chem. Res. 48 (2015) 2516-
2528, respectively. 
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- Cu(I) salts 
The sources of Cu(I) species for the CuAAC reaction are summarized by Meldal and 
Tornøe in 2008.[72] Different Cu(I) salts like CuI, CuBr and Cu(OAc) have been commonly 
used. Most frequently, the CuAAC is performed with the copper(I) iodide in THF, CH3CN, or 
DMSO, which is often preferred in polymer reactions. There is no obvious correlation between 
method used and yield of reaction, however, the purity of Cu(I) species may have a significant 
influence on the rate and completion of the reaction.[73] Furthermore, an excess of nitrogen base 
is very important to (i) accelerate the deprotonation of the alkyne to form the reactive copper(I)-
acetylide intermediate,[61a] (ii) avoid the oxidation or disproportion of Cu(I) species. The most 
commonly used nitrogen bases as additives in CuAAC reaction involved triethylamine (TEA), 
N,N-diisopropylethylamine (DIPEA), 2,6-lutidine and N,N,N',N",N"-
Pentamethyldiethylenetriamine (PMDETA). 
More recently, molecularly-defined copper(I) complexes were developed as pre-catalyst 
in the CuAAC reaction, this strategy offering the advantages to better control the 
stereoelectronic properties of the Cu(I) species, to avoid the use of an excess of ligand and/or 
additives and to accelerate the reaction rate.[65b] According to Pearson theory,[12] a plethoria of 
systems including “hard”, “soft” and “borderline” ligand classes was developed. While one of 
the earliest reports on the use of catalytic Cu(I) complexes described phosphine catalyst systems 
((Ph3P)3.CuBr and (EtO)3.CuI in the presence of a base),[74] most of preformed Cu(I) complexes 
were based on N-heteroaromatic amines, these compounds playing the role of both the 
coordinating center and the base.  
 
As examples, Vincent and co-workers described the recyclable, highly reactive Cu(I) 
complex [Cu(C186tren)]Br[ 75 ] (C186tren = tris(2-dioctadecylaminoethyl)amine) (Figure 11, 
compound a) to catalyze the cycloaddition of azides with terminal or internal alkynes.[76] D. 
Astruc team reported excellent results using [Cu(hexabenzyl)tren]Br[ 77 ] as Cu(I) catalyst 
(Figure 11, compound b). The reaction of phenylacetylene with benzyl azide in toluene using 
0.1 mol% amount of the pre-formed catalyst vs. substrates led to the click product in 100% 
yield. Then, a variety of substituted tris(triazolyl-methyl)amine ligands have been 
introduced,[78] in particular, by the groups of Fokin, Sharpless and Finn, in which the water-
soluble derivatives were proved useful in the case of bioconjugation (Figure 11, compounds c, 
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d, e).[ 79 ] A more complete list of preformed Cu(I) systems can be found in two recent 
reviews.[71,80]  
 
Figure 11. (a) and (b): performed Cu(I) complexes bearing N-chelating ligands; (c) to (e): N-chelating ligands for 
Cu(I) ion.  
 
- Cu(0) species 
Most marginally, metallic copper wires or turnings were used to catalyze the CuAAC 
reaction. It requires specific conditions like the use of ultrasound or ultrasound/microwave 
irradiation or solvent-free mechanochemical conditions, as recently shown by Cravotto et al. in 
2010 and Cook et al. and Rinaldi et al. in 2013 and 2015, respectively.[81-83] 
 
 To conclude this part, it is important to mention that: 
- Other metallic catalysts were used to catalyze the Huisgen cycloaddition. A 
recent review of D. Astruc and J.-Y. Saillard described last trends of the metal-catalyzed azide-
alkyne cycloaddition so-called MAAC with catalysts based on various metals. If the RuAAC 
was the first reported in 2005, currently, other transition metals and lanthanides (Ag, Au, Cu, 
Ir, Ln, Ni, Ru, Zn) were investigated as catalyst.[84]  
 
- On the last two decades, click reactions (including CuAAC reaction) that do not 
require any metal catalyst have been intensively investigated. The goal was to benefit of the 
advantages of the CuAAC reaction while avoiding the toxicity of copper (metal) traces, in 
particular when the reaction is developed for biological applications. For more information, the 
reader can refer to the works of Bertozzi or/and reviews dealing with copper(I)-free azide-
alkyne cycloadditions.[85] 
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3.1.2. The CuAAC mechanism 
The initial accepted mononuclear Cu-acetylide intermediate mechanism of CuAAC was 
proposed by Sharpless and co-workers using kinetic studies and DFT calculation (top of Figure 
12).[86] In the first step, the formation of π-alkyne copper complex intermediate 4 was calculated 
to be exothermic by 11.7 kcal/mol. And alkyne coordination significantly acidifies the terminal 
alkyne hydrogen. Then the azide is activated by coordination to copper, forming intermediate 
1. Formation of the first C-N bond (compound 2) was found to be the rate-determining step 
(activation energy was calculated to be 18.7 kcal/mol when L = H2O). Soon afterward, careful 
kinetic investigations of the reaction of phenylacetylene and benzyl azide by Rodionov et al. 
pointed out a strict second-order dependence on copper was involved in the transition state of 
the cycle (bottom of Figure 12).[87] Subsequent DFT calculations, carried out in the same 
group,[88] supported this hypothesis by showing that the complexation of the alkyne unit by a 
second copper center reduces the activation energy barrier by 4–6 kcal/mol.[89] 
 
 
 
Figure 12. Reported mechanism of the reaction between a mononuclear copper(I) acetylide and an organic azide 
(top). Introduction of a second copper(I) atom may favorably influence the energetic profile of the reaction 
(bottom, L = H2O) (Figure extracted from the reference [89]). 
 
Since this first reported mechanism, several theoretical investigations on the CuAAC 
reactions were performed (considering various copper system), most of them leading basically 
to similar qualitative conclusions.[90] The latest experimental mechanistic study by Fokin’s 
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group unambiguously demonstrated the stepwise nature of the C-N bond-forming events and 
the equivalence of the two copper atoms within the cycloaddition steps (Figure 13).[91] It 
revealed that monomeric copper acetylide complexes became reactive toward azides in the 
presence of exogenous copper catalyst. In their study, a stoichiometric equivalent of the 
enriched copper complex [63Cu(MeCN)4]PF6 was added to track the CuAAC reaction by time-
of-flight mass spectrometry (TOF-MS). The results showed that two copper centers were 
involved within the cycloaddition process in the regioselective formation of 1,4-disubstituted 
1,2,3-triazoles. This mechanism was also recently confirmed by Angelis’ group.[92] A dinuclear 
copper intermediate was detected for the first time, by electrospray ionization mass 
spectrometry (ESI-MS). 
 
Figure 13. Fokin’s proposed mechanism for the CuAAC reaction with two copper centers (Figure extracted from 
reference [91]). 
 
3.1.3. Experimental conditions vs. azodiphobiax 
As described above, the CuAAC reaction is defined as a reaction which is versatile, fast, 
simple to use (air- and moisture-insensitive and performed neat or in benign solvents), easy to 
purify, regiospecific, and which gives high product yields. Nevertheless, one drawback 
(excluding the potential toxicity of copper catalyst for biological applications) should be the 
use of organic azide derivatives, these compounds being energy-rich molecules and 
consequently, could explosively decompose, in particular those of low molecular weight. Two 
 
x The term “azidophobia” was first coined by K. B. Sharpless in 2002.[61] 
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rules (the carbon to nitrogen ratioxi and the rule of sixxii) were established in order to assess the 
stability of a given azide.  
To circumvent the use of azide compounds, the cycloaddition can therefore be 
performed in a one-pot two-step sequence using a halide derivative in the presence of sodium 
azide. Thus, the organic azide generated in situ was immediately engaged in the cycloaddition 
step.[93] 
 
3.2. Click-to-Chelate  
3.2.1. “Click-to-Chelate” concept 
As mentioned in the introduction, the highly modular CuAAC reaction was used in 
distinct scientific areas, in particular in radiochemistry.[94] Although the two first reports were 
only published in 2006 (vide infra), the CuAAC reaction is become a powerful tool for the 
design and development of radiopharmaceuticals, xiii  especially for those using short-lived 
isotopes such as 11C (t1/2 ≈ 20 min), 68Ga (t1/2 ≈ 68 min) or 18F (t1/2 ≈ 110 min). Indeed, many 
problems encountered with classical synthetic methods during the preparation of such 
radioactive compounds (multiple-step syntheses of bifunctional chelating agent, cross-
reactivity during the coupling of bifunctional chelating agent on highly functional biomolecule, 
reaction in water…) could be solved using the CuAAC reaction. 
 
In 2006, Marik and Sutcliffe pioneered the use of click chemistry in radiopharmaceutical 
applications and described the click reaction of the conjugation of ω-[18F]fluoroalkynes to 
various peptides decorated with 3-azidopropionic acid.[95] They prepared the corresponding 18F-
labeled products in very short time (10 min) with excellent radiochemical purity (81-99%). The 
same year, Mindt and co-workers first applied the click chemistry to metallic radionuclides.[96] 
In their approach, the 1,4-disubstituted 1,2,3-triazole ring produced by the click ligation acts 
not only as a linker of two well designed biomolecules (as described in the previous example), 
but also forms an integral part of the chelating unit for the complexation of a given radiometal. 
 
xi Carbon to nitrogen ratio: The total number of nitrogen atoms in the organic azide should not exceed that of 
carbon. The following equation allows to evaluate if the azide is stable enough to work with: (NCarbon + NOxygen) / 
NNitrogen ≥ 3, with N equal to the number of atoms.  
 
xii Rules of six: six carbons (or other atoms of about the same size) per azide group should provide enough dilution 
to render the compound relatively safe to work.  
xiii See general introduction for a detailed definition. 
Chapter I 
 35
In their initial report, they proved the viability of this approach by developing different 99mTc-
bioconjugates in which the triazole ring acted as both connector and metal chelating unit for the 
[99mTc(CO)3]+ core (Scheme 3). The broad applicability and efficiency of this 99mTc-
radiolabeling strategy, in particular those provided by convenient one-pot procedures developed 
in the course of the work, prompted the authors to term their approach “Click-to-Chelate”. 
 
Scheme 3. “Click-to-Chelate” strategy developed by Mindt and co-workers (Scheme extracted 
from reference [96]). 
 
Conditions and reagents: (a) Cu(OAc)2, Na(ascorbate), water, 25 °C (15 h) or 100 °C (30 min), (b) M = 99mTc: 
[99mTc(OH2)3(CO)3]+, PBS, pH 7.4, 30 min, 100 °C; M = Re: [ReBr(CO)3]2-, water or alcohols, 50-65 °C, 1-4 h.  
 
Additionally, the authors demonstrated that this approach could be performed by a one-
Pot procedure doing simultaneously the formation of the chelating unit including the triazole 
ring, its bioconjugation to a biomolecule and the radiolabeling of the formed bioconjugate by 
the [99mTc(CO)3]+ core.[97,98,99] To highlight that, they used different pathways to prepare model 
99mTc-bioconjugates. In the first route, after the click reaction, the radiolabeled precursor 
[99mTc(CO)3]+ was added and the mixture was heated at 100 ºC for another 30 min to afford the 
99mTc tricarbonyl complex (Scheme 4, Approach A, one-pot, two-step). HPLC analysis 
confirmed the good yield and purity of the radiolabeled complexes, which were identical to the 
products of pre-synthesized and isolated ligands with [99mTc(CO)3]+ (Scheme 4, Approach C, 
two steps). More interestingly, by doing the “Click-to-Chelate” in only one step, i.e. by simply 
mixing all the substrates with the commercial IsoLink™ kit (to reduce pertechnetate ions 
[99mTcO4]– from the generator eluent as mentioned previously), the same 99mTc tricarbonyl 
complexes were also obtained (Scheme 4, Approach B, One-Pot “Click-to-Chelate” procedure). 
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This synthetic strategy was successfully applied by Schibli’s team to the one-pot synthesis and 
radiolabeling of N3-functionalized thymidine derivatives as potential SPECT imaging agents 
toward human thymidine kinase (hTK1).[100] Finally, it is noteworthy that this one-pot strategy 
could be improved (in terms of time) by the use of microwave irradiation.  
Simplification of the “Click-to-Chelate” procedures, such as the one-pot process and/or 
using microwave irradiation, make this approach a powerful tool for the development of 
chelating systems for biological/clinical applications. 
 
Scheme 4. One-Pot “Click-to-Chelate” procedure for the development of 99mTc-
radiopharmaceuticals (Scheme extracted from reference [98]). 
 
 
 
Conditions and reagents: (A) one-pot, two-step, (B) one-pot, single-step, (C) two-step synthesis with isolation 
of the click ligands before radiolabeling step. 
 
3.2.2. Inverse/regular click ligands 
Depending of the structure of the alkyne and azide derivatives, two different 1,4-
disubstituted 1,2,3-triazoles could be formed: the regular click ligand in which the coordinating 
arm is located on the position 4 of the triazole ring and the inverse click ligand in which the 
coordinating arm is linked to the nitrogen N(1) of the triazole ring. From a chemical point of 
view, in the former type, the N(3) atom of triazole is coordinated to the metal, whereas the N(2) 
atom is involved in the coordination in the latter type (Scheme 3 and Scheme 5).[98] 
 
In 2010, Brans et al. investigated a peptide (a bombesin analog) on which was grafted 
the two kinds of click ligands (Scheme 5).[101] The two contrary molecules displayed quite 
different behavior when radiolabeled with [M(CO)3]+ (M = 99mTc or Re). Compared to the 
“regular click ligand”, the “inverse” one showed a relatively low radiolabeling yield with the 
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[99mTc(CO)3]+ core. In addition, such “inverse” 99mTc-labeled system was found unstable and 
therefore inappropriate for in vivo evaluation. This difference of behavior was explained by 
DFT calculations and resulted from the lower electronic density at N(2) compared to that at 
N(3) of the triazole ring.[96] Consequently, most of chelating ligands developed using a “Click-
to-Chelate” strategy were regular click ligands. 
 
Scheme 5. “Regular and inverse click ligands” conjugated to a bombesin derivative (BBN); 
(Scheme inspired by reference [101], M = 99mTc or Re).  
 
3.2.3. Extension of the “Click-to-Chelate” approach 
In their first report in 2006, Mindt and Schibli defined their “Click-to-Chelate” approach 
as a highly efficient strategy for the radiolabeling of molecules of medicinal interest with 
technetium-99m and cold rhenium-tricarbonyl cores. This method enables the simultaneous 
synthesis and bioconjugation of tridentate chelating systems for the stable complexation of the 
radiometals. Following this concept, a similar approach was investigated by Benny’s group and 
several research groups have also explored the coordination properties of the triazole ring 
against other metals than technetium and rhenium. 
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- Click then Chelate/Chelate then Click 
Alternatively, Benny developed two click strategies (Click, then Chelate and Chelate, 
then Click) to evaluate the impact of the sequence of steps on complex formation and stability 
for technetium(I) and rhenium(I) cores. Thus, using click chemistry with a dipyridylamine 
(DPA) alkyne ligand, a commercial azide (benzyl azide) and a [M(CO)3]+ unit, he demonstrated, 
in both approaches, the preference for pyridine coordination over triazole coordination for the 
[M(CO)3]+ unit.[ 102 ] In another example, he highlighted that the coordination preference 
between pyridine and triazole rings was pH-dependent (Scheme 6).[103] More interestingly, 
these researches proved that for a multidentate ligand, the Click, then Chelate approach offered 
higher possibilities in terms of tridentate coordination modes than with the Chelate, then Click 
approach, the latter one being limited by the nature of the tridentate chelating unit prior to 
perform the click reaction (Scheme 6). 
 
Scheme 6. Click, then Chelate and Chelate, then Click strategies (figure extracted from 
reference [103]).  
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-  Extension of the Click, then Chelate approach 
Extension of this approach to the preparation of structurally diverse chelating agents for 
the complexation of other metals than technetium-99m (and rhenium) was also investigated. A 
vast array of 1,4-disubstituted-1,2,3-triazole-containing ligand architectures and the 
corresponding “click” complexes have been developed in the past ten years. Most of these 
ligands resulted more from a Click, then Chelate approach than from a “Click-to-Chelate” 
strategy, the corresponding click metallic complexes being not necessary linked to a 
biomolecule. In this part, only selected examples of metallic complexes (not including 
technetium or rhenium metals) based on a click ligand and exhibiting a potential interest in 
medicinal and/or biological field will be briefly mentioned (Figure 14).  
 
While generally only one triazole unit participates to the coordination of the metal, 
recently, Baschieri et al. developed a tripodal ligand based on tris-triazole units for the 
complexation of a Ce3+ ion.[104] Concerning the nature of the metal, transition metals were the 
most studied. Several metallic complexes were developed as potential (i) fluorophores (Zn, 
Ru),[105] (ii) nuclear imaging/therapeutic agents (64Cu,[106,107] 111In and 177Lu), (ii) antifongic or 
anticancer compounds (Fe, Pt, Ru).[108] Then, the triazole coordination abilities with lanthanide 
ions were investigated on DOTA xiv  derivatives.[ 109 ] According to DOTA, Faulkner 
demonstrated that the coordination of one of the triazole nitrogen atoms to the metal center 
changed the local coordination environment and consequently the luminescence properties of 
the complex.[109a] Representative structures of such complexes will be gathered in the Figure 14 
and for more examples, the reader could see a review focused on the attractiveness of the 1,2,3-
triazole ring and its coordination chemistry.[110] 
 
Figure 14. Examples of lanthanide (a) or transition metal (b and c) complexes obtained by a Chelate, then Click 
strate. 
 
xiv DOTA means 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. 
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3.3. Examples of technetium- and rhenium-specific click ligands  
3.3.1. Tricarbonyltechnetium(I) complexes via a “Click-to-Chelate” approach  
Since the first report by Mindt et al., the “Click-to-Chelate” methodology based on 
CuAAC has witnessed the wide development of various “organometallic” 99mTc-tricarbonyl-
based radiotracers. Most of examples was reported by Schibli’s group and ranged from 
carbohydrates, peptides, vitamins, and steroids to hypoxia-imaging agents, enzyme substrates 
and ligands for prostate-specific membrane antigen.[98,111] As example, this group created seven 
different tripodal scaffolds, including N3, N2S, and N2O ligand architectures, with distinct 
alkynes as prochelators. Subsequent complexation with [M(CO)3]+ [M = Re, 99mTc] synthons 
resulted in a series of highly stable, low-spin d6-complexes despite differences in the size, 
molecular charge, and hydrophilicity of the prochelator (Figure 15).[112]  
 
Figure 15. Examples of “Click-to-Chelate” chelating systems and their corresponding rhenium complexes, 
developed by Schibli and Mindt (figure extracted from reference [112]). 
 
The radiolabeling process of the ligands with [99mTc(CO)3]+ proceeded under standard 
reaction conditions in PBS buffer (pH 7.4, 100ºC, 20–30 min) at a ligand concentration between 
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10-3 and 10-8 M, which is comparable to one of the most efficient chelators for [99mTc(CO)3]+ 
core.[113] 
 
Based on these chelators, the “Click-to-Chelate” methodology was later extended to the 
preparation of multifunctional 99mTc-tricarbonyl radioconjugates by the use of structural 
modifications of the prochelators employed. Two approaches of such concept have been 
developed by Mindt and Schibli. [114,115] The first extension strategy involved the use of N(α)-
propargyl lysine (Lys) derivatives as click prochelator (Scheme 7a).[114] This method not only 
offers a convenient and efficient method for 99mTc-labeling targeted biomolecules, but also 
allows the concurrent introduction of a second entity of interest such as the same (multivalency 
concept) or a different targeting entity or a different imaging marker (bimodal probes).[116]  
 
The second strategy involves tridentate bis-1,2,3-triazole ligand systems derived from a 
double CuAAC reaction between two azides bearing different pendant arms at the N(1) position 
(R2 and R3 moieties, Scheme 7b) and a dialkyne precursor.[115] The bisalkyne species were 
tripodal platforms allowing the selective introduction of various moieties (biomolecules, 
markers…) on its tertiary nitrogen and on each formed triazole rings (Scheme 7b). In detail, 
two other chemical or biological azides (R2 and R3) are successively conjugated by click 
reaction to the dialkyne precursor: first with terminal alkyne to form the first triazole unit, then 
the removal of the TMS protecting group furnished the second alkyne, which was subjected to 
the second click ligation. The difference from the first strategy is that here two functionalized 
1,2,3-triazoles are formed, giving more possibilities to the design of the molecular structures.  
 
In principle, by the extended “Click-to-Chelate” approach, an almost infinite number of 
azide-functionalized moieties of interest could be attached to the dialkyne-derived precursor to 
form the multifunctional chelators for corresponding metallic conjugates. Interestingly, a one-
pot, three-step procedure was also conducted by Mindt et al. to yield the asymmetric di-1,2,3-
triazoles directly.[115]  
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Scheme 7. Assembly of multifunctional 99mTc/Re conjugates based on (a) mono-1,2,3-triazoles 
and (b) di-1,2,3-triazoles by “Click-to-Chelate” approach (Inspired from reference [98]).  
 
 
While the “Click-to-Chelate” approach was first studied using various peptides[117] or 
sugars[ 118 ] as biomolecules, it was also applied for the development of small bioactive 
compounds such as targeting of hypoxia-targeting markersxv or for central nervous system 
(CNS) imaging agent. Thus, Fernández and co-workers and more recently Bhadwal et al. 
developed tridentate nitroimidazole chelators, as well as corresponding 99mTc(I)-tricarbonyl 
complexes by a “Click-to-Chelate” protocol (Figure 16a).[119] 99mTc complexes were stable in 
radiolabeling conditions and resulted in high radiolabeled yield (> 90%). The results showed 
99mTc-complexes exhibited favorable biodistributions in terms of blood and liver uptake and 
the 5-nitroimidazole radiolabeled compound displayed the best tumor uptake than other 
nitroimidazole radiocomplexes. 
 
Concerning, central nervous system (CNS) imaging agent, the “Click-to-Chelate” 
strategy allowed the development of various neutral 99mTc-MPP derivatives (MPP = 1-(2-
methoxyphenyl)piperazine), the MPP pharmacophore having a high affinity for serotonin 
receptors, in particular 5-HT1A receptors. For instance, Hassanzadeh and co-workers developed 
a pharmacophore 1-(2-methoxyphenyl)piperazine (MPP) on which is grafted a tridentate click 
 
xv Hypoxia literally means "low oxygen". It corresponds to a deficiency in the amount of oxygen that reaches the 
tissues of the body. More details will be given in the chapter II, part 3. 
 
Chapter I 
 43
ligand (Figure 16b left).[120] Its radiolabeled 99mTc(I) complex was used as a potential CNS 
imaging agent for 5-HT1A. In the same time, our group developed a bidentate pyta ligand which 
was connected to the MPP pharmacophore via an ethylene bridge (Figure 16b right).[121] If 
tridentate ligands are known to be more efficient for the stabilization of fac-[M(CO)3]+ core 
than bidentate ones,[8a] we demonstrated that our system was stable enough in biological media 
and offered the advantage to be use as nuclear probe (with technetium-99m) but also as 
fluorophore (with cold rhenium), the rhenium complex exhibiting promising photo-physical 
properties such as a quantum yield of 0.32% in methanol, with λexc=330 nm and λem=522 nm 
(concept of bimodal imaging probes).  
 
 
Figure 16. (a) 99mTc-complexes bearing an appended nitroimidazole unit for tissue hypoxia imaging, (b) 99mTc-
complexes as CNS imaging agents 
 
3.3.2. Tricarbonylrhenium(I) complexes via a Chelate, then Click approach 
Particular interest has been recently devoted to the “click synthesis” of 
monofunctionalized 2-pyridyl-1,2,3-triazole derivatives (or pyta) as alternative ligands to 2,2’-
bipyridines. Indeed, these functionalized pyta derivatives were readily both prepared in high 
yield and few steps and converted into the corresponding fac-[Re(CO)3Cl] complexes which 
exhibited promising photo-physical properties (as just mentioned before). Most of the 
corresponding rhenium(I) complexes developed by Crowley,[108c,122] Policar[27a,45a,123] or our 
group,[121,124] were functionalized by an aryl group or an alkyl chain without biological interest 
and these examples constitute, in our opinion, the most relevant examples of a 
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tricarbonylrhenium(I) complexes prepared by the Chelate, then Click approach. As highlighted 
in part 2.2.6, these rhenium(I) complexes are not only (generally) luminescent but some of them 
are suitable for cellular imaging and more interestingly for bimodal imaging. Policar reported 
recently rhenium tris-carbonyl derivatives able to couple infrared and luminescent detection in 
cells, so-called SCoMPIs (SCoMPIs for Single Core Multimodal Probes for Imaging) and in 
our group, we developed the first example of a water-soluble functionalized dual 
fluorescent/radiolabelled imaging agent based on a heterobimetallic 99mTc/Re complex (Figure 
17). 
 
 
Figure 17. Bimodal imaging probes based on a pyta scaffold: (a) SCoMPI, (b) heterobimetallic 99mTc/Re complex. 
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4. Project of the thesis 
 
Recently, John F. Valliant claimed “Senior researchers should encourage young 
scientists to explore unique directions and not listen to statements such as “we have enough 
ligands or agents.” It is always easier to state that today’s technology is sufﬁcient than it is to 
come up with tomorrow’s innovation”.[125] With this idea in mind, the main objectives of this 
work was focused on the development on new rhenium(technetium)-specific chelators and the 
evaluation of the corresponding metallic complexes as efficient imaging/therapeutic probes. 
 
According to the bibliographic part, two important conclusions for the design of new 
rhenium complexes can be drawn: 
- While oxorhenium complexes are still of interest, it is clear that rhenium complexes 
based on the fac-tricarbonylrhenium(I) core were currently the most investigated rhenium 
complexes. With suitable ligands, Re(I) complexes offered applicative interests in optical 
imaging (photoluminescent complexes) or in therapeutic purposes (188Re-
radiopharmaceuticals, photoCORMS). The easy access of the starting bidentate or tridentate 
ligands is another advantage. Then, it is noteworthy that to the best of our knowledge, the 
development of a family of chelating systems for stable Re(I) and Re(V) complexes has rarely 
been explored, 
- The “Click-to-Chelate” strategy or the analogous Click, then Chelate approach are 
elegant methods and powerful tools allowing the readily preparation of a rhenium specific-
bidentate or tridentate ligands. 
 
Among the different types of chelating systems for technetium and rhenium 
complexation we developed over the last decade,[121,124,126] two molecular frameworks attracted 
our attention. In this work, we developed a pre-organized N2O tripodal system[126c,127] and a 
pyta scaffold,[124] as illustrated in Figure 18. 
 
4.1. Based on a N2O tripodal system 
In 2014, our group designed a tridentate N2O ligand for the fac-[M(CO)3]+ core (M = 
99mTc, Re) in three steps from the commercial 2-aminophenol.[126c] The corresponding 99mTc-
labeled radiotracer was obtained in good yield (>90%) and displayed high serum stability in 
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vitro. Moreover, biodistribution studies showed a rapid in vivo clearance and no uptake in 
healthy organs, making this Tc-complex a promising bifunctional chelating agent for SPECT 
imaging. Based on this previous work,xvi we are stimulated to (i) extend our family of semi-
rigid chelators using the Click, then Chelate approach and (ii) develop more applicable chelators 
as imaging agents and/or therapeutic radiopharmaceuticals using the “Click-to-Chelate” 
strategy (Figure 18).  
 
Concerning the extension of our chelating species, we designed tetradentate chelating 
ligands for [MVO]3+ (M = 99mTc, Re) core base on “clickable” triazoles. This idea was supported 
by Machura and Wolff’s work which reported a theoretical and experimental work on the 
formation of stable oxorhenium(V) complexes with benzotriazole-containing ligands,[128] and 
Dugave group which first presented an oxotechnetium tetradentate chelating agents based on a 
Click, then Chelate approach. Additionally, this latter 99mTc-complex exhibited promising 
properties as novel tracer for molecular imaging.[129]  
 
Concerning the development of more applicable chelators, the best and easiest way 
consisted to graft different bioactive groups on our tripodal N2O scaffold to design targeted 
99mTc-radiopharmaceuticals. We decided to introduce different nitro groups, in particular a 
nitroimidazole group, the latter moiety being commercially available, easy to handle, and the 
most important, able to be reduced or retained exclusively in hypoxic cells, making the 
corresponding 99mTc-complexes with an appended nitro moiety, potential hypoxia imaging 
agents.[130]   
These two different ways will be detailed in the second chapter (part 1 and part 3) as 
well as an unexpected reaction which occurred during the development of tetradentate chelating 
ligands (part 2) 
 
4.2. Based on a pyta scaffold 
As we have shown in this introduction, pyta framework was an excellent chelator for a 
fac-[Re(CO)3]+ core, leading to luminescent probes.[123,124] If such tricarbonyl rhenium(I) have 
been mainly studied in solution, their solid-state emission properties have attracted less interest 
 
xvi As a continuation of previous study and in parallel to this project, we demonstrated that this tripodal chelator 
led to stable 188Re-complexes (see R. Eychenne, S. Guizani, J.-H. Wang, C. Picard, N. Malek, P.-L. Fabre, M. 
Wolff, B. Machura, N. Saffon, N. Lepareur, E. Benoist, Eur. J. Inorg. Chem. 1 (2017) 69-81). 
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and have mainly been considered in other applications than biomedical field. Keeping in mind 
that organic luminophores and more recently transition metal complexes can show higher 
photoluminescence efficiency in its aggregated state than in solution (this phenomenon is called 
aggregation-induced emission or AIE), our objective was to design highly emissive rhenium(I) 
luminescent probes exhibiting an AIE effect, these Re-complexes could be promising tools for 
imaging and image-guided combination therapy. 
 
In this part, new tricarbonyl Re(I) complexes containing a pyta ligand grafted onto a 2-
phenylbenzoxazole (PBO) moiety will be studied. This organic dye was chosen with the aim to 
improve the spectroscopic behavior of our hybrid system (composed by an organic fluorophore 
and a coordination complex). Moreover, as previously demonstrated in our group, the PBO 
moiety exhibited excellent stability and optical properties and has been widely used in the field 
of fluorescent materials (many of them are strongly emissive in the solid state,[131] sometimes 
display AIE behavior).[132] In our compounds, the organic dye PBO is connected to the pyta 
group by a single bond that allows its free rotation but is not directly involved in rhenium 
complexation, unlike most of the complexes reported in the literature. At least, four compounds 
were developed and investigated, the different complexes differing by (i) the nature of the 
triazole ring (2-pyridyl-1,2,3-triazole or 2-pyridyl-1,2,4-triazole scaffolds), (ii) the structure of 
the PBO unit, (iii) the position of the pyta rhenium complex with regard to the organic moiety 
(connection by the phenyl ring or the benzoxazole unit) (Figure 18). 
 
This work ranging from synthesis to characterization of these compounds including 
electrochemical and spectroscopic studies, along with DFT calculations, as well as in vitro and 
in cellulo studies will be detailed in the third chapter of this manuscript. 
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Figure 18. General Scheme of the work presented in this manuscript with some representative compounds for 
each chapter. 
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As previously explained, this chapter will be devoted to the investigations of technetium 
and rhenium-specific multidentate chelators inspired from a semi-rigid tripodal ligand 
developed recently in our group. 
 
The first strategy was to extend our family of chelating species by developing potentially 
tetradentate ligands. This work, which constitutes the two first parts of this chapter led to: (i) a 
new series of multidentate compounds which act as tetradentate or bidentate ligands depending 
both on their structures and the rhenium cores we investigated (first part of this chapter), (ii) 
an unexpected benzoxine derivative obtained as a side-product, during the development of the 
first part. The benzoxazine gave a new kind of dinuclear rhenium species with one 1,2,3-triazole 
as a bridging ligand (second part of this chapter). 
 
The second strategy was to include on our tripodal scaffold a reductive nitro entity in 
order to assess the potential of their corresponding technetium-99m complexes as hypoxic cells 
targeting. Two nitro moieties were investigated: a nitrophenyl group and a metronidazole 
framework, this research being detailed in the third part on this chapter. 
 
A general scheme hereafter illustrates all the parts developed in this chapteri 
  
 
i All the synthetized molecules are gathered in the book of annexes 
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1. Design, synthesis and reactivity of multidentate ligands with rhenium(I) 
and rhenium(V) cores 
 
1.1. Introduction 
Rhenium coordination chemistry has gained considerable attention in the last three 
decades.[1] Reports on the applications of rhenium (or technetium) complexes range from 
radiopharmaceuticals[2] to various imaging agents, such as luminescent and infrared probes.[3] 
These have been thoroughly discussed in former Chapter. 
 
The structure of Re-specific chelating systems is largely influenced by the oxidation 
state of rhenium and the constitution of its metallic core. It is well known that tridentate or 
bidentate ligands including oxygen or N-heteroaromatic nitrogen donor atoms are preferable to 
stabilize the tricarbonyl rhenium(I) core [Re(CO)3]+. But for oxorhenium(V) species, mainly 
[ReO]3+ and [ReN]2+ moieties, they are usually stabilized by tetradentate ligands combining 
sulfur, nitrogen, phosphorus and in a lesser extent oxygen donor atoms. These considerations 
have drawn our attention to the possibility of applying the Copper(I)-catalyzed Alkyne-Azide 
Cycloaddition (CuAAC) to the synthesis of multidentate ligands for rhenium(I) cores (and 
analogous technetium-99m cores as well).[4] Its remarkable simplicity and efficiency combined 
to the Click-to-Chelate approach developed by the group of Schibli,[5] as illustrated in the first 
chapter, has made it a powerful tool for the conception of technetium(I) and rhenium(I) labelled 
radiopharmaceuticals.[6] In contrast, no example of an oxorhenium(V) complex based on a click 
ligand have been reported so far. In addition, although coordination behaviors of chelators 
towards rhenium(I) and rhenium(V) cores have been reported,[7] the development of a family 
of chelating systems for stable Re(I) and Re(V) complexes has rarely been explored.  
 
Our group previously reported a tripodal N2O chelating cavity including a pre-organized 
moiety. The rigidity of the molecular skeleton reduces the freedom of donor atoms, and this 
spatial pre-organisation induces a more efficient complexation, notably by reducing the reaction 
entropy.[8] Then, using a Click-to-Chelate strategy, semi-rigid chelating systems containing an 
aromatic backbone and the triazole unit and bearing different functionalized arms (carboxylate, 
amino group…) were developed as well as stable technetium-99m and rhenium-188 tricarbonyl 
complexes.[9] Interestingly, the corresponding neutral 99mTc(CO)3 complex was obtained in 
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excellent yield, and exhibited interesting in vivo behaviors (biodistribution on healthy male 
normal Swiss mice), in particular a high stability against exchange reactions with blood 
proteins, a fast clearance of the radiotracer from the blood-stream and a non-specific uptake in 
healthy organs or tissues).[9a] More recently, a preliminary study proved the affinity of these 
tripodal N2O bifunctional chelating agents (BCAs) with the radioactive tricarbonylrhenium 
core, fac-[188Re(CO)3]+. The 188Re-radiolabeling yield ranged from 80% to 96%, depending on 
the nature of the functionalized arm of the BCAs.[9b] 
 
Due to the excellent coordination capability of tripodal N2O bifunctional chelating 
agents towards the fac-[M(CO)3]+ (M = 99mTc or 188Re) moieties, we tried to extend the studies 
to a series of potentially N3O tetradentate ligands suitable to rhenium complexation. So in this 
present work, two synthetic strategies are reported for the preparation of three new semi-rigid 
tetradentate ligands, as depicted in Scheme 1. L1 and L2 act exclusively as bidentate ligands 
and lead to the formation of mononuclear tricarbonyl rhenium(I) complexes of general formula 
[Re(CO)3Cl(L)] (L = L1 or L2). In contrast, the ligand L5 acts as a tetradentate ligand and gives 
in high yield, its charge-neutral oxorhenium(V) and oxotechnetium(V) complexes [MO(L5)] 
(M = Re or 99mTc). 
 
1.2. Syntheses of the ligands and their corresponding rhenium complexes 
1.2.1. Syntheses of the ligands 
To develop potential tetradentate (N,O)-donor BCAs, two methods are employed based 
on a semi-rigid scaffold for rhenium cores (Scheme 1). One is by introducing on the aromatic 
hydroxyl group a pyridyl or a carboxylic coordinating arm (O-extension), while the other route 
is by the insertion of a glycine moiety between the aromatic and triazole rings (N-extension).  
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Scheme 1. Design features of novel semi-rigid tetradentate ligands.  
 
 
1.2.1.1. O-extension, pyridine coordinating arm 
The preparation of L1 and L2 follows a five-step procedure as shown in Scheme 2. 
Starting from 2-aminophenol, it first reacted with Di-tert-butyl dicarbonate to get N-Boc 
protected derivative 1. Then by the reflux of 1 with 2-picolyl chloride hydrochloride in basic 
acetonitrile conditions, we selectively obtained hydroxyl substituted compound 2. One side 
reaction should be noticed that a Boc deprotection happened with/after the formation of 
compound 2. 
Then the N-alkylation of compound 2 with propargyl bromide in the presence of sodium 
hydride yielded compound 3. Subsequent treatment with an excess of triﬂuoroacetic acid 
resulted in the Boc deprotected compound 4a with a yield of 92%. It is noteworthy that in this 
step, a different protocol according to the literature was performed.[10] After 6 hours of reaction 
at room temperature, a 28% w/w NH4OH solution was used to neutralize the TFA. Surprisingly, 
a trifluoroacylated substituted product 4b was obtained with a moderate yield of 66%. Similar 
trifluoroacylated derivatives were previously reported in the literature, using pyridine as a base 
to neutralize TFA.[11] 
At last, 1,2,3-triazole ligands L1 and L2 were afforded by CuAAC reaction of 4a with 
freshly prepared methyl 2-azidoacetate and 4-nitrophenyl azide, respectively.[9b] Compound L2 
has also been prepared by conducting first the click reaction of compound 3, followed by the 
N-Boc deprotection. In this process, a lower yield was observed for the CuAAC reaction (69% 
for 5 vs. 81% for L2), probably due to a steric hindrance generated by the Boc group. 
Chapter II 
 
 
63 
 
Additionally, ESI-MS analysis revealed that no detectable coordination of copper(I) species to 
L1, L2 or compound 4a was observed during the click chemistry step. 
 
Compounds L1 and L2 were stable in air and moisture at ambient temperature. Both 
ligands were fully characterized by NMR and HR-MS as well as X-Ray diffraction. Indeed, 
Suitable crystals of L1 and L2 for X-ray crystal structure determination were grown by slow 
evaporation of an acetonitrile and dichloromethane mixture. Molecular structures of ligands L1 
and L2 as well as their crystal data and structure refinement were presented in the annex part,ii 
in Figure S1 and Table S1, respectively. 
 
Scheme 2. Synthesis of O-extension, pyridine coordinating arm. 
 
 
Conditions and reagents (i) (Boc)2O, THF, rt, overnight; (ii) 2-picolyl chloride hydrochloride, K2CO3, CH3CN, 
reflux, overnight; (iii) NaH, propargyl bromide, DMF, 0ºC to rt, overnight; (iv) trifluoroacetic acid, CH2Cl2, 0ºC, 
2 h for 4a or L2 and rt, 6 h, NH4OH for 4b; (v) methyl 2-azidoacetate and 4a for L1 and 4-nitrophenyl azide for 5 
and L2, Cu(OAc)2.H2O, NaAsc., t-BuOH/H2O, rt, overnight. 
 
ii Refer to the book of annexes for Figure Sx (x = 1 to 5) and Tables Sx (x = 1 to 8). 
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1.2.1.2. O-extension, carboxylate coordinating arm 
We also attempted to prepare expanded analogues of L1 and L2 by introducing a 
carboxylic coordinating arm instead of a pyridine one, but we did not succeed to obtain the 
desired N2O2 tetradentate ligand (blue ligand in Scheme 3). Regardless of the approaches we 
tried, a ring closure reaction was always observed, yielding to benzoxazine derivatives as the 
major product.  
 
The preparation of L3 and L4 follows a four- or five-step procedure depending on two 
different routes, both starting from 2-aminophenol, as shown in Scheme 3. The first route was 
similar as the route depicted before for the synthesis of L1 and L2. Using N-Boc protected 
derivative 1, which reacted to methyl bromoacetate or tert-butyl bromoacetate in the basic 
acetonitrile, we got in high yield hydroxyl substituted compounds 6 and 7, respectively. When 
doing the N-alkylation, followed by the deprotection of Boc group, a ring-closed benzoxazine 
derivative 9 was obtained. This might be due to the existence of NaOH generated by sodium 
hydride that made the hydrolysis of esters to give the acid 8. After treatment with trifluoroacetic 
acid, an intramolecular amidation occurred from 8 leading to compound 9 in good yield. It 
should also be noticed that even without the presence of base, the lactam formation could still 
arise under acidic conditions (as from 13 to L3). Even if the intermediate 9 was not the product 
we expected, we engaged it in the next step. Finally, two 1,2,3-triazole ligands L3 and L4 were 
afforded by CuAAC reaction of 9 with freshly prepared 4-nitrophenyl azide and methyl 2-
azidoacetate, respectively.  
 
Compound L3 has also been prepared by an alternative route with first N-alkylation of 
2-hydroxyaniline, followed either by hydroxyl substitution then Click reaction or hydroxyl 
substitution after Click reaction to give compound 13, with an overall yield of 49% and 30%, 
respectively. We found that after CuAAC reaction, the hydroxyl substitution yield (48%) was 
much lower than that starting from the alkyne 10 (91%). It may be because of the steric effect 
of 1,4-disubstituted 1,2,3-triazole group that hindered the hydroxyl substitution reaction. When 
compound 13 was hydrolyzed by trifluoroacetic acid, we once again obtained the ring-closed 
ligand L3 (we did not prepare L4 by this way). 
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Scheme 3. Synthesis of O-extension, carboxylate coordinating arm. 
  
Conditions and reagents: (i) (Boc)2O, THF, rt, 16 h; (ii) methyl bromoacetate for 6 and tert-butyl bromoacetate 
for 7, K2CO3, CH3CN, reflux, 16 h; (iii) NaH, propargyl bromide, DMF, 0ºC to rt, 16 h; (iv) trifluoroacetic acid, 
CH2Cl2, 0ºC, 2 h; (v) 4-nitrophenyl azide for L3, 12 or 13 and methyl 2-azidoacetate for L4, Cu(OAc)2.H2O, 
NaAsc., t-BuOH/H2O, rt, 16 h; (vi) propargyl bromide, EtOH, rt, 4d; (vii) tert-butyl bromoacetate, K2CO3, KI, 
CH3CN, reflux, 16 h. 
 
Compounds L3 and L4 were stable in air and moisture at ambient temperature. Both 
ligands were fully characterized by NMR and HR-MS as well as X-Ray diffraction for L4. The 
white crystals of L4 were obtained by slow evaporation from its acetone/ethanol (v/v = 1:1) 
solution, as illustrated hereafter by the ORTEP diagram (Figure 1).   
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Figure 1. An ORTEP drawing of ligand L4 with its numbering scheme. Thermal ellipsoids are drawn at a 30% 
probability level. Selected data: Crystal system and space group: monoclinic, P21/n; Unit cell dimensions: a = 
13.6642(9) Å, b = 4.6031(3) Å, c = 22.6165(13) Å, D = 90°, E = 103.662(2)°, J = 90°; selected bond lengths and 
angles: C(23)-O(11) = 1.421(3) Å, C(23)-C(24) = 1.509(3) Å; C(24)-O(12) = 1.220(2) Å; C(24)-N(4) = 1.353(2) 
Å; O(12)-C(24)-N(4) = 123.40(19)°; O(12)-C(24)-C(23) = 120.63(18)°; O(11)-C(23)-C(24) = 114.01(17)°. 
 
Since our original idea was to obtain the tetradentate N2O2 ligand for Re(V) coordination 
chemistry, we still investigated the coordination chemistry of rhenium cores with the 
unexpected ring-closed ligands L3 and L4. Surprisingly, they exhibited interesting coordination 
fashion with the tricarbonyl rhenium(I) precursor. The results of this study will be presented in 
the second part of this chapter. 
 
1.2.1.3. N-extension 
As depicted in Scheme 4, L5 was prepared in five steps with a global yield of 33%. 
Starting from the N-alkylation of N-Boc glycine with propargyl bromide, compound 14 was 
obtained with a good yield of 85%. In order to activate the carboxyl group, N-
hydroxysuccinimide (NHS) was introduced with dicyclohexylcarbodiimide (DCC) as a 
coupling agent to afford a highly reactive succinate ester 15. Then the activated ester 15 was 
reacted with the amine of 2-aminophenol, using 4-dimethylaminopyridine (DMAP) as the 
nucleophilic catalyst to form the amide 16. We also tried to use an inorganic base of sodium 
hydrogen carbonate (NaHCO3) and conducted the reaction in distilled DMF.[12] However, some 
side reactions, such as the esterification of the hydroxyl group, were occurred, making the yield 
very low. 
After that, a CuAAC reaction of 16 with methyl 2-azidoacetate, followed by N-Boc 
deprotection in trifluoroacetic acid yielded L5 as brown liquid. 
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Scheme 4. Synthetic N-extension. 
 
 
Conditions and reagents:  (i) NaH, propargyl bromide, DMF, 0ºC to rt, overnight; (ii) NHS, DCC, DMAP, 
CH2Cl2, 0ºC to rt, overnight; (iii) 2-aminophenol, DMAP, CH3CN, 60ºC, overnight; (iv) methyl 2-azidoacetate, 
Cu(OAc)2.H2O, NaAsc, t-BuOH/H2O, rt, overnight; (v) trifluoroacetic acid, CH2Cl2, 0ºC, 2 h. 
 
1.2.2. Syntheses of rhenium complexes 
The syntheses of oxorhenium(V) complexes by the ligand-exchange reaction in warm 
methanol of a slight excess of trans-[ReOCl3(PPh3)2] with L1 or L2 (metal/ligand ratio of 1.3:1 
) in the presence of sodium acetate as a deprotonating agent and under argon atmosphere 
surprisingly failed, and only led to the recovery of the starting material. In contrast, using the 
same procedure, L5 gave the corresponding oxorhenium complex [ReO(L5)], in modest yield 
(Scheme 5a). Unfortunately, attempts to obtain single crystals of L5 and [ReO(L5)] were 
unsuccessful. 
 
In addition, two tricarbonylrhenium(I) complexes [Re(CO)3Cl(L)] (L = L1 or L2) were 
easily prepared from modest to good yields (60-80%) by the reaction of [Re(CO)5Cl] with L1 
or L2 at a 1.15:1 molar ratio in the presence of Hünig's base in refluxing methanol (Scheme 5b). 
The yellow single crystals of complex [Re(CO)3Cl(L2)] were afforded by slow evaporation of 
acetone/acetonitrile solution. 
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Scheme 5. Rhenium(V) (a) and rhenium(I) (b) complexation. 
 
 
 
 
The three rhenium complexes are soluble in dichloromethane, chloroform, DMSO and 
insoluble in water and methanol at room temperature. They are stable in solid state and found 
no obvious change in CDCl3 after one month. Besides, their stability is not affected by the 
presence of air or moisture. 
 
1.3. Tricarbonylrhenium(I) complexes: structural and computational studies 
Infrared spectra of both complexes [Re(CO)3Cl(L)] (L = L1 or L2) exhibited the 
characteristic Q(CO) stretching bands at ca. 2024, 1910 and 1885 cm-1, attributed to the fac-
[Re(CO)3]+ unit, as expected. More interestingly, ESI-Mass analysis in the positive mode 
generated the parent peak [M+H]+ and/or the [M-Cl]+ ion, indicating that L1 and L2 were 
coordinated to the metal center in an unexpected bidentate fashion.  
 
To elucidate this bidentate coordination mode, we proposed two patterns: coordination 
through the two nitrogen atoms of the triazole and the aromatic rings (Nta-Re-NHarom.), 
respectively or through the oxygen atom and the nitrogen of the pyridine arm (O-Re-Npyr.). The 
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experimental and theoretical 1H and 13C NMR studies were helped to better understand the 
coordination. For complex [Re(CO)3Cl(L1)], the peak of the triazole proton was significantly 
shifted downfield (ca. 0.5 ppm) as compared to the free ligand L1, as highlighted in Figure 2. 
The same trend could also be observed for the protons of the methylene group adjacent to the 
triazole unit. In addition, while no marked shift was found for the signals of the four aromatic 
protons, the shapes of the multiplets of ligand L1 and its corresponding rhenium complex were 
largely different. In contrast, the signals relative to the pyridine protons were not affected by 
the metal complexation. These observations indicated that pyridyl nitrogen was not 
coordinated, whereas the two nitrogen atoms of triazole and aminophenol, respectively were 
coordinated to rhenium center.[13]  
 
 
Figure 2. Partial 1H NMR spectra (300 MHz, CDCl3, 298 K) of compounds L1 (bottom) and [Re(CO)3Cl(L1)] 
(top). 
 
Similar results were also found in the 1H NMR of complex [Re(CO)3Cl(L2)]: the 
triazole proton was shifted downfield (ca. 0.2 ppm) and different shift and shapes of 
aminophenol protons as compared to free ligand L2 were observed. It seemed that 
[Re(CO)3Cl(L2)] should have the same bidentate coordination structure as [Re(CO)3Cl(L1)]. 
However, the pyridyl protons were also influenced by the complexation, no matter the chemical 
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shift or integration. Meanwhile, both methylene groups were influenced by the complexation 
and as a result, the protons were splitted into two separate parts (see Figure S2). In this case, 
we were not able to give an accurate structure of the complex from the two patterns above. So 
the theoretical 1H and 13C NMR shifts of two different coordination patterns of complex 
[Re(CO)3Cl(L2)] were calculated by Dr. Mariusz Wolff (Silesia University, Poland). Only the 
proton NMR shifts will be discussed below (note that proton numbering is associated to carbon 
numbering in Figure 3). 
 
As shown in Table 1, most of the calculated 1H NMR chemical shifts for (Nta-Re-
NHarom.) coordination mode were in good agreement with the experimental data. For instance, 
the experimental shift of triazole proton (H18, 8.20 ppm) was almost identical to the calculated 
Nta-Re-NHarom. coordination (8.16 ppm), yet for (O-Re-Npyr.) coordination , it was far different 
at 8.74 ppm. The two protons on pyridine methylene group (H9A, H9B) were calculated at 5.52 
and 5.28 ppm for (Nta-Re-NHarom.) coordination mode, which was similar to the experimental 
results (5.43 and 5.32 ppm). In contrast, the shifts for (O-Re-Npyr.) coordination fashion were 
calculated at 4.54 and 5.89 ppm, respectively. Of course, experimental and theoretical data were 
not always coincident with the (Nta-Re-NHarom.) coordination mode, some exceptions were also 
noticed. For example, the methylene protons (H16A, H16B) between triazole and NH group were 
calculated at 4.98, 3.93 ppm for (Nta-Re-NHarom.) and 4.60, 4.51 ppm for (O-Re-Npyr.) 
coordination mode, while the experimental shifts were found at 5.00, 4.41 ppm. 
 
With all the information, we thought the (Nta-Re-NHarom.) coordination mode should be 
more reasonable. And fortunately, the obtention of suitable crystals for X-ray diffraction in the 
case of [Re(CO)3Cl(L2)] confirmed that. 
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Table 1. Experimental and theoretical 1H NMR chemical shifts (ppm) of [Re(CO)3Cl(L2)] and 
two potential bidentate coordination modes in CDCl3. 
δ(1H)/ppm* [Re(CO)3Cl(L2)] 
(Nta-Re-NHarom.) 
coordination mode 
(O-Re-Npyr.) 
coordination mode 
exp. calc. calc. 
H(4) 8.60 8.82 8.81 
H(23) 8.50 8.72 8.60 
H(21) 8.48 8.66 8.57 
H(18) 8.20 8.16 8.74 
H(24) 8.05 8.49 8.42 
H(20) 8.03 7.69 7.96 
H(6) 7.78 7.82 7.97 
H(5) 7.26 7.44 7.50 
H(7) 7.25 8.20 7.20 
H(12) 7.23 7.48 6.89 
H(13) 7.18 7.21 7.50 
H(11) 7.10 7.06 7.32 
H(14) 7.04 6.98 6.93 
H(9A) 5.43 5.52 4.54 
H(9B) 5.32 5.28 5.89 
H(16B) 5.00 4.98 4.60 
H(16A) 4.41 3.93 4.51 
H(N2) / 6.02 5.02 
 
* Proton numbering is associated to carbon numbering in Figure 3. 
 
 
1.3.1. X-ray diffraction study  
As mentioned before, the single crystals of both ligands L1, L2 and complex 
[Re(CO)3Cl(L2)] were characterized by X-ray diffraction. The ORTEP diagrams of all these 
compounds were shown in Figure 3 (rhenium complex) and Figure S1 (ligands). The selected 
parameters of all the compounds are listed in Table S1.  
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Figure 3. The molecular structure of complex [Re(CO)3Cl(L2)]. Displacement ellipsoids are drawn at 50% 
probability. 
 
As shown in Figure 3, in bidentate complex [Re(CO)3Cl(L2)], the ligand L2 was 
coordinated to the rhenium by two nitrogen atoms: one of the secondary amine N(2)H and the 
other of triazole nitrogen N(3). The bite angle between Re(I) and the nitrogen atoms N(2)–
Re(1)–N(3) was 75.8(2)° (Table 2), as can be expected for the steric demand of the chelating 
group. The five-membered chelate ring, [ReN(2)C(16)C(17)N(3)], adopted an envelope 
conformation, with the C(16) atom deviating from the N(2)–Re–N(3)–C(17) plane by 0.304 Å. 
The Re(I) atom was six-coordinate with a distorted octahedral geometry and a facial 
configuration of three carbonyl groups. One carbonyl group C(1)-O(1) and one chlorine atom 
occupied the axial positions and coordinated to the Re(I) atom linearly with an angle equal to 
174.9(3)°. The other two carbonyl groups C(2)-O(2) and C(3)-O(3) along with the two 
coordinated nitrogen atoms N(2) and N(3) occupied the equatorial positions. The bond angles 
between adjacent axial CO carbon atoms were close to ideal value of 90°, indicating that CO 
ligands were linearly coordinated.  
 
The calculated octahedral distortion parameter (Σ)iii and the average trigonal distortion 
angle (Θ), which defined the degree of distortion from an ideal octahedron, are equal to 5.53° 
and 4.33°, respectively. The Re–carbonyl bond distances, Re(1)–C(1) = 1.916(10) Å, Re(1)–
 
iii The octahedral distortion parameter Σ (0° for an ideal octahedron Oh) is given by Σ = Σ12 |σ – 90°|, where σ are 
the 12 smallest L–Re–L cis angles. 
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C(2) = 1.910(9) Å and Re(1)–C(3) = 1.923(8) Å, as well as Re(1)–Cl(1) = 2.480(2) Å (Table 
2), were similar to those found for other Re–tricarbonyl complexes containing bidentate 
ligands.[13,[14] In addition, it could be noticed that the longest Re–C(3) bond distance was trans 
to the triazole ring. The Re–N(3)ta bond length (2.157(5) Å) was significantly shorter than the 
length of Re–N(2)amine bond (2.280(7) Å), suggesting a much stronger electron-donating ability 
of the sp2 hybridized triazole N(3) in comparison to the sp3 hybridized secondary amine N(2). 
 
Table 2. Experimental and theoretical selected bond lengths [Å] and angles [q] for 
[Re(CO)3Cl(L2)]. 
Bond 
lengths 
Experimental Optimized Bond angles 
Experimental Optimized 
Re(1)-C(1) 1.916(10) 1.913 C(1)-Re(1)-C(2) 88.4(4) 90.30 
Re(1)-C(2) 1.910(9) 1.918 C(1)-Re(1)-C(3) 88.0(3) 91.02 
Re(1)-C(3) 1.923(8) 1.932 C(2)-Re(1)-C(3) 88.4(4) 89.86 
Re(1)-N(2) 2.280(7) 2.333 C(1)-Re(1)-N(2) 96.4(3) 97.21 
Re(1)-N(3) 2.157(5) 2.184 C(2)-Re(1)-N(2) 172.2(3) 169.38 
Re(1)-Cl(1) 2.480(2) 2.550 C(3)-Re(1)-N(2) 97.9(3) 97.49 
C(1)-O(1) 1.130(10) 1.166 C(1)-Re(1)-N(3) 91.2(3) 92.20 
C(2)-O(2) 1.145(10) 1.160 C(2)-Re(1)-N(3) 98.0(3) 97.16 
C(3)-O(3) 1.145(8) 1.160 C(3)-Re(1)-N(3) 173.5(3) 172.26 
   N(2)-Re(1)-N(3) 75.8(2) 75.13 
   C(1)-Re(1)-Cl(1) 174.9(3) 174.65 
   C(2)-Re(1)-Cl(1) 96.6(3) 94.49 
   C(3)-Re(1)-Cl(1) 92.8(2) 91.39 
   N(2)-Re(1)-Cl(1) 78.53(18) 77.74 
   N(3)-Re(1)-Cl(1) 87.40(16) 84.84 
   Re(1)-C(1)-O(1) 178.1(9) 179.43 
   Re(1)-C(2)-O(2) 175.7(9) 178.29 
   Re(1)-C(3)-O(3) 177.3(8) 179.60 
 
Complex [Re(CO)3Cl(L2)] crystallized in the orthorhombic P212121 space group with 
four molecules per unit cell. The single crystal X-ray structure of [Re(CO)3Cl(L2)] revealed 
two types of hydrogen bonding interaction (Table 3):  
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- Strong intramolecular hydrogen bonding interaction of N—H•••O (2.647(8) Å) between 
the N(2)–H proton of the secondary amine and O(4) atom, as well as C—H•••O 
(2.737(10) Å) between the C(7)–H proton of the 2-pyridyl group and O(4) atom;  
- Weak intermolecular hydrogen bonding interaction C—H•••O of methylene C(9)-H 
donors or 2-aromatic C(11)–H donors to nitro oxygen O(5) acceptors (Figure 4) and 
methylene C(16)–H donors or 4-nitrophenyl C(24)–H donors to carbonyl O(1) 
acceptors (Figure S3A). The weakest interactions involved C—H•••Cl with Cl(1) atoms 
as acceptor groups and methylene C(16)–H donors or triazole C(18)–H donors (Figure 
S3B).  
 
Table 3. Selected hydrogen bonding distances (Å) and angles (°) of [Re(CO)3Cl(L2)]. 
D A D—H [Å] H•••A  [Å] D•••A [Å] D—H•••A [q] 
 
N(2)—H(2) •••O(4) 0.88(2) 2.08(7) 2.647(8) 121(6) 
C(7)—H(7) •••O(4) 0.95 2.41 2.737(10) 99.9 
C(9)—H(9B) •••O(5)_#1 0.99 2.55 3.200(11) 123.0 
C(11)—H(11) •••O(5)_#1 0.95 2.55 3.493(10) 170.2 
C(16)—H(16A) •••Cl(1)_#2 0.99 2.69 3.519(9) 141.1 
C(16)—H(16B) •••O(1)_#3 0.99 2.36 3.242(11) 148.0 
C(18)—H(18) •••Cl(1)_#2 0.95 2.71 3.333(9) 124.0 
C(24)—H(24) •••O(1)_#4 0.95 2.37 3.314(11) 172.6 
     
Symmetry codes: #1: 1/2–x, 1–y, –1/2+z; #2: 1–x, –1/2+y, 1/2–z; #3: 1+x, y, z; #4: –x, 1/2+y, 1/2–z 
 
 
 
 
Figure 4. Intermolecular hydrogen bonding C—H•••O interaction between methylene C(9)-H donors or  2-
aromatic C(11) –H donors and nitro oxygen O(5) acceptors of [Re(CO)3Cl(L2)]. 
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1.3.2. Optimized structural geometries 
To give a further investigation on the stability of potential isomers of tricarbonyl 
rhenium(I) complexes based on L2 (Figure 5), computational studies using the density 
functional theory (DFT) method were carried out. Five different isomers (bidentate, tridentate 
coordination, mer, fac isomers) were optimized with B3LYP/LanL2DZ.[15]  
 
The theoretical calculations resulted in good agreement with those obtained by X-ray 
crystallography for complex [Re(CO)3Cl(L2)], with the bond lengths differing at the most by 
0.05(7)Å, and angles by 3° (Tables S2-S3). As shown in Table 4, the most stable isomer 
corresponds to the complex [Re(CO)3Cl(L2)], in which the rhenium core is coordinated by the 
triazole ring and the amino group of the aromatic moiety (fac-Nta,N coordination). The isomer 
I, is found to be less stable than [Re(CO)3Cl(L2)] with a higher energy of 9.13 kcal mol−1. This 
energy difference at room temperature indicates that this isomer can only exist as a minor 
product. Benny and co-workers previously reported that in a multidentate ligand including 
pyridine and triazole rings, the pyridine favored coordination to the [M(CO)3]+ core (M = 99mTc 
or Re) over the triazole.[16] But in our case, the experimental and DFT findings showed that the 
binding strength of the (Nta-Re-NHarom.) is stronger than that of (Npyr-Re-O).  
Table 4. Energy in [Hartree] and [kcal mol–1] and dipole moment in [Debye] for the optimized 
geometries of complex [Re(CO)3Cl(L2)] and isomers I-III. 
Complex 
Optimized 
geometry 
[Hartree] 
Energy differences [kcal mol–1] Dipole Moment 
[Debye] a b 
[Re(CO)3Cl(L2)] -1799.2545865 0 – 8.90 
I -1799.2511105 9.13 – 9.84 
II-a -1784.1666597 39613.36 3.69 10.67 
III-a -1784.1680635 39609.67 0 8.51 
II-b -1784.1378808 39688.91 79.25 16.22 
III-b -1784.1298483 39710.00 100.33 10.78 
a Relative energy differences were calculated compared to [Re(CO)3Cl(L2)]  
b Relative energy differences were calculated compared to III-a 
 
Then, the significant energy difference between bidentate and tridentate isomers verified 
that the latter coordination mode could not be considered in our ligands L1 and L2. In addition, 
DFT calculations showed mer-tricarbonylrhenium(I) complexes (isomers II-b, III-b) were less 
stable than analogous fac-ones (isomers II-a, III-a), as expected. 
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Bidendate coordinating mode 
 
 
 
[Re(CO)3Cl(L2)] (fac-Nta,N coordination) Isomer I (fac-Npyr,O coordination) 
 
 
Tridendate coordinating mode 
 
 
 
Isomer II-a (fac-Npyr,N,O coordination) Isomer II-b (mer-Npyr,N,O coordination) 
 
 
Isomer III-a (fac-Nta,N,O coordination) Isomer III-b (mer-Nta,N,O coordination) 
 
Figure 5. Optimized geometries of rhenium complexes based on L2 (bidentate, tridentate coordination, mer, fac 
isomers) using B3LYP/LanL2DZ. 
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1.4. Oxorhenium(V) complex: structural characterization and first 99mTc-radiolabeling  
1.4.1. Structural characterization 
A proton NMR comparison between ligand L5 and corresponding complex [ReO(L5)] 
was carried out in order to see the chemical shift after complexation. As shown in Figure 6, the 
methylene group (CH2CON) in the free ligand L5 appeared as a unique singlet at 3.41 ppm. 
After complexation with [ReOCl3(PPh3)2], the singlet peak splitted into two doublets forming 
the pattern of two AB-spin systems at 4.77 and 5.17 ppm with a geminal coupling constant of 
18.0 Hz. The same trend was observed for the two protons next to the triazole ring. In complex 
[ReO(L5)], they were non-equivalent and splitted into two multiplets at 4.03 and 5.22 ppm, 
respectively. Furthermore, upon coordination, the signal of the triazole proton was slightly 
shifted downfield by 0.23 ppm.  
 
Figure 6. Partial 1H NMR spectra (500 MHz, CDCl3, 298 K) of compounds L5 (bottom) and [ReO(L5)] (top). 
 
In carbon NMR (data was collected in the experimental section), the most distinguishing 
feature was the change in the chemical shift of the carbon atoms of the amide group (188.2 ppm 
for [ReO(L5)] vs. 171.2 ppm for L5). The significant downfield shift stemmed from the fact 
that, upon coordination to rhenium the electron density on the nitrogen of the amide bond was 
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less available to participate in resonance delocalization with the carbonyl group. These NMR 
features were consistent with those reported for structurally related oxorhenium complexes.[17] 
In addition, electrospray ionization mass spectrometry of the complex presented two prominent 
ion peaks with an isotope distribution pattern corresponding to the monomeric neutral complex. 
Furthermore, the IR spectrum showed an absorption peak at 959 cm-1, indicating the presence 
of a rhenium-oxo bond, as expected.  
 
1.4.2. Preliminary 99mTc-radiolabeling 
The main objective of this first part was (i) to extend our family of semi-rigid click 
compounds, (ii) to investigate their radiolabeling with technetium-99m or rhenium-188 cores 
and (iii) to assess their potential as imaging (99mTc) or therapeutic (188Re) agents. Given our 
results for ligands L1 and L2 and keeping in mind that a Tc- or Re-tricarbonyl complex with a 
tridentate ligand is less prone to undergo undesired reactions like cross-metalation (due to its 
coordinative saturation) and generally more stable than that based on a bidentate ligand,[18] we 
decided to discard these ligands and we focused the radiolabeling study only with tetradentate 
ligand L5. Additionally, considering that perrhenate anion 188ReO4- is more difficult to reduce 
than pertechnetate anion 99mTcO4- combined with the high tendency of produced oxorhenium 
core [188ReO]3+ to be reoxidized, this preliminary radiochemistry study was carried out with the 
analogous technetium-99m core, [99mTcO]3+ and was performed by Romain Eychenne (PhD 
student) and Nicolas Lepareur (Research Engineer) in the Radiopharmacy/Nuclear Medicine 
Department of the Eugène Marquis Centre (Rennes, France). 
In 2012, Dugave and co-workers[19] developed a tetradentate ligand including a triazole 
ring in the chelating cavity. The structure of this compound is similar to our ligand L5, so we 
decided to optimize their radiolabeling conditions first. Thus, the strict follow-up of this 
protocol allowed us to get the expected 99mTcO-radiocomplex with a moderate yield of 70%. 
Different trials in order to optimize the radiolabeling conditions, for instance, a higher 
temperature (50°C), a lower concentration (1 or 2 mg/mL) of stannous chloride or a smaller 
quantity of NaOH (0.1 M, < 140 µL) showed a negative impact on the radiochemical yield. 
Finally, the best yield was obtained with a higher concentration of stannous chloride (3 mg/mL), 
leading to the expected 99mTc-complex [99mTcO(L5)] in 90% yield (Figure 7). 
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Figure 7. Radiochromatogram of 99mTc-complex [99mTcO(L5)]. 
 
1.5. Conclusion 
In summary, we synthesized a new series of potentially tetradentate semi-rigid ligands 
containing an aromatic ring and a triazole unit, by two distinct synthetic routes. The first route 
(O-extension) led to the formation of two tetradentate ligands L1 and L2 and two compounds 
L3 and L4 which result from an unexpected side-reaction. The coordination behaviors of L1 and 
L2 ligands were investigated and their corresponding fac-rhenium(I) complexes were 
unambiguously characterized by spectroscopic analyses as well as single crystal X-ray 
diffraction for [Re(CO)3Cl(L2)]. L1 and L2 exhibited an unexpected bidentate coordination 
mode through the two nitrogen atoms of the aniline and triazole ring, respectively. 
[Re(CO)3Cl(L)] (L = L1 or L2) represented the most stable structural isomer as confirmed by 
DFT studies. Using a similar synthetic strategy, it was not possible to develop tetradentate 
ligands bearing a carboxylate coordinating arm. The ring closure reaction led to lactame 
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derivatives L3 or L4. Their unexpected coordination with pentacarbonylchlororhenium(I) will 
be discussed in the second part. 
 
Through the N-extension, a mononuclear complex [ReO(L5)] was isolated and fully 
characterized after reaction of the Re(V) precursor [ReOCl3(PPh3)2] with L5. The high affinity 
of the N3O set toward cold [ReVO]3+ and [99mTcVO]3+ make this ligand a promising chelator for 
nuclear imaging applications. Of course this preliminary radiolabelling study has to be 
confirmed and extended with the [188ReVO]3+ core. Moreover, in vitro stability under 
physiological conditions in human plasma and cysteine exchange experiments have to be 
investigated with both radioactive technetium-99m and rhenium-188 complexes in order to 
assess more precisely their potential as imaging and therapeutic probes, respectively. 
 
This work will be published soon in European Journal of Inorganic Chemistry (J.-H. 
Wang et al., Eur. J. Inorg. Chem., accepted). 
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2. Dirhenium(I) hexacarbonyl complexes bridged by a 1,2,3-triazole ligand: 
Synthesis, structural and spectroscopic characterization 
2.1. Introduction 
Tricarbonyl rhenium(I) diimine complexes, like other d6 transition metal complexes, 
exhibit low-lying metal-to-ligand charge transfer (MLCT) excited states, intense luminescence 
in the visible region of the spectrum and moderately long radiative luminescence lifetime. Due 
to these properties, they have been found promising applications such as solar cells,[20] organic 
light-emitting devices (OLEDs),[21] sensors and imaging probes.[22,23] Nevertheless, most of the 
neutral species have very low photoluminescence quantum yields (Φ, usually do not exceed 
0.05)[24] compared to those of cationic species (up to 0.83).[25] As a consequence, particular 
attention was paid on developing some polynuclear, especially neutral dirhenium species to 
improve the emissive performance. The strategy was to connect two heavy metal ions by one 
bridging ligand, so as to enhance the metal orbital character of the orbitals involved in the 
emissive process.[26]  
Using the fac-[Re(CO)3]+ core, two kinds of dinuclear species have been designed and 
successfully synthesized. In the former one, the ancillary ligand was terminally coordinated and 
the metal centers were connected through a bis(chelating) ligand (such as a 2,2’-bipyrimidine 
or oxamide ligands).[ 27 , 28 ] In the latter type, the bidendate ligand such as pyridazine,[ 29 ] 
tetrazole[30] or 1,3,4-oxadiazole[31] was bound to a dinuclear [Re2(CO)6(μ-X)2] core containing 
anionic ancillary bridging ligands (X– = Cl–, Br–, I–, H–, OH–, OCH3–, OC6H5–, SC6H5–), as 
highlighted in Figure 8. The photophysical properties depend on the nature of the starting 
bridging ligand. While dinuclear complexes based on pyridazine (or 1,2-diazine) scaffold 
exhibited strong luminescent properties, dirhenium complexes based on tetrazole and 
disubstituted 1,3,4-oxadiazoles  showed a weak emission.  
 
Figure 8. Different examples of dinuclear rhenium(I) fragments containing bridging ligands: (a) pyridazine (1,2-
diazine), (b) tetrazole, (c) 1,3,4-oxadiazole. 
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Curiously, no work using other five-membered aromatic heterocycles like triazoles as 
bridging ligands in order to develop dirhenium(I) hexacarbonyl complexes of general formula 
[Re2(CO)6(μ-X)2(μ-ta)] (ta = triazole, X = anionic ancillary ligands) was published. 
Nevertheless, A. Raimondi, a PhD student from G. D’Alfonso group, investigated dinuclear 
rhenium(I) complexes containing 1,2,4-triazoles substituted in position 4 with aryl or alkyl 
groups and an alkyl tetrazole ligand.[32] While 3 dirhenium complexes of general formula 
[Re2(CO)6(μ-Cl)2(μ-1,2,4-triazole)] were prepared, characterized and their photo-physical 
properties investigated, neither corresponding RX structures nor publications relative to this 
study were found in the literature. 
 
This lack of investigation is surprising as it is well known the propensity of triazole rings 
to act as bridging ligands between two metal centers, leading to the formation of dinuclear 
complexes of type [M-N-N-M’]. Several reviews from the literature showed that 1,2,4-
triazoles[33] and to a lesser extent 1,2,3-triazoles[34] formed bridged structures with different 
metal ions such as zinc(II), cadmium(II), copper(I/II/III) or silver(I). Due to their easy synthetic 
way, in particular via the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC reaction),[35] 
their similarity to tetrazole and their excellent ability to form stable complexes with 
tricarbonylrhenium(I) cores, we anticipated that 1,4-substituted 1,2,3-triazoles should be very 
interesting frameworks for the preparation of new dirhenium complexes containing a bridging 
1,2,3-triazole ring. Consequently, the aim of this work was to obtain a dinuclear rhenium(I) 
complex containing a bridging 1,2,3-triazole ring and to investigate also its photophysical 
properties. 
 
Using a synthetic Click-to-Chelate approach, several 1,4-disubstituted 1,2,3-triazole 
derivatives as chelating systems for the fac-[M(CO)3]+ core (M = 99mTc, Re) which were proved 
to be promising tools in nuclear imaging or/and as optical markers were previously reported in 
our group.[9,36] In such chelating systems and as shown in the first part of this chapter, the 
triazole ring acts as a monodentate ligand and possesses a coordinating arm in position 4. 
Therefore, as a preliminary investigation into the area of dinuclear rhenium complexes based 
on bridging 1,2,3-triazole ligands we attempted to prepare such compounds using a 1,4-
disubstituted 1,2,3-triazole moiety bearing non-chelating substituents in 1 and/or 4 positions. 
Then, we reported herein the synthesis of original dirhenium(I) hexacarbonyl complexes 
bridged by a 1,2,3-triazole ligand and full structural characterization including X-ray structure 
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of complex [Re2(CO)6(μ-OEt)2(μ-L4)]. Its electronic transitions and the nature of the frontier 
orbitals were also theoretically studied by means of density functional (DFT) and time 
dependent density functional (TDFT) calculations. 
 
2.2. Synthesis of the dirhenium(I) hexacarbonyl complexes 
As we mentioned in the introduction, and keeping in mind previous works developed 
with other five-membered or six-membered aromatic heterocycles, we decided to use a 1,4-
disubstituted 1,2,3-triazole ring with non-chelating substituents in 1 and/or 4 positions. 
Consequently, we used the former synthesized ligand L4, a benzoxazine derivative which 
resulted from an unexpected ring-closed reaction (Cf. part 1),  
 
The complexation was performed with the commercially available pentacarbonyl 
precursor [Re(CO)5Cl]. Generally, the methods used for the synthesis of dinuclear rhenium(I) 
complexes of general formula [Re2(CO)6(P-X)2(P-N-N ligand)] depend on the nature of X. For 
halide derivatives, dinuclear rhenium complexes were obtained in good yields by treating the 
[Re(CO)5X] (X = Br, Cl) precursor with 0.5 equiv. of the corresponding N-N ligand in refluxing 
toluene. In the case of ROH or RSH ligands, rhenium complexes were prepared from 
[Re(CO)5OTf] in the presence of a base.[24] Combining these conditions, i.e. reaction of 
[Re(CO)5Cl] with L4 in a 2:1 molar ratio in the presence of Hünig's base in refluxing methanol, 
an original mixed methoxy and chloride complex [Re2(CO)6(μ-Cl)(μ-OMe)(μ-L4)] was 
obtained, according to eq. 1 and Scheme 6. The complex was isolated in a modest yield (60%), 
as a white microcrystalline solid. The presence of one bridging methoxy group was confirmed 
by 1H NMR. It is also worth mentioning that this dinuclear species was also observed when L4 
was treated with a slight excess of [Re(CO)5Cl] (1.1 equivalent). Recrystallization of complex 
[Re2(CO)6(μ-Cl)(μ-OMe)(μ-L4)] from an acetone/ethanol mixture (1:1 volume ratio) gave 
complex [Re2(CO)6(μ-OEt)2(μ-L4)], according to eq. 2 and Scheme 6. 
 
2[Re(CO)5Cl] + L4 + B + MeOH→ [Re2(CO)6(μ-Cl)(μ-OMe)(μ-L4)] + 4CO + BH+Cl-           (eq. 1) 
[Re2(CO)6(μ-Cl)(μ-OMe)(μ-L4)] + 2EtOH→ [Re2(CO)6(μ-OEt)2(μ-L4)] + HCl + CH3OH      (eq. 2)  
 
Both complexes [Re2(CO)6(μ-Cl)(μ-OMe)(μ-L4)] and [Re2(CO)6(μ-OEt)2(μ-L4)] 
were quite air-stable in the solid states at ambient temperature and were non-hygroscopic in 
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nature. They were soluble in acetone, CHCl3, CH2Cl2 and methanol giving colorless solutions 
and they were sparingly soluble in pentane. 
 
Scheme 6. Formation of dinuclear rhenium species containing a bridging 1,2,3-triazole ring. 
 
 
Conditions and reagents: (i) [Re(CO)5Cl], DIPEA, MeOH, 65°C, 16 h., (ii) crystallization in EtOH/CH3CN 
mixture, (iii) [Re(CO)5Cl], DIPEA, toluene, 65°C, 16 h. 
 
2.3. Structural characterization and computational studies 
For convenience, we will use these acronyms for our complexes in the following 
parts: [Re2(Cl)(OMe)] for [Re2(CO)6(μ-Cl)(μ-OMe)(μ-L4)], [Re2(OEt)2] for [Re2(CO)6(μ-
OEt)2(μ-L4)] and [Re2(Cl)2] for [Re2(CO)6(μ-Cl)2(μ-L4)]. 
 
2.3.1. Spectroscopic analysis 
Ligand L4 and both complexes [Re2(Cl)(OMe)] and [Re2(OEt)2] were characterized by 
means of IR, NMR and MS spectroscopy as well as crystallographic characterization for the 
Chapter II 
 
 
85 
 
latter complex (as a reminder, the RX structure of ligand L4 was presented in the first part of 
this chapter in Figure 1).  
 
Specifically, the IR spectra of both complexes showed bands in the region between 2026 
and 1866 cm–1 corresponding to the facial orientation of the carbonyl groups. Five or six bands 
are expected but some of them were partially overlapped, giving a four band pattern. These 
values were similar with reported dirhenium complexes.[29-31] The strong stretching vibrations 
of the two carbonyl groups of COOMe and benzoxazine ring were close in the ligand and the 
complexes (1752 and 1670 cm–1 for L4 vs. 1760 and 1686 cm-1 for [Re2(OEt)2]), highlighting 
that carbonyl groups did not participate in the complexation of rhenium cores. 
 
In NMR analysis, the peaks related to the ligand moiety in both complexes were shifted 
slightly downfield compared to those of free ligand L4. The discrepancy between two 
complexes was clearly found in 1H NMR comparison (Figure 9). For complex [Re2(Cl)(OMe)], 
a single peak at 4.17 ppm which integrated for three hydrogen atoms, was assigned to the 
methoxo group bridged to the two rhenium cores, while for complex [Re2(OEt)2], we observed 
a triplet at 1.16 ppm and a quartet at 4.18 ppm which integrated for 6 and 4 protons respectively, 
belonged to two bridging ethoxo groups. The most significant shifts of the carbon spectra were 
observed on the triazole ring, the peaks corresponding to C(14) and C(15) being shifted from 
124.9 and 143.7 ppm in ligand L4 to 127.8 and 148.6 ppm in complex [Re2(OEt)2], 
respectively. (See Figure 10 for the numbering of the carbons and Table S4 for theoretical and 
experimental NMR values). Besides, characteristic signals of six carbonyl ligands were 
adverted between 195.9 and 197.0 ppm. This is in agreement with the X-Ray structure of 
complex [Re2(OEt)2] (vide infra). 
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Figure 9. Partial 1H NMR spectra (300 MHz, CDCl3, 298 K) of compounds L4 (bottom), [Re2(Cl)(OMe)] 
(middle) and [Re2(OEt)2] (top). 
 
In mass spectra (electrospray ionization in positive mode), the peak found at m/z = 857 
for [Re2(OEt)2] suggested the loss of an ethoxy and an ethyl groups. The same fragmentation 
peak with identical isotopic pattern was also observed for [Re2(Cl)(OMe)], indicating the loss 
of a methyl group and a chlorine atom ([M-Cl-CH3+H]+).  
 
At least, the presence of the chlorine ion in complex [Re2(Cl)(OMe)] has been indirectly 
confirmed by an additional experiment in which ligand L4 and [Re(CO)5Cl] in a 1:2 molar ratio 
were refluxed in toluene in the presence of diisopropylethylamine. The proton NMR spectrum 
is consistent with the formation of the dihalide derivatives of general formula [Re2(CO)6(μ-
Cl)2(μ-L4)] (acronym [Re2(Cl)2]) and no methoxo group were observed (Scheme 6 and eq. 3). 
In the mass spectrum, the main fragmentation peak corresponds to the loss of one chlorine ([M-
Cl]+).  
2[Re(CO)5Cl] + L4 → [Re2(CO)6(μ-Cl)2(μ-L4)] + 4CO        (eq. 3) 
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2.3.2. X-ray diffraction  
Complex [Re2(OEt)2] was crystallized in a monoclinic system, and its crystal structures 
was solved in P21/c space groups (Table 5). Its molecular structure (ORTEP view) is shown in 
Figure 10, and selected bond lengths and angles are listed in Tables S5-S6. 
 
 
Figure 10. ORTEP diagram of complex [Re2(OEt)2]. (Molecular A) Displacement ellipsoids are both drawn at 
30% probability. 
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Table 5. Crystal data and structure refinement for complex [Re2(OEt)2]. 
 Complex [Re2(OEt)2] 
Empirical formula C24H24N4O12Re2 
Formula weight 932.89 
Temperature [K] 193(2) 
Wavelength [Å] 0.71073 
Crystal system monoclinic 
Space group  P21/c 
Unit cell dimensions [Å,q] a = 10.3605(4) 
 b = 22.7419(10) 
 c = 24.3461(11) 
 β = 90.630(2) 
Volume [Å3] 5736.0(4) 
Z 8 
Density (calculated) [Mg/m3] 2.160 
Absorption coefficient [mm-1] 8.502 
F(000) 3536 
Crystal size [mm] 0.40×0.02×0.02 
T range for data collection [q] 2.72 to 29.14 
Index ranges -14 ≤ h ≤ 14 
-31 ≤ k ≤ 31 
-33 ≤ l ≤ 33 
Reflections collected 192866 
Independent reflections 15405 (Rint = 0.0707) 
Completeness to 2theta (2theta =29.14q) 99.7% 
Min. and max. transm. 0.7458 and 0.5423 
Data / restraints / parameters 15405 / 47 / 782 
Goodness-of-fit on F2 1.060 
Final R indices [I>2V(I)] R1 = 0.0267 
wR2 = 0.0373 
R indices (all data) R1 = 0.0507 
wR2 = 0.0419 
Largest diff. peak and hole [e Å-3] 1.059 and -0.976 
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The crystal structure of complex [Re2(OEt)2] consists of two independent neutral 
molecules (A and B) with very similar but not identical geometries in the asymmetric unit of 
the unit cell (Z = 8). In the dinuclear unit, the two rhenium centers are bridged by two ethoxo 
ligands and one triazole ligand via the two nitrogen atoms. The triazole ligand coordinates in 
an exo-bidentate form. The N(1)–N(2) bond is almost coplanar with the two Re atoms [torsion 
angle: Re(1)–N(1)–N(2)–Re(2) = 0.26° (molecule A); Re(3)–N(5)–N(6)–Re(4) = 10.54° 
(molecule B)]. Each rhenium atom is in a six-coordinate pseudo-octahedral coordination 
environment. The octahedral distortion parameter Σ is 86.92° for Re(1), 94.25° for Re(2), 
99.78° for Re(3) and 101.61° for Re(4), indicating a significant deformation from octahedral 
geometry.[37]  
 
The Re–Oethoxo bridging distances (from 2.111 to 2.133 Å in molecule A and from 2.108 
to 2.134 Å in molecule B) and the Re–Oethoxo–Re′ bite angles (103.51° and 104.33° in molecule 
A, 103.50° and 104.75° in molecule B, respectively) differ slightly and indicate that Re–Oethoxo–
Re′ bridges are asymmetric. Their values are close to those observed for other dinuclear Re(I) 
complexes with bridging alkoxides.[38,39] As expected, the Re–O bridging distances of our 
complex [Re2(OEt)2] are shorter than those for related dirhenium complexes based on tetrazole 
(X = Br, Re–Br, a 2.64 Å),[30] disubstituted 1,3,4-oxadiazole or 1,2-diazine (X = Cl, Re–Cl, a 
2.49 Å),[29,31] which can be explained by the stronger electronegativity of O than Cl and Br. 
Besides, the Re–Oethoxo–Re′ bite angles here are also larger than the reported Re-X-Re 
dirhenium complexes (Re–Cl–Re, a 91° and Re–Br–Re, a 82°). This steric bite angle effect is 
mainly caused by the bulky group (OEt) compared to the halide. 
 
The combination of all bridges gives rise to a Re•••Re′ nonbonding distance of 3.344(1) 
Å (molecule A) and 3.346(1) Å (molecule B), which is in agreement with its (formal) Re-Re 
bond order 0 and comparable to the previously reported alkoxo-bridged dinuclear rhenium(I) 
complexes. In turn, this Re•••Re′ value is in the lower range than those found for analogous 
complexes [Re2(CO)6(P-X)2(P-N-N ligand)] (X = Br, P-N-N ligand = oxadiazole; 3.58 Å; X = 
SPh, P-N-N ligand = pyridazine; 3.57 Å; X = Br, P-N-N ligand =  tetrazole; 3.70 Å).[24,30,31] 
 
At least, The average Re–N bond length [2.200(3) Å (in both molecules A and B)] is 
common for classical mononuclear Re(I) complexes with triazole ligands[4c,40] and the Re–C 
distances are in the usual range found in Re(I) complexes with fac-[Re(CO)3]+ core.[7,41]  
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2.3.3. Computational studies 
2.3.3.1. The ground-state and absorption properties of L4 and [Re2(OEt)2] 
The ground-state (S0) structures of ligand L4 and complex [Re2(OEt)2] were fully 
optimized in methanol by the DFT at the B3LYP by Dr. Mariusz Wolff (Silesia University, 
Poland). The optimized bond lengths and bond angles of ligand L4 and complex [Re2(OEt)2] 
are found to be in good agreement with the corresponding experimental data (see Tables S5-S6 
for the complex).[ 42 ] Some negligible discrepancies observed between the calculated and 
experimental results may be due to the contribution of the intramolecular and intermolecular 
forces or crystal packing effects, which are not well described by DFT.[43] 
 
The corresponding frontier molecular orbital (FMOs) compositions and energy levels 
were determined for ligand L4 and complex [Re2(OEt)2] are given in Tables S7 and S8, 
respectively. The isodensity plots of the frontier molecular orbitals involved in the electronic 
transitions for complex [Re2(OEt)2] and ligand L4 are shown in Figure 11 and Figure S4, 
respectively.  
 
For complex [Re2(OEt)2], the HOMO, HOMO–1, HOMO–3 and HOMO–4 are 
composed of rhenium d-orbitals and the π-type orbitals of the carbonyl ligands. Additionally, 
the HOMO and HOMO–1 have almost equal contribution from the π-type orbitals of the ethoxo 
ligands. The HOMO–2 is mainly located (more than 90%) on benzoxazine unit of the ligand 
L4. In turn, the lowest unoccupied molecular orbital (LUMO) is concentrated on triazolyl ring. 
The LUMO+1, LUMO+2 and LUMO+3 are mainly composed of π*(CO) with a small 
contribution from Re atom, whereas the LUMO+4 corresponds to π*-type orbitals localized 
(91%) on benzoxazine unit. Molecular orbital analysis of ligand L4 showed that the HOMO and 
HOMO–1 are localized on benzoxazine unit, whereas HOMO–2 is centered on triazolyl ring 
and benzoxazine unit. The LUMO and LUMO+1 are composed of π*-type orbitals of 
benzoxazine unit and triazolyl ring. 
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HOMO–3 (–6.69 eV) HOMO–2 (–6.32 eV) HOMO–1 (–6.26 eV) 
  
HOMO (–6.05 eV) LUMO (–2.13 eV) 
   
LUMO+1 (–1.38 eV) LUMO+2 (–1.15 eV) LUMO+3 (–1.05 eV) 
Figure 11. Isodensity plots of the frontier molecular orbitals of complex [Re2(OEt)2]. 
 
The electronic absorption spectra of both compounds (ligand L4 and complex 
[Re2(OEt)2]) were simulated by TD-DFT method and they match nicely with the experimental 
absorption spectra. The calculated absorption energies associated with their oscillator strengths 
and contributions, and their assignments, as well as the experimental data, are given in Table 6. 
The simulated UV-Vis absorption spectra, presented as oscillator strength against wavelength, 
and the experimental one for both compounds are shown in Figure S5. The absorption bands of 
ligand L4 are assigned to π→π* transitions. For complex [Re2(OEt)2], the lowest-energy 
absorption band at 338 nm (29586 cm–1) originates from the transitions between the two highest 
occupied molecular orbitals HOMO and HOMO–1 and the lowest unoccupied molecular orbital 
LUMO. As shown in Figure 11, the HOMO and HOMO–1 are mainly composed of rhenium d-
orbitals and the π-type orbitals of the carbonyl and ethoxy ligands, whereas LUMO is mainly 
centred on the triazolyl ring of the ligand L4. Accordingly, these transitions can be described as 
{[d(Re)+π(CO)+π(OEt)]→[π*(P2)]} with MLCT/LLCT characters. The next two bands with 
Chapter II 
 
 
92 
 
higher energy absorptions appears at 301 nm (33223 cm–1) and 281 nm (35587 cm–1) and 
possesses MLCT/LLCT/ILCT character. The transition of HOMO–2→LUMO+4 is responsible 
for the band at 261 nm (38314 cm–1), which shows the ILCT character. 
 
Table 6. The main electronic transitions for ligand L4 and complex [Re2(OEt)2] (in methanol), 
calculated with TDDFT method at the B3LYP/LanL2DZ level. 
Electronic 
transition 
Contribution Assignment 
E  
(eV) 
λcalc 
(nm) 
f 
λexp 
(nm) 
ligand L4  
S0→S1 H→L π(P1)→π*(P1)+π*(P2) 4.62 268.58 0.1115 284 
S0→S5 H–2→L π(P2)+π(P1)→π*(P1)+π*(P2) 5.28 234.91 0.0424 253 
S0→S7 H–1→L π(P1)→π*(P1)+π*(P2) 5.67 218.75 0.1390 210 
complex [Re2(OEt)2] 
S0→S1 H→L d(Re)+π(CO)+π(OEt)→π*(P2) MLCT/LLCT 3.08 401.97 0.0027  
S0→S2 H–1→L d(Re)+π(CO)+π(OEt)→π*(P2) MLCT/LLCT 3.37 367.49 0.0480 338 
S0→S11 H–4→L d(Re)+π(CO)→π*(P2) MLCT/LLCT 4.11 301.36 0.0716 301 
 H–1→L+2 d(Re)+π(CO)+π(OEt)→p(Re)
+π*(CO) 
MLCT/LLCT/IL
CT 
    
S0→S12 H→L+3 d(Re)+π(CO)+π(OEt)→p(Re)
+π*(CO) 
MLCT/LLCT/IL
CT 
4.13 300.21 0.0696 281 
 H–4→L d(Re)+π(CO)→π*(P2) MLCT/LLCT     
S0→S20 H–2→L+4 π(P1)→π*(P1) ILCT 4.63 267.77 0.0687 261 
P1: benzoxazine unit, P2: triazolyl ring, P3: –CH2COOMe arm 
MLCT: metal-to-ligand charge transfer; LMCT: ligand-to-metal charge transfer; LLCT: ligand-to-ligand charge 
transfer; ILCT: intraligand charge transfer 
 
2.3.3.2. Lowest lying triplet excited state and emission properties of [Re2(OEt)2] 
The lowest lying triplet excited state (3T1) structure of complex [Re2(OEt)2] was fully 
optimized in methanol by the DFT at the B3LYP level (Table 7). The structure parameters for 
excited-state have small differences from those of the ground state. In the lowest triplet excited 
state (3T1), the Re–N and Re–O bond distances are shortened, while the Re–CO bonds are 
elongated in comparison with the optimized geometry of the ground state S0. The bond 
shortening and elongation is due to electron density changes in the excited states. 
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Table 7. Calculated emission energies of 3T1 and their transition nature for [Re2(OEt)2] (in 
methanol). 
DFT TD-DFT 
ΔET1–S0 
(eV / nm) Character 
Major contribution 
(Ci coefficient) 
E 
(eV) λcal (nm) Character 
2.05 / 606.04 3MLCT/3LLCT/3ILCT H → L (0.703) 1.87 661.68 3MLCT/3LLCT/3ILCT 
ΔET1–S0 is the energy difference between the ground singlet and triplet states 
 
The phosphorescence emission energy for the lowest lying triplet excited state was 
calculated in methanol employing the ΔSCF (self-consistent field) approach, i.e. considering 
the vertical energy gap between the ground singlet and the triplet states in the triplet state 
optimized geometry. The calculated emission wavelength is equal to 606.04 nm for the triplet 
state. The spin density in the lowest triplet excited state of complex [Re2(OEt)2] was calculated 
in methanol. The spin density distribution shows well the sharing of the two unpaired electrons 
among the metal and O and the triazolyl ring (π* orbital), with smaller contributions from the 
CO group, and confirms the 3MLCT/3LLCT character of the optimized triplet state (Figure 12).  
 
Figure 12. Spin-density distribution in the lowest triplet excited state of complex [Re2(OEt)2] (in MeOH). 
 
The emission spectrum of complex [Re2(OEt)2] was also calculated in methanol by the 
TD-DFT method on the basis of the triplet excited state optimized geometry. According to these 
calculations, the emission at 661.68 nm originates from 3{d(Re)+π(CO)+p(O)→π*(P2)} excited 
state with 3MLCT/3LLCT character. In comparison to the experimental values, the 
phosphorescence emission energies calculated by the DFT method (ΔET1–S0) usually lie closer 
than that computed by the TD-DFT method. At least, the photoluminescent behaviors of ligand 
L4 and complexes [Re2(Cl)(OMe)]/[Re2(OEt)2] were investigated in methanol solution at 
room temperature (Table 8).  
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Table 8. Photophysical properties of ligand L4 and complexes [Re2(Cl)(OMe)]/[Re2(OEt)2] in 
methanol at 298 K. 
Compound λabs (nm) λex (nm) λem (nm) 
L4 253/284 280 296 
 [Re2(Cl)(OMe)] 261/279 280 
310 
297 
382 
 [Re2(OEt)2] 261/281/301/338 280 
310 
297 
381 
 
For both complexes, a very weak emission band was observed at 382 nm upon 
irradiation at 310 nm. By shifting the excitation wavelength to 280 nm, complexes 
[Re2(Cl)(OMe)]/[Re2(OEt)2] exhibited an emission band at 297 nm with an identical shape to 
that of the free ligand L4. According to the literature, this first result could suggest that our 
complexes [Re2(Cl)(OMe)]/[Re2(OEt)2] were unstable in solution under UV irradiation and 
dissociated to the ligand.[31] In order to rule on this point, a series of emission spectra were 
acquired upon successive excitations at 280 nm, starting from a very fresh solution of the 
complex [Re2(Cl)(OMe)] or [Re2(OEt)2] (Figure 13).  
 
 
Figure 13. Emission spectra (CH3OH, 298 K) of complex [Re2(OEt)2] upon excitation at 280 nm. 
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Surprisingly, no obvious emission change was found in 2 h, and their absorption spectra 
stayed the same as before irradiation. This proved that this complex was stable in solution under 
UV irradiation, and exhibited the same emission as the free ligand when excited at 280 nm. 
Additionally, the HPLC analysis also confirmed complexes [Re2(Cl)(OMe)]/[Re2(OEt)2] were 
stable after irradiation with high purity and no free ligand was detected (Figure 14). Further 
studies will be required to clarify this point. 
 
Figure 14. HPLC chromatograms (From top to bottom: L4, [Re2(Cl)(OMe)], [Re2(Cl)(OMe)] irradiated at 280 
nm for 2 h, [Re2(OEt)2] and [Re2(OEt)2] irradiated at 280 nm for 2 h). Column: SunFireTM Prep Silica 5 μm (4.6 
x 150 mm), T = 25ºC. Flow rate: 1 mL/min. Waters 996, Photodiode Array Detector, UV = 254 nm. Eluent (A: 
CH2Cl2, B: i-PrOH):a linear gradient of 100% A to 90% A in 10 min and 5 min 90% A. 
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2.4. Conclusion 
The ability of a 1,4-disubstituted 1,2,3-triazole ring acting as a bridging ligand to form 
stable dinuclear rhenium(I) hexacarbonyl complexes has been successfully demonstrated. Two 
dirhenium(I) hexacarbonyl complexes of general formula [Re2(CO)6(μ-X)(μ-X’)(μ-1,2,3-
triazole ligand)] (X = Cl–, X’ = MeO- ([Re2(Cl)(OMe)]), X = X’ = EtO– ([Re2(OEt)2])) were 
synthesized and fully characterized by both experimental (IR, NMR, MS, UV-Vis and X-ray 
structure for [Re2(OEt)2]) and theoretical studies. The single-crystal X-ray analysis of 
[Re2(OEt)2] revealed that two rhenium(I) atoms are linked through two bridging ethoxo groups, 
and one bridging triazole ligand. Each rhenium(I) atom is six coordinated by two ethoxy oxygen 
atoms, one triazole nitrogen atom and three carbonyl carbon atoms, showing a distorted 
octahedral geometry. The data reported here are in good agreement with previous reports on 
similar dirhenium hexacarbonyl complexes based on pyridazine, tetrazole or oxadiazole 
bridging ligands. In turn, the photophysical properties of such complexes were assessed and 
unfortunately, they exhibited very weak emission. The improvement of the photophysical 
properties of these binuclear complexes will demand additional theoretical and experimental 
investigations. 
 
We must admit that this work was a perfect example of serendipity. At the beginning of 
our researches on the developpement on new tetradentate ligands based on a click chemistry 
approach (Cf. part 1), we tried to develop stable mononuclear technetium/rhenium complexes 
for potential applicative interests in nuclear medicine. The obtention of L3 and L4, resulting 
from a ring closure side-reaction encourage us to do complexation trials with the 
tricarbonylrhenium(I) core in order to study the reactivity of a triazole ring without adjacent 
coordinating arms with a Re(I) core. If this research is slightly borderline with regard to our 
thematic area, we succeeded and obtained the first RX structure of a dirhenium hexacarbonyl 
complex bridged by a 1,2,3-triazole ring, this work being published recently in Inorganica 
chimica Acta (J.-H. Wang et al., Inorg. Chim. Acta 466 (2017) 551–558). 
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3. Tricarbonylrhenium(I) complexes functionalized by a nitro or 
metronidazole group as potential imaging agents for hypoxia 
 
3.1. Introduction  
Tissue hypoxia results from an insufficient supply of oxygen and occurs after stroke or 
myocardial infarction (in this case, the oxygen supply is interrupted) or in solid tumors when 
the oxygen delivery is reduced and/or disturbed. When healthy tissues lose their O2 supply 
acutely, the cells usually die, whereas partly gradually become hypoxic.[44] It is well-known 
that hypoxic tissues are a tradmark of advanced solid tumors. The inability of the vascular 
system to supply oxygen in all the cell mass makes tumors highly heterogeneous, one specific 
consequence being that solid tumors which are hypoxic tend to be more aggressive and resistant 
to traditional therapeutic strategies (radioresistance).[45] For this reason, hypoxia is a high-
priority target, information about its presence in tumor cells could have a substantial influence 
on the choice of the treatment strategy and/or on the treatment efficiency. 
 
Nuclear imaging using radiotracers which is one of the preferred non-invasive 
modalities for the detection of hypoxia have a key role to play in increasing the understanding 
of hypoxia in tumor biology.[ 46 ] Among markers of hypoxia, iv  the class of compounds 
containing nitroimidazoles (NIs) is among the most popular molecules used for tracking and 
imaging hypoxia. The nitroimidazole tracers have the ability to be reduced or retained 
exclusively in hypoxic cells, by a series of enzymatic one-electron reductions while in normoxic 
cells, the reduction does not proceed beyond first step and hence there is no accumulation of 
the tracer.[44,47,48] 
 
More precisely, due to the absence of sufficient oxygen supply, the nitro radical anion 
(NO2•−) formed in the hypoxic cell undergo further reactions to more reactive species that bind 
to cell components. In contrast, in normoxic tissue, the nitro radical anion (NO2•−) can be re-
oxidized by O2, to the parent NO2 compound which can leave the cell, as illustrated in the 
 
iv Cu(II)diacetyl-bis(N4-methylthiosemicarbazone) so-called Cu-ATSM which is a non-nitroimidazole compound 
was extensively studied as PET-hypoxia radiomarker with firstly 60Cu and nowadays with 64Cu. This kind of 
molecules will be not developed in this part, but more information about his mechanism of action and biological 
results could be found in the publication [45d] or in the following reference: J. P. Holland, R. Ferdani, C. J. 
Anderson, J. S. Lewis, PET Clinics 4 (2009) 49-67. 
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Figure 15.[49] It is note worthy that 2-nitroimidazole compounds (2-NIs) possess the more 
positive Single-Electron Reduction Potential (SERP) values which facilitates efficient trapping 
inside the hypoxic cells. 
 
 
Figure 15. Accepted trapping mechanism of NIs in hypoxic cells. (Figure extracted from reference [49a]). 
 
Fluorine radiotracers, in particular [18F]fluoromisonidazole (F-MISO), have been the 
major 2-NI clinical tracers investigated for the bioreductive trapping mechanism, using the 
positron emission tomography imaging so-called PET-imaging (Figure 16). If they exhibited 
ideal SERP values, most of them are too lipophilic and suffers from relatively slow cell uptake 
and poor clearance from normoxic tissue.[50 ] Another drawbacks of these compounds are 
associated to the characteristics of the fluorine-18 radionuclide such as a relative short half-life, 
a limited availability and consequently a high production cost (a cyclotron is required for its 
production). Consequently, other radiomarkers have been investigated, in particular those based 
on technetium-99m using the single photon emission computed tomography imaging so-called 
SPECT-imaging. Indeed, the technetium-99m is still the most important radionuclide in 
diagnostic nuclear medicine due to its ideal nuclear properties (T1/2 = 6 hours, 140 KeV pure 
gamma emitter, convenient availability from a commercial generator). 
 
Figure 16. Several examples of 18F-labeled 2-NI hypoxia tracers F-MISO, EF5 and HX4. 
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There are many examples in the literature reporting the development of technetium 
complexes for selective hypoxia detection (Figure 17). If the first classes of technetium 
compounds were technetium BATOv nitromidazoles, lot of efforts to produce hypoxia selective 
technetium complexes were focused on oxotechnetium complexes based on tetradentate ligands 
with appended nitroimidazole functional groups, in particular, PnAO§ and amido PnAO 
derivatives (N4 ligands), MAMA ligand (N2S2 ligand) and NxS4-x derivatives and Schiff bases 
(N2O2 ligands).[51-56] Without detailled all the results obtained with these compounds, it is 
important to note that best results are reported for PnAO derivatives. For example, the first 
promising results were obtained with BMS181321, an oxotechnetium complex derived from a 
PnAO framework [TcO(PnAO-1-(2-nitroimidazole)] (Figure 17, compounds a). This complex 
presented favorable lipophilic features and exhibited a high uptake in hypoxic cells (in vitro 
study). Unfortunatly, in the in vivo studies, its clearance from the blood was slow and a high 
hepatobiliary background was observed.[51]   
 
More recently, the development of novel hypoxia-selective 99mTc radiopharmaceuticals 
based on the 99mTc(CO)3 complexes has attracted growing attention since Alberto and coll. 
developed a convenient low-pressure synthesis for the preparation of 99mTc-tricarbonyl 
complexes from the pertechnetate ion TcO4-.[57] The kinetic inertness and chemical robustness 
of complexes with this core, the high affinity of the Tc(I) ion for a large variety of donor atoms, 
the organometallic nature of this core which renders chelation more covalent in character, 
conjugated with the easy production of the fac-[99mTc(CO)3(H2O)3]+ precursor (which is 
commercially available) explain this interest.[58]  
 
Although different new ligand systems have been developed in this field, most of them 
are based on tridentate chelating systems, since they form organometallic compounds with more 
favourable pharmacokinetics. Generally, tridentate scaffolds are built on dipycolylamine (DPA) 
and iminodiacetic acid (IDA) or mixed structure derived from both ligands or on modified 
amino acid including a imidazole or 1,2,3-triazole unit.[59] The resulting biological studies 
clearly showed that the nature of the chelator has a significative impact on the biological results 
and even if some studies reported promising preliminary results for hypoxia detection, none of 
them are currently used in more advanced phase of clinical studies.  
 
v BATO = boronic acid adduct of technetium dioxime, PnAO = propylene amine oxime, MAMA = monoamine-
monoamide dithiol. 
Chapter II 
 
 
100 
 
Figure 17. Non-exhaustive list of Tc-complexes reported as potential hypoxia marker: (a) [TcO(PnAO-1-(2-
nitroimidazole)] (BMS181321), (b) 99mTcO MAMA-complexes, (c) system 99mTcO-Azadibenzocyclooctyne-
MAMA (AM) and 2-nitroimidazole-azide (2NIM-Az), (d) 99mTc(CO)3 IDA, (e) 99mTc(CO)3 DPA and derivatives, 
(f) 99mTc(CO)3 homocysteine derivatives. 
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This brief overview showed that (i) technetium-99m radiocompounds could be a good 
alternative to radioactive fluorine ones for the hypoxia tissue targeting, in terms of easier 
availability and lower cost, (ii) 99mTc-tricarbonyl complexes development has attracted growing 
attention over the last two decades, due to the high kinetic inertness and chemical robustness of 
these complexes, (iii) although many studies on Tc(V) and Tc(I) complexes as potential hypoxia 
markers were reported, in vivo results were not relevant enough for a clinical assessment of 
tissue hypoxia. The development of new hypoxia selective 99mTc-complexes is still of interest. 
 
Starting from our tripodal 2-aminophenol 1,2,3-triazole unit, in this study, a series of 
rhenium complexes containing either a metronidazole (Mtz) framework or a nitroaromatic 
group have been prepared and characterized by means of classical analytical methods and 
electrochemistry. Preliminary 99mTc-radiolabeling trials will also be mentioned. Metronidazole 
moiety (Mtz) has demonstrated high in vitro and in vivo affinity for hypoxia tumors[60] and 
nitrobenzene-containing rhenium and technetium complexes may be equally as effective as 2-
NIs-based complexes.[61] At least, three Mtz-coupling possibilities were considered: one on the 
functionalized arm (in order to develop a similar nitro-compound of ligand 12) and the two 
others on nitrogen and oxygen donor atoms participating to the metal coordination (Figure 18). 
 
 
 
Figure 18. Nitro and Mtz compounds considered in this study. 
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3.2. Syntheses and characterization 
3.2.1. Syntheses of the ligands 
Mtz-coupling on the triazole ring: The designed chelating agent L6 was synthesized by 
the CuAAC reaction of alkyne 10[9b] with the azide 19, as outlined in Scheme 7. Compound 19 
was prepared from the commercially available antiparasite drug metronizadole (Mtz) according 
to a procedure reported in the literature by Fernández et al.[59c] Firstly, the Mtz hydroxyl group 
was transformed into the sulfonate intermediate 18 by the reaction with the methanesulfonyl 
chloride. Triethylamine was used as a non-nucleophilic base in CH2Cl2 at 0ºC for 2 h. Mesylate 
18 was converted in azide compound 19 with sodium azide in DMF, with a yield of 85% without 
chromatographic purification. 
 
Scheme 7. Synthesis of ligand L6. 
 
Conditions and reagents: i) Methanesulfonyl chloride, Et3N, CH2Cl2, 0ºC, 2 h; (ii) NaN3, DMF, 100ºC, 4 h; (iii) 
propargyl bromide, EtOH, rt, 4 days; [9b]  (iv) Cu(OAc)2.H2O, NaAsc., t-BuOH/H2O, rt, 16 h. 
 
Mtz-coupling on the oxygen atom: the Mtz hydroxyl group was transformed into the 
tosylate intermediate 20, using similar procedure than for compound 18. After the nucleophilic 
substitution reaction between 20 and alkyne 10, compound 22 was obtained with a moderate 
yield of 60%, due to the competition between substitution reaction and E-elimination reaction 
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of 20 which lead to compound 21 in 30% yield. Huisgen cycloaddition reaction between 22 and 
4-nitrophenyl azide using classical copper catalytic conditions gave ligand L7 in 67% yield. 
 
Scheme 8. Synthesis of ligand L7. 
 
Conditions and reagents : (i) 4-Methyl-benzenesufonyl chloride, Et3N, CH2Cl2, 0ºC, 5 h; (ii) 2-aminophenol, 
DMF, K2CO3, 80ºC, 22 h; (iii) 4-nitrophenyl azide, Cu(OAc)2.H2O, NaAsc, t-BuOH/H2O, rt, 16 h. 
 
Mtz-coupling on the aromatic nitrogen: Surprisingly, all our trials to introduce the 
metronidazole group on the aromatic nitrogen, in order to prepare L7’, failed. Either no reaction 
occurred or the main product which was obtained was the compound 21 (resulting from the E-
elimination of the activated metronidazole (activation by tosylate, halide…). All our 
experiments were gathered in the Table 9. 
 
In specific, under microwave, the reaction of TBS-protected ligand 12 with bromide 
metronidazole in acetonitrile led to compound 21 as a major product (entry 1). Using TBS-
protected intermediate 10 and mesylate metronidazole in toluene in the presence of 
triethylamine,[ 62 ] no reaction occurred (entry 2). More interestingly, by using iodide 
metronidazole in the presence of potassium carbonate and depending of the solvent, we 
observed either the formation of the E-elimination product 21 (entry 3a, solvent DMF) or no 
reaction (entry 3b, solvent acetonitrile).[63] Using the same conditions as entry 3a with a stronger 
base (NaH), only the deprotection of the TBS group of the starting material was observed (entry 
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3c). At least, by doing the alkylation reaction with 2-(prop-2-ynylamino)phenol 10 (entry 4) or 
commercial 2-aminophenol (entry 5) and iodide metronidazole, we were unable to obtain the 
desired product, unfortunalty. 
 
Table 9. Trials on Mtz-coupling on the aromatic nitrogen. 
Entry Substrates Conditions Results 
 
 
 
1 
 
 
 
K2CO3, CH3CN, microwave,  
100w, 60°C, 2 h 
 
  
 
 
 
2 
 
 
 
NEt3, toluene, 115°C, 16 h 
 
 
 
No reaction 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
(a) K2CO3/Cs2CO3, DMF, 80°C, 
18 h 
 
 
 
 
(b) K2CO3, CH3CN, 80°C,18 h 
 
 
No reaction 
 
 
(c) NaH, DMF, 0°C-30°C, 18 h 
 
 
 
 
4 
  
 
 
K2CO3, CH3CN, 80°C,18 h 
 
 
 
No reaction 
 
5 
 
 
K2CO3, CH3CN, 80°C,18 h 
 
 
Mixture of products 
 
3.2.2. Syntheses and characterization of corresponding rhenium complexes 
The rhenium complex [Re(CO)3(L6)] was prepared in quite good yield (72%) by 
reacting ligand L6 and 1.15 eq. of rhenium (I) precursor [Re(CO)5Cl] in methanol in the 
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presence of diethylpropylamine as deprotonating agent (Scheme 9). Coordination took place in 
16 hours under reflux and led to a neutral tricarbonylrhenium complex after purified by column 
chromatography. 
The same protocol was applied to ligand L7. Unfortunatly, all our efforts to isolate the 
corresponding pure complex failed. The complex seemed to be unstable on chromatography 
column.  
 
Scheme 9. Synthesis of complexes [Re(CO)3(L6)] and [Re(CO)3Cl(L7)]. 
 
 
Conditions and reagents: [Re(CO)5Cl], MeOH, N,N-Diisopropylethylamine, 65°C, 16 h. 
 
The complex [Re(CO)3(L6)] was fully characterized by 1H NMR, 13C NMR, HR-MS 
and IR spectra. Comparing the 1H NMR spectra of the ligand with its corresponding Re(I) 
complex, the metronidazole proton exhibited nearly no change at 7.95 ppm, whereas the triazole 
proton had a slightly downfield shift from 7.74 ppm for L6 to 7.81 ppm for [Re(CO)3(L6)]. The 
Chapter II 
 
 
106 
 
most distinguished shift belongs to two aromatic protons in ligand L6 (6.71 ppm) as compared 
to complex [Re(CO)3(L6)] (6.93 and 7.24 ppm, respectively). Moreover, the CH2 protons in 
alpha of triazole ring which exhibited a single peak at 4.42 ppm for L6 splitted into two double-
doublet peaks at 4.53 ppm and 4.60 ppm for [Re(CO)3(L6)], respectively. This feature confirms 
that the 2-aminophenol and the 1,2,3-triazole rings were involved in the coordination.[9b]  
 
As expected, the three CO bonds was characterized in 13C NMR by the three typical 
peaks at 195.8, 196.3 and 197.2 ppm and by the three typical stretching bands υ(CO) at 2015 
and 1910-1870 cm–1 in Infrared.  
 
Concerning rhenium complex from L7, the high resolution mass spectrum was 
performed on the crude product and data are consistent with the presence of the expected 
complex [Re(CO)3Cl(L7)]. HR-MS analysis in the positive mode generated the parent peak 
[M+H]+ at 771.0725 and the [M-Cl]+ ion at 735.0970 with the correct isotopic distribution 
patterns, indicating as observed previously for ligands L1 and L2 (Cf. part 1) that L7 was 
coordinated to the metal center in an bidentate fashion, leading a neutral rhenium complex of 
general formula [Re(CO)3Cl(L7)]. Then, a peak at 465.1633 was assigned to the free ligand 
(Figure 19).   
 
Figure 19. HR-MS spectrum of [Re(CO)3Cl(L7)]. 
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3.3. Electrochemical studies 
As mentionned in the introduction of this part, hypoxia-selective accumulation of 
hypoxia markers is initiated by enzyme-mediated one-electron reduction of bioreductive group 
within the cells.[64,65] In particular, the one electron reduction is crucial to the hypoxia-selective 
tumor uptake. So the redox behaviors of both nitro-containing ligands (12, L2 and L6) and 
corresponding tricarbonylrhenium(I) complexes ([Re(CO)3(12)], [Re(CO)3Cl(L2)] and 
[Re(CO)3(L6)]) were determined by cyclic voltammetry in acetonitrile to evaluate their 
bioreductive capacities. Initially, our goal was only to develop and electrochemically test 
rhenium complexes based on tridentate scaffold (due to their high stability). Nevertheless, 
having in our hands a nitro-containing bidentate ligand L2 and its corresponding rhenium 
complex [Re(CO)3Cl(L2)] (Cf. part 1), we decided finally to include them in this 
electrochemical study. 
 
Cyclic voltammograms were recorded for each compound in acetonitrile solution with 
tetrabutylammonium perchlorate (TBAP 0.1 mol L-1) as the supporting electrolyte at a glassy 
carbon (1 mm diameter) or platinum (0.5 mm diameter) disk electrode. The potentials were 
obtained according E° = (Epforward + Epbackward)/2 when the backward peak appeared by changing 
the potential sweep rate. They are reported versus the calomel electrode (SCE) and potential 
are quoted relative to ferrocene/ferrocenium couple (Table 10 and Figure 20). 
 
Table 10. Electrochemical data for ligands 12, L2, L6 and their corresponding rhenium 
complexes. 
Compounds Epc1/V* Epc(qr)/V§ Epox1/V† Epox2/V† 
12 -- –0.96 0.64 -- 
L2 -- -1.02 0.83 -- 
L6 -- -1.22 0.54 -- 
[Re(CO)3(12)] -- -0.97 -- 0.99 
[Re(CO)3Cl(L2)] -0.95 –1.00 -- 1.42 
[Re(CO)3(L6)] -- -1.18 -- 0.97 
* We kept the same notation than P. S. Donnely in his publication.[66] As he mentioned: “Cathodic peak potential 
corresponds to the ﬁrst reduction step. Where there is no value given, the ﬁrst cathodic peak is quasi-reversible, 
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and values are provided in the proceeding column. § Cathodic peak potential corresponding to the second quasi-
reversible (qr) reduction step”, † Epox 1 corresponds to the oxydation step of the ligand and Epox 2 corresponds to 
the oxydation step of the rhenium.  
 
 
Figure 20. Selected cyclic voltammograms (reduction process) of L2 (red solid line), L6 (blue solid line), 
[Re(CO)3Cl(L2)] (red dashed line) and [Re(CO)3(L6)] (blue dashed line). Potential scan rate 1 V/s. 
 
Our results are similar to those reported recently by Donnely group with rhenium(I) 
complexes based on bidentate or tridentate nitro chelating agents using similar 
electrochemically conditions. The two reduction waves being observed within the range 0.0 to 
-1.22 V.[66] As he reported, the first peak is generally irreversible and the second quasi-
reversible, as commonly observed for nitro-aromatic compounds. This feature was only 
observed for [Re(CO)3Cl(L2)], all our rhenium complexes exhibiting only one quasi-reversible 
peak.[67]  
According the the results, here we concluded also that the presence of a metal center in the 
chelating system has not negative influence of the reduction of the nitro group, proving that our 
complexes should be able to induce reduction in hypoxic cells. 
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The close potential values for all compounds demonstrated that the nature of the nitro 
moiety (nitrophenyl or metronidazole group) has nearly no influence on the nitro reduction 
process in our compounds.  
 
Finally, the complexes exhibited an additional irreversible reduction wave which can be 
attributed to the triazole reduction and probably the ReI/Re0 reduction step. This occurred at ca. 
-1.55 to 2.18 V, close to the solvent limit. Some of these values were unusually highly negative, 
the classical values for triazole-based reduction wave in rhenium complexes ranged generally 
from -1.50 to -1.80 V.[9b,40] All the complexes displayed also an irreversible one-electron 
oxidation process in the range +0.97 to +1.42 V, which is classically assigned to the ReII/ReI 
oxidation couple; no reverse peak appeared on varying the potential scan rates. 
 
3.4. Conclusion 
 Three designed semi rigid tripodal click ligands containing a metronidazole (Mtz) 
moiety (L6, L7 and L7’) and their corresponding rhenium were considered. Unfortunatly, only 
two Mtz ligands (L6 and L7) and one tricarbonylrhenium complex [Re(CO)3(L6)] were 
prepared and fully characterized by means of high resolution mass spectroscopy, NMR, IR, as 
well as X-Ray diffraction for L7. Although [Re(CO)3Cl(L7)] was not obtained as a pure 
product, probably due to its labile property, its structure was concluded by HR-MS and 
comparison with bidentate rhenium(I) complexes developed in the first part of this chapter. 
 
Concerning the assessment of these compounds (plus nitrophenyl compounds 12 and L2 
and their corresponding rhenium(I) complexes [Re(CO)3(12)] and [Re(CO)3Cl(L2)] developed 
previously[9b] or during the thesis, respectively) as potential bioreductive markers for hypoxic 
cells, a preliminary electrochemical study was carried out. The results of cyclic voltammetry 
indicated that the reduction potentials are in the same range (no significative difference with 
regard to the nature of the nitro group) and the fluctuation of these values between -0.95 to 1.22 
V is still in the range for potentially bioreductive compounds (Ered (F-MISO) = 1.045 in DMSO, 
0.1 M TBAP vs Fc/Fc+).[49a] Complexes [Re(CO)3(12)] and [Re(CO)3(L6)] seem to be the most 
interesting candidates, according to that rhenium (and technetium-99m) complexes based on 
tridentate ligands are most in vivo stable than those based on bidentate ones. 
Obviously, this work suffers from a lack of in vitro and/or in vivo studies with 
technetium-99m, in order to really assess the potential of these complexes as imaging agents 
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for hypoxia. Some 99mTc-radiolabeling were recently performed by one colleague working at 
the nuclear department of the Oncopole (Toulouse). Unfortunatly, due to technical problems, 
the results were not obtained at this moment.  
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4. Experimental Section 
4.1. Materials and equipment 
All purchased chemicals were of the highest purity commercially available and used 
without further purification. Chemical reactions were monitored by thin layer chromatography 
(TLC) on Merck D.C.-Alufolien Kieselgel 60 F254. Column chromatography was performed 
on silica gel obtained from Merck. 
1H and 13C spectra were recorded on a Bruker Avance 300 (75.5) MHz or on a Bruker 
Avance DRX 500 (125) MHz spectrometer; chemical shifts are reported in parts per million 
(ppm) relative to a residual solvent peak and coupling constants (J) are given in Hertz (Hz). 
Multiplicities were recorded as s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quartlet) 
and m (multiplet). Electrospray (ESI) mass spectra were obtained on a Q TRAP Applied 
Biosystems spectrometer and High-Resolution Mass Spectra (HRMS) on an LCT Premier 
Waters spectrometer. DCI (CH4 or NH3) mass spectra were obtained on a DSQ II Thermo 
Fisher. Infrared spectra were recorded on a Perkin Elmer FTIR 1725 spectrophotometer in the 
range 4000-400 cm-1. UV-Vis absorption spectra were recorded (in MeOH) on a Hewlett 
Packard 8453 spectrophotometer in the range 1100–190 nm in methanol. Fluorescence data 
were obtained with a Cary Eclipse spectrofluorimeter with a xenon flash lamp source and a 
Hamamatsu R928 photomultiplier tube.  
 
Literature methods were used to prepare [ReOCl3(PPh3)2],[68] methyl azidoacetate,[69]  
and 1-azido-4-nitrobenzene[13] (if azido compounds are potentially explosive intermediates, in 
our hands, we never observed hazardous reactions for both azido intermediates). Preparation 
of N2O tridentate ligand (compound 12), its intermediate, 2-(prop-2-yn-1-ylamino)phenol, (10) 
and its tricarbonylrhenium complex [Re(CO)3Cl(12)] have been described previously.[9b] 
 
4.2. Syntheses 
4.2.1. Syntheses for Part 1  
4.2.1.1. O-extension, Pyridine coordinating arm 
N-(tert-butoxycarbonyl)-2-aminophenol (1). A mixture of 2-aminophenol (1.09 g, 10 
mmol) and di-tert-butyldicarbonate (4.37 g, 20 mmol) in THF (15 mL) was stirred at room 
temperature overnight. After concentration under reduced pressure, the residue was purified by 
column chromatography (silica gel, ethyl acetate/petroleum ether, v/v = 1/10) to afford 1 as a 
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light yellow solid (1.51 g, yield 72%). 1H NMR (300 MHz, CDCl3): δ 1.53 (s, 9H), 6.68 (br s, 
1H), 6.85 (td, J = 7.8, 1.7 Hz, 1H), 6.83-7.10 (m, 1H), 8.14 (br s, 1H). 
 
tert-butyl 2-(pyridin-2-ylmethoxy)phenylcarbamate (2). To a solution of 1 (1.12 g, 
5.4 mmol) in CH3CN (10 mL) were added under argon atmosphere, K2CO3 (1.48 g, 10.7 mmol) 
and 2-picolyl chloride hydrochloride (0.88 g, 5.4 mmol). The mixture was heated to reflux 
overnight. The reaction was stopped by evaporation under vacuum. The residue was dissolved 
in ethyl acetate (50 mL) and washed twice with H2O (30 mL) then brine (20 mL). The organic 
layer was dried over anhydrous MgSO4 and the filtrate was concentrated under reduced 
pressure. The residue was purified by column chromatography (silica gel, ethyl 
acetate/petroleum ether, v/v = 1/2) to afford 2 as a yellow oil (1.23 g, yield 78%). 1H NMR (300 
MHz, DMSO-d6): δ 1.49 (s, 9H), 5.24 (s, 2H), 6.91-7.09 (m, 3H), 7.35-7.39 (m, 1H), 7.58 (d, J 
= 7.8 Hz, 1H), 7.70-7.88 (m, 2H), 8.46 (s, 1H), 8.60-8.62 (m, 1H). DCI/NH3-MS: m/z 301.1 
([M+H]+ calcd for C17H21N2O3, 301.1). 
 
tert-butyl prop-2-ynyl(2-(pyridin-2-ylmethoxy)phenyl)carbamate (3). To a solution 
of 2 (0.60 g, 2.0 mmol) in distilled DMF (20 mL) was added under argon atmosphere at 0ºC, 
NaH (0.19 g, 8.0 mmol). The mixture was stirred at 0ºC for 30 min. Then propargyl bromide 
solution (80 wt. % in toluene, 0.3 mL, 2.6 mmol) was added dropwise and stirred at room 
temperature overnight. The reaction mixture was quenched with water (10 mL) and extracted 
twice with ethyl acetate (50 mL). All the organic layers were combined, washed twice with 
H2O (30 mL), brine (20 mL) and dried over anhydrous MgSO4. The filtrate was concentrated 
under reduced pressure and the residue was purified by column chromatography (silica gel, 
ethyl acetate/petroleum ether, v/v = 1/2) to give 3 as a yellow oil (0.54 g, yield 81%). 1H NMR 
(300 MHz, DMSO-d6): δ 1.19-1.46 (m, 9H), 3.14 (s, 1H), 4.21-4.30 (m, 1H), 4.51-4.55 (m, 
1H), 5.23 (s, 2H), 6.97-7.02 (m, 1H), 7.14-7.37 (m, 4H), 7.55 (d, J = 7.8 Hz, 1H), 7.85 (td, J = 
7.7, 1.6 Hz, 1H), 8.57-8.80 (m, 1H). DCI/NH3-MS: m/z 339.1 ([M+H]+ calcd for C20H23N2O3, 
339.2). 
 
N-(prop-2-ynyl)-2-(pyridin-2-ylmethoxy)aniline (4a). To a solution of 3 (0.32 g, 0.95 
mmol) in CH2Cl2 (10 mL) was added an excess of trifluoroacetic acid (3 mL, 40 mmol). The 
reaction was stirred at 0ºC until the consumption of the starting material (2h, monitored by 
TLC). After reaction, the mixture was evaporated to dry and purified by column 
chromatography (silica gel, ethyl acetate/petroleum ether, v/v = 1/2) to give 4a as a brown oil 
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(208 mg, yield 92%).1H NMR (300 MHz, DMSO-d6): δ 3.06 (t, J = 2.4 Hz, 1H, CH), 3.99 (dd, 
J = 6.4 Hz, J = 2.4 Hz, 2H, NCH2), 5.19 (s, 2H, OCH2), 5.48 (t, J = 6.4 Hz, 1H, NH), 6.61 (td, 
J = 1.5 Hz, J = 7.8 Hz, 1H, HAr), 6.73 (dd, J = 1.5 Hz, J = 7.8 Hz, 1H, HAr), 6.86 (td, J = 1.2 
Hz, J = 7.8 Hz, 1H, HAr), 6.93 (dd, J = 1.2 Hz, J = 7.8 Hz, 1H, HAr), 7.34-7.78 (m, 1H, Hpy), 
7.66 (d, J = 7.8 Hz, 1H, Hpy), 7.86 (td, J = 1.8 Hz, J = 7.8 Hz, 1H, Hpyr), 8.59-8.61 (m, 1H, 
Hpyr). DCI/NH3-MS: m/z 239.0 ([M+H]+ calcd for C15H15N2O, 239.1). 
 
2,2,2-trifluoro-N-(prop-2-ynyl)-N-(2-(pyridin-2-ylmethoxy)phenyl)acetamide (4b). 
To a solution of 3 (0.54 g, 1.6 mmol) in CH2Cl2 (20 mL) was added an excess of trifluoroacetic 
acid (0.7 mL, 9.3 mmol). The reaction was stirred at room temperature for 6 h. Then an 
ammonia solution (1 mL, 25%) and water (3 mL) were added to neutralize the excess of 
trifluoroacetic acid. The resulting mixture was extracted by CH2Cl2 (2 x 20 mL) and the organic 
layers were combined and dried over anhydrous MgSO4. The filtrate was concentrated and dried 
to afford 4b as yellow oil (350 mg, yield 66%). 1H NMR (300 MHz, DMSO-d6): δ 3.31 (t, J = 
2.5 Hz, 1H, CH), 4.32 (dd, J = 17.4 Hz, J = 2.5 Hz, 1H, NCH2), 4.85 (dd, J = 17.4 Hz, J = 2.5 
Hz, 1H, NCH2), 5.21-5.31 (m, 2H, OCH2), 7.04-7.10 (m, 1H, HAr), 7.26-7.49 (m, 1H, HAr), 7.85 
(td, J = 1.8 Hz, J = 7.7 Hz, 1H, HAr), 8.57 (ddd, J = 0.9 Hz, J = 1.8 Hz, J = 2.7 Hz, 1H, HAr). 
DCI/NH3-MS: m/z 335.0 ([M+H]+ calcd for C17H14N2O3, 335.1).  
 
methyl 2-(4-((2-(pyridin-2-ylmethoxy)phenylamino)methyl)-1H-1,2,3-triazol-1-
yl)acetate (L1). 4a (140 mg, 0.59 mmol), methyl azidoacetate (88 mg, 0.76 mmol), copper(II) 
acetate monohydrate (35 mg, 0.18 mmol) and sodium ascorbate (59 mg, 0.3 mmol) in t-
BuOH/H2O (v/v = 1/1, 10 mL) were stirred at room temperature overnight. The mixture was 
partitioned between ethyl acetate (25 mL) and saturated Na2EDTA solution (25 mL). The 
organic phase was washed twice with water (20 mL) and dried over anhydrous MgSO4. The 
filtrate was evaporated and purified by column chromatography (silica gel, ethyl acetate) to 
give L1 as a yellow solid (158 mg, yield 76%). Suitable crystals of L1 for X-ray crystal structure 
determination were grown by slow evaporation of an acetonitrile and dichloromethane mixture. 
1H NMR (500 MHz, DMSO-d6): δ 3.70 (s, 3H, OCH3), 4.44 (d, J = 3.7 Hz, 2H, NCH2), 5.18 
(s, 2H, OCH2), 5.37 (s, 2H, CH2CO), 5.59 (t, J = 3.7 Hz, 1H, NH), 6.53 (td, J = 1.5 Hz, J = 7.5 
Hz, 1H, HAr),  6.66 (dd, J = 1.5 Hz, J = 8.0 Hz, 1H, HAr), 6.77 (td, J = 1.5 Hz, J = 7.5 Hz, 1H, 
HAr), 6.93 (dd, J = 1.5 Hz, J = 8.0 Hz, 1H, HAr), 7.33-7.36 (m, 1H, Hpy), 7.62 (dt, J = 1.5 Hz, J 
= 8.0 Hz, 1H, Hpy), 7.84 (td, J = 2.0 Hz, J = 8.0 Hz, 1H, Hpy), 7.95 (s, 1H, Hta), 8.57 (ddd, 2H, 
J = 1.0 Hz, J = 2.0 Hz, J = 3.0 Hz, 1H, Hpy). 13C NMR (125 MHz, DMSO-d6) δ 38.9 (NCH2), 
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50.7 (CH2CO), 53.0 (OCH3), 71.1 (OCH2), 110.5 (CHAr), 112.1 (CHAr), 116.4 (CHAr), 121.9 
(CHpy), 122.0 (CHAr), 123.4 (CHpy), 124.6 (CHta), 137.4 (CHpy), 138.3 (Cq), 145.7 (CqNH), 
146.5 (CqO), 149.5 (CHpy), 157.5 (CqN), 168.2 (CO ester). ESI-HRMS: m/z 354.1559 ([M+H]+ 
calcd for C18H20N5O3, 354.1553). 
 
N-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-(pyridin-2-ylmethoxy)aniline 
(L2). Using same procedure than compound L1 preparation, 4a (0.14 g, 0.59 mmol), 1-azido-
4-nitrobenzene (125 mg, 0.76 mmol), copper(II) acetate monohydrate (35 mg, 0.18 mmol) and 
sodium ascorbate (59 mg, 0.3 mmol) in t-BuOH/H2O (v/v = 1/1, 10 mL) gave, after purification 
by column chromatography (silica gel, ethyl acetate) L2 as a yellow solid (240 mg, yield 81%).  
 
Alternative procedure for the preparation of L2 from compound 3. 
tert-butyl (1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl)-(2-(pyridin-2-
ylmethoxy)phenyl)carbamate (5). Using same procedure than compound L1 preparation, 3 
(0.43 g, 1.27 mmol), 1-azido-4-nitrobenzene (271 mg, 1.65 mmol), copper(II) acetate 
monohydrate (76 mg, 0.38 mmol) and sodium ascorbate (128 mg, 0.64 mmol) in t-BuOH/H2O 
(v/v = 1/1, 20 mL) gave, after purification by column chromatography (silica gel, ethyl acetate), 
5 as a yellow oil (440 mg, yield 69%). 1H NMR (300 MHz, CDCl3): δ 1.27 (s, 6H, N-Boc), 
1.42 (s, 3H, N-Boc), 4.95 (s, 2H, NCH2), 5.12 (s, 2H, OCH2), 6.88-6.92 (m, 2H, HAr), 7.10-
7.20 (m, 3H, HAr), 7.34 (d, J = 7.8 Hz, 1H, Hpy), 7.61 (t, J = 7.5 Hz, 1H, Hpy), 7.88 (d, 2H, J = 
8.7 Hz, 2H, Hpy), 8.28-8.32 (m, 3H, HAr), 8.49 (br s, 1H, Hta). ESI-MS: m/z 503.3 ([M+H]+ 
calcd for C26H27N6O5, 503.2); 403.2 ([M-Boc+2H]+ calcd for C21H19N6O3, 403.2). 
 
L2. To a solution of 5 (0.42 g, 0.84 mmol) in CH2Cl2 (20 mL) was added an excess of 
trifluoroacetic acid (3 mL) at 0ºC. The reaction was stirred at room temperature for 2 h. The 
resulting mixture was concentrated to dry under reduced pressure and purified by column 
chromatography (silica gel, ethyl acetate) to give L2 as a yellow solid (280 mg, yield 86%). 
Suitable crystals of L2 for X-ray crystal structure determination were grown by slow 
evaporation of an acetonitrile and dichloromethane mixture. 1H NMR (500 MHz, CDCl3): δ 
4.59 (s, 2H, NCH2), 5.20 (s, 2H, OCH2), 6.62-6.68 (m, 2H, HAr), 6.81-6.86 (m, 2H, HAr), 7.20-
7.22 (m, 1H, Hpy), 7.45 (d, J = 7.5 Hz, 1H, Hpy), 7.68 (td, J = 1.5 Hz, J = 7.5 Hz, 1H, Hpy), 7.89-
7.91 (m, 2H, HAr), 8.03 (s, 1H, Hta), 8.30-8.33 (m, 2H, HAr), 8.57 (d, J = 4.0 Hz, 1H, Hpy), 13C 
NMR (125 MHz, CDCl3) δ 39.7 (NHCH2), 71.3 (OCH2), 110.7 (CHAr), 111.8 (CHAr), 117.5 
(CHAr), 119.9 (CHta), 120.3 (CHAr), 121.6 (CHpy), 122.0 (CHAr), 122.9 (CHpy), 125.5 (CHAr), 
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137.0 (CHpy), 137.6 (Cqta), 141.2 (CqAr), 145.9 (CqNO2), 147.0 (CqO), 148.5 (CqNH), 149.3 
(CHpy), 157.5 (Cqpy). ESI-HRMS: m/z 403.1519 ([M+H]+ calcd for C21H19N6O5, 403.1513). 
 
4.2.1.2. O-extension, carboxylic coordinating arm 
methyl 2-(2-(tert-butoxycarbonylamino)phenoxy)acetate (6). To a solution of 1 (1.52 
g, 7.3 mmol) in CH3CN (15 mL) was added K2CO3 (1.51 g, 10.9 mmol) and methyl 
bromoacetate (d = 1.616, 0.76 mL, 8.0 mmol) under argon atmosphere. The mixture was heated 
to reflux for 16 h. After reaction, the resulting mixture was evaporated to dry. Then the residue 
was dissolved in ethyl acetate (50 mL) and washed twice with H2O (2 x 30 mL) and brine (20 
mL). The organic layer was dried with anhydrous MgSO4 and concentrated under reduced 
pressure, the residue was purified by column chromatography (silica gel, ethyl 
acetate/petroleum ether, v/v = 1/10) to give 6 as a yellow oil (1.94 g, yield 95%). 1H NMR (300 
MHz, CDCl3): δ (ppm) = 1.53 (s, 9H, Boc), 3.80 (s, 3H, OCH3), 4.68 (s, 2H, CH2), 6.77 (dd, J 
= 8.0, 1.5 Hz, 1H, HAr), 6.90-7.02 (m, 2H, HAr), 7.37 (br s, 1H, NH), 8.11 (d, J = 7.6 Hz, 1H, 
HAr). 13C NMR (75 MHz, CDCl3) δ (ppm) = 28.4 ((CH3)3), 52.4 (OCH3), 66.6 (CH2), 80.3 
(CMe3), 112.4 (CHAr), 118.9 (CHAr), 122.3 (CHAr), 122.7 (CHAr), 129.1 (CqN), 146.2 (CqO), 
152.8 (NHCO), 169.4 (CO ester). DCI/NH3-MS: m/z 282.1 ([M+H]+ calcd for C14H20NO5, 
282.1); 299.0 ([M+NH4]+ calcd for C14H23N2O5, 299.2). 
 
tert-butyl 2-(2-(tert-butoxycarbonylamino)phenoxy)acetate (7). Using same 
procedure than compound 6 preparation, 1 (1.21 g, 5.8 mmol), K2CO3 (1.20 g, 8.7 mmol), and 
tert-butyl bromoacetate (d= 1.321, 0.93 mL, 6.4 mmol) in CH3CN (20 mL) gave, after 
purification by column chromatography (silica gel, ethyl acetate/petroleum ether, v/v = 1/10), 
7 as a light yellow solid (1.77 g, yield 94%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 1.49 (s, 
9H, Boc), 1.52 (s, 9H, t-Bu), 4.55 (s, 2H, CH2), 6.74-6.77 (m, 1H, HAr), 6.89-7.01 (m, 2H, HAr), 
7.38 (br s, 1H, NH), 8.08-8.11 (d, J = 7.6 Hz, 1H, HAr). 13C NMR (75 MHz, CDCl3) δ (ppm) = 
28.1, 28.4 (2(CH3)3), 67.0 (CH2), 80.3, 80.7 (CMe3), 112.2 (CHAr), 118.7 (CHAr), 122.2 (CHAr), 
122.4 (CHAr), 129.1 (CqN), 146.3 (CqO), 152.8 (NHCO), 169.4 (CO ester). DCI/NH3-MS: m/z 
324.2 ([M+H]+ calcd for C17H25NO5, 324.2); 341.2 ([M+NH4]+ calcd for C14H23N2O5, 341.2). 
 
4-(prop-2-ynyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (9). To a solution of 6 (1.94 g, 6.9 
mmol) in distilled DMF (20 mL) was added NaH (0.66 g, 27.6 mmol) under argon atmosphere 
at 0ºC. The mixture was stirred at 0ºC for 30 min. Then propargyl bromide solution (80 wt. % 
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in toluene, 1.0 mL, 9.0 mmol) was added dropwise and stirred at room temperature for 16 h. 
The reaction mixture was quenched with water (10 mL) and extracted twice with ethyl acetate 
(2 x 50 mL). All the organic layers were combined, washed twice with H2O (2 x 30 mL) and 
brine (20 mL), dried over anhydrous MgSO4 and the filtrate was concentrated under reduced 
pressure to give a yellow oil corresponding to 2-(2-(tert-butoxycarbonyl(prop-2-
ynyl)amino)phenoxy)acetic acid (8) (1.87 g, yield 89%; DCI/CH4-MS: m/z 206.0833 ([M-
Boc+2H]+ calcd for C11H12NO3, 206.0812). The product was employed in the following step 
without further purification.  
 
To 0.25 g of 8 (0.81 mmol) in CH2Cl2 (10 mL) was added an excess of trifluoroacetic 
acid (1.5 mL, 20 mmol). The mixture was stirred at 0ºC for 2 h, then concentrated to dry under 
reduced pressure and purified by column chromatography (silica gel, ethyl acetate/petroleum 
ether, v/v = 1/4) to give 9 as a light yellow solid (115 mg, yield 76%). 1H NMR (300 MHz, 
CDCl3): δ 2.26 (t, J = 2.5 Hz, 1H, CH), 4.64 (s, 2H, CH2), 4.70 (d, J = 2.5 Hz, 2H, CH2), 6.99-
7.11 (m, 3H, HAr), 7.19-7.22 (m, 1H, HAr). 
 
tert-butyl 2-(2-(prop-2-ynylamino)phenoxy)acetate (11). To a solution of 10 (180 
mg, 1.22 mmol) in CH3CN (15 mL) was added K2CO3 (337 mg, 2.44 mmol), KI (41 mg, 0.24 
mmol) and tert-butyl bromoacetate (d = 1.321, 0.20 mL, 1.35 mmol) under an argon 
atmosphere. The mixture was heated to reflux for 16 h and the reaction was stopped by 
evaporation under vacuum. The residue was dissolved in ethyl acetate (50 mL) and washed 
twice with H2O (2 x 30 mL) and brine (20 mL). The organic layer was dried over anhydrous 
MgSO4 and the filtrate was concentrated under reduced pressure, the residue was purified by 
column chromatography (silica gel, ethyl acetate/petroleum ether, v/v = 1/10) to give 11 as a 
light yellow oil (290 mg, yield 91%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 1.49 (s, 9H, t-
Bu), 2.19 (t, J = 2.4 Hz, 1H, CH), 3.98 (d, J = 2.4 Hz, 2H, NCH2), 4.52 (s, 2H, OCH2), 6.69-
6.76 (m, 3H, HAr), 6.93-6.97 (m, 1H, HAr). 13C NMR (75 MHz, CDCl3) δ (ppm) = 28.1 ((CH3)3), 
33.2 (NCH2), 66.8 (OCH2), 71.0 (CH), 79.8 (CqCH), 82.4 (CMe3), 11.3 (CHAr), 111.9 (CHAr), 
117.5 (CHAr), 122.5 (CHAr), 137.6 (CqN), 145.9 (CqO), 168.2 (CO ester). DCI/CH4-MS: m/z 
262.14 ([M+H]+ calcd for C15H20NO3, 262.14). 
 
tert-butyl 2-(2-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-
yl)methylamino)phenoxy)acetate (13). 11 (280 mg, 1.07 mmol), 4-nitrophenyl azide (211 mg, 
1.29 mmol), copper(II) acetate monohydrate (64 mg, 0.32 mmol) and sodium ascorbate (106 
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mg, 0.54 mmol) in t-BuOH/H2O (v/v = 1/1, 20 mL) were stirred at room temperature for 16 h. 
The mixture was partitioned between ethyl acetate (50 mL) and saturated Na2EDTA solution 
(50 mL). The organic phase was washed twice with water (2 x 50 mL) and dried over anhydrous 
Mg2SO4. The filtrate was evaporated and purified by column chromatography (silica gel, ethyl 
acetate/petroleum ether, v/v = 1/3) to give 13 as an orange solid (320 mg, yield 81%).  
 
Alternative way: To a solution of compound 12 (90 mg, 0.29 mmol) in CH3CN (15 mL) 
were added K2CO3 (80 mg, 0.58 mmol), KI (10 mg, 0.058 mmol) and tert-butyl bromoacetate 
(d = 1.321, 0.047 mL, 0.32 mmol) under argon atmosphere. The mixture was heated to reflux 
for 16 h and stopped by evaporation under vacuum. The residue was dissolved in ethyl acetate 
(50 mL) and washed twice with H2O (2 x 30 mL) and brine (20 mL). The organic layer was 
dried over anhydrous MgSO4 and the filtrate was concentrated under reduced pressure. The 
residue was purified by column chromatography (silica gel, ethyl acetate/petroleum ether, v/v 
= 1/2) to give 13 as an orange solid (60 mg, yield 48%). 1H NMR (300 MHz, CDCl3): δ (ppm) 
= 1.50 (s, 9H, t-Bu), 4.60 (s, 2H, NCH2), 4.66 (s, 2H, OCH2), 6.65-6.75 (m, 3H, HAr), 6.85-6.90 
(m, 1H, HAr), 7.97 (dt, J = 2.7, 9.0 Hz, 2H, HArNO2), 8.14 (s, 1H, Hta), 8.35 (dt, J = 2.7, 9.0 Hz, 
2H, HArNO2). 13C NMR (75 MHz, CDCl3) δ (ppm) = 28.1 ((CH3)3), 39.9 (NCH2), 66.5 (OCH2), 
82.6 (Cqt-Bu), 111.4 (CHAr), 111.9 (CHta), 117.5 (CHAr), 119.9 (CHAr), 120.3 (CHArNO2), 122.7 
(CHAr), 125.4 (CHAr-NO2), 137.9 (Cqta), 141.3 (CqNH), 145.7 (CqN), 147.0 (CqO), 149.1 (CqNO2), 
168.5 (CO ester). ESI-HRMS m/z 426.1775 ([M+H]+ calcd for C21H24N5O5, 426.1777). 
 
4-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2H-benzo[b][1,4]oxazin-
3(4H)-one (L3). To a solution of 13 (72 mg, 0.17 mmol) in CH2Cl2 (10 mL) was added an 
excess of trifluoroacetic acid (1.5 mL, 20 mmol). The reaction was stirred at 0ºC for 2 h. The 
mixture was concentrated to dry under reduced pressure and purified by column 
chromatography (silica gel, ethyl acetate/petroleum ether, v/v = 1/2) to give L3 as a white solid 
(45 mg, yield 75%). 
  
Alternative way: 9 (0.110 g, 0.59 mmol), 4-nitrophenyl azide (125 mg, 0.76 mmol), 
copper(II) acetate monohydrate (35 mg, 0.18 mmol) and sodium ascorbate (59 mg, 0.30 mmol) 
in t-BuOH/H2O (v/v = 1/1, 10 mL) were stirred at room temperature for 16 h. The mixture was 
partitioned between ethyl acetate (50 mL) and saturated Na2EDTA solution (50 mL). The 
organic phase was washed twice with water (2 x 30 mL) and dried over anhydrous MgSO4. The 
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filtrate was evaporated and purified by column chromatography (silica gel, ethyl 
acetate/petroleum ether, v/v = 1/2) to give L3 as a white solid (153 mg, yield 74%).  
1H NMR (300 MHz, CDCl3): δ (ppm) = 4.70 (s, 2H, NCH2), 5.34 (s, 2H, OCH2), 6.99-7.11 (m, 
3H, HAr), 7.46-7.50 (m, 1H, HAr), 8.00 (dt, J = 2.7, 9.0 Hz, 2H, HArNO2), 8.32 (s, 1H, Hta), 8.41 
(dt, J = 2.7, 9.0 Hz, 2H, HArNO2). ESI-HRMS m/z 352.1040 ([M+H]+ calcd for C17H14N5O4, 
352.1046). 
 
methyl 2-(4-((3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)methyl)-1H-1,2,3-triazol-1-
yl)acetate (L4). Using same procedure than compound L3 preparation, 9 (96 mg, 0.51 mmol), 
methyl 2-azidoacetate (76 mg, 0.66 mmol), copper(II) acetate monohydrate (29 mg, 0.15 mmol) 
and sodium ascorbate (49 mg, 0.25 mmol) in t-BuOH/H2O (v/v = 1/1, 10 mL) gave, after 
purification by column chromatography (silica gel, ethyl acetate/petroleum ether, v/v = 1/1), L4 
as a light yellow solid (103 mg, yield 67%). 1H NMR (500 MHz, CDCl3): δ (ppm) = 3.78 (s, 
3H, OCH3), 4.60 (s, 2H, OCH2CO), 5.12 (s, 2H, NCH2CO), 5.20 (s, 2H, NCH2), 6.95-7.05 (m, 
3H, HAr), 7.50-7.52 (m, 1H, HAr), 7.73 (s, 1H, Hta). 13C NMR (125 MHz, CDCl3) δ (ppm) = 
37.7 (CH2), 50.8 (CH2), 53.1 (OCH3), 67.8 (CH2), 116.0 (CHAr), 116.9 (CHAr), 123.2 (CHAr), 
124.2 (CHAr), 124.9 (CHta), 128.7 (CqN), 143.7 (Cqta), 145.1 (CqO), 164.9 (CO amide), 166.5 
(CO ester). ESI-HRMS m/z 303.1096 ([M+H]+ calcd for C14H15N4O4, 303.1093). Suitable 
crystals for X-ray structure determination were grown by slow evaporation of a mixture of 
acetone and ethanol solution. 
 
4.2.1.3. N-extension 
2-(tert-butoxycarbonyl(prop-2-ynyl)amino)acetic acid (14). To a solution of N-Boc-
glycine (0.175 g, 1.0 mmol) in distilled DMF (10 mL) was added under argon atmosphere at 
0ºC, sodium hydride (0.096 g, 4 mmol) in two portions. After stirring 30 minutes, propargyl 
bromide (0.18 mL, 1.7 mmol, 80% in toluene) was added dropwise. The resulting mixture was 
stirred at room temperature overnight. The reaction was quenched with water, followed by 
addition of 1 M HCl solution until the pH was 3. Then the mixture was extracted twice with 
ethyl acetate (50 mL). All the organic layers were combined, washed twice with water (15 mL), 
brine (15 mL) and dried over anhydrous MgSO4. The filtrate was concentrated to give 14 as 
yellow oil (180 mg, yield 85%). The compound was used in the next step without further 
purification. 1H NMR (300 MHz, CDCl3): δ 1.45 (s, 9H, Boc), 2.50 (t, J = 2.5 Hz, 1H, CH), 
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3.97 (d, J = 5.6 Hz, 2H, CH2), 4.75 (d, J = 2.5 Hz, 2H, CH2). DCI/NH3-MS: m/z 214.1 ([M+H]+ 
calcd for C10H16NO4, 214.1); 231.0 ([M+NH4]+ calcd for C10H19N2O4, 231.1). 
 
N-hydroxysuccinimidyl 2-(tert-butoxycarbonyl(prop-2-ynyl)amino)acetate (15). 
To a solution of 14 (180 mg, 0.84 mmol) in CH2Cl2 (10 mL) was added under an argon 
atmosphere at 0ºC, N-hydroxysuccinimide (146 mg, 1.27 mmol) and catalytic amount of 
dimethylaminopyridine (10 mg, 0.08 mmol). Then dicyclohexylcarbodiimide (262 mg, 1.27 
mmol) in CH2Cl2 (10 mL) was added dropwise. The reaction was stirred at 0ºC for another 45 
minutes and at room temperature overnight. The resulting mixture was filtered and the filtrate 
was washed with 0.5 M HCl, until the pH was 3, then brine (15 mL). The organic phase was 
dried over anhydrous MgSO4, filtered and concentrated under vacuum. The residue was 
dissolved in a minimum volume of ethyl acetate and placed at -20ºC to allow dicyclohexylurea 
to precipitate. After filtration and concentration of the solution, 15 was obtained as a yellow 
solid (250 mg, yield 81%). 1H NMR (300 MHz, CDCl3): δ 1.48 (s, 9H, Boc), 2.33 (t, J = 2.4 
Hz, 1H, CH), 2.85 (s, 4H, 2CH2), 4.25 (d, J = 2.4 Hz, 2H, CH2), 4.39 (s, 2H, CH2). NH3-MS: 
m/z 211.1 ([M-Boc+2H]+ calcd for C9H11N2O4, 211.4). 
 
tert-butyl 2-(2-hydroxyphenylamino)-2-oxoethyl(prop-2-ynyl)carbamate (16). To a 
solution of 15 (380 mg, 1.2 mmol) and 2-aminophenol (158 mg, 1.45 mmol) in CH3CN (10 
mL) was added 4-dimethylaminopyridine (146 mg, 1.2 mmol). The mixture was heated to 60ºC 
under argon overnight. After cooling to room temperature, the resulting solution was 
concentrated to dryness and the residue was purified by column chromatography (silica gel, 
ethyl acetate/petroleum ether, v/v = 1/2) to afford 16 as a pale white solid (280 mg, yield 77%). 
1H NMR (300 MHz, CDCl3): δ 1.48 (s, 9H, Boc), 2.34 (s, 1H, CH), 4.13 (s, CH2), 4.20 (s, 2H, 
CH2), 6.82-6.87 (m, 1H, HAr), 6.96-7.11 (m, 3H, HAr). DCI/NH3-MS: m/z 305.4 ([M+H]+ calcd 
for C16H21N2O4, 305.1); 205.3 ([M-Boc+2H]+ calcd for C11H13N2O2, 205.1). 
 
methyl 2-(4-((tert-butoxycarbonyl(2-(2-hydroxyphenylamino)-2-
oxoethyl)amino)methyl)-1H-1,2,3-triazol-1-yl)acetate (17). Using same procedure as the 
preparation of compound L1, 16 (0.28 g, 0.92 mmol), methyl azidoacetate (138 mg, 1.2 mmol), 
copper (II) acetate (55 mg, 0.28 mmol) and sodium ascorbate (91 mg, 0.46 mmol) in t-
BuOH/H2O (v/v = 1/1, 20 mL) gave after purification by column chromatography (silica gel, 
ethyl acetate/petroleum ether, v/v = 2/1), 17 as a brown solid (289 mg, yield 75%). 1H NMR 
(300 MHz, CDCl3): δ 1.39 (s, 9H, Boc), 3.76 (s, 3H, OCH3), 4.13 (s, 2H, CH2CO), 4.62 (s, 2H, 
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CH2N), 5.14 (s, 2H, CH2COO), 6.82-7.09 (m, 3H, HAr), 7.34 (d, J = 6.3 Hz, 1H, HAr), 7.65 (s, 
1H, Hta). DCI/NH3-MS: m/z 420.5 ([M+H]+ calcd for C19H26N5O6, 420.2). 
 
methyl 2-(4-((2-(2-hydroxyphenylamino)-2-oxoethylamino)methyl)-1H-1,2,3-
triazol-1-yl)acetate (L5). To a solution of 17 (0.30 g, 0.72 mmol) in CH2Cl2 (10 mL) was added 
an excess of trifluoroacetic acid (3 mL, 40 mmol). The reaction was stirred at 0ºC until the 
consumption of the starting material (2 h, monitored by TLC). After reaction, the mixture was 
evaporated to dry and purified by column chromatography (silica gel, ethanol/dichloromethane, 
v/v = 1/10) to give L5 as a brown oil (188 mg, yield 82%). 1H NMR (500 MHz, CDCl3): δ 3.41 
(s, 2H, CH2CO), 3.74 (s, 3H, OCH3), 3.94 (s, 2H, CH2N), 5.11 (s, 2H, CH2COO), 6.82 (t, J = 
7.5 Hz, 1H, HAr), 6.95 (d, J = 8.0 Hz, 1H, HAr), 7.04 (t, J = 7.5 Hz, 1H, HAr), 7.33 (d, J = 8.0 
Hz, 1H, HAr), 7.60 (s, 1H, Hta). 13C NMR (125 MHz, CDCl3) δ (ppm) = 44.3 (NCH2), 50.7 
(CH2COO), 51.6 (COCH2), 53.1 (OCH3), 118.6 (CHAr), 120.2 (CHAr), 121.9 (CHAr),123.6 
(CHta), 125.4 (CqNH), 126.5 (CHAr), 145.7 (Cqta), 148.2 (CqO), 166.8 (CO ester), 171.2 (CO 
amide); ESI-HRMS: m/z 320.1359 ([M+H]+ calcd for C14H18N5O4, 320.1353).  
 
4.2.1.4. Rhenium complexation 
[Re(CO)3Cl(L1)]. A 10 mL methanolic solution of ligand L1 (100 mg, 0.28 mmol), 
[Re(CO)5Cl] (118 mg, 0.33 mmol) and diisopropylethyl amine (40 mg, 0.31 mmol) was stirred 
at 65ºC overnight. After cooling to room temperature, the solution was concentrated under 
reduced pressure. The resulting residue was purified by column chromatography (silica gel, 
ethyl acetate) to give a light yellow solid (102 mg, yield 80%). 1H NMR (300 MHz, CDCl3): δ 
3.86 (s, 3H, OCH3), 4.93 (d, J = 6.3 Hz, 2H, NCH2), 5.23 (s, 2H, OCH2), 5.29 (t, J = 6.3 Hz, 
1H, NH), 5.49 (s, 2H, CH2COO), 6.56-6.61 (m, 1H, HAr), 6.72-6.78 (m, 1H, HAr), 6.87-6.94 
(m, 2H, HAr), 7.28-7.30 (m, 1H, Hpy), 7.47 (d, J = 7.8 Hz, 1H, Hpy), 7.75 (td, J = 1.0 Hz, J = 7.5 
Hz, 1H, Hpy), 8.02 (s, 1H, Hta), 8.60-8.62 (m, 1H, Hpy). 13C NMR (75 MHz, CDCl3) δ 41.7 
(NHCH2), 52.3 (CH2CO), 54.1 (OCH3), 71.7 (OCH2), 110.8 (CHAr), 112.4 (CHAr), 
118.7(CHAr), 121.9 (CHpy), 122.3 (CHAr), 123.2 (CHpy), 128.4 (CHta), 136.5 (Cq), 137.1 (CHpy), 
146.2 (CqO), 149.5 (CHpy), 152.9 (CqNH), 156.5 (CqN), 164.3 (CO ester), 196.5, 197.2. 197.5 
(Re(CO)3). IR (ATR): ν(CO) = 2025, 1905, 1883, ν(C=O) = 1756 cm–1. ESI-HRMS: m/z 
624.0903 ([M-Cl]+ calcd for C21H19N5O6187Re, 624.0894). Anal. calcd (%) for 
C21H19N5O6ReCl: C 38.27, H 2.91, N 10.63; found: C 38.54, H 2.98, N 11.02. 
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[Re(CO)3Cl(L2)]. Using the same protocol than above, 10 mL methanolic solution of 
ligand L2 (100 mg, 0.25 mmol), [Re(CO)5Cl] (104 mg, 0.29 mmol) and diisopropylethyl amine 
(36 mg, 0.28 mmol) gave, after purification by column chromatography (silica gel, ethyl 
acetate), a light yellow solid (100 mg, yield 60%). Suitable crystals of [Re(CO)3Cl(L2)] for X-
ray crystal structure determination were grown by slow evaporation of an acetonitrile and 
diethyl ether mixture. 1H NMR (500 MHz, CDCl3): δ 4.39-4.43 (m, 1H, NCH2), 4.98-5.02 (m, 
1H, NCH2), 5.31-5.44 (m, 2H, OCH2), 7.02-7.10 (m, 2H, HAr), 7.15-7.18 (m, 1H, HAr), 7.21-
7.25 (m, 2H, HAr, Hpy), 7.75-7.76 (m, 2H, Hpy), 8.03-8.05 (m, 2H, HAr), 8.20 (s, 1H, Hta), 8.47-
8.50 (m, 2H, HAr), 8.59-8.60 (m, 1H, Hpy). 13C NMR (125 MHz, CDCl3) δ 50.9 (NCH2), 72.1 
(OCH2), 113.6 (CHAr), 118.3 (CHta), 120.4 (CHpy), 121.3 (CHAr), 122.2 (CHAr), 122.5 (CHpy), 
123.2 (CHAr), 125.9 (CHAr), 127.0 (CHAr), 137.4 (CHpy), 139.6 (CqNH), 148.1 (CqO), 148.3 
(CqNO2), 149.1(CHpy), 150.4 (Cqta), 155.6 (Cqpy), 191.7, 193.9, 195.7 (Re(CO)3). IR (ATR): 
ν(CO) = 2023, 1914, 1886 cm–1. ESI-HRMS: m/z 709.0598 ([M+H]+ calcd for 
C24H19ClN6O6187Re, 709.0607); 673.0836 ([M-Cl]+ calcd for C24H18N6O6187Re, 673.0845). 
Anal. calcd (%) for C24H19N6O6ReCl: C 40.65, H 2.70, N 11.85; found: C 40.97, H 2.35, N 
11.59. 
 
[ReO(L5)]. A 20 mL-methanolic solution of ligand L5 (200 mg, 0.63 mmol), 
[ReO(PPh3)2Cl3] (678 mg, 0.82 mmol) and sodium acetate (206 mg, 2.52 mmol) was stirred at 
65ºC overnight. After cooling to room temperature, the solution was concentrated under 
reduced pressure. The resulting residue was purified by column chromatography (silica gel, 
ethanol/dichloromethane, v/v = 1/10) to give a dark brown solid (210 mg, yield 64%). 1H NMR 
(500 MHz, CDCl3): δ 3.84 (s, 3H, OCH3), 4.03-4.07 (m, 1H, CH2N), 4.77 (AB syst., J = 18.0 
Hz, 1H, CH2CON), 5.17 (AB syst., J = 18.0 Hz, 1H, CH2CON), 5.22-5.26 (m, 1H, CH2N), 5.41 
(br s, 2H, CH2COO), 6.87 (t, J = 7.5 Hz, 1H, HAr), 6.95 (t, J = 7.5 Hz, 1H, HAr), 7.10 (d, J = 
7.5 Hz, 1H, HAr), 7.83 (s, 1H, Hta), 8.12 (dd, J = 1.0 Hz, J = 7.5 Hz, 1H, HAr). 13C NMR (125 
MHz, CDCl3) δ 53.9 (OCH3), 54.1 (CH2CO), 64.5 (NCH2), 70.9 (COCH2), 115.7 (CHAr), 118.5 
(CHAr), 120.4 (CHAr), 124.2 (CHAr), 141.8 (CqN), 159.3 (Cqta), 165.2 (CO ester), 169.0 (CqO), 
188.2 (CO amide). IR (ATR): ν(C=O) = 1753 and 1667 cm–1, ν(Re=O) 959 cm–1. ESI-HRMS: 
m/z 520.0631 ([M+H]+ calcd for C14H15N5O5187Re, 520.0625); 542.0450 ([M+Na]+ calcd for 
C14H15N5O5187ReNa, 542.0445). Anal. calcd (%) for C14H14N5O5Re: C 32.43, H 2.72, N 13.51; 
found: C 32.70, H 2.57, N 13.28. 
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4.2.2. Syntheses for Part 2: Dirhenium(I) complexation 
[Re2(CO)6(μ-Cl)(μ-OMe)(μ-L4)]. A mixture of ligand L4 (131 mg, 0.43 mmol), 
[Re(CO)5Cl] (312 mg, 0.86 mmol) and diisopropylethyl amine (0.08 mL, 0.45 mmol) in 
methanol (10 mL) were stirred at 65ºC for 16 h. After cooling to room temperature, the solution 
was concentrated under reduced pressure. The resulting residue was purified by column 
chromatography (silica gel, acetone/dichloromethane, v/v = 1/1) to give [Re2(CO)6(μ-Cl)(μ-
OMe)(μ-L4)] as a light yellow solid (236 mg, yield 60%). 1H NMR (300 MHz, CDCl3): δ (ppm) 
= 3.87 (s, 3H, COOCH3), 4.17 (s, 3H, OCH3), 4.75 (s, 2H, COCH2O), 5.53 (s, 2H NCH2CO), 
5.64 (s, 2H, NCH2), 6.96-7.00 (m, 1H, HAr), 7.08-7.10 (m, 3H, HAr), 7.80 (s, 1H, Hta), ESI-MS 
m/z 857 ([M-Cl-CH3+H]+).  
 
[Re2(CO)6(μ-OEt)2(μ-L4)]. Suitable crystals for X-ray structure determination were 
grown by slow evaporation of a mixture of acetone and ethanol solution to give [Re2(CO)6(μ-
OEt)2(μ-L4)] as white crystals: 1H NMR (300 MHz, CDCl3): δ (ppm) = 1.16 (t, J = 6.9 Hz, 6H, 
2CH3), 3.86 (s, 3H, COOCH3), 4.18 (q, J = 6.9 Hz, 4H, 2OCH2), 4.75 (s, 2H, COCH2O), 5.53 
(s, 2H, NCH2CO), 5.65 (d, J = 0.54 Hz, 2H, NCH2), 6.96-6.97 (m, 1H, HAr), 7.06-7.10 (m, 3H, 
HAr), 7.77 (s, 1H, Hta). 13C NMR (75 MHz, CDCl3) δ (ppm) = 19.8 (2CH3), 39.3 (NCH2), 53.5 
(NCH2CO), 54.3 (OCH3), 67.7 (COCH2O), 76.4 (2OCH2), 115.0, 117.8, 123.7, 125.3 (CHAr), 
127.4 (CqN), 127.8 (CHta), 145.4 (CqO), 148.6 (Cqta), 164.0 (CO amide), 165.3 (CO ester), 
195.9, 196.0, 196.3, 196.5, 196.9, 197.0 (CO), ESI-MS m/z 857 ([M-(C2H5O)-(C2H5)+H]+), 
UV-Vis (MeOH; λmax (nm) (ε; [dm3·mol–1·cm–1]): 338 (3100), 301 (7900), 281 (12700), 261 
(13500), 207 (50900).  
 
[Re2(CO)6(μ-Cl)2(μ-L4)]. A mixture of ligand L4 (40 mg, 0.13 mmol), [Re(CO)5Cl] (96 
mg, 0.26 mmol) in toluene (10 mL) were stirred at 65ºC for 16 h. After cooling to room 
temperature, the solution was concentrated under reduced pressure. The resulting residue was 
purified by column chromatography (silica gel, acetone/dichloromethane, v/v = 1/10) to give 
[Re2(CO)6(μ-Cl)2(μ-L4)] as a white solid (78 mg, yield 65%). 1H NMR (300 MHz, CDCl3): δ 
(ppm) = 3.87 (s, 3H, OCH3), 4.76 (s, 2H, COCH2O), 5.59 (s, 2H NCH2CO), 5.67 (s, 2H, NCH2), 
6.89-6.92 (m, 1H, HAr), 7.08-7.13 (m, 3H, HAr), 7.77 (s, 1H, Hta), ESI-HRMS m/z 874.9458 
([M-Cl]+: calcd for C20H14N4O10Cl185Re2, 874.9457). 
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4.2.3. Syntheses for Part 3 
4.2.3.1. Syntheses of the ligands 
2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl methanesulfonate (18). To an ice-cooled 
solution of metronidazole (2.04 g, 12 mmol) and triethylamine (2.5 mL, 18 mmol) in distilled 
CH2Cl2 (50 mL) was added methane sulfonyl chloride (1.4 mL, 18 mmol) dropwise. The 
reaction mixture was stirred at 0ºC for 2h (monitored by TLC). The resulting mixture was 
filtered and washed with water (3 x 20 mL) and dried in vacuo to give 18 as a white powder 
(2.32 g, yield 78%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) = 2.48 (s, 3H, Mtz-CH3), 3.17 
(s, 3H, CH3SO2), 4.59 (t, J = 4.8 Hz, 2H, OCH2), 4.69 (t, J = 4.8 Hz, 2H, NCH2), 8.09 (s, 1H, 
HMtz). 13C NMR (75 MHz, DMSO-d6): δ (ppm) = 14.5 (CH3-Mtz), 37.2 (CH3SO2), 45.6 (NCH2), 
69.0 (OCH2), 133.6 (CqNO2), 138.9 (CHMtz), 152.2 (CqCH3). ESI-MS: m/z 250.3 ([M+H]+ calcd 
for C7H12N3O5S, 250.0). 
 
1-(2-azidoethyl)-2-methyl-5-nitro-1H-imidazole (19). A mixture of 18 (1.25 g, 5 
mmol) and NaN3 (0.41 g, 6 mmol) in distilled DMF (50 mL) was heated to 100ºC for 4 h. After 
cooling to room temperature, 50 mL of water were added and the solution became clear. The 
resulting mixture was extracted with ethyl acetate (3 x 30 mL). All the organic layers were 
combined, washed with water (2 x 30 mL), dried with anhydrous Na2SO4 and concentrated in 
vacuo to give 19 as a yellow oil (0.83 g, yield 85%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 
2.50 (s, 3H, CH3), 3.72-3.76 (m, 2H, CH2), 4.39-4.42 (m, 2H, CH2), 7.93 (s, 1H, HMtz). ESI-
MS: m/z 197.0 ([M+H]+ calcd for C6H9N6O2, 197.1). 
 
2-((1-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)-1H-1,2,3-triazol-4-
yl)methylamino)phenol (L6). A mixture of azide 19 (0.98 g, 5.0 mmol), alkyne 10 (0.57 g, 3.8 
mmol), copper (II) acetate monohydrate (0.23 g, 1.1 mmol) and sodium ascorbate (0.38 g, 1.9 
mmol) in t-BuOH/H2O (v/v = 1/1, 20 mL) was stirred at room temperature for 16 h and then 
partitioned between ethyl acetate (50 mL) and saturated Na2EDTA solution (50 mL). The 
organic phase was washed with water (2 x 50 mL) and dried over anhydrous Na2SO4. The 
filtrate was evaporated and purified by column chromatography (silica gel, ethyl acetate) to 
give L6 as a yellow solid (0.53 g, yield 41%). 1H NMR (500 MHz, MeOD): δ (ppm) = 1.78 (s, 
3H, CH3), 4.42 (s, 2H, NHCH2), 4.75-4.77 (m, 2H, CH2), 4.84-4.86 (m, 2H, CH2), 6.52-6.56 
(m, 1H, HAr), 6.59-6.61 (m, 1H, HAr), 6.68-6.71 (m, 2H, HAr), 7.74 (s, 1H, Hta), 7.98 (s, 1H, 
HMtz). 13C NMR (125 MHz, MeOD): δ (ppm) = 11.6 (CH3), 38.7 (NHCH2), 46.2, 49.1 (CH2), 
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111.3, 113.4, 117.5, 119.8 (CHAr), 123.4 (CHta), 131.6 (CHMtz), 136.3 (CqO), 138.6 (CqNO2), 
144.8 (CqNH), 147.5 (Cqta), 151.1 (CqCH3). ESI-MS: m/z 344.1479 ([M+H]+ calcd for 
C15H18N7O3, 344.1471). 
 
2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-methylbenzenesulfonate (20). To a 
solution of Metronidazole (3.14 g, 20 mmol) and triethylamine (3.0 mL, 22 mmol) in CH2Cl2 
(20 mL) was added 4-methyl-benzenesufonyl chloride (3.83 g, 20.1 mmol) in CH2Cl2 (10 mL) 
dropwise. The reaction mixture was stirred at 0ºC for 5 h followed by the addition of 50 mL of 
ice water. Then, the layers were separated and the aqueous layer was extracted with ethyl acetate 
(2 x 50 mL). All the organic layers were combined, washed with saturated NaHCO3 (2 x 30 
mL), dried with anhydrous Na2SO4 for 0.5 hour and concentrated in vacuo to give 20 as a light 
yellow solid (4.94 g, yield 75%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 2.45 (s, 3H, CH3), 
2.51 (s, 3H, Mtz-CH3), 4.35-4.38 (m, 2H, CH2), 4.52-4.55 (m, 2H, CH2), 7.27-7.28 (m, 1H, 
HAr), 7.30-7.31 (m, 1H, HAr), 7.57-7.59 (m, 1H, HAr), 7.60-7.62 (m, 1H, HAr), 7.80 (s, 1H, HMtz). 
ESI-MS: m/z 326.1 ([M+H]+ calcd for C13H16N3O5, 326.1). 
 
2-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy)-N-(prop-2-ynyl)aniline (22). To a 
mixture of 10 (147 mg, 1 mmol) and K2CO3 (690 mg, 5 mmol) in DMF (20 mL) stirred at 80ºC 
for 0.5 h, was added 20 (390 mg, 1.2 mmol) in DMF (10 mL) dropwise. The resulting mixture 
was stirred at 80ºC for 22 h. After cooling to room temperature, water (30 mL) was added and 
the mixture was extracted with ethyl acetate (2 x 50 mL). All the organic layers were combined, 
dried with anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, ethyl acetate/petroleum ether, v/v = 2/1) to give 22 as a yellow solid 
(180 mg, yield 60%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 2.23 (t, J = 2.4 Hz, 1H, CH), 2.54 
(s, 3H, Mtz-CH3), 3.89 (s, 2H, NHCH2), 4.35 (t, J = 5.1 Hz, 2H, CH2), 4.74 (t, J = 5.1 Hz, 2H, 
CH2), 6.55-6.72 (m, 3H, HAr), 6.88-6.94 (m, 1H, HAr), 7.96 (s, 1H, HMtz). ESI-MS: m/z 301.1 
([M+H]+ calcd for C15H17N4O3, 301.1). 
 
During this reaction, the following by-product 21 was obtained in 30% yield: 
2-methyl-5-nitro-1-vinyl-1H-imidazole (21). 1H NMR (300 MHz, CDCl3): δ (ppm) = 
2.49 (s, 3H, CH3), 5.42 (dd, J = 1.2, 15.6 Hz, 1H, CH2), 5.64 (dd, J = 1.2, 8.1 Hz, 1H, CH2), 
7.08 (dd, J = 8.1, 15.6 Hz, 1H, CH), 7.90 (s, 1H, HMtz). ESI-MS: m/z 154.1 ([M+H]+ calcd for 
C16H8N3O2, 154.1). 
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2-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy)-N-((1-(4-nitrophenyl)-1H-1,2,3-
triazol-4-yl)methyl)aniline (L7). A mixture of compound 22 (270 mg, 0.9 mmol), 4-
nitrophenyl azide (177 mg, 1.1 mmol), copper (II) acetate monohydrate (60 mg, 0.3 mmol) and 
sodium ascorbate (90 mg, 0.45 mmol) in t-BuOH/H2O (v/v = 1/1, 20 mL) was stirred at room 
temperature for 16 h and then partitioned between ethyl acetate (50 mL) and saturated 
Na2EDTA solution (50 mL). The organic phase was washed with water (2 x 30 mL) and dried 
over anhydrous MgSO4. The filtrate was evaporated and purified by column chromatography 
(silica gel, ethyl acetate) to give L7 as a yellow solid (140 mg, yield 67%). Suitable crystals for 
X-ray structure determination were grown by slow evaporation of a mixture of acetonitrile and 
ethyl ether solution giving light yellow crystals.vi 1H NMR (300 MHz, CDCl3): δ (ppm) = 2.51 
(s, 3H, CH3), 4.37 (t, J = 5.1 Hz, 2H, OCH2), 4.54 (d, J = 5.4 Hz, 2H, NHCH2), 4.81 (t, J = 5.1 
Hz, 2H, NCH2), 6.66-6.76 (m, 3H, HAr), 6.88-6.93 (m, 1H, HAr), 7.96 (s, 1H, HMtz), 8.04-8.09 
(m, 2H, HAr), 8.13 (s, 1H, Hta), 8.39-8.44 (m, 2H, HAr). 13C NMR (75 MHz, CDCl3): δ (ppm) = 
14.6 (CH3), 39.7 (NHCH2), 45.6 (NCH2), 66.8 (OCH2), 111.1, 117.6 (CHAr), 119.9 (CHta), 
120.5, 122.7, 125.6 (CHAr), 133.4 (CHMtz), 137.4 (CqNH), 141.3 (CqAr), 145.1 (CqO), 147.2 
(CqNO2), 147.9 (Cqta), 120.5 (CqMtz). ESI-HRMS: m/z 465.1634 ([M+H]+ calcd for C21H21N8O5, 
465.1635). 
 
4.2.3.2. Rhenium complexation 
[Re(CO)3(L6)]. A 20 mL-methanolic solution of ligand L6 (130 mg, 0.38 mmol), 
[Re(CO)5Cl] (160 mg, 0.44 mmol) and diisopropylethyl amine (54 mg, 0.42 mmol) was stirred 
at 65ºC for 16 h. After cooling to room temperature, the solution was concentrated under 
reduced pressure. The resulting residue was purified by column chromatography (silica gel, 
ethyl acetate) to give a light yellow solid (168 mg, yield 72%). 1H NMR (500 MHz, MeOD): δ 
(ppm) = 1.75 (s, 3H, CH3), 4.53 (dd, J = 1.0, J = 15 Hz, 1H, NHCH2), 4.60 (dd, J = 1.0, J = 15 
Hz, 1H, NHCH2) 4.72-4.78 (m, 1H, CH2-Mtz), 4.89-4.94 (m, 2H, CH2-Mtz, CH2-ta), 4.96-5.01 (m, 
1H, CH2-ta), 6.52-6.56 (m, 2H, HAr), 6.90-6.93 (m, 1H, HAr), 7.22-7.24 (m, 1H, HAr), 7.81 (s, 
1H, Hta), 7.95 (s, 1H, HMtz). 13C NMR (125 MHz, MeOD): δ (ppm) = 11.7 (CH3), 45.9 (CH2-
Mtz), 50.6 (CH2-ta), 54.0 (NHCH2), 115.7, 118.9 (CHAr), 123.7 (CHta), 124.5, 128.6 (CHAr), 
131.7 (CHMtz), 133.4 (CqNH), 138.6 (CqNO2), 147.9 (Cqta), 151.0 (CqCH3), 165.3 (CqO), 195.8, 
196.3, 197.2 (Re(CO)3). IR (ATR): ν(CO) = 2015, 1910-1870 cm–1. ESI-HRMS: m/z 612.0782 
 
vi Crystal data was not shown in this manuscript. 
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([M+H]+ calcd for C18H17N7O6185Re, 612.0770); 614.0812 ([M+H]+ calcd for 
C18H17N7O6187Re, 614.0798).  
 
[Re(CO)3Cl(L7)]. Using the same protocol than above, a 20 mL-methanolic solution of 
ligand L7 (100 mg, 0.27 mmol), [Re(CO)5Cl] (114 mg, 0.32 mmol) and diisopropylethyl amine 
(38 mg, 0.30 mmol) gave a crude yellow solid. Unfortunatly, it was not possible to correctly 
isolate the desired product and consequently any acceptable NMR spectrum was obtained. ESI-
MS: m/z 771.0725 ([M+H]+ calcd for C24H21N8O8187ReCl, 771.0723); 735.0970 ([M-Cl]+ calcd 
for C24H20N8O8187Re, 735.0962). 
 
4.3. X-ray crystallography and data analysis 
X-ray intensity data of compounds L1, L2, L4, L7 and complexes [Re(CO)3Cl(L2)] and 
[Re2(CO)6(μ-OEt)2(μ-L3)] were collected on a Bruker D8 VENTURE diffractometer and using 
graphite monochromated Mo Kα radiation (λ = 0.71073 Å) at 193 K. The semi-empirical 
absorption corrections were employed [SADABS, Program for data correction, Bruker-AXS]. 
The crystallographic data and refinement details are given in the annex part in tables S1 and 
S5-S6 for ligand L1, L2, complex [Re(CO)3Cl(L2)] and dinuclear complex [Re2(CO)6(μ-
OEt)2(μ-L4)], respectively. The structures were solved by direct methods and completed by 
subsequent difference-Fourier syntheses, and refined by full matrix least squares procedures on 
F2. All non-hydrogen atoms were refined with anisotropic displacement coefficients. The 
hydrogen atoms bound to carbon atoms were placed in calculated positions and treated as riding 
on their parent atoms with d(C—H) = 0.93 Å, Uiso(H) = 1.2 Ueq(C) (aromatic); and d(C—H) = 
0.96 Å, Uiso(H) = 1.5 Ueq(C) (methyl). The methyl groups were allowed to rotate about their 
local threefold axis. The SHELX software package[ 70 ] within Ole2[ 71 ] was used for the 
calculations. 
 
4.4. Computational details 
The GAUSSIAN09 program package[72] was used for all the calculations with the aid 
of the ChemCraft visualization program.[73] The ground-state geometries of complexes were 
fully optimized in gas-phase without any symmetry constraint with the DFT method using the 
hybrid exchange-correlation B3LYP functional.[15] In all calculations, the "double-ζ" quality 
basis set LanL2DZ with Hay and Wadt’s relative effective core potential ECP (outer-core 
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[(5s25p6)] electrons and the (5d6) valence electrons)[74,75] was employed for the Re atom. The 
6-31g basis set for H atom, 6-31+g* basis set for C atom and 6-31+g** basis set for N, O and 
Cl atoms were used.[76] The vibrational frequencies calculations were performed using the 
optimized structural parameters of complexes, to confirm that each optimized structure 
represents a local minimum on the potential energy surface and all eigenvalues are non-
negative. The 1H and 13C NMR spectra of the complex [Re(CO)3Cl(L2)] were calculated with 
the magnetic field perturbation method by applying the Gauge-invariant atomic orbital (GIAO) 
algorithm[77] with the NMR = spin-spin keyword incorporated in the Gaussian 09W program. 
The solvent effect (chloroform) was simulated using the Self-Consistent Reaction Field (SCRF) 
under the Polarizable Continuum Model (PCM).[78] The relative chemical shift of a given 
nucleus X in the molecule was defined as δXcalc [ppm] = σXcalc − σXref,[ 79 ] where 
tetramethylsilane (TMS) was used as a reference molecule optimized at the same level of 
theory.  
 
4.5. Radiochemistry 
99mTc as carrier-free Na[99mTcO4] was obtained in physiological solution by saline 
elution from a commercially available 99Mo/99mTc generator (Institut des Radioéléments, 
Belgium). Activities were measured with a CRC-127R well-counter (Capintec). The 
radiochemical purities (RCP) of the complex were determined by using a Cyclone Storage 
Phosphor Imager (PerkinElmer) with the Packard Optiquant software. The product was also 
characterized by HPLC (Thermo Fischer Scientific), on a Dionex Ultimate 3000 instrument 
equipped with a diode array detector and a radiochromatographic fLumo (Berthold) detector 
piloted by the Chromeleon software. The chromatographic analytic system employs a Thermo 
Accucore C18 100 x 3mm, 2.6 µm column with A = H2O/0.1% TFA; B = CH3CN. The elution 
profile was a linear gradient 0-100% B in 30 min at the flow rate of 0.4 mL/min. 
 
99mTc-radiolabeling of L5: The generator eluent (200 µL, 40 MBq) was added to a 
mixture containing 40 µL of ligand solution (1 mg/mL in ethanol), 70 µL of stannous chloride 
solution (3 mg/mL in water) and 140 µL of NaOH 0.1 M. After stirring 10 min at room 
temperature, the reaction was stopped by adding 14 µL of HCl 1 M. [99mTcO(L5)]: Rf (silica, 
CH2Cl2/ethanol, 60:40) = 0.50; tr = 11.41 min. 
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4.6. Electrochemical studies 
Electrochemical behaviors of ligands 12,[9b] L2 and L6 as well as corresponding 
complexes [Re(CO)3Cl(12)],[9b] [Re(CO)3Cl(L2)] and [Re(CO)3Cl(L6)] were carried out in 
acetonitrile with tetrabutylammonium perchlorate (TBAP) as a supporting electrolyte. Cyclic 
voltammograms were recorded on an Autolab Potentiostat (EcoChemie) workstation with three 
electrode: a glassy carbon disk (diameter 1 mm) working electrode, a platinum wire counter 
electrode and an Ag/Ag+ reference electrode. O2 was removed by argon bubbling, then 
maintained above the solution. The measurements were performed in various scan rate from 
0.1 to 16 V/s at room temperature. The voltammograms were corrected and displayed with 
respect to the satured calomel electrode (ECS). For the diffusion-controlled process, the forward 
peak current was proportional to the square root of potential sweep rate. So the standard graphs 
of f (E) = I/V1/2 was applied to observe the impact of scan rate. 
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1. Introduction 
Luminophores that take advantage of aggregation to trigger the emission of light have 
been the subject of intense research effort over the past two decades, and they now find 
increasing applications as bioprobes and in the field of fluorescent materials where they show 
superior performance as compared to conventional compounds.[1]  
 
The concept of aggregation-induced emission (AIE) has first been developed in the 
organic field before being extended to transition metal complexes, where the phenomenon is 
much more rarely observed. However, as recently reviewed, a number of complexes have been 
shown to exhibit significant AIE activity and design principles for efficiently emitting 
compounds have begun to emerge.[2] Like for organic compounds, the prerequisite for AIE 
behavior is the presence of aromatic groups connected by a C-C, C-N or N-N single bond. In 
solution, the excitation energy is lost in rotations and vibrations, and the compound is weakly 
luminescent. In the solid state, the restriction of internal rotation induces emission enhancement. 
Other mechanisms can be involved. In most cases, the predominant emission process in metal 
complexes is phosphorescence, whose long lifetime may bring benefits in terms of 
detection. Some of these compounds give highly luminescent aggregates and could be ideal 
candidates for high-tech applications in the field of chemosensors, bioprobes, stimuli-
responsive nanomaterials and optoelectronic materials. However, many types of complexes 
have hardly been studied from this point of view and this is the case, in particular, for tricarbonyl 
rhenium(I) complexes.  
 
In fact, tricarbonyl rhenium(I) complexes have mainly be studied in solution,[3-15] and 
their solid-state emission properties have attracted little interest, except for applications in the 
fields of organic light emitting diodes (OLEDs) and light emitting electrochemical cells 
(LEECs).[ 16 ] Only some rare examples of aggregation-induced phosphorescence emission 
(AIPE) have been reported.[2] Whether the complexes are based on small molecules [17,18] or on 
dendrimers,[19] they are generally weakly emissive in the solid state. A remarkable exception is 
the dinuclear Re complex that has been introduced by De Cola and coll., whose two distinct 
polymorphic crystals are both strongly phosphorescent.[ 20 ] From a practical viewpoint, 
applications as potential sensors for explosives[18] and for the detection of β-amyloid 
aggregation[21] only begin to be considered. 
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In our opinion, the AIE effect in tricarbonyl Re(I) complexes deserves being much better 
explored. The association of the AIE effect with the intrinsic properties of Re(I) complexes 
could lead to very attractive compounds. The cell uptake, recognition and biological properties 
also depend on the ligand nature, so that complexes may be engineered for precise cell imaging. 
In addition to allow detection in the visible, the Re(I) complexes strongly absorb in the middle 
infrared where light penetration in tissues is optimal, and so they enable multimodal bioimaging. 
Their analogy with complexes built around the [99mTc (CO)3]+ core allows correlations with 
radioimaging studies. Finally, these compounds are also photoactive and can be used in the 
frame of phototherapy and theranostics. For all of these reasons, AIE-active Re(I) complexes 
could be a new generation of compounds for light-responsive materials, sensing, imaging and 
image-guided combination therapy.  
 
In the present work, four new tricarbonyl Re(I) complexes have been studied (Scheme 
1). They all contain a pyridyl-triazole (pyta) ligand that combines the coordination abilities of 
pyridine and triazole rings, and has strong V-electron-donating capability. They also contain a 
2-phenylbenzoxazole (PBO) moiety that has been introduced on the pyta ligand with the aim to 
improve the spectroscopic behavior. This organic dye was chosen for its excellent stability and 
optical properties. PBO derivatives are indeed widely used in the field of fluorescent materials, 
whatever they are dissolved in solution or dispersed in an appropriate matrix.[22] Many of them 
are strongly emissive in the solid state[23,24] and sometimes display AIE behavior.[25] It is 
noteworthy that in our compounds the organic dye PBO is not directly involved in complexation 
unlike most of the complexes reported in the literature. It is connected to the pyta group by a 
single bond that allows its free rotation and this design should favor the appearance of an AIE 
behavior. The four compounds are distinguished by the arrangement of the pyta and PBO 
building blocks in relation to each other. 
 
The first two compounds differ by the nature of the triazole ring that exhibits distinct 
substitution patterns. The [Re(CO)3Cl(L8)] complex contains the 3-(2-pyridyl)-1,2,4-triazole 
fragment that has recently proven to be very useful for the preparation of luminescent rhenium 
complexes[26] and electroluminescent iridium complexes.[27,28] The complex [Re(CO)3Cl(L9)] 
includes the 4-(2-pyridyl)-1,2,3-triazole fragment that is comparatively a much more popular 
ancillary ligand since the rediscovery of Huisgen reaction by Sharpless and coll., as detailed in 
the Chapter I.[29] The position of the organic dye PBO therefore depends on the structure of the 
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triazole ring. Complexes [Re(CO)3Cl(L8)] and [Re(CO)3Cl(L9)] have been studied thoroughly 
via a crystallographic, electrochemical, spectroscopic and photophysical approach. 
Experimental data were supported by DFT calculations. It is shown that both complexes look 
very similar at first sight but behave in a very different way. This study sheds light on the 
spectacular role of the pyta ligand’s structural isomerism that has not so far been suspected. In 
particular, it reveals how the position of the substituent on the pyta ligand can be of prior 
importance regarding original photoluminescence properties.  
 
In a second phase, the framework of complex [Re(CO)3Cl(L8)] that contains the 3-(2-
pyridyl)-1,2,4-triazole fragment was selected because of its superior emission properties in the 
solid state, and the PBO moiety was substituted by a tert-Butyl group at the 4-position of the 
phenyl ring, to give complex [Re(CO)3Cl(L10)]. The aim was to increase the steric hindrance 
that governs the crystal packing mode.[30] It was expected that, in the solid state, the molecules 
would drift apart from each other and be prevented from stacking. In fact, the S-S stacking that 
currently takes place between aromatic groups is extremely detrimental to the emission of light 
and must be avoided, to the extent possible.[31] This strategy has been successfully implemented 
in the group for benzoxazole-based organic dyes.[24,25b] Here, it should allow the solid-state 
emission properties of our complexes to be optimized.  
 
Finally, complex [Re(CO)3Cl(L11)] was also synthesized and studied. In this complex, 
the PBO moiety is connected to the pyta group by its phenyl ring, and not by the benzoxazole 
ring like in [Re(CO)3Cl(L8)]. It is known that the emission properties of PBO in solution are 
strongly affected by the substitution pattern.[32] Comparing these two complexes allows the 
effect of these structural modifications upon the solid-state emission properties to be better 
understood. 
 
Throughout this study, the four complexes were of course compared with their 
corresponding ligands. In summary, this chapter tries to give the keys for the rational design of 
AIE-active, strongly emissive rhenium complexes substituted by organic fluorophores. 
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Scheme 1. Chemical structures of the four complexes. 
 
For convenience, we will use these acronyms for our compounds in the following text: 
ReL8 for [Re(CO)3Cl(L8)], ReL9 for [Re(CO)3Cl(L9)], ReL10 for [Re(CO)3Cl(L10)], and 
ReL11 for [Re(CO)3Cl(L11)]. 
  
Chapter III 
 
 139
2. Studies of complexes ReL8 and ReL9: Influence of the pyta ligand’s 
structural isomerism 
 
2.1. Syntheses of the ligands and corresponding rhenium complexes 
The synthetic pathways for preparation of the ligands and corresponding 
tricarbonylrhenium(I) complexes are shown in Scheme 2. 6-Nitro-2-phenylbenzoxazole (23) 
was obtained in good yield by classical condensation of 2-amino-5-nitrophenol with benzoic 
acid in the presence of polyphosphoric acid, and then it was catalytically reduced to yield the 
corresponding amino derivative (24). From this compound, ligand L8 was obtained in modest 
yield through a one-pot condensation reaction as described in the literature.[33] The preparation 
of ligand L9 went through an azide derivative (25) that was subsequently condensed with 2-
ethynylpyridine via a Copper(I) catalyzed alkyne-azide cycloaddition using classical click 
reaction conditions. Although the synthesis of L9 required an additional step, its overall yield 
was better than for L8 (40% vs. 22%). As expected, the formation of the pyridyl-1,2,3-triazole 
scaffold by CuAAC reaction was thus easier than that of the other isomer.  
 
The corresponding tricarbonylrhenium(I) complexes ReL8 and ReL9 were then easily 
prepared in good yields (ca. 66%) by reacting [Re(CO)5Cl] with L8 or L9 in refluxing 
methanol. All compounds were obtained with good overall yields after purification by 
chromatography. Detailed synthesis procedures and characterization data are given in the 
experimental section. 
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Scheme 2. Synthesis of ligands L8, L9, and complexes ReL8, ReL9. 
 
Conditions and reagents: (i) benzoic acid, polyphosphoric acid, 110 ºC, 16 h; (ii) 10% Pd/C, H2, MeOH/CHCl3, 
6 bars, rt, 24 h; (iii) dimethoxy-N,N-dimethylmethanamine, pyridine-2-carbohydrazide, acetic acid, CH3CN, 50–
120ºC, 16 h; (iv) [Re(CO)5Cl], MeOH, 65ºC, 16 h; (v) HCl (6N), NaNO2, NaN3, 0ºC to rt; (vi) 2-ethynylpyridine, 
Cu(OAc)2.H2O, NaAsc., CH3CN, rt, 16 h.   
 
2.2. Structural characterization  
Both ligands and complexes were characterized by means of IR spectroscopy, as well 
as by NMR and HR-MS spectrometry. The structures of ligand L9 and complexes ReL8 and 
ReL9 were also confirmed by X-ray crystallography. 
 
2.2.1. Spectroscopic and spectrometric analysis 
Specifically, the IR spectra of both complexes ReL8 and ReL9 showed bands in the 
region 2030-1880 cm–1 corresponding to the facial orientation of v(CO) stretching bands. These 
values were similar with previous tricarbonyl rhenium(I) complexes [Re(CO)3Cl(L)] (For 
instance, L = L1 or L2).  
In 1H NMR analysis, special attention was paid to the shift of triazole proton. As shown 
in Figure 1, the triazole proton was situated downfield in L9 (9.44 ppm) compared to L8 (8.97 
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ppm). The same trend was observed in their corresponding complexes, with peaks at 10.04 ppm 
for ReL9 and 9.31 ppm for ReL8. This indicates that the 1,2,4-triazole unit has a higher 
electron-donating ability than the 1,2,3-triazole unit. In addition, the triazole proton of both 
ligands was shifted downfield after complexation, which is in agreement with our previous 
work (Cf. Chapter II) and reported bibliography. It is also noteworthy that the pyridyl proton 
H4 (around 8.2 ppm) in both ligands were shifted significantly downfield after complexation 
(around 9.1 ppm).  
In 13C NMR spectra,i the opposite chemical shift was observed concerning the triazole 
carbon C10. The signal was at 147.1 ppm for L8, while it was at 122.2 ppm for L9. The 
complexes followed the same trend than the ligands: the C10 signal was shifted downfield in 
ReL8 (148.9 ppm) compared to ReL9 (125.4 ppm). Nevertheless, when comparing the ligands 
with their corresponding Re(I) complexes, it appeared that the carbon signals were shifted 
downfield after complexation, as it was the case for protons. 
 
Figure 1. Comparison of partial 1H NMR spectra (500 MHz, DMSO-d6, 298 K) between ligands and complexes. 
From top to bottom: ReL9, ReL8, L9 and L8.  
 
i Numbering of carbons and hydrogens are indicated in the RX structures of complexes ReL8 and ReL9 in Figure 
2. 
L8
L9
ReL8
ReL9
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The high resolution mass spectra of both complexes showed a peak corresponding to 
[M-Cl]+, which is commonly found for bidentate tricarbonyl rhenium(I) complexes. 
 
2.2.2. X-ray diffraction  
2.2.2.1. Geometry of complexes ReL8 and ReL9 
Fortunately, monocrystals of the complexes ReL8 and ReL9 suitable for X-ray 
crystallography analysis were successfully grown by slow evaporation of organic solvents. In 
the analysis of crystal structures, particular attention was paid to the conformation of each 
molecule, as well as to interactions that were taken place between the most closely stacked 
molecules, because these features govern the solid-state spectroscopic behavior. Selected 
crystallographic data and structure refinement details for ReL8 and ReL9 are shown in Table 
S1.ii The molecular views of these two compounds are given in Figure 2. 
 
Figure 2. Molecular view of the asymmetric unit of complexes ReL8 (left) and ReL9 (right). Thermal ellipsoids 
are drawn at the 50% probability level. H atoms are omitted for clarity.  
 
Both crystalline complexes are solvated. Complex ReL8 crystallized in the monoclinic 
P21/c space group with two crystallographically distinct molecules of complex and one 
acetonitrile molecule in the asymmetric unit. Interestingly, the free rotation between the triazole 
group and the PBO moiety allowed the latter to occupy two distinct positions in one of the 
molecules (Figure 3). In 32% of the cases (type I), the oxygen atom of the benzoxazole group 
and the chlorine atom of the coordination sphere pointed in the same directions, and the 
benzoxazole group was twisted by 16.2(6)° with respect to the phenyl group. In the remaining 
68% (type II), the benzoxazole oxygen and the chlorine atom pointed in the opposite direction, 
 
ii As in chapter 2, Figures Sx (x = 1 to 10) and Tables Sx (x = 1 to 17) refer to the annex part.  
C18
C19
C20
C21
C22C23
C24
C16
C15
C14
C11
C12
C13
C10
C9
C8C4
C5
C6
C7
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and the benzoxazole group was twisted by 21.7(1)° with respect to the phenyl group. No 
disorder was observed for complex ReL9 that crystallized in the monoclinic P21/c space group 
with one acetone molecule per molecule of complex (Figure 3).  
 
Indeed, the most striking difference between the complexes probably comes from the 
conformation of their conjugated system. In complex ReL9, the entire organic ligand pyta-PBO 
was almost planar (Figure 3). The angle between the benzoxazole group and the triazole group 
was only 9.0(2)°, thus promoting strong interaction between these moieties. On the contrary, in 
complex ReL8, this angle was 64.0(2)° in type I, and 69.3(3)°/82.0(6) in type II molecule. This 
strong bending of the organic ligand suggests that the π-electron systems of the pyta and PBO 
moieties have little interaction and should behave almost independently in ReL8. 
 
Figure 3. Crystal packing mode of complexes ReL8 and ReL9. From left to right: crystal cell, arrangement and 
plan view of stacked molecules. The oranger color indicates the overlap of the aromatic systems.  
 
In contrast, both complexes showed many similarities with regard to the rhenium 
environment. They present a distorted octahedral geometry, as expected. The Re(I) atom is 
coordinated to three carbonyl ligands arranged in a facial configuration, one chlorine atom and 
two nitrogen atoms of the pyta moiety. Two carbonyl groups C(2)-O(2) and C(3)-O(3) along 
with pyridine nitrogen atom N(2) and triazole nitrogen atom N(3) occupy the equatorial 
positions. The third carbonyl group and one chlorine atom occupy the axial positions, and 
ReL8
ReL9
9°
82°
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coordinate to the Re(I) atom linearly with an angle C(1)-Re(1)-Cl(1) equal to 177.0(2)° in ReL9 
and 176.1(2)°/174.8(2)° in ReL8 (Table S2). The bond angles between adjacent axial CO 
carbon atoms are close to ideal value of 90° (90.5(2)° in ReL9, 87.6(3)°/88.0(3)° in ReL8), 
indicating that CO ligands are linearly coordinated. It can be noticed that the C-O bonds of the 
two carbonyl groups that are facing the pyta moiety were found to be slightly elongated as 
compared to axial CO group.  
 
The triazole N(3)-Re bond is shorter than the pyridine N(2)-Re bond (2.157(4) Å vs. 
2.203(4) Å in ReL9 and 2.143(5)/2.138(5) Å vs. 2.189(5)/2.200(5) Å in ReL8), indicating the 
stronger electron-donating ability of the triazole ring in comparison to the pyridine ring. This 
can also be explained by competition for M→L back-bonding abilities of ligands with a trans 
configuration. It is well-known that the nature of the metal-ligand bond can be described as a 
donation from a σ orbital of the ligand toward an empty d orbital of the metal and a concurrent 
back-donation from a filled d orbital to a π* antibonding orbital of the ligand. Since the chlorine 
ligand has stronger electron donation ability to the metal d orbital than the equatorial N atoms, 
the axial carbonyl ligand benefits from increased back-bonding to give a shorter and stronger 
axial Re-C bond.  The bite angle of the pyta ligand with Re(I) was only 73.7(2)°/74.1(2)° for 
ReL8 and 74.9(2)° for ReL9, as can be expected for the steric demand of this chelating group. 
For both complexes, only a small twist angle of approximately 5° was observed between the 
triazolyl and pyridyl components. These values are in line with those reported for other rhenium 
complexes, either containing various azole ligands combined with a 2-pyridyl group,[34] or 
based on 4-(2-pyridyl)-1,2,3-triazole ligands and developed by our team.[35] 
 
2.2.2.2. Hydrogen bonding 
The crystal structures are stabilized by a network of intermolecular interactions. 
Selected hydrogen bonding distances and angles are shown in Table S3.  
The crystal structure of ReL8 is stabilized by a network of classical intermolecular 
hydrogen bonding interactions. Three interactions are of the type C—H•••O. They take place 
between  the C(5)–H proton of the 2-pyridyl group and the carbonyl oxygen O(1), the C(12)–
H proton of the benzoxazole and the carbonyl oxygen O(5), and the C(15)–H proton of the 
benzoxazole and the carbonyl oxygen O(5). One interaction is of the type C—H•••Cl (3.550(7) 
Å) between the C(10)–H proton of triazole and Cl(1) attached to the rhenium atom (Figure S1). 
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Additionally, one intramolecular hydrogen bonding C—H•••O interaction between C–H proton 
of the phenyl ring and the benzoxazole oxygen atom O is also observed in the crystal lattice.  
In complex ReL9 (Figure S2), which crystallizes with an acetone molecule, the 
uncoordinated oxygen atom O(5) of the acetone molecule is involved in two intermolecular 
hydrogen bonding interactions. It is with C(10)-H proton of the triazole and the C(7)–H proton 
of the 2-pyridyl group C—H•••O (3.482(9) Å). Two intermolecular hydrogen bonding 
interactions of C—H•••O type take place between the C(19)–H and the carbonyl oxygen O(3), 
as well as between the C(21)–H and the carbonyl oxygen O(2). One more interaction is 
observed between C(23)–H and the benzoxazole oxygen O(4). All these interactions stabilize 
the crystal structures.  
 
2.2.2.3. Packing mode 
For each complex, the crystal cell, the arrangement of stacked molecules in the network, 
and the overlap of the aromatic systems are given in Figure 3. Regarding the molecular packing 
of ReL8, the most closely stacked PBO groups belonging to type I were approximately 3.5 Å 
apart. They were slipped laterally, so that no overlap of the aromatic systems was observed 
between neighboring molecules. There are also π–π stacking interactions between two parallel 
2-pyridine rings, two parallel triazole rings. The system seemed to be compact and well-
structured by short contacts that involve the carbonyl groups and the bisimine ligand. For type 
II molecules, the network seemed to be looser than in the former case.  
 
ReL9 complexes exhibited crossed arrangement. This unusual arrangement has already 
been reported by us and other groups for 2-phenylbenzoxazole and naphthoxazole 
derivatives[ 36 ] and thus seems to be quite frequent in this series of compounds. Stacked 
molecules were roughly situated in parallel planes, offset from one another and oriented in the 
same direction. They were approximately 3.3 Å apart and exhibited partial overlap of their 
aromatic systems. More precisely, slipped π–π stacking interactions take place between the 2-
phenyl ring and the benzene ring of benzoxazole, the oxazole ring of benzoxazole and the 
triazole, the benzene ring of benzoxazole and the 2-pyridyl ring from adjacent molecules.  
Consequently, strong intermolecular interactions can be expected to take place in the solid state. 
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2.2.2.4. Crystal structure of ligand L9 
Making a comparison with the crystal structure of the free ligands would be instructive. 
Unfortunately, single crystals of ligand L8 suitable for X-rays analysis were not obtained 
despite our efforts. However, single crystals of L9 were grown successfully. Selected 
crystallographic data are collected in Table S1. Their analysis revealed that these molecules are 
almost planar, except for the triazole group that describes an angle of approximately 15° with 
both the benzoxazole and the pyridyl groups (Figure 4). Planarity of the ligand was thus 
enhanced after complexation. Molecules of L9 were directed along the same axis, but 
distributed according to two distinct planes. Stacked molecules were displayed head to tail, with 
a significant overlap of their aromatic system. The arrangement is therefore very different from 
that found for the corresponding complex ReL9. 
 
Figure 4. Crystal packing mode of ligand L9. From left to right: crystal cell, arrangement and plan view of stacked 
molecules. The orange color indicates the overlap of the aromatic systems.  
 
2.3. Computational studies 
Before going any further in the experimental study of our compounds, computational 
studies based on the time dependent density functional theory (TD-DFT) method at the 
PBE1PBE/LANL9DZ/6-31+G** level were performed by Dr. Mariusz Wolff (Silesia 
University, Poland). The results were used to get deep insight into the nature of the electronic 
transitions of the complexes and subsequently support the interpretation of the electrochemical 
and photophysical data. 
 
As long as the ground state S0 was considered, calculations gave a very good estimation 
of a number of coordinating bonds and angles with respect to corresponding X-ray 
crystallographic data, with the bond lengths differing at the most by 0.05Å, and angles differing 
3,2 Å
L9
15°
3.2 Å
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at the most by 3° (Table S2). Upon excitation of ReL8 and ReL9, the geometries of the first 
singlet excited state S1 and first triplet excited state T1 kept octahedral conformation. However, 
in comparison with the ground-state, the Re-N bonds in S1 state were shortened by about 0.05–
0.06Å, while Re-CO bonds were elongated by ca. 0.04–0.06Å, which indicated that the CO 
ligands tended to break away from the Re atom and that the chelate ligand is getting close to 
the Re atom in the excited state. This effect can be attributed to the transfer of electron density 
from the Re–CO bonding orbital to the ligand π* orbital upon excitation. For instance, the trans 
angles in equatorial plane (N(2)-Re(1)-C(3) and N(3)-Re(1)-C(2) for ReL8 and N(2)-Re(1)-
C(2) and N(3)-Re(1)-C(3) for ReL9) were increased and the angle in axial direction Cl(1)-
Re(1)-C(1) was slightly reduced. A similar trend was observed for the lowest triplet state T1 of 
both complexes. 
 
Methods of natural population analysis (NPA) and natural bond orbitals (NBOs) were 
used to calculate the charges that are transferred between the donor and acceptor moieties, and 
bonding orbitals with maximum electron density, respectively. The results, reported in the 
Annex (Table S4), are consistent with similar studies.[37]  
 
The maps of electrostatic potentials (MEP) surface have been drawn. Regions 
represented by different colors correspond to different values of the electrostatic potential. The 
maximum negative region, which is the preferred site for electrophilic attack, is indicated by 
red color, whereas the maximum positive region that is the preferred site for nucleophilic attack 
is indicated by blue color. The potential increases in the order red < orange < yellow < green < 
cyan < blue, where red shows the strongest repulsion and blue shows the strongest attraction. 
As expected, the regions having strong negative potential are over the electronegative atoms, 
while the regions with high positive potential are over the electropositive atoms. For instance, 
in Figure 5, the negative electrostatic potential regions of ligands L8 and L9 are mainly 
localized around the oxygen O(1) and the nitrogen N(1) of the benzoxazole, the nitrogen N(2) 
of the pyridine ring and the nitrogens N(3) and N(4) of the triazole ring. The positive 
electrostatic potential regions are around the hydrogen atoms.  
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L8 
 
L9 
Figure 5. Molecular electrostatic potential (MEP) surface of L8 and L9. The electrostatic potential is mapped onto 
the total electron density.  
 
Regarding complexes, Figure 6 shows that the negative charges are localized around the 
heteroatoms of the PBO moieties and the nitrogen atoms of the pyta group, as well as on the 
chlorine and carbonyl oxygen atoms. The negative and positive charges appeared to be evenly 
distributed over the whole complex ReL9. In contrast, the positive charges were more 
concentrated on the pyta and PBO ligand, and negative charges were more concentrated around 
the rhenium moiety for ReL8, thus suggesting that the charges are blocked more efficiently in 
the latter case.   
 
ReL8 
 
ReL9 
 
Figure 6. Molecular electrostatic potential (MEP) surface of ReL8 and ReL9. The electrostatic potential is mapped 
onto the total electron density.  
 
The electrochemical and optical properties of the compounds are related to frontier 
molecular orbitals (FMOs), especially the highest occupied molecular orbital (HOMO) and the 
lowest unoccupied molecular orbital (LUMO), whose chemical reactivity parameters are 
tabulated in Table 1.  
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Table 1. Absolute electronegativity, absolute hardness, dipole moment (μ), electrophilicity 
index (ω) and global softness (σ) of ligands L8 and L9, and complexes ReL8 and ReL9 in 
CH2Cl2. 
Parameters 
Compounds 
L8 L9 ReL8 ReL9 
EHOMO (eV) –6.83 –6.83 –6.60 –6.61 
ELUMO (eV) –1.99 –1.99 –2.53 –2.23 
Energy gap ΔE (eV) 4.84 4.84 4.07 4.38 
Electronegativity μ (eV) 4.41 4.41 4.57 4.42 
Hardness η (eV) 2.42 2.42 2.04 2.19 
Dipole moment μ 
(Debye) 10.78 2.25 19.98 15.25 
Electrophilicity ω 
(Debye/eV) 24.01 1.05 97.85 53.10 
Softness σ (eV) 0.09 0.44 0.05 0.07 
     
 
The frontier molecular orbital descriptors such as ionization potential (IP = –EHOMO), electron affinity (EA = –
ELUMO), global hardness (η = (I – A)/2), electronegativity (χ = (I + A)/2) chemical potential (μ = –χ), softness (σ = 
1/η), global electrophilicity index (ω = μ2/2η) were calculated according to Koopmans theorem (Koopmans, T. 
Physica, 1 (1933) 104–113).  
 
The compositions and energy levels in dichloromethane (DCM) are given in Table 2 for 
complexes ReL8 and ReL9, and in Table S5 and S6 for the ligands. Figures 7 and 8 show the 
isodensity plots of the ligands and complexes, respectively. Only the FMOs involved in the first 
electronic transitions are presented. For ligands L8 and L9, the HOMOs and LUMOs have 
respectively π and π* character and a given orbital has exactly the same energy level in both 
compounds. The orbitals of L9 are delocalized and some of them even spread over the whole 
molecules, while the orbitals of L8 are confined on well defined regions. In L8, the HOMO and 
the LUMO are centered on the PBO moiety. It is also the case for L9, in a lesser extent.  The 
HOMO-LUMO gap is 4.84 eV in both cases.  
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Figure 7. Isodensity plots of selected frontier MOs (at the PBE1PBE/LANL9DZ/6-31+G** level of theory) 
involved in the electronic transitions of ligands L8 and L9.  
L8 L9
LUMO+1
LUMO
HOMO
HOMO-1
Orbitals
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Figure 8. Isodensity plots of selected frontier MOs (at the PBE1PBE/LANL9DZ/6-31+G** level of theory) 
involved in the electronic transitions of ReL8 and ReL9.  
 
Complexation by rhenium totally changes the nature of the orbitals. For complexes 
ReL8 and ReL9, the two highest occupied orbitals (HOMO and HOMO–1) as well as HOMO–
3 are now almost totally centered on the rhenium moiety. Only the HOMO–2 is dominantly 
localized on the organic ligand, and more precisely on the PBO moiety with a contribution 
around 75% for ReL9, and up to 96% for ReL8. The energy level of the HOMO is almost the 
ReL8 ReL9
LUMO+3
LUMO+2
LUMO+1
LUMO
HOMO
HOMO-1
HOMO-2
HOMO-3
Orbitals
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same for the two complexes. Regarding the LUMOs, the first four orbitals are predominantly 
based on the organic moiety with π* character, with interesting differences between the two 
complexes. As a matter of fact, orbitals of ReL9 extend significantly over the whole organic 
ligand while those of ReL8 are well centered either on the pyta moiety (LUMO and LUMO+2) 
or on the PBO moiety (LUMO+1). Moreover, the LUMO energy level is 0.30 eV higher for 
ReL9 than for ReL8. Therefore, the nature of the triazole group and the functionalization by a 
PBO moiety on a different position strongly influence the electron distribution over the 
complexes especially in the excited state. The effect on the energy levels is also remarkable, 
making ReL8 a much more stable compound than ReL9. A molecular orbital diagram is given 
in Figure 9 to allow comparison between the energy levels of the four compounds. 
 
Figure 9. From left to right, molecular orbital diagrams of L9, ReL9, L8 and ReL8. 
 
TD-DFT calculations were also performed on the electronic absorption spectra of the 
two complexes and corresponding ligands in DCM. The calculated absorption energies 
associated with their oscillator strengths and contributions, and their assignments, are given in 
Tables S7 to S10. The comparisons with experimental spectra are given in Figure S3. The 
energy of emission coming from the first singlet state was also calculated for the four 
compounds (Tables S11 and S12), and emission resulting from the first triplet state was also 
considered for the complexes (Table S13). In this last case, the isodensity plots of the orbitals 
involved are given in Figure 10. For both complexes, these orbitals are centered on the metal 
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environment and on the pyta ligand, with no contribution of the PBO moiety. These data will 
be discussed further in the text. 
 
 
 
 
 
 
 
 
Figure 10. Spin density distribution for the lowest triplet state T1 of ReL8 and ReL9 in CH2Cl2, according to a 
calculation based on the optimized triplet state with DFT method at the PBE1PBE/LanL2DZ level. 
 
 
 
 
 
  
 
ReL8 ReL9
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  Table 2. Composition of the frontier molecular orbitals (%) and energy levels for complexes ReL8 and ReL9 in CH2Cl2. 
  ReL8  ReL9 
 Orbital Energy (eV) MO Contribution (%) Main bond type  Energy (eV) MO Contribution (%) Main bond type 
   Re CO Cl P1 P2    Re CO Cl P1 P2  
126 LUMO+5 –0.73 12 17 0 1 71 p(Re) + π*(CO) + π*(P2)  –0.74 2 2 0 3 92 π*(P2) 
125 LUMO+4 –0.82 29 54 0 6 13 p(Re) + π*(CO)  –0.83 35 59 0 5 2 p(Re) + π*(CO) 
124 LUMO+3 –0.88 5 6 0 13 77 π*(P2)  –1.35 1 3 0 71 25 π*(P1) + π*(P2) 
123 LUMO+2 –1.63 0 1 0 95 4 π*(P1)  –1.55 0 1 0 78 21 π*(P1) + π*(P2) 
122 LUMO+1 –2.12 0 0 0 2 98 π*(P2)  –2.16 1 2 0 25 73 π*(P2) + π*(P1) 
121 LUMO –2.53 3 4 1 91 2 π*(P1)  –2.23 3 4 0 88 5 π*(P1) 
   HOMO–LUMO gap (E =  4.07 eV)    HOMO–LUMO gap (E =  4.38 eV)  
120 HOMO –6.60 52 24 20 4 0 d(Re) + π(CO) + p(Cl)  –6.61 48 22 18 4 7 d(Re) + π(CO) + p(Cl) 
119 HOMO–1 –6.71 52 22 22 5 0 d(Re) + π(CO) + p(Cl)  –6.71 47 20 20 4 8 d(Re) + π(CO) + p(Cl) 
118 HOMO–2 –7.05 1 1 0 3 96 π(P2)  –6.92 9 3 8 5 75 π(P2) 
117 HOMO–3 –7.15 68 30 1 0 1 d(Re) + π(CO)  –7.19 69 30 1 0 0 d(Re) + π(CO) 
116 HOMO–4 –7.74 0 0 0 0 100 π(P2)  –7.68 0 0 0 9 90 π(P2) 
115 HOMO–5 –7.81 2 0 29 68 1 π(P1) + p(Cl)  –7.72 0 0 2 60 38 π(P1) + π(P2) 
 
P1: pyridyltriazole (pyta), P2: 2-phenylbenzoxazole (PBO) 
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2.4. Electrochemical studies 
The electrochemical behaviors of the ligands and complexes were studied with the help 
of Dr. Béatrice Delavaux-Nicot (Laboratoire de Chimie de Coordination du CNRS, Toulouse) 
by cyclic voltammetry (CV) and Osteryoung square wave voltammetry (OSWV) 
measurements. OSWV study was performed on a Pt working electrode in CH2Cl2 + 0.1 M [n-
Bu4N][BF4] at room temperature in the presence of ferrocene used as internal reference. 
(Frequency 20 Hz, amplitude 20 mV, step potential 5 mV). Cyclic voltammograms of the 
indicated compounds were performed on a Pt working electrode in CH2Cl2 + 0.1 M [n-
Bu4N][BF4] at room temperature. The scan rate was 200 mVs-1 toward anodic or cathodic 
potentials. 
 
In Figure 11, the OSWVs anodic and cathodic scans of ligands L8 and L9 showed no 
significant oxidation peaks, only a single reduction process was detected around –1.94 V for 
both compounds. This reduction process was also clearly visible in cyclic voltammetry (Figure 
S4) and its reversibility was not improved with increasing the scan rate. It is very likely 
attributed to the reduction of the PBO moiety of the ligand.[38] These results are in agreement 
with the theoretical calculations that evidenced important similarities between both ligands, and 
in particular the role of the π*(PBO) orbital as the LUMO in both compounds. 
 
      
Figure 11. OSWVs anodic (left) and cathodic (right) scans of ligands L8 (black) and L9 (grey).  
 
Complexation of these ligands affording respectively complexes ReL8 and ReL9 
induced the appearance of two new oxidation processes around 1.46 and 1.76 V in the OSWV 
anodic part (Figure 12a). The former process can be assigned to an irreversible Re(I) oxidation 
process[39] which is slightly easier for compound ReL8 than for compound ReL9. It could be 
expected that in comparison with the folded structure of the organic moiety in compound ReL8, 
the planar ligand structure of ReL9 favors electron delocalization, thus rendering the rhenium(I) 
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less electron rich and slightly decreasing the ease of its oxidation. The reversibility of this 
process is not improved with a decrease or an increase in scan rate. The differences between 
the behaviors of the ligands and corresponding complexes are in line with the theoretical 
calculations. The latter indicates that complexation induces an increase of the energy level of 
the HOMO and HOMO-1 respectively around 0.2 and 0.6 eV when compared to the 
corresponding ligands, thus predicting an easier oxidation. Moreover, in contrast with the free 
ligands, the nature of these HOMOs deeply changes in the complexes. Effectively, it implies 
now an important contribution of the Re part (around 50 %) in agreement with the 
electrochemical assignment. In the free ligands, the HOMO only concerns the π (PBO) orbital 
with an energy of –6.83 eV, in the complexes, the first HOMO level involving now the π (PBO) 
orbital is the HOMO-2 level situated around –7.0 eV. 
 
 
     
 
Figure 12. OSWVs anodic (a) and cathodic (b) scans of complexes ReL8 (red) and ReL9 (blue) on a Pt working 
electrode in CH2Cl2 + 0.1 M [n-Bu4N][BF4] at room temperature (frequency 20 Hz, amplitude 20 mV, step 
potential 5 mV). 
 
Considering now the cathodic part, both complexes still presented a reduction process 
around –1.9 V, revealing that the ligand PBO moiety is not involved in the complexation 
process (Figure 12b). However, a new reduction process appeared at more anodic potential. In 
a first approach, it could be attributed to the reduction process of the substituted triazole ring 
whose potential value may substantially decrease by complexation as observed in related 
compounds.[40,41] Remarkably, the value of the latter reduction potential strongly differs by 
about 300 mV between the two compounds: –1.31 V for compound ReL8 and –1.60 V for 
compound ReL9 (Table 3).  
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Table 3. Electrochemical data of ligands L8, L9 (3.4 × 10–3 M), and complexes ReL8, ReL9 
(6.5 × 10–3 M). Values determined by OSWV on a Pt working electrode in CH2Cl2 + 0.1 M [n-
Bu4N][BF4] at room temperature.a,b Ferrocene was used as internal reference. 
Compounds Oxidation Reduction 
E1 E2 E1 E2 
L8 --- --- -1.96 --- 
L9 --- 1.45c -1.92 --- 
ReL8 1.74 1.44 -1.31 -1.90 
ReL9 1.79 1.48 -1.60 -1.89 
a OSWVs were obtained using a sweep width of 20 mV, a frequency of 20 Hz, and a step potential of 5 mV. 
b Potential values in Volts vs SCE (Fc+/Fc is observed at 0.55 V ± 0.01 V vs. SCE). 
c Very broad peak. 
 
These trends are supported by theoretical calculations: (i) the rhenium, induces a general 
stabilization in lowering the energy values of the whole LUMO levels when compared to those 
of the corresponding ligands; (ii) the first calculated LUMO energy level involving the pyta (π*) 
moiety is lower for ReL8 (–2.53 eV) than for ReL9 (–2.23 eV). Remarkably, electrochemical 
HOMO–LUMO gap values (Egel)[42] found for complexes ReL8 and ReL9, i.e. 2.55 and 2.85 
eV respectively, fit very well with the calculated gap values 2.71 and 3.01 eV, highlighting 
good correlations with theoretical studies (Table 4).  
 
Table 4. Experimental electrochemical data used, and calculated values of the energy gaps (Eg) 
for compounds ReL8 and ReL9. 
Compound 
 
Eonset ox 
(V) 
Eonset red 
(V) 
EHOMO 
(eV) 
ELUMO 
(eV) 
Egel 
(eV) 
Ecalc* 
(eV) 
Ocalc* 
(nm) 
ReL8 1.38 –1.17 –6.12 –3.57 2.55 2.31 537 
ReL9 1.40 –1.45 –6.14 –3.29 2.85 2.67 436 
* These values are from Table S12. 
The onset oxidation and reduction potentials (Eonset ox, Eonset red) were measured by cyclic voltammetry in volt 
versus SCE. The CVs were carried out at a potential scan rate of 200 mV s-1 at room temperature. The HOMO and 
LUMO energy levels (EHOMO and ELUMO) in electron volt (eV) were calculated according to the empirical equations 
(1) and (2):[43] 
EHOMO (eV) = -e (Eonset ox (V vs. SCE) + 4.74 V)      Eq(1)     
ELUMO (eV) = -e (Eonset red (V vs. SCE) + 4.74 V)     Eq(2),     
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and, the energy gap value was obtained as followed: Egel = (ELUMO - EHOMO) 
 
Interestingly, the thorough examination of the first reduction process of the Re 
complexes at different scan rates shows that it becomes quasi-reversible around 1 V/s only in 
the case of compound ReL8 (Figure 13). This is rather uncommon as this process is generally 
irreversible when implying the π*(pyta). It is noteworthy that, in cyclic voltammetry, a 1/1 
intensity ratio is clearly observed between the first one-electron reduction process and the first 
one-electron oxidation process of compound ReL9 (Figure S5). The use of a glassy carbon 
electrode allows us to highlight the same phenomenon for compound ReL8 (Figure S6). 
 
Figure 13. First reduction process of complex ReL8 at respectively 0.2 (dashed black), 0.5 (dashed grey), 1.0 
(black), and 5.0 (grey) V/s. 
 
To sum up, when comparing both complexes, the two main characteristic features are a 
significantly lower electrochemical gap for compound ReL8 than for compound ReL9, and a 
different electrochemical behavior for the first reduction process. The latter property is probably 
related to the different nature of the two compounds. For compound ReL9, the LUMO and 
LUMO+1 energy levels are close: 0.07 eV (around 70 mV). Consequently, the first reduction 
potential detected at –1.60 V probably originates from the contribution of both the LUMO and 
LUMO+1 energy levels involving respectively the π* (pyta) and π*(pyta) + π*(PBO) orbitals. 
In contrast for ReL8, the energy difference between these levels is greater (0.41 eV) and allows 
an easier electrochemical assignment of this reduction process exclusively resulting from the 
π*(pyta) moiety. 
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2.5. Spectroscopic properties  
The spectroscopic properties of the four compounds have first been studied in solution 
in three different organic solvents, i.e. DCM, acetonitrile and methanol. With a few exceptions 
that will be outlined below, the results were close in the three solvents as shown in Table S14 
and in Figures S7 and S8, indicating that the dissolved compounds were weakly sensitive to the 
polarity and proticity of their environment. Consequently, we will focus on results obtained in 
DCM for the sake of homogeneity with calculations and electrochemistry, and because these 
results are enough to illustrate the main behavior of our compounds. Selected data are given in 
Table 5. It must also be noticed that all measurements were conducted in aerated solutions. 
Bubbling with argon led to an increase of the emission band intensity lower or equal to 15%, 
whatever the band considered. 
 
Table 5. Wavelengths of maximum absorption (λabs) and emission (λem), fluorescence and 
photoluminescence quantum yields (ΦF and ΦPL), luminescence decay times (Wi) and their 
respective fractions of intensity (fi), for the four compounds in DCM solution and in the solid 
state. For studies in solutions, the concentration of ligands L8 and L9 was around 2.5 × 10-5 M 
for absorption and 1.8 × 10-6 M for emission. The concentration of complexes ReL8 and ReL9 
was close to 2.0 × 10-5 M and 1.3 × 10-5 M, respectively, for absorption and below 1.1 × 10-6 
M for emission. Fluorescence quantum yields of complexes were measured on very dilute 
solutions to limit the formation of aggregates. 
[a] If not specified, λex between 300 and 306 nm. [b] the decay times Wi and the corresponding fractions of intensity 
fi are defined by the multiexponential analysis of the decay curves: IF(t)=6aiuexp(-t/Wi) and fi=aiuWi/(6ajuWj). [c] a 
very weak and short component <5 ps has been neglected (scattering). [d] λex = 380 nm. [e] λem = 620 nm ± 80 nm. 
[f] λem = 565 ± 65 nm. [g] λex = 340 nm.   
 
 
Compounds Dichloromethane Solid state 
λabs (nm) λem (nm) [a] ΦF [a] Wi (fi) [a,b] λem (nm) [a] ΦPL [a] 
L8 304 370 0.025 30-40 ps (0.09) [c], 1.11 ns 
(0.56), 2.00 ns (0.35) 
--- --- 
L9 311 361 0.559 0.51 ns (0.97), 3.75 ns (0.03) --- --- 
ReL8 300,381 358, 626 0.008 73.5 ns [d,e] 584 [d], 622[d] 0.065 [d] 
ReL9 309 360, 544 0.007 4.79 ns (0.04) [d f], 192 ns (0.96) 542 [g] 0.016 [g] 
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2.5.1. UV-vis absorption spectroscopy of the four compounds in solution  
All experimental absorption spectra were in very good agreement with TD-DFT 
calculations as shown in Figure S3 for the complexes. Regarding the free ligands L8 and L9, 
the absorption spectra in DCM had maxima at around 304 nm and 311 nm, respectively (Figure 
14a). The shape and position of these spectra are typical of the PBO framework,[32] as could be 
expected for π-π* transitions centered on this part of the molecule (Tables S7 and S8). 
Regarding complexes, the main absorption band was situated at 300 nm and 309 nm for ReL8 
and ReL9 (Figure 14b), respectively, and it was strongly reminiscent of the corresponding 
ligands. Most likely, it arises from the S0→S8 and S0→S9 transitions for ReL8, and S0→S6 
transition for ReL9.  
 
The oscillator strength of these transitions is strong and they are predicted to take place 
at 292.8 nm and 304.1 nm, respectively (see Tables S9 and S10). They involve HOMO–2 and 
LUMO+1 orbitals, which both are centered on the ligand, more precisely on the PBO moiety. 
Besides, the complexes exhibited absorption at long wavelengths, as typically observed in 
rhenium(I) tricarbonyl diimine complexes [Re(CO)3(α,α’-diimine)X] (Cf. Chapter I). The 
spectrum of ReL8 showed a distinct band of low intensity peaking at around 384 nm and tailing 
up to 450 nm, while the spectrum of ReL9 smoothly extended above 400 nm. For ReL8, this 
low-energy absorption band results from a S0→S2 transition, which is predicted to be quite 
active. The calculated absorption maximum is 378.4 nm, and the involved FMOs are HOMO-
1 and LUMO. For ReL9, the S0→S2 transition has only moderate oscillator strength. Most 
probably, the absorption tail mainly arises from the convolution of S0→S3 and S0→S5 
transitions, whose starting orbitals are HOMO and HOMO-1, and final orbital is the LUMO+1. 
All these transitions have strong metal-to-ligand charge transfer (MLCT) character, in which 
the ligand is either the pyta or PBO group for ReL8, and a combination of both for ReL9.  
 
2.5.2. Emission spectroscopy of ligands L8 and L9 in solution 
For ligands, the excitation spectrum (Figure S8) was similar to the absorption spectrum 
for L9, and the emission spectrum was independent of the excitation wavelength, showing that 
only one species emits in solution. In contrast for L8, the excitation spectrum was markedly 
narrower than the absorption spectrum at short wavelengths, and the emission spectra was 
slightly varied with the excitation wavelength. This observation suggests the presence of at least 
two species in solution.  
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The emission spectrum of L8 showed only a broad unresolved band peaking at 370 nm 
(Figure 14a). Remarkable variations were noticed with increasing concentration, showing the 
presence of aggregates that emit at longer wavelengths. The spectrum of L9 exhibited fine 
vibrational structure and peaked at 361 nm. The position of the emission spectrum was in very 
good agreement with calculations for L8, slightly less for L9, since maxima were predicted at 
377.2 nm and 394.9 nm, respectively. As expected, transitions are of the S1→S0 type with π-π* 
character, involving the LUMO and the HOMO that are both centered on the PBO group in L8, 
and spread over the pyta and PBO groups in L9. Curiously, the fluorescence efficiency was 
very different for both ligands. Like a large number of PBO derivatives in solution,[32] ligand 
L9 was a good fluorophore, with a fluorescence quantum yield close to 0.56. By comparison, 
the emission quantum yield of L8 was lower by a factor 20. The examination of the energy 
levels of L8 and L9 does not explain why the compounds behave so differently. A possible 
explanation is that poorly emissive conformers or aggregates are responsible for the low 
quantum yield of L8 in solution.  
The lifetimes of the compounds were measured in DCM solutions by Dr. Rémi Métivier 
(ENS Cachan) (Table 5 and Figure S9). For Ligand L8, the decay was multiexponential. Two 
main components were around 1-2 ns, and these values are perfectly in line with those reported 
for PBO in cyclohexane and ethanol solutions.[44] A very short component around 30-40 ps was 
also detected. A possibility is that the multiple lifetimes arise from distinct species, and this 
supports the presence of distinct conformers or aggregates that could be formed at low 
concentration in DCM. For ligand L9, the decay was almost monoexponential with a lifetime 
of 0.51 ns. 
     
Figure 14. (a and b) Normalized absorption (dotted line) and emission spectra (solid line) of compounds in DCM, 
λex = 300-306 nm. (a) Ligands L8 (red) and L9 (blue). (b) Complexes ReL8 (red) and ReL9 (blue). (c) Complex 
ReL8 in methanol (green line) and acetonitrile (black line) with λex = 370 nm. Concentrations: 2.5 × 10-5 M for 
absorption and 1.8 × 10-6 M for emission.for L8 and L9; close to 2.1 × 10-5 M and 1.5 × 10-5 M for ReL8 and 
ReL9 respectively, for absorption and below 1.1 × 10-6 M for emission. 
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2.5.3. Fluorescence emission of complexes ReL8 and ReL9 in dilute solution with excitation 
around 300 nm 
Let us now turn our attention towards the emission properties of the complexes (Figure 
14b). With excitation around 300 nm, the emission spectrum of ReL8 was detected at around 
358 nm, slightly blue-shifted with respect to that of the corresponding ligand L8. The emission 
spectrum of ReL9 showed a band centered at 360 nm with weak vibrational resolution, almost 
superimposable with that of ligand L9. The fluorescence quantum yields were found to be very 
low for both complexes ReL8 and ReL9. The values were weaker by one and two orders of 
magnitude, respectively, with respect to the free ligands. It was not possible to measure the 
decay by exciting at 300 nm and collecting emission around 400 nm because the signal was too 
weak for our experimental set up. 
 
It was tempting to assign this emission at short wavelengths to the presence of residual 
free ligands, but no traces of the latter were detected whatever the method used, including HPLC 
(Figure S10). Emission around 360 nm was thus solely due to complexes, and it is centered on 
the organic ligand.  
 
The origin of this emission is delicate to attribute. According to calculations (Table S12), 
emission from the first singlet state is predicted to take place at long wavelengths (537.3 and 
463.6 nm in ReL8 and ReL9, respectively). The large discrepancy with experimental values 
makes this attribution unsatisfactory, especially since the transition is associated with very 
small oscillator strength. Therefore, singlet states of higher energy must be considered. 
Emission from S2 is expected at shorter wavelengths (457.1 and 411.0 nm for ReL8 and ReL9 
respectively), and the transition is quite active in both complexes. For ReL9, emission could 
also come from S3.  All these transitions have strong ligand-to-metal charge transfer (LMCT) 
character. Alternatively, due to the similarity of the emission spectra with those of the 
corresponding ligands, it can be thought that emission comes from a state that involves orbitals 
more or less located on the PBO group. Consequently, the S0→S4 transition could be involved 
in this emission process, because it involves the LUMO+1 that is situated on the PBO group 
for ReL8 and on the whole PBO-pyta ligand for ReL9. This transition exhibits a high oscillator 
strength value for ReL9, it is much less active for ReL8.  
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2.5.4. Fluorescence emission of ReL8 in methanol and acetonitrile with excitation at 370 nm 
When exciting at around 300 nm, fluorescence emission at around 360 nm was observed 
for both complexes in the three solvents investigated. Moreover, upon excitation at 370 nm, a 
new emission band was clearly observed for ReL8 in methanol and acetonitrile, with maximum 
at 460 and 438 nm, respectively, and weak quantum yield (Figure 14c). It is noteworthy that 
this band was not detected with excitation at shorter wavelengths. In DCM, varying the 
excitation wavelength had no influence upon the emission spectra of ReL8, thus suggesting a 
solvent effect. This emission could arise from the first or second singlet states, the latter being 
more likely in terms of energy and oscillator strength (Table S12). In both cases, the transition 
involves an electron transfer from the ligand to the metal. Similar transitions also exist for ReL9, 
but experimental evidence was difficult to obtain. It must be kept in mind that dissolved 
complexes emit weakly in solution, making these measurements quite delicate.  
 
2.5.5. Aggregation-induced phosphorescence emission in concentrated solution 
Very dilute solutions of complexes emitted weakly in the violet-blue range upon 
illumination by a hand-hold UV lamp. However, with slightly increasing concentration, strong 
orange-red and green emissions were seen with the naked eye for ReL8 and ReL9, respectively 
(Figure 15a). The corresponding spectra showed the presence of strong bands peaking around 
626 nm and 544 nm, respectively, whatever the excitation wavelength. Their intensity was 
clearly enhanced with increasing the compound concentration, as illustrated for ReL9 in Figure 
15b. It was much less intense in solvents where the compounds were more soluble, i.e. methanol 
(Figure 15c) and acetonitrile.  
 
Figure 15. (a) Picture of the complexes in concentrated organic solution under illumination by a UV lamp, λex = 
365 nm. (b) Normalized emission spectra of complexes ReL8 (red line) and ReL9 (blue lines) in concentrated 
DCM solution, λex = 306 nm. Concentrations: ReL8 around 4.2 × 10-6 M, concentration of ReL9 around 6 × 10-7 
M, 1.4 × 10-6 M and 3.5 × 10-6 M from bottom to top. (c) Emission spectra (λex = 306 nm, BPem = 4 nm) of complex 
ReL9 in methanol at various concentrations (increasing with absorbance at 306 nm).  The spectra are normalized 
at the maximum of the short-wavelengths band. 
ReL9
Concentrated
solutions
ReL8 a b c
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The position of the bands at long wavelengths is in good agreement with the maxima at 
645.1 and 553.2 nm that have been predicted by TD-DFT calculations for emission coming 
from the first triplet state (Table S12). The corresponding photoluminescence decays were 
mostly monoexponential (Figure 16). Long lifetimes of 73.5 ns and 192 ns were measured for 
ReL8 and ReL9, respectively (Table 5), thus confirming that emission is due to 
phosphorescence. 
 
 
Figure 16. Fluorescence decays of complexes ReL8 (left) and ReL9 (right) in dichloromethane. 
 
Our complexes therefore emit both fluorescence and phosphorescence. The close 
correlation of phosphorescence intensity with the concentration of complexes strongly suggests 
that this emission arises from aggregates that could be formed in the millimolar range. In this 
case, we would be in the presence of a strong AIPE effect. The weak solubility of our complexes 
would allow this effect to be identified in pure solvents, just by increasing the compound 
concentration and without the need to add a bad solvent to induce precipitation. Furthermore, 
dual emission from dissolved complexes seems to be well supported by the detection of the 
phosphorescence band in very dilute solutions of complexes, for which the clarity of the 
samples and the care brought to their preparation make it unlikely that aggregates could be 
formed. However, the absence of phosphorescence noticed for ReL9 in methanol at low 
concentration (Figure 15c) is not in line with this hypothesis. Further experiments aimed at 
detecting/enhancing the presence of aggregates in the various samples will be useful to clarify 
this point. It is noteworthy that in the literature, dual emission arising from multiple 
phosphorescence emission or concomitant emission from the singlet and triplet states has 
already been reported in Re complexes.[45] 
 
ReL8,
ReL9,
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2.5.6. Aggregation-induced phosphorescence emission in the solid-state 
After the study in solutions, the four compounds were investigated in the solid state. 
They were used as pristine powders. Ligands L8 and L9 were virtually not emissive in the solid 
state. The crystal packing mode of L8 is unknown, but the strong π-π stacking and significant 
overlap of the aromatic system that was observed for L9 is fully consistent with the absence of 
luminescence.  
 
In contrast, the solid complex ReL8 strongly emitted yellow light, while solid ReL9 
emitted in the green when illuminated by a hand-held UV lamp (Figure 17a). For ReL8, the 
emission spectrum, recorded with an integration sphere, had two maxima at 584 and 622 nm. 
The emission band at long wavelengths is reminiscent of that observed for concentrated 
solutions. For ReL9, the spectrum was centered on 542 nm (Figure 17b), also very close from 
that attributed to aggregates. By analogy, solid-state emission is assigned to phosphorescence. 
The photoluminescence quantum yields (PLQY) were 0.065 and 0.016, for ReL8 and ReL9, 
respectively. When comparing with the corresponding fluorescence quantum yields in solution, 
the emission intensity has been multiplied by a factor of 8 for ReL8 and 2.2 for ReL9 (Table 
5). The difference between the complexes can be explained by the bended conformation of 
ReL8 that prevents stacking between the aromatic rings and promotes light emission. 
Alternatively, the fact that the energy level of T1 is slightly lower for ReL8 than for ReL9 may 
also favor the better collection of energy in the final sink for the former complex. 
 
The band observed at 584 nm for the solid complex ReL8 can be attributed to a mixture 
of amorphous and crystalline complexes in the solid state, the wavelength shift resulting from 
various intermolecular interactions. It must be kept in mind that the solid-state characteristics 
reported here only refer to the investigated powders. Most likely, other values could have been 
found with single crystals as well as with powders prepared from recrystallization in other 
solvents or by mechanical milling, because the molecular arrangement and surface defects play 
an essential role in solid-state properties.[46]  
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Figure 17. (a) Picture of the complexes as pristine powders under illumination by a UV lamp, λex = 365 nm. (b) 
Normalized emission spectra of the same samples of ReL8 (λex = 380 nm, red line) and ReL9 (λex = 340 nm, blue 
line). 
 
2.6. Energy diagrams and photophysical processes 
 It is instructive to gather all our data and draw the energy diagrams (Figure 18), to get 
a clear overview of the photophysical behavior. To do so, the particularities of our complexes, 
highlighted by TD-DFT calculations, must be taken into account. As seen above, the HOMO 
and HOMO-1 have very close energy levels in both complexes, and the gap with HOMO-2 is 
not large. The LUMO and LUMO+1 are also very close, in particular for ReL9. As a result, 
many transitions occur at relatively close energies. On the other hand, the orbitals have different 
electron distributions and this effect is particularly marked for ReL8 where electrons are clearly 
localized on different parts of the complex according to the orbital considered. Transitions 
involving the same type of orbitals are probably favored with respect to those requiring a large 
reorganization of the electron cloud.  
 
Regarding the absorption process, the above characteristics explain that excited states 
of high energy are easily populated. These are essentially the S2, S8 and S9 singlet states for 
ReL8, and the S3, S5 and S6 states for ReL9.  
 
The emission at short wavelengths has been assigned to fluorescence, arising from a 
singlet state with intra-ligand (IL) π-π* character. This is in good agreement with the literature 
data. To our knowledge, this is the first time that this assignment is confirmed by DFT/TD-DFT 
calculations for rhenium(I) tricarbonyl complexes containing bidentate N-donor ligands. Our 
theoretical approach also indicates that fluorescence emission takes place at energies higher 
Solid state
a bReL9 ReL8
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than predicted, and does not correspond to S1→S0 transition. It seems that Sn→S0 transitions 
are involved here. Moreover, the observation that fluorescence of ReL8 in methanol and 
acetonitrile closely depends on the excitation energy suggests that emission arises from the 
excited state that has been directly populated by the absorption process. This could indicate that 
internal conversion between Sn and S1 is not very efficient, because for symmetry reasons it is 
probably quite difficult to pass from an excited state involving the LUMO+1 to an excited state 
involving the LUMO. So, direct deactivation of the high-energy singlet state toward the ground 
state would be the preferred pathway. To our knowledge, this mechanism seems to be 
unprecedented for this class of complexes.  
 
The energy diagram highlights the differences in the emission behavior of ReL8 and 
ReL9. These differences can be explained by the fact that the emitting states of ReL8 involve 
orbitals centered either on the pyta or on the PBO group, while the emitting states of ReL9 
involve orbitals centered on the pyta ligand and on the whole PBO-pyta ligand. The oscillator 
strength is very variable, depending on the considered transition.  
 
We have shown that the broad emission at long wavelengths is phosphorescence, the 
type of emission most frequently encountered for Re complexes on the basis of both 
experimental and theoretical investigations. It can be assigned to the lowest-energy triplet 
excited state with 3MLCT or 3MLCT/3LLCT character, generated in the usual way by 
intersystem crossing from the S1 excited state. In our case, weak or no phosphorescence 
emission was observed for the dissolved complexes, probably due to inter and intramolecular 
quenching of the 3MLCT state. In contrast, strong phosphorescence emission appears with the 
formation of aggregates and in the solid state. The reduction of intermolecular quenching with 
respect to solutions, as well as the restriction of the intermolecular rotation that takes place in 
solution between the pyta and PBO groups, may both explain this behavior. Phosphorescence 
emission therefore becomes predominant and dominates the emission properties in the solid 
state, hence the spectacular AIPE effect.  
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Figure 18. Simplified schematic energy level diagram describing the photophysical processes of complexes ReL8 
and ReL9 in CH2Cl2, in optimized ground state, first singlet excited state and first triplet excited state geometry 
(from left to right). The unlikely S1→S0 transition is in dashed lines and internal conversion is in dotted line. 
 
2.7. Evaluation of cytotoxicity and cell uptake 
Since our final aim is to use our compounds for biological imaging, a preliminary study 
has been undertaken by Dr. Laure Gibot (Institut de Physiologie et Biologie Cellulaire, 
Toulouse). Cellular investigations were made on human cells using two types of normal cells, 
i.e. dermal fibroblasts and keratinocytes, as well as two types of cancer cells from colorectal 
adenocarcinoma (HCT-116) and hypopharyngeal carcinoma (FADU). The toxicity of both 
complexes was evaluated using a PrestoBlue test on plated cells after 24 h incubation in 
complete medium with increasing concentrations of these compounds. The results are shown 
in Figure 19. For ReL8, the viability of every type of cells decreased gradually when the 
complex concentration was above 10 µM, and even showed an abrupt fall in the case of FADU. 
Complex ReL9 seemed to be less toxic than the other analog. The difference was evident for 
keratinocytes, since 75% cells survived in the presence of 100 µM compound. 
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Figure 19.  Evaluation of cytotoxicity of ReL8 (top) and ReL9 (bottom) in four different types of cells,  after 24h 
incubation at 37°C in complete medium (PrestoBlue test).  
 
The cell uptake was investigated on fibroblasts and HCT-116 cells (Figure 20). A 
suspension of the complexes at 10 µM was generated in the cell culture medium and spread 
onto the cells. After 30 min of incubation, cells were washed and observed by confocal 
ReL8 
ReL9 
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microscopy. With ReL8, HCT-116 cells showed a weak fluorescence signal both in the orange 
(620 nm ± 50 nm) and in the blue (460 nm ± 50 nm). The signals had the same origin and this 
observation suggests that they both arouse from aggregates. It was not possible to say if the 
aggregates were incorporated into the cells or adsorbed at the cell surface. In fibroblasts, the 
blue fluorescence signal was mostly detected, and it seemed to come from the cytoplasm, 
suggesting that the complexes were mainly dissolved inside the cells. With ReL9, no signal 
was detected in both types of cells, at various wavelengths. 
 
Figure 20.  Observation by confocal microscopy of HCT116 cells (top) and fibroblasts (bottom) after 30 min 
incubation at 37°C in DMEM without serum, in the presence of ReL8  (10 µM) and in the absence of dye. 
 
FluorescenceTransmitted light
λem = 620 nm ± 50 λem = 460 nm ± 50
Fi
br
ob
la
st
s
HC
T 1
16
Bl
an
k
Bl
an
k
Re
L8
Re
L8
Chapter III 
 
 171
2.8. Summary 
The present work revealed that the discrepancies observed between the electronic 
properties of complexes built with 1,2,3 and 1,2,4-triazole fragments were very spectacular. 
Not only the sequence of the nitrogen atoms on the triazole group was changed, but this 
impacted the functionalization of this group by the PBO moiety. In particular, with a 1,2,4-
triazole fragment like in ReL8, steric hindrance occurs due to proximity of PBO with the 
pyridinyl group. The PBO moiety is then positioned out of plane and behaves more 
independently from an electronic point of view. Consequently, the electrochemical and 
spectroscopic properties are markedly changed, and an unusual photophysical behavior has 
been evidenced and rationalized. Moreover, it was shown that the triazole fragment 
functionalization totally governs the conformation of the complex in the solid state, and thus 
plays a major role for photoluminescence. The triazole isomerism also strongly impacts the 
biological properties of cytotoxicity and cell uptake. At the moment, the compounds are not 
very good imaging agents, but the experimental conditions can certainly be improved. 
Moreover, in the following section, structural modifications of the complexes will be introduced 
in order to enhance the spectroscopic properties. 
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3. Synthesis and spectroscopic studies of PBO-based 1,2,4-triazole 
derivatives and corresponding Re(I) complexes ReL10 and ReL11:  toward 
improved photoluminescent properties 
 
3.1. Structural description 
It has been shown that the triazole fragment governs the conformation of the complexes. 
In particular, the 2-pyridyl-1,2,4-triazole containing Re(I) complex ReL8 emitted much more 
efficiently in the solid state than the 2-pyridyl-1,2,3-triazole analog, ReL9. Consequently, we 
decided to develop two new 2-pyridyl-1,2,4-triazole ligands and corresponding rhenium(I) 
complexes, with small modifications of the previous structures (Scheme 5). Ligand L10 and 
complex ReL10 bear a tert-butyl group at the 4-phenyl position of the PBO moiety. The 
electron system being similar to that of L8 and ReL8, respectively, the same behavior can be 
expected in solution. However, the bulky tert-butyl group should introduce some variations in 
the solid state arrangement, so that to decrease the π–π stacking and enhance the 
photoluminescence properties. Ligand L11 and complex ReL11 exhibit an inversion of the 
PBO unit, since the latter is now linked by its phenyl group to the pyta group. The conjugated 
electron system is therefore different from that of L8 and ReL8, respectively, and different 
spectroscopic properties in solution may be expected. Regarding the molecular arrangement in 
the solid state and the effect on the photoluminescence properties, both are very difficult to 
predict.  
 
3.2. Synthesis of the ligands and their corresponding rhenium complexes 
As shown in Scheme 5, ligand L10 was synthesized using a procedure similar to the one 
adopted for preparing L8. 2-Amino-5-nitrophenol was first reacted with 4-tert-butylbenzoic 
acid to obtain the 4-tert-butyl substituted PBO 26. After reduction of NO2 to NH2 (27), and a 
condensation reaction with hydrazonamide 28, ligand L10 was obtained with a modest overall 
yield of 40%. It is noteworthy that the intermediate product 28 was synthesized as a stable 
ready-to-use hydrazonamide (Scheme 6), which was conveniently used to prepare all the 1,2,4-
triazole derivatives presented in this manuscript, therefore markedly improving the yield of this 
step.[47]  
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Scheme 5. Synthesis of ligand L10 and complex ReL10. 
 
Conditions and regents: (i) 4-tert-butylbenzoic acid, polyphosphoric acid, 120ºC, 16 h; (ii) 10% Pd/C, H2, 
CH3OH/CH2Cl2, 6 bars, 24 h; (iii) N,N-dimethyl-N'-picolinoylformohydrazonamide, acetic acid, CH3CN, 90ºC, 
24 h; (iv) [Re(CO)5Cl], MeOH, 65ºC, 16 h. 
 
 
Scheme 6. Synthesis of hydrazonamide 28. 
 
Conditions and regents: CH2Cl2, reflux, 2h. 
 
 
The synthesis of ligand L11 was slightly different from the former ligands L8 and L10 
(Scheme 7). To swap the position of the PBO unit on the pyta moiety, an amine group was 
introduced on the PBO phenyl group, instead of the benzoxazole group. Firstly, PBO derivative 
29 was obtained from the reaction of 2-aminophenol with 4-nitrobenzoyl chloride in microwave 
conditions, which markedly promote the synthetic efficiency.[48] Then, a reduction process was 
carried out to get amine 30. Followed by the condensation reaction, ligand L11 was obtained 
with an overall yield of 29%. 
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Scheme 7. Synthesis of ligand L11 and complex ReL11. 
 
Conditions and regents: (i) 4-nitrobenzoyl chloride, 1,4-dioxane, 150 ºC, microwave, 20 min; (ii) 10% Pd/C, H2, 
MeOH/CH2Cl2, 6 bars, 24 h; (iii) N,N-dimethyl-N'-picolinoylformohydrazonamide, acetic acid, CH3CN, 90ºC, 24 
h; (iv) [Re(CO)5Cl], MeOH, 65ºC, 16 h. 
 
The corresponding tricarbonylrhenium(I) complexes ReL10 and ReL11 were then 
easily prepared in good yields (ca. 66%) by reacting [Re(CO)5Cl] with L10 or L11 in refluxing 
methanol. Detailed synthesis procedures and characterization data are given in the experimental 
section. 
 
3.3. Structural characterization  
3.3.1. Spectroscopic and spectrometric analysis 
Both ligands and complexes were characterized by means of IR, NMR and HR-MS 
spectroscopy. The structures of ligand L10 and complexes ReL10, ReL11 were also confirmed 
by X-ray crystallography. 
 
In detail, the IR spectra of both complexes ReL10 and ReL11 showed bands in the 
region 2030-1880 cm–1 corresponding to the facial orientation of Q(CO) stretching bands. These 
values were similar with previous tricarbonyl rhenium(I) complexes ReL8 or ReL9. For NMR 
analysis, the same trend in the chemical shift of the triazole proton was found compared to 
1,2,4-triazole ligand L8 and its rhenium complex ReL8. The signal was situated at 8.97 ppm in 
L10 and 9.03 ppm in L11, but shifted downfield to 9.30 ppm and 9.33 ppm in complexes ReL10 
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and ReL11, respectively. The HR-MS spectra of both complexes showed a peak corresponding 
to [M–Cl]+, as it was the case for ReL8 and ReL9.  
 
3.3.2. X-ray diffraction 
Monocrystals of ligand L10 and complexes ReL10 and ReL11 suitable for X-ray 
crystallography analysis were successfully grown by slow evaporation of organic solvent. As 
described above, we focus on the conformation of each molecule and interactions with the 
closest neighbors, since these features govern the solid-state spectroscopic behavior. Molecular 
views are displayed in Figure 21. Selected crystallographic data and structure refinement details 
are collected in Table S15. 
 
 
Figure 21. Molecular views of L10, ReL10 (Type I conformer) and ReL11. Thermal ellipsoids are drawn at the 
50% probability level. H atoms are omitted for clarity. 
 
 
3.3.2.1. Crystal structures of ligand L10 and complex ReL10 
Since we did not obtain the X-Ray structure of the 1,2,4-triazole ligand L8, the structure 
of ligand L10 is particularly instructive. It gives us an intuitive impression on the conformation 
of the pyta and PBO unit in the free ligand, and the corresponding changes after complexation. 
Ligand L10 (Figure 21) crystallized in the triclinic P-1 space group. The angle between the 
benzoxazole and 1,2,4-triazole group was 78.3q. The molecules were also twisted by around 
20° between the benzoxazole and the phenyl groups. In the packing, all benzoxazole groups 
L10
ReL10
ReL11
Chapter III 
 
 176
were aligned in the same plane, while the phenyl rings were alternatively twisted in one 
direction of another with respect to the benzoxazole ring. Molecules are displayed as 
antiparallel dimers, in which the phenyl rings present a small overlap but are distant by 4.3 Å. 
This suggests that the interaction between them is not very strong. This distance between 
molecules is probably due to the steric hindrance of the tert-butyl group (Figure 22).  
 
Complex ReL10 (Figure 21) also crystallized in the triclinic P-1 space group. 
Interestingly, the benzoxazole and phenyl ring are now almost aligned in the same plane. The 
angle between the benzoxazole and 1,2,4-triazole group was 69.6q, slightly reduced with 
respect to the free ligand and comparable to unsubstituted complex ReL8. Like in the former 
complex ReL8, the strong bending of pyta and PBO units suggests little interaction of the 
respective π-electron systems. A disorder was also found between the chlorine atom and one 
CO group. This resulted in a conformation similar to that found for complex ReL8, in which 
the benzoxazole oxygen and the chlorine atom point in the same (Type I) or opposite (Type II) 
direction, respectively. Besides, the free rotation of the tert-butyl group led to a continuous 
disorder at room temperature.  
 
The rhenium ion displays distorted octahedral coordination geometry. Like for the other 
complexes, the rhenium atom is coordinated to two nitrogens of the pyta ligand, one chlorine 
atom and three carbonyl groups in a fac configuration. The selected bond lengths and angles 
are shown in Table S16 (For the sake of simplicity, the values given only refer to Type I 
molecules of ReL10). The Re-C bond lengths in complex ReL10 (1.922-1.976 Å) are longer 
than the unsubstituted complex ReL8 (1.894-1.930 Å), while the Re-N bond is shorter (2.122 
and 2.146 Å in ReL10 compared to 2.143 and 2.189 Å in ReL8). This could be attributed to 
the electron donor effect of the tert-butyl group. In complex ReL10, the C-Re-C angles are in 
the 85.8-91.0q range. The trans bond angles are respectively 173.0(6), 172.9(5) and 175.1(17)q, 
showing a moderate distortion in the octahedral geometry. The N(1)-Re-N(2) angle has a value 
of 73.7(5)q, comparable to that found for ReL8 and reflecting the constrained five-membered 
coordination ring.  
 
The crystal cell and the arrangement of stacked molecules in the network are shown in 
Figure 22. The tert-butyl group structures the network. It is involved in intermolecular short 
contacts with the oxygen atoms of the carbonyl groups, as well as with the carbon atoms of the 
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pyridyl and phenyl groups of neighboring molecules. Other short contacts are found between 
the benzoxazole heteroatoms and the phenyl hydrogen atoms of neighboring molecules. No 
stacking of the aromatic systems, and therefore no overlap, was detected between complexes, 
suggesting that this new compound should have good photophysical properties in the solid state. 
 
 
Figure 22. Crystal packing mode of ligand L10 and complex ReL10. From left to right: crystal cell, arrangement 
and views of stacked molecules. The orange color indicates the overlap of the aromatic systems. Hydrogen atoms 
are not represented for the sake of clarity. 
 
3.3.2.2. Crystal structure of complex ReL11 
Complex ReL11 crystallized in the orthorhombic P212121 space and no disorder was 
observed. The PBO unit was practically planar (Figure 23). The benzoxazole and 1,2,4-triazole 
group were almost orthogonal, with an angle value of 83.11q. This is the largest angle among 
the four complexes studied, and this suggests minimal interaction of the π-electron systems. 
The coordination geometry of rhenium is the same as in the other complexes. Interestingly, the 
bond lengths and angles of complex ReL11 are comparable to the ReL8 isomer, showing that 
the inversion of the PBO group with respect to pyta has no influence on the coordination sphere.  
 
The complexes are arranged as antiparallel dimers, with very small overlap between the 
benzoxazole group of one molecule and the pyridyl group of the neighboring one. At first glance, 
78.3q 4.32Å
L10
ReL10
69.6q
20q
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this arrangement should favor the emission of light in the solid state. The dimers are themselves 
displayed in a herringbone manner, which is unprecedented in our series of complexes. The 
inorganic ligands of the coordination sphere participate in structuring the whole network. 
 
Figure 23. Crystal packing mode of complex ReL11. From left to right: crystal cell, arrangement and views of 
stacked molecules. The orange color indicates the overlap of the aromatic systems. Hydrogen atoms are not 
represented for the sake of clarity. 
 
3.4. Spectroscopic properties 
3.4.1. UV-visible absorption spectra in solution 
Like in the previous studies, the spectroscopic properties have been first studied in three 
different organic solvents, i.e. DCM, acetonitrile and methanol. The electronic absorption 
spectra of ligands L10 and L11 and complexes ReL10 and ReL11 in DCM are shown in Figure 
24. For each compound, the spectra are very similar, indicating that the dissolved compounds 
were weakly sensitive to the polarity and proticity of their environment. Consequently, we will 
focus on the results obtained in DCM for comparison with the former ligand L8 and complex 
ReL8. 
    
Figure 24. UV-Visible absorption spectra of four compounds in DCM: (a) ligands L10 (black), L11 (blue); (b) 
complexes ReL10 (red), ReL11 (green). Concentrations are around 2.5 × 10-5 M. 
ReL11
83.1q
3.3 Å
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As shown in Table 6, the two ligands L10 and L11 have almost the same absorption 
spectra in DCM, namely one intense, slightly resolved band with maximum at 308 nm. The 
shape and position of these spectra are typical of the PBO framework, as could be expected for 
π-π* transitions centered on this part of the molecule. Regarding the corresponding complexes, 
the absorption spectra displayed two types of bands. The main absorption band was situated at 
306 nm and 310 nm for ReL10 and ReL11, respectively, and it was strongly reminiscent of the 
corresponding ligands. As previously established for complexes ReL8 and ReL9, this intense 
band has strong intra-ligand character. In contrast, the absorption band situated at long 
wavelengths (383 and 377 nm for ReL10 and ReL11, respectively) is characteristic of rhenium 
complexes and has most likely a mixed MLCT and LLCT character. The full data set for the 
four compounds in three organic solvents is given in Table S17. 
Table 6. Wavelengths of maximum absorption (λabs) and emission (λem), fluorescence and 
photoluminescence quantum yields (ΦF and ΦPL) for ligands L10 and L11, and complexes 
ReL10 and ReL11 in DCM. The concentration of all compounds was around 2.5 × 10-5 M for 
absorption studies, and close to 1.2 × 10-6 M for emission if not specified. Fluorescence 
quantum yields of complexes were measured on dilute solutions to limit the formation of 
aggregates. 
Compounds Dichloromethane Solid state 
λabs (nm) λem (nm) [a] ε (M-1cm-1) ΦF [a] λem (nm) [c] ΦPL [c] 
L10 308 369 31800 0.016 --- --- 
L11 308 360 34800 0.085 --- --- 
ReL10 306, 383 359, 612 [b] 33600, 4400 0.003 567  0.21  
ReL11 310, 377 373, 617 [b] 22800, 4000 0.007 558  0.31  
[a] λex between 300 and 306 nm. [b] Results obtained in concentrated solution (8.5 × 10-6 M).  [c] λex = 380 nm. 
 
3.4.2. Emission spectra in dilute solutions 
Both ligands L10 and L11 have weak emission in solution. A faint violet-blue light was 
detected by the naked eye upon illumination by a UV lamp. In fact, the spectra of L10 displayed 
a single band, with maxima around 369 nm and a fluorescence quantum yield of 0.016 (Table 
6 and Figure 25a). Within experimental error, this compound behaves in solution like ligand 
L8, as could be expected from the similarity of electron systems. The electron donor effect of 
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the tert-butyl group was not noticed. The emission spectrum of L11 peaked at 360 nm, it was 
slightly broader than for L8 and the fluorescence quantum yield (0.085) was higher. 
 
We then studied the emission properties of the rhenium complexes ReL10 and ReL11 
at a concentration about 1.2 µM in CH2Cl2 (Figure 25b). Upon excitation at 303 nm, complex 
ReL10 showed a band centered at around 359 nm, just like the ReL8 analog. Comparatively, 
the emission band of ReL11 that peaked at 373 nm was slightly shifted to long wavelengths. 
For both complexes, this band probably results from transitions involving orbitals centered on 
the organic ligand. To prove the absence of contribution due to some residual ligand in the 
complexes, different methods such as Elemental analysis, NMR and HPLC were used, and no 
traces of free ligands were discovered. The quantum yield values of complexes ReL10 and 
ReL11 were very low in all three solvents, at around 0.003 and 0.007, respectively. These 
values are significantly lower than those of the free ligands, as observed in the previous series 
of compounds.   
 
Interestingly, when excited at 380 nm, a peak at around 430 nm attributable to 
fluorescence was obtained in all three solvents, for both complexes. This behavior is 
reminiscent of ReL8. 
 
Figure 25. Normalized emission spectra of compounds in DCM, λex = 303 nm. (a) Ligands L10 (black) and L11 
(red). (b) Complexes ReL10 (black) and ReL11 (red). Concentrations were around 1.5 × 10-6 M for ligands and 
1.2 × 10-6 M for complexes. 
 
3.4.3. Emission spectra in concentrated solution 
As described above, both complexes emitted weakly in the violet-blue range upon 
illumination by a UV lamp (365 nm). However, when the concentration was increased, strong 
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orange emission was seen with the naked eye for both complexes (Figure 26). Its intensity was 
markedly increased with increasing concentration. The corresponding emission spectra 
displayed two bands: a weak emission band corresponding to fluorescence, and an intense band 
that peaked around 612 nm for ReL10 and 617 nm for ReL11, whatever the excitation 
wavelength. This emission band is most probably phosphorescence that originates from a triplet 
3MLCT state, like for related tricarbonyl rhenium(I) complexes. It is interesting to notice that 
this band is slightly shifted to short wavelengths with respect to ReL8 that emitted at 626 nm. 
This band can related to the formation of aggregates, as hypothesized for complexes ReL8 and 
ReL9. However, this band was already detected for complexes ReL10 and ReL11 at 1.2 × 10-
6 M in the three solvents.  
 
Consequently, here again, additional experiments will be necessary to confirm the 
presence of aggregates in suspension, and to determine whether phosphorescence only arises 
from aggregates or contributes to dual emission from dissolved complexes.  
 
Figure 26. (a) Pictures of the complexes in concentrated DCM solution under illumination by a UV lamp (365 
nm). (b) Normalized emission spectra of complexes ReL10 (black line) and ReL11 (red lines) in concentrated 
DCM solution, λex = 306 nm. Concentrations: ReL10 at 8.5 × 10-6 M, concentration of ReL11 at 6.8 × 10-6 M.  
 
3.4.4. Emission spectra in solid state 
After the studies in solutions, the four compounds were investigated in the solid state as 
pristine powders. While ligands L10 and L11 were virtually not emissive in the solid state, the 
solid complexes strongly emitted yellow light. The corresponding emission spectra, recorded 
with an integration sphere, displayed a band with maxima at 567 nm and 558 nm, for Re10 and 
ReL11, respectively. In both case, a shoulder was visible above 610 nm (Figure 27). Emission 
is therefore situated at shorter wavelengths than that of ReL8, and the difference is particularly 
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strong for ReL11. The photoluminescence quantum yield of ReL10 was 0.21. The steric 
hindrance brought by the tert-butyl group has successfully resulted in a marked increase of the 
PLQY with respect to ReL8. The AIE effect was very strong, since emission was multiplied by 
70 in the solid state with respect to DCM solutions. 
 
For ReL11, the PLQY value reached 0.31 and this is the highest value obtained in this 
series of complexes. The emission intensity was enhanced 44 fold with passing to the solid 
state. The AIE effect was strong, but not as strong as for ReL10, because ReL11 was slightly 
more emissive in solution.  
 
Figure 27. (a) Picture of the complexes as pristine powders under illumination by a UV lamp, λex = 365 nm. (b) 
Photoluminescence spectra of complexes ReL10 (bue line) and ReL11 (red line), λex = 380 nm. 
  
Chapter III 
 
 183
4. Conclusion 
For a long time, various triazole ligands have been used to introduce a chelating group 
in coordination complexes using click chemistry. Triazole groups thus play the role of linkers 
or are part of the coordinating agent, as it is the case for pyta ligands. However, the importance 
of the nature of the triazole group in complexes has gone unnoticed. Very recently, a study by 
Lo et al. has attracted attention on this point, through a comparison between regular and inverse 
isomers of 2-pyridyl-1,2,3-triazole complexes.[40] Another study dealing with iridium 
complexes containing the 2-pyridyl-1,2,4-triazole ligand has also shown that modulating the 
strength of donor/acceptor on the ligand is a smart strategy to tune aggregation-induced 
emission.[28] The influence of regioisomerism in 1,2,3-triazole based chromophores has also 
been reported.[49]  
 
In the first part of this chapter, our work revealed that the discrepancies observed 
between the electronic properties of complexes built with 1,2,3 and 1,2,4-triazole fragments are 
very spectacular. Not only the sequence of the nitrogen atoms on the triazole group was changed, 
but this impacted the functionalization of this group by the PBO moiety. In particular, with a 
1,2,4-triazole fragment like in ReL8, steric hindrance occurs due to proximity of PBO with the 
pyridinyl group. The PBO moiety is then positioned out of plane and behaves more 
independently from an electronic point of view. Consequently, the electrochemical and 
spectroscopic properties are markedly changed, and an unusual photophysical behavior has 
been evidenced and rationalized. Moreover, it was shown that the triazole fragment 
functionalization totally governs the conformation of the complex in the solid state, and thus 
plays a major role for photoluminescence. The triazole ligand must then be carefully chosen 
depending on the envisaged applications. 
 
In the second part of this chapter, we tried to optimize the photoluminescence properties 
of the complexes. The strategy that consists in increasing the steric hindrance of the molecule 
has paid off in terms of photoluminescence efficiency. We have also seen that the way the PBO 
group is linked to pyta determines the molecular arrangement and therefore the 
photoluminescence properties. Now we know that among the four complexes investigated, the 
substitution pattern ReL11 must be retained if the aim is to obtain a compound strongly 
emissive in the solid state. If a strong AIE effect is desired, the framework of ReL10 should be 
preferred. 
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This work also confirmed the interest of the PBO moiety to access rhenium(I) 
complexes that show significant luminescence in the solid state. This is especially true for 
neutral complexes that can no longer be considered of negligible value for spectroscopic and 
imaging applications. Our complexes will now be tested in view of various applications, 
including as nanoparticles for biological staining. The preliminary tests on ReL8 have shown 
that this compound was uptaken by cells, but gave a rather weak signal. Better results could be 
obtained with complexes ReL10 and ReL11, which could be used directly or after 
incorporation in elaborated nanoparticles, since their emission properties in the solid state are 
really attractive. 
 
Finally, this work paves the way for further investigations. Various organic dyes could 
be introduced using the synthesis strategy that has been developed here, to modulate the 
spectroscopic and photophysical behavior of a new generation of complexes. All of this data 
will be useful to move from an empirical approach to a rational design of highly emissive 
rhenium(I) luminescent probes. 
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5. Experimental Section 
5.1. Materials and Equipment 
All purchased chemicals were of the highest purity commercially available and used 
without further purification. Analytical grade solvents were used as received unless specified. 
Reactions were monitored by analytical thin layer chromatography (TLC) on Kieselgel 60 F254 
(Merck). Chromatography purifications were conducted using silica gel or neutral alumia 
obtained from Merck. NMR, mass and infrared spectra were obtained in the relevant “Services 
communs de l’Institut de Chimie de Toulouse, Université de Toulouse III-Paul-Sabatier”. 1H- 
and 13C-NMR spectra were measured with Bruker Avance DRX 500 MHz or Bruker Avance 
300 MHz spectrometers. Attributions of the signals were made using 2D NMR data (COSY, 
HSQC and HMBC). Electrospray mass spectra were obtained using a QTRAP Applied 
Biosystems spectrometer and high-resolution mass spectra (HRMS) were recorded using an 
LCT Premier Waters spectrometer. Desorption chemical ionization (DCI) mass spectra (NH3 
or CH4) were obtained on a DSQ II Thermofisher apparatus. Infrared spectra were obtained on 
a Nexus Thermonicolet apparatus with DTGS as the detector. The microanalyses were 
performed with a Perkin Elmer 2400 elemental analyzer in the ‘Service d’Analyse Chimique 
du Laboratoire de Chimie de Coordination de Toulouse’ (LCC, Toulouse). 
 
5.2. Experimental Procedure 
6-nitro-2-phenylbenzoxazole (23). The mixture of 2-amino-5-nitrophenol (10 mmol, 
1.54 g), benzoic acid (10 mmol, 1.22 g) and polyphosphoric acid (24 g) was heated to 110 ºC 
with stirring for 16 h. After reaction, ice water (100 mL) was added. The resulting mixture was 
neutralized with 10% NaOH solution and extracted with ethyl acetate (3 × 60 mL). All organic 
layers were combined, washed with water, dried over anhydrous MgSO4, filtered and 
concentrated to dry. The residue was purified by column chromatography using ethyl 
acetate/petroleum ether (v/v = 1/5) as eluent to obtain 23 as a yellow solid (1.91 g, yield 80%). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 8.48 (dd, J = 0.5 Hz, J = 2.2 Hz, 1H, ArH), 8.33-8.26 
(m, 3H, ArH), 7.83 (dd, J = 0.5 Hz, J = 8.8 Hz, 1H, ArH), 7.65-7.53 (m, 3H, ArH). DCI/CH4-
MS: m/z 241.0607 ([M+H]+ calcd for C13H9N2O3, 241.0608). 
 
6-amino-2-phenylbenzoxazole (24). To a solution of 23 (1.07 g, 4.5 mmol) in 
MeOH/CHCl3 (1:2 v/v, 30 mL) was added 10% Pd/C (0.33 g). The mixture was carried out 
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under 6 bars pressure of H2 and stirred at room temperature for 24 h. After reaction, the mixture 
was filtered twice to remove the catalyst. The filtrate was concentrated to dry and purified by 
column chromatography using DCM as eluent to obtain 24 as a pale white solid, (0.82 g, yield 
87%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 8.20-8.16 (m, 2H, ArH), 7.54-7.48 (m, 4H, ArH), 
6.88 (d, J = 2.2 Hz, 1H, ArH), 6.70 (dd, J = 2.1 Hz, J = 8.4 Hz, 1H, ArH). DCI/NH3-MS: m/z 
211.0 ([M+H]+ calcd for C13H11N2O: 211.1). 
 
6-azido-2-phenylbenzoxazole (25). To an aqueous solution of HCl (6N, 20 mL), 24 
(420 mg, 2 mmol) was added at 0–4 ºC with stirring, then extra ethanol was added until the 
solid dissolved completely. Then, sodium nitrite (262 mg, 3.8 mmol) in water was added 
dropwise and the mixture was stirred at 0–4 ºC for 45 min. Sodium azide (195 mg, 3 mmol) 
was added slowly. The mixture was stirred for another 2 h and extracted with diethyl ether (3 x 
50 mL). All the organic layers were combined, washed with saturated NaHCO3 aqueous 
solution (2 x 50 mL), dried over anhydrous MgSO4, filtered and concentrated to dry. The 
residue was dried under vacuum without further purification to afford 25 as a yellow solid (405 
mg, yield 86%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 7.04 (dd, J = 2.1 Hz, J = 8.5 Hz, 1H, 
ArH), 7.27 (dd, J = 0.5 Hz, J = 2.1 Hz, 1H, ArH), 7.53-7.53 (m, 3H, ArH), 7.72 (dd, J = 0.5 
Hz, J = 8.5 Hz, 1H, ArH), 8.21-8.24 (m, 2H, ArH). DCI/NH3-MS: m/z 237.0 ([M+H]+calcd for 
C13H9N4O: 237.1); IR(ATR): ν(N3) = 2113 cm−1. 
 
For ligands L8 and L9, carbon numbering for NMR consists with corresponding 
complexes, as shown in Figure 2. Proton numbering corresponds to the carbon numbering (e.g. 
H10 is the hydrogen on C10). 
 
2-phenyl-6-(3-(pyridin-2-yl)-4H-1,2,4-triazol-4-yl)benzoxazole (L8). To a solution 
of pyridine-2-carbohydrazide (287 mg, 2.1 mmol) in distilled CH3CN (5 mL), N,N-
dimethylformamide dimethyl acetal (250 mg, 2.1 mmol) was added dropwise under argon. The 
mixture was heated to 50 ºC with stirring for 3 h and then 2 (400 mg, 1.9 mmol) in CH3CN (15 
mL) was added as well as acetic acid (3 mL). The mixture was heated to 120 ºC for 16 h. After 
cooling to room temperature, the mixture was filtered and the precipitate was washed with 
diethyl ether. The residue was purified on column chromatography using MeOH/DCM (v/v = 
1/10 ) as eluent to afford L8 as a light yellow solid (200 mg, yield 31%). 1H NMR (500 MHz, 
DMSO-d6): δ (ppm) = 8.97 (s, 1H, H10), 8.35 (ddd, J = 4.9, J = 1.8, J = 0.9 Hz, 1H, H4), 8.28–
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8.16 (m, 2H, H20, 24), 8.10 (dt, J = 7.9, J = 1.1 Hz, 1H, H7), 8.02 (d, J = 2.0 Hz, 1H, H12), 7.97 
(td, J = 7.8, 1.8 Hz, 1H, H6), 7.88 (d, J = 8.4 Hz, 1H, H15), 7.71–7.60 (m, 3H, H21, 22, 23), 7.41 
(ddd, J = 8.6, 5.2, 1.7 Hz, 2H, H14, 5). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 164.3 (C18), 
152.1 (C8), 150.2 (C11), 149.5 (C4), 147.1 (C10), 146.9 (C9), 142.0 (C13), 137.8 (C6), 133.0 (C16), 
132.9 (C22), 129.9 (C21, 23), 127.9 (C20, 24), 126.5 (C19), 125.0 (C5), 124.4 (C7), 124.0 (C14), 120.1 
(C15), 110.0 (C12). ESI-HRMS m/z 340.1195 ([M+H]+ calcd for C20H14N5O, 340.1198). Anal. 
calcd (%) for C20H13N5O: C 70.79, H 3.86, N 20.64; found: C 70.51, H 3.63, N 20.79. 
 
2-phenyl-6-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)benzoxazole (L9). A mixture of 2-
ethynylpyridine (103 mg, 1 mmol), 6-azido-2-phenylbenzoxazole (25) (260 mg, 1.1 mmol),  
copper(II) acetate monohydrate (60 mg, 0.3 mmol) and sodium ascorbate (100 mg, 0.5 mmol) 
in acetonitrile (20 mL) was stirred at room temperature for 16 h. The resulting mixture was 
evaporated to remove the solvent and then dissolved in dichloromethane (50 mL), washed with 
saturated Na2EDTA solution (2 x 30 mL), dried with anhydrous MgSO4 and filtered. The filtrate 
was evaporated and recrystallized with DCM and diethyl ether to afford L9 as a pale solid (225 
mg, yield 66%). 1H NMR (500 MHz, DMSO-d6):  δ (ppm) = 9.44 (s, 1H, H10), 8.69 (m, 1H, 
H4), 8.53 (d, J = 2.1 Hz, 1H, H16), 8.26 - 8.24 (m, 2H, H19, 23), 8.16 - 8.12 (m, 2H, H12, 13), 8.05 
(d, J = 8.6 Hz, 1H, H7), 7.99 - 7.96 (m, 1H, H6), 7.70 - 7.64 (m, 3H, H20, 21, 21), 7.44 - 7.42 (m, 
1H, H5). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 164.4 (C17), 150.9 (C8), 150.2 (C4), 149.9 
(C15), 148.8(C11), 142.1 (C14), 137.8 (C6), 134.5 (C9), 132.9 (C21), 129.9 (C20, 22), 128.0 (C19, 
23), 126.5 (C18), 123.5 (C5), 122.2(C10), 121.1 (C7), 120.3 (C12), 118.1 (13), 104.2 (C16). ESI-
HRMS: m/z 340.1197 ([M+H]+ calcd for C20H14N5O, 340.1198), m/z 362.1015 ([M+Na]+ calcd 
for C20H13N5ONa: 362.1018); found 362.1015. Anal.  calcd (%) for C20H13N5O: C 70.79, H 
3.86, N 20.64; found: C 70.49, H 3.69, N 20.52. 
 
2-(4-tert-butylphenyl)-6-nitrobenzoxazole (26). Using same procedure than 
compound 23 preparation, 2-amino-5-nitrophenol (2.31 g, 15 mmol), 4-tert-butylbenzoic acid 
(2.67 g, 15 mmol) and polyphosphoric acid (24 g) gave, after purification by column 
chromatography (silica gel, ethyl acetate/petroleum ether, v/v = 1/10), 26 as a yellow solid (3.33 
g, yield 75%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 8.49 (d, J = 1.8 Hz, 1H), 8.33 (dd, J = 
2.2 Hz, J = 8.8 Hz, 1H), 8.24-8.19 (m, 2H), 7.84 (d, J = 8.8 Hz, 1H), 7.61-7.57 (m, 2H), 1.39 
(s, 9H, t-Bu). 
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2-(4-tert-butylphenyl)benzo[d]oxazol-6-amine (27). Using same procedure than 
compound 24 preparation, 26 (1.72 g, 5.8 mmol) and 10% Pd/C (30% w/w, 0.52 g) gave, after 
purification by column chromatography (silica gel, ethyl acetate/petroleum ether, v/v = 1/3), 27 
as a pale white solid (1.27 g, yield 82%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 8.12-8.08 (m, 
2H), 7.53-7.50 (m, 3H), 6.87 (dd, J = 2.2 Hz, J = 0.5 Hz, 1H), 6.70 (dd, J = 8.4 Hz, J = 2.2 Hz, 
1H), 1.36 (s, 9H, t-Bu). ESI-MS: m/z 267.1 ([M+H]+ calcd for C17H19N2O, 267.1). 
 
N,N-dimethyl-N'-picolinoylformohydrazonamide (28). A mixture of pyridine-2-
carbohydrazide (0.82 g, 6 mmol) and N,N-dimethylformamide dimethyl acetal (1.06 mL, 8 
mmol) in CH2Cl2 (20 mL) was stirred at 50ºC for 2 h. After the consumption of pyridine-2-
carbohydrazide, the solvent was evaporated and the resulting precipitate was purified by 
column chromatography using CH3OH/CH2Cl2 (v/v = 1/10) as eluent to afford 28 as a yellow 
solid (1.09 g, yield 95%). 1H NMR (300 MHz, CDCl3): δ (ppm) = 10.04 (s, 1H, NH), 8.49 (ddd, 
J = 2.6 Hz, J = 1.7 Hz, J = 0.9 Hz, 1H), 8.19 (dt, J = 7.8 Hz, J = 1.1 Hz, 1H), 7.96 (s, 1H, 
HC=N), 7.83 (td, J = 7.6 Hz, J = 1.7 Hz, 1H), 7.38 (ddd, J = 6.1 Hz, J = 4.8 Hz, J = 1.3 Hz, 
1H), 2.93 (s, 6H, 2CH3). DCI/NH3-MS: m/z 193.1 ([M+H]+ calcd for C9H13N4O, 193.1). 
 
2-(4-tert-butylphenyl)-6-(3-(pyridin-2-yl)-4H-1,2,4-triazol-4-yl)benzoxazole (L10). 
To a mixture of 27 (0.38 g, 1.4 mmol) and 28 (0.27 g, 1.4 mmol) in CH3CN (10 mL) was added 
1 mL acetic acid. The resulting mixture was refluxed at 90ºC with stirring for 24 h. After cooling 
to room temperature, the mixture was concentrated to dryness and purified on column 
chromatography using CH3OH/CH2Cl2 (v/v = 1/10) as eluent to afford a light yellow solid. 
Then the crude product was washed twice with methanol (2 x 10 mL) to remove the impurity. 
After dried in vacuum, L10 was obtained as a white powder (0.35 g, yield 64%). 1H NMR (500 
MHz, DMSO-d6): δ (ppm) = 8.97 (s, 1H, Hta), 8.36 (ddd, J = 2.7 Hz, J = 1.8 Hz, J = 0.9 Hz, 
1H), 8.16-8.14 (m, 2H), 8.10 (dt, J = 7.9 Hz, J = 1.1 Hz, 1H), 8.00 (dd, J = 2.0 Hz, J = 0.5 Hz, 
1H), 7.99-7.97 (m, 1H), 7.86 (dd, J = 8.4 Hz, J = 0.5 Hz, 1H), 7.68-7.65 (m, 2H), 7.42 (ddd, J 
= 6.0 Hz, J = 4.8 Hz, J = 1.2 Hz, 1H), 7.39 (dd, J = 8.4 Hz, J = 2.0 Hz, 1H), 1.34 (s, 9H, t-Bu). 
13C NMR (125 MHz, DMSO-d6): δ (ppm) = 164.4, 155.9, 152.1, 150.2, 149.5, 146.9 (CHta), 
142.1, 137.8, 132.8, 127.8, 126.8, 125.0, 124.4, 123.9, 123.8, 122.2, 120.0, 109.8, 35.4 (Cqt-
Bu), 31.3 (CH3). DCI/CH4-HRMS: m/z 396.1813 ([M+H]+: calcd for C24H22N5O, 396.1824). 
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2-(4-nitrophenyl)benzoxazole (29) was synthesized according to reference[48] with a 
slight change. The mixture of 2-aminophenol (1.8 mmol, 196 mg) and 4-nitrobenzoyl chloride 
(2 mmol, 370 mg) in 1,4-dioxane (2.5 mL) was treated with microwaves (150 W) in a sealed 
tube for 20 min at 150 ºC. After cooling to room temperature, the resulting mixture was slowly 
transferred to a stirred solution of 1N NaOH (50 mL). The precipitate was filtered, washed with 
water and then dried in vacuum. The crude product was purified by column chromatography 
using DCM as eluent to afford 29 as an orange-yellow solid (307 mg, yield 71%). 1H NMR 
(300 MHz, CDCl3): δ (ppm) = 8.46-8.37 (m, 4H), 7.85-7.82 (m, 1H), 7.66-7.62 (m, 1H), 7.48-
7.39 (m, 2H). DCI/CH4-MS: m/z 241.06 ([M+H]+ calcd for C13H9N2O3, 241.06). 
 
4-(benzoxazol-2-yl)aniline (30). Using same procedure than compound 24 
preparation, 29 (1.20 g, 5.0 mmol) and 10% Pd/C (30% w/w, 0.36 g) gave, after purification 
by column chromatography (silica gel, ethyl acetate/petroleum ether, v/v = 1/1), 30 as a pale 
white solid (0.99 g, yield 95%). 1H NMR (300 MHz, CD3OD): δ (ppm) = 7.97-7.92 (m, 2H), 
7.64-7.58 (m, 2H), 7.38-7.29 (m, 2H), 6.81-6.76 (m, 2H). DCI/CH4-MS: m/z 211.09 ([M+H]+ 
calcd for C13H11N2O, 211.09). 
 
2-(4-(3-(pyridin-2-yl)-4H-1,2,4-triazol-4-yl)phenyl)benzoxazole (L11). Using same 
procedure than compound L10 preparation, 30 (0.42 g, 2.0 mmol) and 28 (0.38 g, 2.0 mmol) 
gave after purification on column chromatography (silica gel, ethyl acetate) and two washings 
with methanol, L11 as a white powder (0.29 g, yield 43%). 1H NMR (500 MHz, DMSO-d6): δ 
(ppm) = 9.03 (s, 1H, Hta), 8.41 (ddd, J = 2.7 Hz, J = 1.8 Hz, J = 1.0 Hz, 1H), 8.29-8.26 (m, 2H), 
8.13 (dt, J = 7.8 Hz, J = 1.2 Hz, 1H), 8.02 (td, J = 7.6 Hz, J = 1.8 Hz, 1H), 7.86-7.81 (m, 2H), 
7.64-7.61 (m, 2H), 7.49-7.43 (m, 3H). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 161.8, 151.8, 
150.8, 149.5, 146.7, 146.5 (CHta), 141.9, 138.4, 138.0, 128.5, 127.3, 126.9, 126.3, 125.5, 125.1, 
124.4, 120.5, 111.5. DCI/CH4-HRMS: m/z 340.1194 ([M+H]+ calcd for C20H14N5O, 340.1198). 
 
General procedure for the preparation of tricarbonylrhenium(I) complexes. A mixture 
of ligand and [Re(CO)5Cl] (1.15 eq.) in methanol was stirred overnight at 65 ºC. After 
consumption of the ligand, the mixture was cooled to room temperature and filtered, the 
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precipitate was purified by chromatography on silica gel using ethylacetate as eluent to afford 
the desired product.iii 
 
ReL8. 50 mg (0.15 mmol) of L8 and 58 mg (0.16 mmol) of [Re(CO)5Cl] afforded 
complex ReL8 as a yellow solid (65 mg, yield 67%).  1H NMR (500 MHz, DMSO-d6): δ (ppm) 
= 9.31 (s, 1H, H10), 9.17-9.06 (m, 1H, H4), 8.47 (s, 1H, H12), 8.35-8.21 (m, 2H, H20, 24), 8.15 (d, 
J = 8.4 Hz, 1H, H22), 8.04 (td, J = 8.0, J = 1.5 Hz, 1H, H6), 7.84-7.55 (m, 5H, H5, 14, 15, 21, 23), 
7.21 (dd, J = 8.1, J = 1.1 Hz, 1H, H7). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 198.3, 197.7, 
189.5 (CO), 165.4 (C18), 155.1 (C9), 155.0 (C4), 150.8 (C11), 148.9 (C10), 144.5 (C8), 144.2 
(C16), 141.2 (C6), 133.3 (C14), 130.0 (C21, 23), 129.3 (C13), 128.8 (C5), 128.2 (C20, 24), 126.2 (C19), 
124.7 (C15), 123.8 (C7), 121.7 (C22), 111.4 (C12). ESI-HRMS: m/z 666.0096 ([M+Na]+ calcd for 
C23H13N5O4Cl185ReNa: 666.0083), m/z 608.0510 ([M-Cl]+ calcd for C23H13N5O4185Re: 
608.0497); Anal. calcd (%) for C23H13N5O4ReCl: C 42.83, H 2.03, N 10.86; found: C 42.59, H 
1.92, N 10.67. IR(ATR): ν(CO) = 2025, 1919, 1884 cm−1. 
 
ReL9. 100 mg (0.30 mmol) of L9 and 123 mg (0.34 mmol) of [Re(CO)5Cl] afforded 
ReL9 as a pale yellow solid (130 mg, yield 68%). 1H NMR (500 MHz, DMSO-d6): δ (ppm) = 
δ (ppm) = 10.04 (s, 1H, H10), 9.05 (ddd, J = 5.1 Hz, J = 1.8 Hz, J = 0.8 Hz, 1H, H4), 8.57 (dd, 
J = 2.1 Hz, J = 0.5 Hz, 1H, H16), 8.39 (td, J = 7.9 Hz, J = 1.5 Hz, 1H, H6), 8.33-8.27 (m, 3H, 
H7, 19, 23), 8.15 (dd, J = 8.6 Hz, J = 0.5 Hz, 1H, H12), 8.10 (dd, J = 8.6 Hz, J = 2.1 Hz, 1H, H13), 
7.74–7.67 (m, 4H, H5, 20, 21, 22). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 198.0, 197.1, 190.0 
(CO), 165.2 (C17), 153.7 (C4), 150.8 (C8), 149.6 (C15), 148.9 (C11), 143.4 (C14), 141.4 (C6), 
133.2 (C21), 133.1 (C9), 130.0 (C20, 22), 128.1 (C19, 23), 127.3 (C5), 126.3 (C18), 125.4 (C10), 123.2 
(C7), 121.5 (C12), 119.1 (C13), 105.5 (C16). ESI-HRMS: m/z 666.0099 ([M+Na]+ calcd for 
C23H13N5O4Cl185ReNa: 666.0083); m/z 608.0513 ([M-Cl]+ calcd for C23H13N5O4185Re: 
608.0497); Anal. calcd (%) for C23H13N5O4ReCl: C 42.83, H 2.03, N 10.86; found: C 43.15, H 
2.21, N 11.18. IR(ATR): ν(CO) = 2030, 1920, 1903 cm−1. 
 
ReL10. 130 mg (0.33 mmol) of L10 and 130 mg (0.36 mmol) of [Re(CO)5Cl] afforded 
ReL10 as a yellow solid (164 mg, yield 71%). 1H NMR (500 MHz, DMSO-d6): δ (ppm) = 9.30 
(s, 1H, Hta), 9.10 (ddd, J = 2.2 Hz, J = 1.5 Hz, J = 0.8 Hz, 1H), 8.45 (br s, 1H), 8.24-8.21 (m, 
 
iii  For complexes ReL8 and ReL9, carbon numbering for NMR is shown in Figure 2. Proton numbering 
corresponds to the carbon numbering (e.g. H10 is the hydrogen on C10). 
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2H), 8.13 (dd, J = 8.5 Hz, J = 0.5 Hz, 1H), 8.07 (td, J = 7.9 Hz, J = 1.6 Hz, 1H), 7.75-7.73 (m, 
1H), 7.72-7.70 (m, 3H), 7.23 (ddd, J = 2.1 Hz, J = 1.2 Hz, J = 0.9 Hz, 1H), 1.36 (s, 9H, t-Bu). 
13C NMR (125 MHz, DMSO-d6): δ (ppm) = 198.3, 197.7, 189.5 (CO), 165.4, 156.3, 155.1, 
155.0, 150.7, 149.0 (CHta), 144.5, 144.3, 141.2, 129.1, 128.8, 128.1, 126.9, 124.6, 123.8, 123.5, 
121.5, 115.1, 111.3, 35.4 (Cqt-Bu), 31.3 (CH3). DCI/CH4-HRMS: m/z 699.0806 ([M]+ calcd for 
C27H21N5O4185ReCl, 699.0812), m/z 664.1116 ([M-Cl]+ calcd for C27H21N5O4185Re 664.1123); 
Anal. calcd (%) for C27H21N5O4ReCl: C 46.25, H 3.02, N 9.99; found: C 45.97, H 3.53, N 10.08. 
IR(ATR): ν(CO) = 2028, 1920, 1883 cm−1.   
 
ReL11. 130 mg (0.38 mmol) of L11 and 158 mg (0.44 mmol) of [Re(CO)5Cl] afforded 
ReL11 as a yellow solid (197 mg, yield 80%). 1H NMR (500 MHz, DMSO-d6): δ (ppm) = 9.33 
(s, 1H, Hta), 9.11 (ddd, J = 5.4 Hz, J = 4.7 Hz, J = 0.7 Hz, 1H), 8.55 (dd, J = 7.6 Hz, J = 1.3 Hz, 
2H), 8.15-8.06 (m, 3H), 7.92-7.87 (m, 2H), 7.76 (ddd, J = 6.7 Hz, J = 5.5 Hz, J = 1.2 Hz, 1H), 
7.54-7.47 (m, 2H), 7.29 (d, J = 8.1 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 198.3, 
197.7, 189.5 (CO), 161.4, 155.0, 154.8, 150.9, 148.5 (CHta), 144.5, 141.8, 141.1, 135.2, 129.8, 
129.5, 128.8, 128.6, 126.8, 125.8, 123.7, 120.7, 111.7. ESI/CH4-HRMS: m/z 608.0502 ([M-
Cl]+ calcd for C23H13N5O4185Re 608.0497), m/z 649.0767 ([M-Cl+CH3CN]+ calcd for 
C25H16N6O4185Re 649.0763); Anal. calcd (%) for C23H13N5O4ReCl: C 42.83, H 2.03, N 10.86; 
found: C 42.58, H 1.98, N 10.62. IR(ATR): ν(CO) = 2021, 1934, 1887 cm−1.  
 
5.2. X-ray crystallography 
 X-Ray quality crystals of ReL8 were obtained by diffusion crystallization of 
acetonitrile and diethyl ether. Single crystals of ReL9 and L9 were slowly grown in acetone 
and DCM, respectively. Single crystals of L10 were slowly grown in acetone and diethyl ether. 
Suitable crystals of ReL10 and ReL11 were obtained by diffusion of diethyl ether in DMF. 
 Crystal data were collected on a Bruker AXS Quazar APEX II diffractometer using a 
30 W air-cooled microfocus source (ImS) with focusing multilayer optics using MoKD 
radiation (wavelength = 0.71073 Å). Phi- and omega-scans were used. The structures were 
solved by direct methods (SHELXS 97) or using intrinsic phasing method (SHELXT).[50],[51] 
All non-hydrogen atoms were refined anisotropically using the least-square method on F2.[51] 
Full crystallographic data are collected in Table S1 and Table S15. 
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5.3. Computational details 
The GAUSSIAN09 program package[ 52 ] was employed for all calculations (the 
geometry optimization, the ground-state and excited-state electronic structures, and optical 
spectra) with the aid of the ChemCraft visualization program.[53] The ground state (S0), the first 
excited state (S1) and the lowest triplet state (T1) geometries of compounds were fully optimized 
with the restricted and unrestricted density functional theory (R-DFT and U-DFT) method using 
the Perdew-Burke-Ernzerhof PBE1PBE functional without symmetry constraints.[54] In all 
calculations, the "double-ζ" quality basis set LANL9DZ with Hay and Wadt’s relative effective 
core potential ECP (outer-core [(5s25p6)] electrons and the (5d6) valence electrons)[55] was 
employed for the Re atom. The 6-31+g** basis set for H, C, N, O and Cl atoms was used.[56]  
The vibrational frequencies calculations were performed using the optimized structural 
parameters of compounds, to confirm that each optimized structure represents a local minimum 
on the potential energy surface and all eigenvalues are non-negative. On the basis of the 
optimized ground and excited state geometries, the absorption and emission properties were 
calculated by the time dependent density functional theory (TD-DFT) method at the 
PBE1PBE/LANL9DZ/6-31+G** level. The solvent effect (dichloromethane, ε = 9.08) was 
simulated using the Self-Consistent Reaction Field (SCRF) under the Polarizable Continuum 
Model (PCM).[ 57 ] These methods have already shown good agreement with experimental 
studies for different rhenium(I) complexes.[58] 
 
5.4. Electrochemistry 
Osteryoung square wave voltammetry (OSWV) and cyclic voltammetry (CV) 
measurements were made in DCM at a ligand concentration of 3.4 × 10–3 M and a complex 
concentration of 6.5 × 10–3 M. The supporting electrolyte [n-Bu4N][BF4] (Fluka, 99% 
electrochemical grade) was used as received and simply degassed under Ar. Dichloromethane 
was dried in an MB SPS-800 Solvent Purification System just prior to use. The measurements 
were carried out with a potentiostat Autolab PGSTAT100 controlled by GPES 4.09 software. 
Experiments were performed at room temperature in a homemade airtight three-electrode cell 
connected to a vacuum/Ar line. The reference electrode consisted of a saturated calomel 
electrode (SCE) separated from the solution by a bridge compartment. The counter electrode 
was a Pt wire of ca 1 cm  apparent surface. The working electrode was a Pt microdisk (0.5 mm 
diameter). OSWV experiments were carried out at room temperature using a sweep width of 20 
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mV, a frequency of 20 Hz, and a step potential of 5 mV. Before each measurement, the solutions 
were degassed with Ar and the working electrode was polished with a polishing machine (Presi 
P230). Ferrocene was used as internal reference (Fc+/Fc, 0.55 ± 0.01 V vs. SCE). 
 
5.5. Spectroscopy and photophysics 
Dye solutions were prepared by gentle heating in a solvent, sonication and filtration on 
paper filter prior to measurement. Spectroscopic measurements in solutions were conducted at 
20°C in a temperature-controlled cell. UV-visible absorption spectra were recorded on a 
Hewlett Packard 8453 spectrometer. Fluorescence spectra in solutions were measured with a 
Cary Eclipse spectrofluorometer and a Xenius SAFAS spectrofluorometer using cells of 1 cm 
optical pathway. All fluorescence spectra were corrected. The fluorescence quantum yields in 
solution (ΦF) were determined using the classical formula: ΦFx = (As × Fx × nx2 × ΦFs)/(Ax × Fs 
× ns2) where A is the absorbance at the excitation wavelength, F the area under the fluorescence 
curve and n the refraction index. Subscripts s and x refer to the standard and to the sample of 
unknown quantum yield, respectively. 2,5-Diphenyloxazole (PPO) in methanol (ΦF = 0.86) was 
used as the standard for excitation around 300 nm.[59] Coumarin 102 (ΦF = 0.764) in ethanol 
was used as the standard for excitation at 370 nm.[60] The absorbance of the solutions was equal 
or below 0.055 at the excitation wavelength. The error on the quantum yield values is estimated 
to be about 10 %.  
Solid state photoluminescence quantum yields were recorded on a SAFAS Xenius 
spectrofluorometer equipped with a BaSO4 integrating sphere and a Hamamatsu R2658 
detector. Solid samples were deposited on a metal support and luminescence spectra were 
corrected. The absolute photoluminescence quantum yield values (ΦP) were determined by a 
method based on the one developed by De Mello et al.[61] The excitation source was scanned in 
order to evaluate the reflected light for the empty sphere (La), the samples facing the source 
light (Lc) and the sample out of the irradiation beam (Lb). The fluorescence spectra were 
recorded with the sample facing the source light (Ec) and out from the direct irradiation (Eb). 
The PM voltage was adapted to the measurement of reflected light and emission spectra, 
respectively, and proper correction was applied to take into account the voltage difference. The 
ΦP values were then calculated using the formula:  
ΦP = Ec – (1 – α) Eb / La α 
with α =1– Lc /Lb. The error was estimated to be about 20%. 
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 Fluorescence decay curves were obtained by the time-correlated single-photon counting 
(TCSPC) method with a femtosecond laser excitation composed of a Titanium Sapphire laser 
(Tsunami, Spectra-Physics) pumped by a doubled Nd:YVO4 laser (Millennia Xs, Spectra-
Physics). Light pulses at 760 nm (resp. 900nm) from the oscillator were selected by an acousto-
optic crystal at a repetition rate of 4 MHz, and then doubled at 380 nm (resp. tripled at 300 nm) 
by non-linear crystals. Fluorescence photons were detected at 90°, through a polarizer at magic 
angle and a monochromator, by means of a Hamamatsu MCP R3809U photomultiplier, 
connected to a SPC-630 TCSPC module from Becker & Hickl. The instrumental response 
function was recorded before each decay measurement with a full width at half-maximum 
(fwhm) of ~25 ps. The fluorescence data were analyzed using the Globals software package 
developed at the Laboratory for Fluorescence Dynamics at the University of Illinois at Urbana-
Champaign, which includes reconvolution analysis and global non-linear least-squares 
minimization method. 
 
5.6. Cytotoxicity and dye uptake evaluation 
Primary human dermal fibroblast cells isolated from foreskin biopsy as previously 
described, human keratinocytes, human adenocarcinoma colorectal cells HCT-116 (ATCC, no. 
CCL-247), and human hypopharyngeal carcinoma FADU cells were cultured as monolayers, 
in a humidified atmosphere with 5% CO2 at 37°C, in Dulbecco’s modified Eagles medium 
(Invitrogen) containing 4.5 g·L-1 of glucose as well as L-glutamine and pyruvate, supplemented 
with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 100 U mL-1 of penicillin, and 100 
µg·mL-1 of streptomycin.  
 
To quantify the dye cytotoxicity, 5000 normal cells or 10000 tumor cells were plated on 
96-well plates the day prior to experiment. Aliquots of dye solutions, obtained by cascade 
dilution of dye stock solutions in DMSO in cell culture medium, were added to each well so 
that the final dye concentration ranged from 0. 1 to 100 PM. Six wells were considered for each 
concentration. Controls were cells grown without any dye, and cells grown with DMSO 
concentrations equivalent to those of the dye solutions. After 24 h of incubation, cell viability 
was assessed with PrestoBlue assay (Invitrogen) according to the manufacturer protocol. 
Briefly, after 3 washes with PBS, cells were incubated for 30 min at 37 °C with 50 µl of reagent. 
Absorbance was read at 570 nm and 600 nm with a spectrophotometer (Clariostar, BMG). 
Statistical differences between values were calculated after a one-way ANOVA analysis and a 
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Dunnett’s multiple comparison post-test, which compares each condition with its respective 
control. Overall statistical significance was set at p < 0.05. 
 
To study cellular uptake, cells were grown in Lab-Tek culture chambers coated with 
gelatin. After 24 h, the culture medium was removed. A solution of the dye in DMSO was 
introduced in cell culture medium containing neither antibiotics nor FBS, so that the dye 
concentration was 2 × 10-5 M and DMSO was at 2% v/v. The mixture was left to stand for 1h 
before being deposited onto the cells. Cells were then incubated for 1 h at 37 °C. They were 
washed with cell culture medium before observation. 
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As mentioned in the introduction, rhenium complexes play a significant role in various 
research fields. For instance, in nuclear medicine, rhenium has been widely used as a surrogate 
of technetium for a long time, and the promising physical features of E--emitters, 186Re and 
188Re, make 186/188Re-complexes promising candidates as therapeutic radiopharmaceuticals. 
Similarly, the interesting photoactive and photoluminescence properties of non-radioactive Re-
complexes make them excellent catalysts, luminescent materials and imaging sensors. Thus, in 
this work, our goal was to (i) develop, using a click chemistry strategy, multidentate ligands for 
the stabilization of different rhenium cores [Re(CO)3]+ and [ReO]3+ (M = Re or 188Re) as well 
as the analogous 99mTc-cores in some examples, (ii) assess the potential of the 
rhenium(technetium) complexes as imaging (natRe or 99mTc) or therapeutic (188Re) agents. To 
do so, two rhenium(technetium) specific-chelating systems were used: a semi-rigid tripodal 
system in the second chapter and a pyta moiety in the third chapter, these two chelators being 
developed previously in our group. 
 
Thus, based on a N2O tridentate click ligand, two different studies were carried out in 
chapter II. In the first one, two synthetic pathways to a range of potentially N3O tetradentate 
ligands, designed to coordinate rhenium cores as well as their coordination behaviors towards 
different rhenium cores (oxidation states +I and +V), were investigated. The first route (O-
extension) led to the formation of two tetradentate ligands L1 and L2, as well as two benzoxazine 
derivatives L3 and L4 that resulted from an unexpected side-reaction. The synthesis of 
oxorhenium(V) complexes failed with L1 or L2. However, surprisingly, they exhibited an 
unexpected bidentate coordination mode with the rhenium(I) core fac-[Re(CO)3]3+. The X-Ray 
analysis and DFT studies proved that the most stable isomers of fac-[Re(CO)3Cl(L)] (L = L1 
or L2) are those in which two nitrogen atoms of the aniline and triazole rings, respectively, act 
as the bidentate coordination sites. Through the second route (N-extension), we succeeded to 
get the tetradentate oxorhenium(V) complex [ReO(L5)]. The N3O donor ligand was shown as 
an excellent chelator to stabilize the [ReVO]3+ and the [99mTcVO]3+ cores (the radiolabelling 
study was performed using 99mTc ion instead of 188Re radionuclide considering the ease of 
reduction of 99mTcO4- vs. that of 188ReO4- ). The first radiolabeling results combined with the 
recent work reported by Dugave and co-workers 26  indicated that this ligand could be a 
 
26 See Ref. 19, Chapter II. 
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promising 99mTc-chelator for nuclear imaging applications. As perspectives to this work, the 
extension of the radiolabelling work using the [188ReVO]3+ core should be performed, and the 
in vitro stability should be tested under physiological conditions in human plasma and by 
cysteine exchange experiments (collaboration with Eugene Marquis Centre at Rennes). If the 
results are promising, biodistribution on animal model and/or bioconjugation of this 188Re-
complex on a given biomolecule could be considered. 
Concerning L3 and L4, their complexation with the Re(I) precursor [Re(CO)5Cl] 
resulted in dirhenium(I) hexacarbonyl complexes. The X-Ray structure of complex 
[Re2(CO)6(μ-OEt)2(μ-L4)] ([Re2(OEt)2]) revealed that two rhenium(I) atoms were linked 
through two bridging ethoxo groups, and one bridging triazole ligand. Both rhenium(I) atoms 
display a distorted octahedral configuration, with two carbonyl carbon atoms and two ethoxy 
oxygen atoms in the equatorial plane, and one carbonyl carbon atom trans to one triazole 
nitrogen in axial positions. The computational studies provided a thorough view of this novel 
dirhenium(I) structure compared with other reported similar bridging ligands, such as 
pyridazine, tetrazole or oxadiazole. Although its emission was very weak, complex [Re2(OEt)2] 
represents the first example of dinuclear species in which a 1,2,3-triazole ring is bound to two 
rhenium atoms in low oxidation state. We also showed that the use of a 1,4-disubstituted 1,2,3-
triazole moiety bearing non-chelating substituents seems to be required for the preparation of 
such dirhenium complexes. Although the improvement of the photophysical properties of these 
binuclear complexes would be interesting, the continuation of this work will not be a priority 
in a near future. 
 
The second study was focused on the development of novel hypoxia-selective 99mTc 
radiopharmaceuticals. Our semi-rigid tripodal click framework was decorated with an appended 
nitro group (either a nitrobenzyl group or a metronidazole (Mtz) unit). Different positions were 
considered and at least only two metronidazole (Mtz)-containing ligands and one nitro group-
containing ligand as well as their corresponding tricarbonyl rhenium(I) complexes were 
obtained and characterized, in particular by electrochemistry. The reduction potentials of NO2 
group in complexes [Re(CO)3Cl(L2)] and [Re(CO)3(L6)] were similar to those of reported 
hypoxic imaging agents, prompting us to further investigate other properties of these 
complexes. Unfortunately, no corresponding 99mTc-complexes could be obtained before the end 
of this project. As for [ReO(L5)] (vide supra), the preparation of such radiocomplexes, in 
particular the one containing L6 (which should be the most stable), as well as in vitro stability 
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under physiological conditions should be assessed before considering further biological 
investigations.  
 
Chapter III was focused on the study of AIE (aggregation-induced emission) effect in 
tricarbonyl Re(I) complexes, the association of this effect with the intrinsic properties of Re(I) 
complexes being expected to lead to very attractive compounds. To do that, we combined an 
organic fluorophore (PBO) which exhibits excellent stability and optical properties, with a 
tricarbonylrhenium(I) complex based on a pyta unit (either a 2-pyridyl-1,2,3-triazole or a 2-
pyridyl-1,2,4-triazole ligands). Four compounds were studied. The X-Ray structures revealed 
spectacular discrepancies between the two first triazole-based complexes ReL8 and ReL9. In 
complex ReL9, the organic ligand was almost planar, but it was strongly bended in ReL8, 
therefore hindering electron delocalization. As a result, their electrochemical and spectroscopic 
properties were markedly changed. The AIE effect was observed in both complexes. Most 
interestingly, this study revealed that the functionalized triazole fragment totally governs the 
conformation of the complex in the solid state, and thus plays a major role for 
photoluminescence. 
 
Following this first results, two optimized structures based only on a 2-pyridyl-1,2,4-
triazole moiety, were developed. In the first one, a bulky t-Bu group was added on the PBO 
scaffold (ReL10), in order to increase the steric hindrance of the molecule. In the other one, the 
pyta-based [Re(CO)3]+ core was located to the other side of the PBO moiety (ReL11), in order 
to assess the impact of this structural modification (ReL8 vs. ReL11) upon the solid-state 
emission properties. These small chemical modifications had a dramatic effect on the 
photophysical properties of the complexes. ReL10 displayed enhanced AIE effect, while 
complex ReL11 exhibited the most intense emission in the solid state among the four 
complexes investigated. In subsequent work, AIE complexes ReL8 to ReL11 will be tested in 
view of various applications, including after incorporation in nanoparticles for biological 
staining. Moreover, this study being a novel orientation in our group, this work is a great starting 
point for further investigations. Various organic dyes and/or structural modifications of the 
organic moiety will soon be considered in order to develop highly emissive rhenium(I) 
luminescent probes.   
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Table S1. Crystal data and structure refinement for L1, L2 and [Re(CO)3Cl(L2)] 
 
 L1 L2 [Re(CO)3Cl(L2)] 
Empirical formula C18H19N5O3 C21H18N6O3 C24H18ClN6O6Re 
Formula weight 353.38 402.41 708.10 
Temperature [K] 193(2) 193(2) 193(2) 
Wavelength [Å] 0.71073 0.71073 0.71073 
Crystal system orthorhombic monoclinic orthorhombic 
Space group  Pna21 P21/c P212121 
Unit cell dimensions [Å,q] a = 23.0933(13) a = 10.5160(4) a = 7.7223(7) 
 b = 5.3680(3) b = 24.6454(10) b = 10.7568(9) 
 c = 13.8595(7) c = 7.7012(3) c = 31.175(3) 
  β = 107.501(2)  
Volume [Å3] 1718.09(16) 1903.54(13) 2589.6(4) 
Z 4 4 4 
Density (calculated) [Mg/m3] 1.366 1.404 1.816 
Absorption coefficient [mm-1] 0.096 0.098 4.847 
F(000) 744 840 1376 
Crystal size [mm] 0.18×0.04×0.04 0.20×0.10×0.04 0.08×0.08×0.01 
T range for data collection [q] 4.07 to 26.35 2.89 to 29.57 3.23 to 25.03 
Index ranges -28 ≤ h ≤ 28 
-6 ≤ k ≤ 5 
-14 ≤ l ≤ 17 
-13 ≤ h ≤ 14 
-33 ≤ k ≤ 34 
-10 ≤ l ≤ 10 
-9 ≤ h ≤ 9 
-8 ≤ k ≤ 12 
-37 ≤ l ≤ 36 
Reflections collected 9477 46691 18252 
Independent reflections 2941 [R(int) = 0.0586] 5331 [R(int) = 0.0470] 4490 [R(int) = 0.0599] 
Completeness to 2theta = 26.35q 
for L1 
Completeness to 2theta = 29.57q 
for L2 
Completeness to 2theta = 25.03q 
for [Re(CO)3Cl(L2)] 
94.2 % 99.7 % 98.8 % 
Min. and max. transm. 0.7454 and 0.6632 0.7462 and 0.6968 0.7454 and 0.6358   
Data / restraints / parameters 2941 / 2 / 240 5331 / 0 / 275 4490 / 1 / 347 
Goodness-of-fit on F2 1.026 1.013 1.060 
Final R indices [I>2V(I)] R1 = 0.0459 
wR2 = 0.0943 
R1 = 0.0498 
wR2 = 0.1172 
R1 = 0.0395 
wR2 = 0.0707 
R indices (all data) R1 = 0.0751 
wR2 = 0.1060 
R1 = 0.0811 
wR2 = 0.1364 
R1 = 0.0512 
wR2 = 0.0744 
Largest diff. peak and hole [e Å-3] 0.190 and -0.230 0.365 and -0.322 0.821 and -1.059 
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Table S2. Experimental and optimized bond lengths [Å] for complex [Re(CO)3Cl(L2)] and isomers I-III. 
 
Bond lengths 
[Re(CO)3Cl(L2)] I II-a III-a II-b III-b 
exp. opt. opt. opt. opt. opt. opt. 
Re(1)-C(1) 1.916(10) 1.913 1.912 1.934 1.928 1.996 1.925 
Re(1)-C(2) 1.910(9) 1.918 1.931 1.936 1.942 1.999 1.994 
Re(1)-C(3) 1.923(8) 1.932 1.899 1.907 1.908 1.903 2.002 
Re(1)-N(1) – – 2.226 2.230 – 2.159 – 
Re(1)-N(2) 2.280(7) 2.333 – 2.287 2.274 2.236 2.239 
Re(1)-N(3) 2.157(5) 2.184 – – 2.183 – 2.098 
Re(1)-Cl(1) 2.480(2) 2.550 2.543 – – – – 
Re(1)-O(4) – – 2.271 2.238 2.276 2.218 2.249 
C(1)-O(1) 1.130(10) 1.166 1.165 1.157 1.158 1.153 1.161 
C(2)-O(2) 1.145(10) 1.160 1.159 1.157 1.155 1.152 1.153 
C(3)-O(3) 1.145(8) 1.160 1.163 1.161 1.160 1.164 1.152 
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Table S3. Selected experimental and optimized bond angles [q] for complex [Re(CO)3Cl(L2)] and isomers I-III. 
 
Bond angles [Re(CO)3Cl(L2)] I II-a III-a II-b III-b 
exp. opt. opt. opt. opt. opt. opt. 
C(1)-Re(1)-C(2) 88.4(4) 90.30 91.42 90.14 90.53 173.86 86.69 
C(1)-Re(1)-C(3) 88.0(3) 91.02 90.56 89.11 88.55 87.42 87.18 
C(2)-Re(1)-C(3) 88.4(4) 89.86 88.86 90.05 90.29 86.97 173.79 
C(1)-Re(1)-N(1) – – 92.99 92.58 – 88.23 – 
C(2)-Re(1)-N(1) – – 170.91 171.47 – 90.55 – 
C(3)-Re(1)-N(1) – – 99.03 98.07 – 102.33 – 
C(1)-Re(1)-N(2) 96.4(3) 97.21 – 172.32 170.62 94.11 177.72 
C(2)-Re(1)-N(2) 172.2(3) 169.38 – 92.71 96.98 89.55 92.68 
C(3)-Re(1)-N(2) 97.9(3) 97.49 – 98.02 97.01 102.70 93.49 
C(1)-Re(1)-N(3) 91.2(3) 92.20 – – 97.33 – 100.02 
C(2)-Re(1)-N(3) 98.0(3) 97.16 – – 171.07 – 92.23 
C(3)-Re(1)-N(3) 173.5(3) 172.26 – – 94.14 – 89.82 
N(1)-Re(1)-N(2) – – – 83.62 – 154.94 – 
N(2)-Re(1)-N(3) 75.8(2) 75.13 – – 74.80 – 77.80 
C(1)-Re(1)-Cl(1) 174.9(3) 174.65 174.38 – – – – 
C(2)-Re(1)-Cl(1) 96.6(3) 94.49 92.18 – – – – 
C(3)-Re(1)-Cl(1) 92.8(2) 91.39 93.82 – – – – 
C(1)-Re(1)-O(4) – – 93.01 96.89 99.48 91.65 106.06 
C(2)-Re(1)-O(4) – – 99.02 97.43 92.53 93.95 92.59 
C(3)-Re(1)-O(4) – – 171.25 170.37 171.45 179.03 88.15 
N(1)-Re(1)-Cl(1) – – 82.86 – – – – 
N(2)-Re(1)-Cl(1) 78.53(18) 77.74 – – – – – 
N(3)-Re(1)-Cl(1) 87.40(16) 84.84 – – – – – 
N(1)-Re(1)-O(4) – – 72.83 74.22 – 77.38 – 
N(2)-Re(1)-O(4) – – – 75.67 74.65 77.62 76.16 
N(3)-Re(1)-O(4) – – – – 82.02 – 153.70 
Cl(1)-Re(1)-O(4) – – 82.16 – – – – 
Re(1)-C(1)-O(1) 178.1(9) 179.43 179.06 178.49 178.22 176.03 179.40 
Re(1)-C(2)-O(2) 175.7(9) 178.29 178.43 178.67 178.94 175.97 176.83 
Re(1)-C(3)-O(3) 177.3(8) 179.60 178.01 177.47 177.92 179.38 176.10 
Σ a 5.53 5.31 5.44 6.11 6.52 5.68 5.94 
Θ b 4.33 4.58 4.31 4.17 4.23 2.93 5.11 
a Octahedral distortion parameter Σ = Σ(|90 − φi|)/12 [Σ = 0° for an ideal octahedron; φi represents the 12 smallest 
L–M–L angles] (see M. G. B. Drew, C. J. Harding, V. McKee, G. G. Morgan, J. Nelson, J. Chem. Soc., Chem. 
Commun. 10 (1995) 1035-1038).  
b Average trigonal distortion angle Θ = Σ(|60 − i|)/24 [Θ = 0° for an ideal octahedron; i represents the trigonal 
angles of the eight faces of the octahedron] (see N. Ortega-Villar, A. L. Thompson, M. C. Muñoz, V. M. Ugalde-
Saldívar, A. E. Goeta, R. Moreno-Esparza, J. A. Real, Chem. Eur. J. 11 (2005) 5721-5734). 
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Table S4. 1H NMR and 13C NMR chemical shifts (in ppm) of ligand L4 and complex [Re2(OEt)2] in CDCl3 
 
δ(1H) 
/ppm 
L4 [Re2(OEt)2] δ(13C) 
/ppm 
L4 [Re2(OEt)2] 
exp. calc. exp. calc. exp. calc. exp. calc. 
H(23A) 4.60 4.59 4.75 4.63 C(24) 164.9 158.6 164.0 159.9 
H(23B) 4.60 4.60 4.75 4.66 C(23) 67.8 68.7 67.7 68.9 
H(21) 6.97 6.85 6.97 7.03 C(22) 145.1 140.2 145.4 141.1 
H(20) 6.99 6.90 7.05 7.05 C(21) 124.2 112.6 117.8 113.3 
H(19) 7.03 6.98 7.10 7.03 C(20) 123.2 118.6 125.3 119.9 
H(18) 7.52 7.53 7.10 7.15 C(19) 116.9 117.7 123.7 118.8 
H(16A) 5.20 6.00 5.65 5.08 C(18) 116.0 111.8 115.0 110.8 
H(16B) 5.20 4.64 5.65 6.17 C(17) 128.7 122.8 127.4 122.4 
H(14) 7.73 7.74 7.77 7.28 C(16) 37.7 36.3 39.3 37.9 
H(13A) 3.78 3.99 3.86 3.87 C(15) 143.7 140.4 148.6 143.8 
H(13B) 3.78 3.81 3.86 3.81 C(14) 124.9 121.2 127.8 123.5 
H(13C) 3.78 3.98 3.86 3.96 C(13) 53.1 54.4 54.3 55.3 
H(11A) 5.12 5.31 5.53 5.59 C(12) 166.5 164.0 165.3 161.4 
H(11B) 5.12 4.80 5.53 4.86 C(11) 50.8 51.5 53.5 52.1 
H(10A) – – 1.16 0.70 C(10) – – 19.8 19.8 
H(10B) – – 1.16 0.79 C(9) – – 76.4 75.5 
H(10C) – – 1.16 0.81 C(8) – – 19.8 20.6 
H(9A) – – 4.18 3.82 C(7) – – 76.4 76.2 
H(9B) – – 4.18 3.82 C(6) – – 195.9 201.8 
H(8A) – – 1.16 0.77 C(5) – – 196.0 203.2 
H(8B) – – 1.16 0.85 C(4) – – 196.9 205.4 
H(8C) – – 1.16 1.28 C(3) – – 197.0 205.3 
H(7A) – – 4.18 3.80 C(2) – – 196.3 203.5 
H(7B) – – 4.18 4.15 C(1) – – 196.5 204.4 
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Table S5. The experimental and optimized selected geometrical parameters [Å and q] for complex [Re2(OEt)2] 
 
Molecule A Molecule B  
Parameter Exp. Opt. Δ Parameter Exp. 
Re(1)…Re(2) 3.344 3.380 0.036 Re(3)…Re(4) 3.346 
Re(1)–O(7) 2.111 2.168 0.057 Re(3)–O(19) 2.134 
Re(2)–O(7) 2.124 2.159 0.035 Re(4)–O(19) 2.127 
Re(1)–O(8) 2.125 2.144 0.019 Re(3)–O(20) 2.108 
Re(2)–O(8) 2.133 2.145 0.012 Re(4)–O(20) 2.117 
Re(1)–N(1) 2.192 2.243 0.051 Re(3)–N(5) 2.200 
Re(2)–N(2) 2.208 2.257 0.049 Re(4)–N(6) 2.200 
N(1)–N(2) 1.332 1.316 –0.016 N(5)–N(6) 1.323 
Re(1)–O(7)–Re(2) 104.33 102.74 –1.59 Re(3)–O(19)–Re(4) 103.50 
Re(2)–O(8)–Re(1) 103.50 104.03 0.53 Re(4)–O(20)–Re(3) 104.75 
Re(1)–N(1)–N(2) 115.94 116.04 0.10 Re(3)–N(5)–N(6) 115.76 
Re(2)–N(2)–N(1) 118.50 118.56 0.06 Re(4)–N(6)–N(5) 118.44 
Re(1)–Re(2)–C(4)ax 109.19 110.16 0.97 Re(3)–Re(4)–C(28) 113.99 
Re(2)–Re(1)–C(3)ax 109.79 109.95 0.16 Re(4)–Re(3)–C(27) 112.47 
eq1/eq2(a) 28.90 
(29.01) 
30.52 1.62 
(1.51) 
eq1/eq2(a) 32.04 (32.18) 
C2N3/CH2-COOCH3(b) 83.45 78.69 –4.76 C2N3/CH2-COOCH3(b) 87.93 
C2N3/CH2-C8H6NO2(c) 70.12 84.54 14.42 C2N3/CH2-C8H6NO2(c) 88.16 
 
(a) eq1 and eq2 are the planes defined by the equatorial ligands of the two rhenium atoms; 
(b) C2N3 and CH2-COOCH3 are the least-squares planes defined by the triazole five-membered ring and – CH2-
COOCH3 arm; 
(c) C2N3/CH2-C8H6NO2 are the least-squares planes defined by the triazole five-membered ring and CH2-C8H6NO2 
arm.  
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Table S6. The experimental and optimized selected bond lengths [Å] and bond angles [q] for complex [Re2(OEt)2] (Molecule 
A) 
Bond length Exp. Opt. Δ Bond angles Exp. Opt. Δ 
Molecule A 
Re(1)-C(1) 1.909(4) 1.913 +0.004 C(1)-Re(1)-C(2) 88.27(17) 89.94 +1.67 
Re(1)-C(2) 1.895(4) 1.918 +0.023 C(2)-Re(1)-C(3) 87.65(16) 89.43 +1.78 
Re(1)-C(3) 1.921(4) 1.922 +0.001 C(1)-Re(1)-C(3) 89.67(15) 89.94 +0.27 
Re(1)-N(1) 2.192(3) 2.243 +0.051 C(1)-Re(1)-O(7) 170.80(13) 169.06 –1.74 
Re(1)-O(7) 2.111(2) 2.144 +0.033 C(2)-Re(1)-O(7) 100.27(14) 99.47 –0.80 
Re(1)-O(8) 2.125(2) 2.168 +0.043 C(3)-Re(1)-O(7) 94.07(13) 95.69 +1.62 
C(1)-O(1) 1.150(5) 1.169 +0.019 C(1)-Re(1)-O(8) 98.50(13) 96.86 –1.64 
C(2)-O(2) 1.162(5) 1.166 +0.004 C(2)-Re(1)-O(8) 171.35(13) 170.67 –0.68 
C(3)-O(3) 1.148(4) 1.161 +0.013 C(3)-Re(1)-O(8) 97.72(12) 96.93 –0.79 
    O(7)-Re(1)-O(8) 72.69(9) 73.18 +0.49 
    C(1)-Re(1)-N(1) 95.77(13) 95.00 –0.77 
    C(2)-Re(1)-N(1) 96.45(13) 95.05 –1.40 
    C(3)-Re(1)-N(1) 173.27(13) 173.33 +0.06 
    O(7)-Re(1)-N(1) 79.98(10) 78.72 –1.26 
    O(8)-Re(1)-N(1) 77.60(9) 78.06 +0.46 
    O(1)-C(1)-Re(1) 179.2(4) 178.05 –1.15 
    O(2)-C(2)-Re(1) 179.4(4) 178.97 –0.43 
    O(3)-C(3)-Re(1) 178.2(3) 179.44 +1.24 
        
Re(2)-C(4) 1.911(4) 1.919 +0.008 C(4)-Re(2)-C(5) 87.60(17) 89.26 +1.66 
Re(2)-C(5) 1.905(4) 1.917 +0.012 C(5)-Re(2)-C(6) 89.03(17) 89.76 +0.73 
Re(2)-C(6) 1.913(4) 1.916 +0.003 C(4)-Re(2)-C(6) 88.18(17) 89.71 +1.53 
Re(2)-N(2) 2.208(3) 2.257 +0.049 C(4)-Re(2)-O(7) 94.82(14) 96.18 +1.36 
Re(2)-O(7) 2.124(2) 2.145 +0.021 C(5)-Re(2)-O(7) 98.22(14) 96.89 –1.33 
Re(2)-O(8) 2.133(2) 2.159 +0.026 C(6)-Re(2)-O(7) 172.25(13) 171.15 –1.10 
C(4)-O(4) 1.143(5) 1.160 +0.017 C(4)-Re(2)-O(8) 96.14(13) 96.70 +0.56 
C(5)-O(5) 1.153(5) 1.167 +0.014 C(5)-Re(2)-O(8) 170.01(14) 168.98 –1.03 
C(6)-O(6) 1.156(5) 1.168 +0.012 C(6)-Re(2)-O(8) 100.33(13) 99.49 –0.84 
    O(7)-Re(2)-O(8) 72.28(9) 73.32 +1.04 
    C(4)-Re(2)-N(2) 171.16(14) 172.15 +0.99 
    C(5)-Re(2)-N(2) 99.05(15) 96.37 –2.68 
    C(6)-Re(2)-N(2) 97.69(14) 95.76 –2.03 
    O(7)-Re(2)-N(2) 78.54(10) 77.76 –0.78 
    O(8)-Re(2)-N(2) 76.37(10) 76.87 +0.50 
    O(4)-C(4)-Re(2) 178.5(4) 179.50 +1.00 
    O(5)-C(5)-Re(2) 177.5(4) 178.85 +1.35 
    O(6)-C(6)-Re(2) 178.9(4) 178.60 –0.30 
    Re(1)-O(7)-Re(2) 104.33(10) 104.03 –0.30 
    Re(1)-O(8)-Re(2) 103.51(10) 102.74 –0.77 
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Table S7. The frontier molecular orbital compositions (%) and energy levels (in methanol) for ligand L4 
 
Orbital Energy (eV) 
MO Contribution (%) 
Main bond type L4 
P1 P2 P3 
85 LUMO+5 0.54 36 61 3 π*(P2) + π*(P1) 
84 LUMO+4 0.34 80 19 1 π*(P1) + π*(P2) 
83 LUMO+3 –0.26 95 5 0 π*(P1) 
82 LUMO+2 –0.53 0 3 97 π*(P3) 
81 LUMO+1 –0.75 25 71 4 π*(P2) + π*(P1) 
80 LUMO –0.84 79 20 1 π*(P1) + π*(P2) 
HOMO–LUMO gap (E =  5.29 eV) 
79 HOMO –6.14 99 1 0 π(P1) 
78 HOMO–1 –6.80 98 2 0 π(P1) 
77 HOMO–2 –7.32 32 64 3 π(P2) + π(P1) 
76 HOMO–3 –7.79 74 24 2 π(P1) + π(P2) 
75 HOMO–4 –8.06 2 97 2 π(P2) 
74 HOMO–5 –8.38 1 40 59 π(P3) + π(P2) 
 
P1: benzoxazine unit, P2: triazolyl ring, P3: –CH2COOMe arm 
 
Table S8. The frontier molecular orbital compositions (%) and energy levels (in methanol) for complex 
[Re2(OEt)2] 
 
Orbital Energy (eV) 
MO Contribution (%) 
Main bond type Re CO OEt L4 
P1 P2 P3 
167 LUMO+5 –0.81 6 29 2 2 15 46 π*(P3) + π*(CO) 
166 LUMO+4 –0.95 2 6 0 91 1 0 π*(P1) 
165 LUMO+3 –1.05 21 64 1 8 5 0 p(Re) + π*(CO) 
164 LUMO+2 –1.15 28 65 1 1 3 3 p(Re) + π*(CO) 
163 LUMO+1 –1.38 41 61 -3 0 2 0 p(Re) + π*(CO) 
162 LUMO –2.13 5 10 1 2 79 3 π*(P2) 
HOMO–LUMO gap (E = 3.92 eV) 
161 HOMO –6.05 43 26 29 1 0 0 d(Re) + π(OEt) + π(CO) 
160 HOMO–1 –6.26 44 25 30 1 1 0 d(Re) + π(OEt) + π(CO) 
159 HOMO–2 –6.32 1 1 1 97 1 0 π(P1) 
158 HOMO–3 –6.69 66 31 3 0 0 0 d(Re) + π(CO) 
157 HOMO–4 –6.89 61 27 1 2 8 0 d(Re) + π(CO) 
156 HOMO–5 –6.94 5 2 0 92 0 0 π(P1)  
P1: benzoxazine unit, P2: triazolyl ring, P3: –CH2COOMe arm 
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Figure S1. Molecular structures of ligands L1 and L2. Displacement ellipsoids are both drawn at 30% probability. 
 
 
Ligand L1 
 
Ligand L2 
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Figure S2. Partial 1H NMR spectra (500 MHz, CDCl3, 298 K) of compounds L2 (bottom) and [Re(CO)3Cl(L2)] 
(top)  
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Figure S3A. Intermolecular hydrogen bonding C—H•••O interaction between methylene C(16)–H donors or 4-
nitrophenyl C(24)–H donors and carbonyl O(1) acceptors of [Re(CO)3Cl(L2)]. 
 
 
 
 
Figure S3B. Intermolecular hydrogen bonding C—H•••Cl between Cl(1) atoms as acceptor groups and 
methylene C(16)–H donors or triazole C(18)–H donors of [Re(CO)3Cl(L2)]. 
 
 
 
Figure S4. The isodensity plots of the frontier molecular orbitals of ligand L4 
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Figure S5. The experimental (black) and simulated (red) UV-Vis absorption spectra (CH3OH, 298 K) of ligand 
L4 (left) and complex [Re2(OEt)2] (right). 
 
  
  
 Annexes 
221 
 
4. Molecules relative to chapter III 
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Table S1. Crystallographic data and structure refinement details for ReL8, ReL9 and L9. 
 ReL8 ReL9 L9 
Empirical formula 2(C23H13ClN5O4Re),C2H3N C23H13ClN5O4Re.C3H6O C20H13N5O 
Formula weight 1331.14 703.12 339.35 
Temperature [K] 193.0(2) 193.0(2) 193.0(2) 
Wavelength [Å] 0.71073 0.71073 0.71073 
Crystal system Monoclinic Monoclinic Monoclinic 
Space group  P21/c  P21/c  P21/c  
Unit cell dimensions [Å,q] a = 17.9665(7) a = 6.6979(5) a = 15.9921(11) 
 b = 11.6047(4) b = 19.6258(13) b = 5.8038(5) 
 c = 25.2810(9) c = 19.4187(13) c = 16.9649(11) 
 β = 104.804(2) β = 91.552(3) β = 99.774(4) 
Volume [Å3] 5096.0(3) 2551.7(3) 1551.7(2) 
Z 4 4 4 
Density (calculated) [Mg/m3] 1.735 1.830 1.453 
Absorption coefficient [mm-1] 4.914 4.914 0.095 
F(000) 2568 1368 704 
Crystal size [mm] 0.12 × 0.04 × 0.04 0.38 × 0.02 × 0.02 0.40 × 0.12 × 0.02 
T range for data collection [q] 4.15 to 25.35 3.65 to 25.02 5.119 to 28.280 
Index ranges -21 ≤ h ≤ 21 
-13 ≤ k ≤ 13 
-30 ≤ l ≤ 30 
-7 ≤ h ≤ 7 
-23 ≤ k ≤ 23 
-21 ≤ l ≤ 23 
-21 ≤ h ≤ 21 
-7 ≤ k ≤ 7 
-22 ≤ l ≤ 22 
Reflections collected 129739 28067  30207 
Independent reflections 9290 [R(int) = 0.0735] 4484 [R(int) = 0.0731] 3836 [R(int) = 0.0921] 
Completeness to 2theta = (°)  (25.35q) 99.5 %  (25.02q) 99.6 % (25.24q) 99.0 % 
Min. and max. transm. 0.7461 and 0.6305 0.7457 and 0.6129 0.7340 and 0.6828 
Data / restraints / parameters 9290 / 394 / 757 4484 / 0 / 345 3836 / 0 / 235 
Goodness-of-fit on F2 1.059 1.029 1.009 
Final R indices [I>2V(I)] R1 = 0.0355 
wR2 = 0.0849 
R1 = 0.0354 
wR2 = 0.0612 
R1 = 0.0550 
wR2 = 0.1054 
R indices (all data) R1 = 0.0531 
wR2 = 0.0932 
R1 = 0.0613 
wR2 = 0.0681 
R1 = 0.1041 
wR2 = 0.1275 
Largest diff. peak and hole [e Å-3] 1.792 and -1.108 0.666 and -0.868 0.206 and -0.287 
CCDC CCDC 1555800 CCDC 1555801 CCDC1555895 
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Table S2. Experimental and theoretical selected bond lengths (Å) and angles (q) for ReL8 (type I & II) and ReL9. Experimental data are from X-ray analysis; theoretical data 
has been calculated for molecules in CH2Cl2.  
 
Bond lengths Experimental Optimized Bond angles Experimental Optimized S0 S1 T1 S0 S1 T1 
ReL8 (type I) 
Re(1)-C(1) 1.930(8) 1.896 1.954 1.951 C(1)-Re(1)-C(2) 90.4(3) 90.35 93.46 92.52 
Re(1)-C(2) 1.894(8) 1.912 1.949 1.933 C(1)-Re(1)-C(3) 91.8(3) 90.60 90.44 89.19 
Re(1)-C(3) 1.912(7) 1.916 1.958 1.986 C(2)-Re(1)-C(3) 88.0(3) 89.69 85.18 88.26 
Re(1)-N(2) 2.189(5) 2.211 2.152 2.165 C(1)-Re(1)-N(2) 95.5(2) 93.83 88.78 91.50 
Re(1)-N(3) 2.143(5) 2.146 2.098 2.041 C(2)-Re(1)-N(2) 171.7(3) 170.82 173.96 171.78 
Re(1)-Cl(1) 2.4850(17) 2.524 2.421 2.455 C(3)-Re(1)-N(2) 97.6(3) 98.43 100.43 76.48 
     C(1)-Re(1)-N(3) 90.9(2) 94.09 90.52 90.68 
C(1)-O(1) 1.110(8) 1.164 1.148 1.149 C(2)-Re(1)-N(3) 100.5(3) 97.58 98.20 96.30 
C(2)-O(2) 1.159(9) 1.158 1.150 1.153 C(3)-Re(1)-N(3) 171.1(3) 171.31 176.43 175.44 
C(3)-O(3) 1.150(8) 1.160 1.151 1.148 N(3)-Re(1)-N(2) 73.70(19) 73.98 76.16 76.48 
     C(1)-Re(1)-Cl(1) 176.1(2) 176.43 174.93 174.18 
     C(2)-Re(1)-Cl(1) 91.4(2) 92.47 91.56 91.64 
     C(3)-Re(1)-Cl(1) 91.7(2) 91.62 90.67 86.87 
     N(2)-Re(1)-Cl(1) 82.40(13) 83.07 86.16 84.89 
     N(3)-Re(1)-Cl(1) 85.35(14) 83.36 88.07 92.91 
          
     Re(1)-C(1)-O(1) 175.6(7) 179.84 179.23 179.46 
     Re(1)-C(2)-O(2) 178.5(7) 178.84 179.96 179.03 
     Re(1)-C(3)-O(3) 178.8(7) 179.27 178.58 179.00 
          
ReL8 (type II) 
Re(2)-C(25) 1.944(8)    C(27)-Re(2)-C(26) 87.6(3)    
Re(2)-C(26) 1.928(8)    C(27)-Re(2)-C(25) 91.5(3)    
Re(2)-C(27) 1.916(8)    C(26)-Re(2)-C(25) 86.8(3)    
Re(2)-N(7) 2.200(5)    C(27)-Re(2)-N(8) 170.3(3)    
Re(2)-N(8) 2.138(5)    C(26)-Re(2)-N(8) 101.6(2)    
Re(2)-Cl(2) 2.4896(17)    C(25)-Re(2)-N(8) 92.0(2)    
     C(27)-Re(2)-N(7) 96.7(3)    
C(25)-O(5) 1.079(8)    C(26)-Re(2)-N(7) 175.6(2)    
C(26)-O(6) 1.138(8)    C(25)-Re(2)-N(7) 92.3(2)    
C(27)-O(7) 1.151(8)    N(8)-Re(2)-N(7) 74.08(18)    
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     C(27)-Re(2)-Cl(2) 93.4(2)    
     C(26)-Re(2)-Cl(2) 95.2(2)    
     C(25)-Re(2)-Cl(2) 174.78(19)    
     N(8)-Re(2)-Cl(2) 82.89(13)    
     N(7)-Re(2)-Cl(2) 85.33(13)    
          
     Re(2)-C(25)-O(5) 174.6(6)    
     Re(2)-C(26)-O(6) 175.8(6)    
     Re(2)-C(27)-O(7) 179.7(8)    
          
ReL9 
Re(1)-C(1) 1.944(7) 1.897 1.954 1.950 C(1)-Re(1)-C(2) 90.9(3) 90.44 93.65 88.36 
Re(1)-C(2) 1.915(6) 1.913 1.950 1.990 C(1)-Re(1)-C(3) 88.3(3) 90.55 90.16 90.24 
Re(1)-C(3) 1.923(7) 1.915 1.957 1.929 C(2)-Re(1)-C(3) 90.5(2) 89.57 85.26 90.73 
Re(1)-N(2) 2.203(4) 2.211 2.148 2.079 C(1)-Re(1)-N(2) 94.2(2) 93.66 88.80 89.48 
Re(1)-N(3) 2.157(4) 2.152 2.104 2.130 C(2)-Re(1)-N(2) 169.9(2) 171.24 173.96 171.65 
Re(1)-Cl(1) 2.4799(17) 2.522 2.421 2.451 C(3)-Re(1)-N(2) 98.3(2) 98.13 176.35 172.26 
     C(1)-Re(1)-N(3) 93.0(2) 94.09 90.85 94.69 
C(1)-O(1) 1.061(7) 1.163 1.148 1.150 C(2)-Re(1)-N(3) 96.2(2) 97.55 98.18 95.37 
C(2)-O(2) 1.151(6) 1.158 1.151 1.147 C(3)-Re(1)-N(3) 173.2(2) 171.46 176.35 172.26 
C(3)-O(3) 1.144(7) 1.159 1.150 1.154 N(2)-Re(1)-N(3) 74.94(16) 74.45 76.24 76.77 
     C(1)-Re(1)-Cl(1) 176.98(17) 176.41 174.84 175.46 
     C(2)-Re(1)-Cl(1) 91.93(19) 92.25 91.51 87.23 
     C(3)-Re(1)-Cl(1) 92.71(19) 91.85 90.34 90.88 
     N(2)-Re(1)-Cl(1) 82.80(12) 83.36 86.05 94.74 
     N(3)-Re(1)-Cl(1) 85.64(13) 83.20 88.34 84.67 
          
     Re(1)-C(1)-O(1) 176.0(6) 179.86 179.21 179.16 
     Re(1)-C(2)-O(2) 177.4(5) 178.94 179.89 178.72 
     Re(1)-C(3)-O(3) 177.6(6) 179.44 178.55 179.41 
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Table S3. Selected hydrogen bonding distances (Å) and angles (°) of ReL8, ReL9 and L9.  
D A D—H [Å] H•••A  [Å] D•••A [Å] D—H•••A [q] 
 
ReL8 
C(5)—H(5)•••O(1)_#1 0.95 2.56 3.359(8) 141.9 
C(10)—H(10) •••Cl(1)_#2 0.95 2.67 3.550(7) 154.6 
C(12)—H(12) •••O(5) 0.95 2.44 3.306(8) 151.2 
C(15)—H(15) •••O(6)_#3 0.95 2.47 3.186(9) 131.8 
C(24)—H(24) •••O(4) 0.95 2.48 2.804(9) 99.8 
C(44)_a—H(44)_a•••O(8)_a 0.95 2.45 2.797(13) 101.1 
     
ReL9 
C(7)—H(7) •••O(5) 0.95 2.57 3.482(9) 160.6 
C(10)—H(10) •••O(5) 0.95 2.07 2.987(8) 160.4 
C(19)—H(19) •••O(3)_#4 0.95 2.60 3.545(8) 174.5 
C(23)—H(23) •••O(4) 0.95 2.46 2.797(7) 100.6 
     
L9 
C(10)—H(10) •••N(5)_#5 0.95 2.56 3.429(3) 152.9 
     
D:Donor; A:Acceptor 
Symmetry codes: #1: 3/2–x, 1/2+y, 3/2–z; #2: 1–x, –y, 1–z; #3: x, –1+y, z; #4: 1+x, 1/2–y, –1/2+z; #5: 1–x, –y, 
1–z.  
 
Table S4. Atomic charges from the Natural Population Analysis (NPA) for ReL8 and ReL9. 
 
 
 
Table S5. Frontier molecular orbital composition (%) and energy levels (in CH2Cl2) for ligand L8. 
Orbital Energy (eV) 
MO Contribution (%) 
Main bond type ligand 
P1 P2 
94 LUMO+5 –0.39 15 85 π*(P2) + π*(P1) 
93 LUMO+4 –0.63 3 97 π*(P1) + π*(P2) 
92 LUMO+3 –0.68 13 87 π*(P2) 
91 LUMO+2 –0.99 90 10 π*(P1) 
90 LUMO+1 –1.44 94 6 π*(P1) 
89 LUMO –1.99 4 96 π*(P2) 
HOMO–LUMO gap (E =  4.84 eV) 
88 HOMO –6.83 9 91 π(P2) 
87 HOMO–1 –7.32 97 3 π(P1) 
86 HOMO–2 –7.66 4 96 π(P2) 
85 HOMO–3 –7.74 23 77 π(P2) + π(P1) 
84 HOMO–4 –7.78 69 31 π(P1) + π(P2) 
83 HOMO–5 –8.03 88 12 π(P1) + π(P2) 
  
P1: pyridyltriazole; P2: 2-phenylbenzoxazole 
Atom Charge ReL8 ReL9 
Re(1) –0.99 –1.00 
C(1) +0.74 +0.74 
O(1) –0.50 –0.50 
C(2) +0.78 +0.78 
O(2) –0.48 –0.48 
C(3) +0.76 +0.76 
O(3) –0.48 –0.48 
N(2) –0.39 –0.40 
N(3) –0.23 –0.18 
Cl(1) –0.46 –0.46 
   
The calculated charge on Re(I) is slightly lower 
than the formal charge of +1 (which 
corresponds to a d6 configuration of the central 
ion), as a result of charge donation from the 
N(2) and N(3) atoms of the ligand. The charge 
on the nitrogen atoms is only weakly negative, 
indicating high electron density delocalization 
from the N(2) and N(3) atoms to Re(I) atom. 
The positively charged carbon atoms of the 
carbonyl ligands are found to accept as much as 
∼0.76 (e) from Re(I). The N(2) and N(3) atoms 
donate as much as ∼0.40 (e) to Re(I). 
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Table S6. Frontier molecular orbital composition (%) and energy levels (in CH2Cl2) for ligand L9. 
 
Orbital Energy (eV) 
MO Contribution (%) 
Main bond type ligand 
P1 P2 
94 LUMO+5 –0.39 14 86 π*(P2) + π*(P1) 
93 LUMO+4 –0.63 3 97 π*(P2) 
92 LUMO+3 –0.68 14 86 π*(P2) + π*(P1) 
91 LUMO+2 –0.99 89 11 π*(P1) 
90 LUMO+1 –1.44 92 8 π*(P1) 
89 LUMO –1.99 6 94 π*(P2) 
HOMO–LUMO gap (E =  4.84 eV) 
88 HOMO –6.83 7 93 π(P2) 
87 HOMO–1 –7.32 96 4 π(P1) 
86 HOMO–2 –7.66 10 90 π(P2) 
85 HOMO–3 –7.74 25 75 π(P2) + π(P1) 
84 HOMO–4 –7.78 69 31 π(P1) + π(P2) 
83 HOMO–5 –8.03 86 14 π(P1) + π(P2) 
P1: pyridyltriazole; P2: 2-phenylbenzoxazole 
 
 
Table S7. Main electronic transitions for ligand L8 (in CH2Cl2), calculated with TDDFT method at the PBE1PBE 
level. 
 
Electronic 
transition Contribution Assignment 
Ecalc 
/eV 
λcalc 
/nm f 
λexp 
/nm 
S0 → S1 HOMO → LUMO π(P2) → π*(P2) 4.14 299.2 1.0359  
S0 → S7 H – 1 → L + 1 π(P1) → π*(P1) 5.03 246.6 0.2796  
S0 → S13 H – 1 → L + 2 π(P1) → π*(P1) 5.43 228.5 0.1142  
S0 → S19 HOMO → L + 5 π(P2) → π*(P2) + π*(P1) 5.80 214.0 0.0947  
       
P1: pyridyltriazole; P2: 2-phenylbenzoxazole 
 
 
Table S8. Main electronic transitions for ligand L9 (in CH2Cl2), calculated with TDDFT method at the PBE1PBE 
level. 
 
Electronic 
transition 
Contribution Assignment Ecalc 
/eV 
λcalc 
/nm 
f λexp 
/nm 
S0 → S1 HOMO → LUMO π(P2) → π*(P2) 3.95 313.6 1.4061  
S0 → S3 HOMO → L + 1 π(P2) → π*(P1) 4.63 267.8 0.2073  
 H – 1 → LUMO π(P1) → π*(P2)     
S0 → S7 HOMO → L + 2 π(P2) → π*(P1) 5.01 247.5 0.1605  
 H – 1 → L + 1 π(P1) → π*(P1)     
S0 → S9 HOMO → L + 3 π(P2) → π*(P2) + π*(P1) 5.24 236.7 0.2314  
S0 → S16 HOMO → L + 5 π(P2) → π*(P2) + π*(P1) 5.50 225.3 0.1511  
       
P1: pyridyltriazole; P2: 2-phenylbenzoxazole 
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Table S9. The main electronic transitions for complex ReL8 (in CH2Cl2), calculated with TDDFT method at the 
PBE1PBE/LANL9DZ level in comparison to the experimental values recorded in dichloromethane. 
 
Electroni
c 
transition 
Contribution Assignment Ecalc /eV 
λcalc 
/nm f 
λexp 
/nm 
S0 → S1 HOMO → 
LUMO 
d(Re) + π(CO) + p(Cl) → π*(P1) MLCT/LLC
T 
3.07 403.9 0.0010  
S0 → S2 H – 1 → LUMO d(Re) + π(CO) + p(Cl) → π*(P1) MLCT/LLC
T 
3.28 378.4 0.1251 384 
S0 → S6 HOMO → L + 2 d(Re) + π(CO) + p(Cl) → π*(P1) MLCT/LLC
T 
4.12 300.9 0.0568  
 HOMO → L + 1 d(Re) + π(CO) + p(Cl) → π*(P2) MLCT/LLC
T 
    
S0 → S8 H – 2 → L + 1 π(P2) → π*(P2) IL 4.24 292.8 0.6072 300 
 H – 1 → L + 2 d(Re) + π(CO) + p(Cl) → π*(P1) MLCT/LLC
T 
    
S0 → S9 H – 2 → L + 1 π(P2) → π*(P2) IL 4.24 292.6 0.5016  
 H – 1 → L + 2 d(Re) + π(CO) + p(Cl) → π*(P1) MLCT/LLC
T 
    
S0 → S12 H – 5 → LUMO π(P1) + p(Cl) → π*(P1) LLCT/IL 4.43 279.6 0.1741 272 
S0 → S25 H – 3 → L + 4 d(Re) + π(CO) → p(Re) + π*(CO) MLCT/ILCT 5.08 244.2 0.0446  
 H – 3 → L + 6 d(Re) + π(CO) → p(Re) + π*(CO) + 
π*(P2) 
MLCT/LLC
T/ILCT 
    
S0 → S30 H – 5 → L + 2 π(P1) + p(Cl) → π*(P1) LLCT/IL 5.34 232.1 0.1156 230 
P1: pyridyltriazole; P2: 2-phenylbenzoxazole  
MLCT: metal-to-ligand charge transfer; LMCT: ligand-to-metal charge transfer; LLCT: ligand-to-ligand charge transfer; 
ILCT: intraligand charge transfer. 
 
Table S10. The main electronic transitions for complex ReL9 (in CH2Cl2), calculated with TDDFT method at the 
PBE1PBE/LANL9DZ level in comparison to the experimental values recorded in dichloromethane. 
 
Electroni
c 
transition 
Contribution Assignment Ecalc /eV 
λcalc 
/nm f 
λexp 
/nm 
S0 → S1 HOMO → 
LUMO 
d(Re) + π(CO) + p(Cl) → π*(P1) MLCT/LLC
T 
3.39 365.3 0.0040 ~350a 
S0 → S2 H – 1 → LUMO d(Re) + π(CO) + p(Cl) → π*(P1) MLCT/LLC
T 
3.57 347.4 0.0801  
S0 → S3 HOMO → L + 1 d(Re) + π(CO) + p(Cl) → π*(P2) + 
π*(P1) 
MLCT/LLC
T 
3.82 324.4 0.5028  
S0 → S5 H – 1 → L + 1 d(Re) + π(CO) + p(Cl) → π*(P2) + 
π*(P1) 
MLCT/LLC
T 
3.92 316.4 0.3102  
S0 → S6 H – 2 → L + 1 π(P2) → π*(P2) + π*(P1) ILCT/IL 4.08 304.1 0.6416 311 
 H – 2 → LUMO π(P2) → π*(P1) ILCT     
S0 → S7 H – 2 → LUMO π(P2) → π*(P1) ILCT 4.17 297.5 0.0478  
 H – 2 → L + 1 π(P2) → π*(P2) + π*(P1) ILCT/IL     
S0 → S17 H – 5 → LUMO π(P1) + π(P2) → π*(P1) ILCT/IL 4.71 263.2 0.1093 278 
S0 → S18 H – 5 → L + 1 π(P1) + π(P2) → π*(P2) + π*(P1) ILCT/IL 4.72 262.5 0.0882  
 H – 2 → L + 2 π(P2) → π*(P1) + π*(P2) ILCT/IL     
S0 → S27 H – 2 → L + 3 π(P2) → π*(P1) + π*(P2) ILCT/IL 5.05 245.6 0.0954  
S0 → S28 H – 3 → L + 4 d(Re) + π(CO) → p(Re) + π*(CO) MLCT/ILCT 5.12 242.2 0.1173  
S0 → S34 H – 4 → L + 2 π(P2) → π*(P1) + π*(P2) ILCT/IL 5.43 228.5 0.1500 229 
 HOMO → L + 5 d(Re) + π(CO) + p(Cl) → π*(P2) MLCT/LLC
T 
    
S0 → S36 H – 5 → L + 2 π(P1) + π(P2) → π*(P1) + π*(P2) ILCT/IL 5.47 226.6 0.0761  
P1: pyridyltriazole; P2: 2-phenylbenzoxazole  
MLCT: metal-to-ligand charge transfer; LMCT: ligand-to-metal charge transfer; LLCT: ligand-to-ligand charge transfer; 
ILCT: intraligand charge transfer. 
a: absorption tail. 
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Table S11. Four calculated singlet states for ligands L8 and L9 in S1 optimized geometry with TDDFT method at 
PBE1PBE/LANL2DZ level. 
 
State Contribution Assignment Ecalc /eV 
λcalc 
/nm f 
L1 
1 HOMO → LUMO π(P2) → π*(P2) 3.29 377.2 1.3053 
2 HOMO → L+1 π(P2) → π*(P1) 4.14 299.2 0.0786 
3 H – 1 → LUMO π(P1) → π*(P2) 4.28 289.8 0.0420 
4 H – 4 → LUMO π(P2) → π*(P2) 4.44 279.0 0.0149 
 H – 2 → LUMO π(P2) + π(P1) → π*(P2)    
      
L2 
1 HOMO → LUMO π(P2) + π(P1) → π*(P2) + π*(P1) 3.14 394.9 1.6562 
2 HOMO → L+1 π(P2) + π(P1) → π*(P1) + π*(P2) 4.02 308.7 0.0939 
3 H – 1 → LUMO π(P1) + π(P2) → π*(P2) + π*(P1) 4.15 298.7 0.0922 
4 H – 2 → LUMO π(P2) → π*(P2) + π*(P1) 4.42 280.3 0.0135 
      
P1: pyridyltriazole; P2: 2-phenylbenzoxazole 
 
Table S12. Four calculated singlet states for complexes ReL8 and ReL9 in S1 optimized geometry with TDDFT method at 
the PBE1PBE/LANL9DZ level. 
 
State Contribution Assignment Ecalc /eV 
λcalc 
/nm f 
ReL8  
1 HOMO → LUMO d(Re) + π(CO) + p(Cl) → π*(P1) MLCT/LLCT 2.31 537.3 0.0017 
2 H – 1 → LUMO d(Re) + π(CO) + p(Cl) → π*(P1) MLCT/LLCT 2.71 457.1 0.1748 
3 H – 2 → LUMO d(Re) + π(CO) → π*(P1) MLCT/LLCT 3.00 413.5 0.0022 
4 HOMO → L + 1 d(Re) + π(CO) + p(Cl) → π*(P2) MLCT/LLCT 3.60 344.0 0.0022 
ReL9  
1 HOMO → LUMO d(Re) + π(CO) + p(Cl) → π*(P1) MLCT/LLCT 2.67 463.6 0.0018 
2 H – 1 → LUMO d(Re) + π(CO) + p(Cl) → π*(P1) MLCT/LLCT 3.01 411.0 0.1242 
3 H – 2 → LUMO d(Re) + π(CO) + π(P2) → π*(P1) MLCT/LLCT/ILCT 3.35 370.5 0.0453 
 H – 3 → LUMO d(Re) + π(CO) + π(P2) → π*(P1) MLCT/LLCT/ILCT    
4 HOMO → L + 1 d(Re) + π(CO) + p(Cl) → π*(P2) + 
π*(P1) 
MLCT/LLCT 3.35 369.8 0.1848 
        
P1: pyridyltriazole; P2: 2-phenylbenzoxazole 
 
 
 
Table S13. Calculated phosphorescence emission energies of ReL8 and ReL9. 
 
Compound 
DFT TD-DFT 
ΔET1–S0 
(eV / nm) Character 
Major contribution 
(Ci coefficient) 
E 
(eV) λcal (nm) Character 
ReL8 2.03 / 610.8 3MLCT/3LLCT/3IL H → L (0.674) 1.92 645.1 3MLCT/3LLCT/3IL 
ReL9 2.38 / 520.9 3MLCT/3LLCT/3IL H → L (0.656) 2.24 553.2 3MLCT/3LLCT/3IL 
ΔET1–S0 is the energy difference between the ground singlet and triplet states.  
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Table S14. Full spectroscopic data of L8, L9, Re8 and Re9 in the three organic solvents and in the solid state.  
 
Maximum absorption wavelengths (λabs), molar extinction coefficients (ε), maximum emission wavelengths (λem), fluorescence quantum yields (ΦF) and photoluminescence 
quantum yields (ΦPL), luminescence lifetimes (τ) and their respective contributions, for the four compounds. For absorption studies, the ligand concentration was around 2.5 × 
10-5 M and the concentration of complexes ReL8 and ReL9 was close to 2.0 × 10-5 M and 1.3× 10-5 M, respectively. The molar extinction coefficients (ε) were measured in 
acetonitrile for solubility reasons. The most intense peaks are underlined. For emission in dilute solutions, the concentrations were around 1.8 × 10-6 M for ligands and below 
1.1 × 10-6 M for complexes. Fluorescence quantum yields of complexes were measured on very dilute solutions to limit the formation of aggregates.  
 
Not specified: λex between 300 and 306 nm; a: λex = 380 nm; b: λex = 370 nm; c: λex = 340 nm.  
d: λem = 620 nm ± 80 nm; e: λem = 565 ± 65 nm.
Compounds Acetonitrile Methanol Dichloromethane Solid state 
λabs (nm) ε (M-1cm-1) λem (nm) ΦF  λabs (nm) λem (nm)  ΦF   λabs (nm) λem  (nm)  ΦF   τ (%) λem (nm) ΦPL 
L8 302 29100 375  0.025  301 376  0.028  304 370  0.025  33 ps (0.09)  
1.11 ns (0.56)  
2.00 ns (0.35)  
--- --- 
L9 309 27400 359 0.496  308 360  0.599  311 361  0.559  0.51 ns (0.97)  
3.75 ns (0.03)  
--- --- 
ReL8 299, 364 34000, 4600 360, 710  
438 b, 625 b 
0.004  
 
299, 362 360, 690  
460 b, 620 b 
0.003  
0.008 b 
300, 384 370, 626  0.008  73.54 ns a,d 584 a, 622 a 0.065 a 
ReL9 307 45100 359, 543  0.004  307 359, 543   0.006  309 360, 544  0.007  4.79 ns (0.04) a,e 
192 ns (0.96) a,e 
542 c 0.016 c 
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Table S15. Crystallographic data and structure refinement details for L10, ReL10 and ReL11. 
 
 
  
 L10 ReL10 ReL11 
Empirical formula C24H21N5O C27H21ClN5O4Re C23H13ClN5O4Re 
Formula weight 395.46 701.15 645.04 
Temperature [K] 193.0(2) 193.0(2) 193.0(2) 
Wavelength [Å] 0.71073 0.71073 0.71073 
Crystal system Triclinic Triclinic Orthorhombic 
Space group  P-1  P-1 P212121 
Unit cell dimensions [Å,q] a = 5.7169(5) a = 12.1819(9) a = 8.0086(3) 
 b = 8.7862(9) b = 13.8261(10) b = 10.5904(4) 
 c = 19.9367(19) c =  20.0905(14) c = 25.9678(9) 
 β = 85.580(4) β = 75.370(4) β =  90 (4) 
Volume [Å3] 974.49(16) 3107.5(4) 2202.44(14) 
Z 2 4 4 
Density (calculated) [Mg/m3] 1.348 1.499 1.945 
Absorption coefficient [mm-1] 0.086 4.033 5.681 
F(000) 416 1368 1240 
Crystal size [mm] 0.160 x 0.060 x 0.010 0.100 x 0.080 x 0.020 0.100 x 0.100 x 0.020 
T range for data collection [q] 3.835 to 24.711 1.101 to 23.463 2.988 to 27.865 
Index ranges -6 ≤ h ≤ 6 
-10 ≤ k ≤ 10 
-23 ≤ l ≤ 23 
-13 ≤ h ≤ 13 
-15 ≤ k ≤ 15 
-22 ≤ l ≤ 22 
-10 ≤ h ≤ 10 
-13 ≤ k ≤ 13 
-34 ≤ l ≤ 34 
Reflections collected 8339 63669 60111 
Independent reflections 3311 [R(int) = 0.0495] 9032 [R(int) = 0.0857] 5251 [R(int) = 0.0899] 
Completeness to 2theta = (°)  (24.771q) 99.3 %  (24.463q) 98.6 % (25.242q) 99.8 % 
Min. and max. transm. 0.7452 and 0.7077 
0.7465 and 0.6759 
0.761 and 0.6156 
Data / restraints / parameters 3311/88/312 9032/336/816 5251 / 0 / 307 
Goodness-of-fit on F2 1.018 1.091 1.060 
Final R indices [I>2V(I)] R1 = 0.0504 
wR2 = 0.1024 
R1 = 0.0642 
wR2 = 0.1951 
R1 = 0.0281 
wR2 = 0.0391 
R indices (all data) R1 = 0.0947 
wR2 = 0.1199 
R1 = 0.1065 
wR2 = 0.2480 
R1 = 0.0525 
wR2 = 0.0441 
Largest diff. peak and hole [e Å-3] 0.156 and -0.210 1.007 and -2.619 1.381 and -1.121 
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Table S16. Selected bond lengths (Å) and angles (q) for ReL10 and ReL11  
 
Bond lengths ReL10 ReL11 Bond angles ReL10 ReL11 
Re(1)-C(1) 1.922 1.902 C(1)-Re(1)-C(2) 87.1(7) 89.7(2) 
Re(1)-C(2) 1.941 1.920 C(1)-Re(1)-C(3) 86.7(17) a 87.2(3) 
Re(1)-C(3) 1.976 a 1.903 C(2)-Re(1)-C(3) 85.8(17) a 91.0(3) 
Re(1)-N(1) 2.146 2.198 C(1)-Re(1)-N(2) b 99.7(6) 170.8(2) 
Re(1)-N(2) 2.122 2.155 C(2)-Re(1)-N(2) b 173.0(6) 97.5(2) 
Re(1)-Cl(1) 2.471 2.488 C(3)-Re(1)-N(2) 93.1(16) a 98.4(2) 
   C(1)-Re(1)-N(1) b 172.9(5) 98.2(2) 
C(1)-O(1) 1.132 1.160 C(2)-Re(1)-N(1) b 99.4(6) 172.0(2) 
C(2)-O(2) 1.125 1.148 C(3)-Re(1)-N(1) 91.0(17) 90.9(3) 
C(3)-O(3) 1.168 a 1.151 N(2)-Re(1)-N(1) 73.7(5) 74.49(18) 
   C(1)-Re(1)-Cl(1) 91.9(6) 92.64(18) 
   C(2)-Re(1)-Cl(1) 96.1(7) 94.06(19) 
   C(3)-Re(1)-Cl(1) 175.1(17) 175.0(2) 
   N(2)-Re(1)-Cl(1) 88.0(4) 81.15(13) 
   N(1)-Re(1)-Cl(1) 84.7(5) 84.20(13) 
   Re(1)-C(1)-O(1) 169.9(17) 179.4(6) 
   Re(1)-C(2)-O(2) 177.0(16) 178.9(6) 
   Re(1)-C(3)-O(3) 171(5)a 175.8(6) 
a Due to the disorder of CO and Cl in complex ReL10, the C(3) is renumbered as C(100), O(3) is as O(100). 
b The numbering of C(1) and C(2) in complexes ReL10 and ReL11 are in exchange 
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Table S17. Full spectroscopic data of L10, L11, ReL10 and ReL11 in solvents and in the solid state. 
 
Maximum absorption wavelengths (λabs), molar extinction coefficients (ε), maximum emission wavelengths (λem), fluorescence quantum yields (ΦF) and photoluminescence 
quantum yields (ΦPL). For absorption studies, the concentration of both ligands and complexes ReL10 and ReL11 was around 2.5 × 10-5. The molar extinction coefficients (ε) 
were measured in acetonitrile for solubility reasons. The most intense peaks are underlined. For emission in dilute solutions, the concentrations were close to 1.2 × 10-6 M. 
Fluorescence quantum yields of complexes were measured on very dilute solutions to limit the formation of aggregates.  
 
[a] If not specified, λex between 300 and 306 nm. [b] Results obtained in concentrated solution.  [c] λex = 380 nm 
 
 
Compounds Acetonitrile Methanol Dichloromethane Solid state 
λabs (nm) ε 
 (M-1cm-1) 
λem (nm) a ΦF a λabs (nm) λem (nm) a ΦF a λabs (nm) λem  (nm) a ΦF  a λem (nm) 
a 
ΦPL a 
L10 306 35000 362 0.007 306 365 0.014 308 369 0.016 --- --- 
L11 305 31500 359 0.075 306 362 0.073 308 360 0.003 --- --- 
ReL10 304, 362 33800, 4400 364, 623 
417 [c], 601 [c] 
0.004 304, 362 355, 590 0.003 306, 383 359, 612[b] 
429 [c], 613 [c] 
0.085 567 [c] 0.21 [c] 
ReL11 305, 362 25100, 4000 377,  
429 [c], 609 [c] 
0.007 306, 370 378,  
432 [c], 595 [c] 
0.005 310, 377 373, 617[b] 
432 [c], 613 [c] 
0.007 558 [c] 0.31 [c] 
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Crystallography 
 
Figure S1. Hydrogen bonding and distances between centroids in ReL8. 
 
Intermolecular hydrogen bonding C—H•••O interactions (magenta dash line) between C(12)-H donors and 
carbonyl oxygen O(5) acceptors, and between C(15)-H donors and carbonyl oxygen O(6) acceptors, as well as 
C—H•••Cl interactions (orange dash line) between triazole C(10)-H donors and chloride Cl(1) acceptors in 
ReL8. 
 
Intermolecular "pyridyl-pyridyl" and "triazolyl-triazolyl" distances between centroids in ReL8. Dashed lines 
link the centroids of two rings involved in each stacking interaction. 
 
Intermolecular "benzyl-benzyl", "triazolyl-benzyl" distances between centroids in ReL8. Dashed lines link the 
centroids of two rings involved in each stacking interaction. 
Annexes 
 
235 
 
Figure S2. Hydrogen bonding and distances between centroids in ReL9. 
 
Intermolecular hydrogen bonding C—H•••O interactions (magenta dash line) between C(19)–H and carbonyl 
oxygen O(3) and between C(21)–H and carbonyl oxygen O(2), as well as C—H•••O interactions (blue dash line) 
between C(10)–H proton of the triazole or 5-C(7)–H proton of the 2-pyridyl group and the oxygen atom O(5) of 
acetone molecule in ReL9. 
 
Intermolecular "benzyl-benzyl", "triazolyl-oxazolyl" or "pyridyl-benzyl" π,π-stacking interactions in ReL9. 
Dashed lines link the centroids of two rings involved in each stacking interaction. 
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TD-DFT Calculations 
 
Figure S3. Comparison between the experimental (black) and simulated (red) UV-vis absorption spectra of 
complex ReL8 (left) and (right) ReL9 in CH2Cl2. 
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Electrochemistry 
Cyclic voltammograms of the indicated compounds on a Pt working electrode in CH2Cl2 + 0.1 M [n-Bu4N][BF4] 
at room temperature at a scan rate of 200 mVs-1 toward anodic or cathodic potentials. 
 
Figure S4. Cyclic voltammograms of ligands L8 (left) and L9 (right). 
 
Figure S5. Cyclic voltammograms of complexes ReL8 (left) and ReL9(right). 
 
Figure S6. Cyclic voltammograms of complex ReL8 on a glassy carbon working electrode (left), and after 
ferrocene addition (right) on a Pt working electrode. 
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Spectrophotometry 
Figure S7. Absorption spectra of compounds L8 (A), L9 (B), ReL8 (C), ReL9 (D) in dichloromethane (blue line), 
acetonitrile (red line) and methanol (green line). Maximum absorbance of the samples before normalization was 
very close to 0.7. 
 
 
 
Figure S8. Normalized excitation (λem = 377 nm) and emission spectra (λex = 303 nm) of ligands L8 (left) and L9 
(right) in dichloromethane (blue line), acetonitrile (red line) and methanol (green line).  
  
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
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Figure S9. Fluorescence decays of ligands L8 (top) and L9 (bottom) in dichloromethane. 
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Figure S10. From top to bottom, HPLC chromatograms of ReL8, L8, L9 and ReL9. Column: SunFire TM Prep 
Silica 5 μm, 4.6 × 150 mm. T = 25 ºC. Flow rate: 1 mL/min. Detection: UV (Waters 996, Photodiode Array 
Detector, 254 nm). Eluent: Linear gradient of 10% i-PrOH and 90% DCM to 25% i-PrOH and 75% DCM in 10 
min. 
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Introduction générale 
Malgré les progrès réalisés par la médecine moderne et les nouvelles méthodes de traitement, 
le cancer menace toujours l'espérance de vie humaine. Selon l'Agence internationale pour la recherche 
sur le cancer,i environ 14,1 millions de nouveaux cas de cancer et 8,2 millions de décès liés au cancer 
ont eu lieu en 2012. De plus, le nombre de nouveaux cas de cancer par an devrait atteindre 19,3 
millions d'ici 2025. De ce fait, durant les dernières décennies, de nombreuses recherches ont porté sur 
le diagnostic précoce et/ou le développement de traitements efficaces contre le cancer. 
Pour diagnostiquer précocement la maladie ou les différents stades de la maladie, de 
nombreuses techniques d'imagerie ont été développées, notamment la radiographie par rayons X, 
l'imagerie par résonance magnétique (IRM), l'imagerie par ultrasons et la médecine nucléaire, cette 
dernière utilisant des radiotraceurs spécifiques appelés radiopharmaceutiques.ii Le grand avantage de 
cette dernière modalité d'imagerie est qu'elle peut facilement être adaptée à des fins thérapeutiques. 
En effet, alors que les radionucléides utilisés pour l'imagerie en médecine nucléaire émettent des 
rayons gamma, qui pénètrent profondément le corps et, par conséquent, peuvent en donner une 
image entière, les radionucléides utilisés en radiothérapie interne possèdent un fort pouvoir ionisant 
et un faible pouvoir pénétrant (émetteur E- ou D) afin d'irradier uniquement les cellules cancéreuses. 
Parmi les radioisotopes utilisables, le technétium-99m (émetteur J) et le rhénium-188 (émetteur β-) 
représentent une intéressante paire de radionucléides pour le diagnostic et la thérapie, le technétium-
99m étant le radioélément le plus utilisé en imagerie nucléaire (environ 85% des 
radiopharmaceutiques utilisées en médecine nucléaire). Les deux métaux appartiennent au groupe 7 
du Tableau Périodique et ont des comportements chimiques très similaires. De plus, les complexes de 
rhénium non radioactifs ont fait l’objet de nombreuses recherches en raison de leurs riches propriétés 
photophysiques et photochimiques qui en font des sondes luminescentes attrayantes et/ou des agents 
photoactifs prometteurs pour la libération contrôlée de monoxyde de carbone (on parle d’agents 
PhotoCORMs; CORM pour CO-Release Molecule en anglais). Par conséquent, un certain nombre de 
groupes de recherche, dont le nôtre, ont axé leurs recherches sur le design et l’évaluation de nouveaux 
complexes de rhénium comme nouvelle classe d'agents d'imagerie ou de thérapie. 
 
 
i see http://globocan.iarc.fr/Default.aspx 
 
ii la loi n° 92-1279 du 8 décembre 1992 définit un médicament radiopharmaceutique comme : «tout médicament qui, lorsqu'il 
est prêt à l'emploi, contient un ou plusieurs isotopes radioactifs, dénommés radionucléides, incorporé à des fins médicales». 
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Parmi les nombreux états d'oxydation du rhénium (allant de -I à VII), les espèces Re(I) et Re(V) 
sont les plus étudiées, respectivement sous forme de coeurs [Re(CO)3]+ et [ReO]3+. Jusqu'à présent, un 
grand nombre de chélatants spécifiques du technétium/rhénium aux degrés +I ou +V ont été décrits. 
Leur structure, leur denticité et la nature des atomes donneurs dépendent des noyaux de rhénium 
considérés. Parmi les différentes stratégies de synthèses développées pour la conception de tels 
chélatants, le concept «Click-to-Chelate», développé en 2006 par le groupe de Schibli, iii  a 
particulièrement attiré notre attention. Ce groupe a montré que le cycle 1,2,3-triazole 1,4-disubstitué 
obtenu par chimie Click était un chélatant efficace pour le noyau [Re(CO)3]+. S’inspirant de cette 
stratégie, nous avons développé plusieurs ligands comprenant un cycle triazole au sein de la cavité 
chélatante pour le développement de sondes d’imagerie et thérapeutiques à base respectivement, de 
coeurs tricarbonylés de technetium-99m et de rhénium.iv  
 
Le travail présenté dans ce manuscrit est dans la continuité de nos précédentes recherches sur 
le design et développement de complexes de technétium et rhénium. Basé sur le concept "Click-to-
Chelate" ou sur une approche similaire nommée "Chelate, then Click", notre objectif a été (i) de 
concevoir une nouvelle série de ligands obtenus par chimie Click pour les noyaux [Re(CO)3]+ et [ReO]3+ 
et (ii) d’évaluer leur potentiel en tant que sondes en imagerie/thérapie.  
 
Avant de détailler nos résultats, le premier chapitre présentera un état de l'art bibliographique 
lié à notre projet de recherche. Dans une première partie, nous décrirons l'intérêt des complexes de 
rhénium et donnerons un aperçu rapide de leur utilisation en tant que radiopharmaceutique ainsi 
qu’un focus détaillé sur leurs propriétés photophysiques. En privilégiant les coeurs [ReO]3+ et 
[Re(CO)3]+, nous donnerons de nombreux exemples d'applications en imagerie et en thérapie dans le 
domaine biomédical. L'accent principal sera mis sur les caractéristiques/propriétés à prendre en 
compte pour le développement de composés encore plus efficaces. Dans une deuxième partie, une 
attention particulière sera accordée à la synthèse et aux avantages de la cycloaddition de Huisgen 
catalysée par les sels de cuivre(I), appelée réaction CuAAC (pour copper(I)-catalyzed azide-alkyne 
 
iii T. L. Mindt, H. Struthers, L. Brans, T. Anguelov, C. Schweinsberg, V. Maes, D. Tourwé, R. Schibli, J. Am. Chem. Soc. 128 (2006) 
15096–15097. 
 
iv M. Wolff, L. Munoz, A. François, C. Carrayon, A. Seridi, N. Saffon, C. Picard, B. Machura, E. Benoist, Dalton Trans. 42 (2013) 
7019–7031. 
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cycloaddition en anglais), et également des stratégies "Click-to-Chelate" ou Chelate, then Click pour la 
conception de ligands spécifiques vis-à-vis des coeurs rhéniés/technétiés. 
 
Le deuxième chapitre, axé sur la conception de nouveaux produits radiopharmaceutiques est 
une extension de nos travaux antérieurs basés sur le développement et l’évaluation d’un chélatant 
tripodal semi-rigide de type N2O.v Deux pistes différentes ont été étudiées : (i) la préparation de 
ligands obtenus par chimie Click, ligands potentiellement tétradentes en vie de stabiliser le noyau 
[188ReO]3+; (ii) le développement de nouvelles sondes d'imagerie à base de 99mTc, sonde combinant la 
cavité chélatante semi-rigide N2O avec des groupes métronidazole ou nitrophényle, les complexes de 
99mTc porteurs d'un groupement nitro pouvant être des agents potentiels d'imagerie pour l’hypoxie. Il 
est intéressant de noter qu'un complexe de rhénium dinucléaire original incluant pour la première fois 
un cycle triazole pontant deux atomes de rhénium différents a été obtenu, le chélatant de départ 
résultant d'une réaction inattendue lors de la préparation de nos espèces chélatantes tétradentes. Ces 
recherches feront l’objet de la troisième partie de ce chapitre. 
 
Le dernier chapitre traite des propriétés d'émission à l'état solide de nouveaux complexes 
tricarbonylrhénium(I), basés sur une partie chélatante de type pyridine-triazole (ou pyta),vi qui est un 
analogue au ligand bipyridine. Si les propriétés photophysiques de ces complexes ont été largement 
étudiées en solution, curieusement, l'étude de leurs propriétés d'émission à l'état solide en est encore 
à ses débuts. Ainsi, l'objectif principal de ce chapitre a été de concevoir des sondes luminescentes de 
rhénium(I) hautement émissives. Pour ce faire, un fluorophore organique de type benzoxazole qui 
possède d'excellentes propriétés optiques a été combiné avec l'unité pyta. Différentes combinaisons 
structurales ont été réalisées et les propriétés photophysiques de ces systèmes hybrides (contenant 
une partie organique plus un complexe de coordination) ont été soigneusement étudiées en solution 
(diluée et concentrée) et à l'état solide. Les résultats ont été confortés par des données 
électrochimiques, et une étude biologique préliminaire in vitro (test d'imagerie, cytotoxicité) a été 
réalisée. Nous avons aussi pu montrer (i) que les propriétés d'émission étaient liées à la géométrie des 
 
v S. Guizani, N. M. Saied, C. Picard, E. Benoist, M. Saidi, J. Label. Compd. Radiopharm. 57 (2014) 158–163. 
 
vi A. Boulay, A. Seridi, C. Zedde, S. Ladeira, C. Picard, L. Maron, E. Benoist, Eur. J. Inorg. Chem. 32 (2010) 5058–5062, S. Clède, 
F. Lambert, C. Sandt, Z. Gueroui, M. Réfrégiers, M. A. Plamont, P. Dumas, A. Vessières, C. Policar. Chem Commun. 48 (2012) 
7729–7731 
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complexes, (ii) l'apparition d'un effet d'émission induit par agrégation (ou effet AIE en anglais), qui a 
été rarement observé pour les complexes de rhénium(I).  
 
Dans deux chapitres II et III, la plupart des études expérimentales ont été combinées à une 
étude théorique. Enfin, nous conclurons en présentant brièvement les résultats les plus pertinents de 
ce travail et en donnant les orientations pour les futures recherches qui découlent de ce projet.  
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Chapitre I : Etat de l’art 
1. Complexes de rhénium et applications 
Les complexes de rhénium sont hautement intéressants car (i) d’un point de vue fondamental, 
le rhénium possédant de nombreux degrés d’oxydation différents (de –I à VII), différents systèmes 
chélatants peuvent être considérés et étudiés, (ii) ils peuvent avoir de nombreuses applications 
notamment en médecine. En effet, en médecine nucléaire, si les complexes de rhénium ont pendant 
longtemps étaient uniquement utilisés comme analogue non-radioactif du technétium-99m (les 
complexes de 99mTc étant fréquemment utilisés en diagnostic), les deux isotopes radioactifs du 
rhénium, notamment le 188Re, possèdent des caractéristiques physiques favorables pour une 
utilisation en radiothérapie interne vectorisée. Les complexes de rhénium non radioactifs sont 
également intéressants car ils peuvent être utilisés en tant que sondes diagnostiques (complexes 
luminescents) ou en thérapie (composés photoCORMs, CORMs pour CO-Release Molecule en anglais).  
Ci-dessous, quelques structures représentatives (mais non exhaustives) de complexes de 
rhénium potentiellement intéressants. Les exemples sélectionnés sont uniquement des complexes de 
rhénium(I) car parmi tous les complexes stables de rhénium, ils offrent le plus de perspectives pour 
des applications en diagnostic/thérapie. 
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2. Click chemistry, “Click-to-Chelate” concept, Click, then Chelate approach 
Si de nombreuses structures chélatantes ont été développées, la stratégie de synthèse qui 
reste la plus intéressante pour développer rapidement des structures chélatantes diverses et variées 
est le « Click-to-Chelate concept » ou l’approche Click, then Chelate développés respectivement par 
les groupes de Schibli et Benny (Schéma 1).[1],[2],[3]  
 
Scheme 1. Stratégie “Click-to-Chelate” (Schéma extrait de la référence [i]). 
 
Conditions : (a) Cu(OAc)2, Na(ascorbate), eau, 25 °C (15 h) ou 100 °C (30 min), (b) M = 99mTc: 
[99mTc(OH2)3(CO)3]+, PBS, pH 7,4, 30 min, 100 °C; M = Re: [ReBr(CO)3]2-, eau ou alcools, 50-65 °C, 1-4 h.  
 
L’approche est similaire et repose sur la cycloaddition de Huisgen catalysée aux sels de 
cuivre(I). Cette réaction réinventée par Sharpless[ 4 ] permet de développer des structures 1,2,3-
triazoles 1,4 disubstitués avec d’excellents rendements et dans des conditions douces, généralement 
compatibles avec de nombreux groupements fonctionnels. L’originalité des approches « Click-to-
Chelate» ou Click, then Chelate est que le triazole formé va faire partie intégrante de la cavité 
(i) (ii) (iii) (iv)
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chélatante, les azotes du cycle triazole pouvant complexer fortement un bon nombre de métaux, 
notamment les cœurs fac-[M(CO)3]+ (M = 99mTc ou Re). Il est à noter que la complexation via l’azote N3 
(regular click) est plus performante que celle issue de l’azote N2 (inverse click). La différence entre ces 
deux stratégies est que dans la première, l’azoture ou l’alcyne est porteur d’une biomolécule. 
 
3. Projet de thèse 
Récemment, John F. Valliant déclarait “Senior researchers should encourage young scientists 
to explore unique directions and not listen to statements such as “we have enough ligands or agents.” 
It is always easier to state that today’s technology is sufﬁcient than it is to come up with tomorrow’s 
innovation”.[5] Partant de ce constat, l’objectif principal de ce travail est de développer des structures 
chélatantes issues de la chimie click et plus particulièrement des approches « Click-to-Chelate» ou 
Click, then Chelate et d’évaluer les complexes du rhénium (rhénium naturel ou 188Re) voire du 
technétium-99m correspondants en tant que sondes pour l’imagerie ou la thérapie. 
 
Parmi les différents systèmes chélatants que nous avons développés au laboratoire durant les 
dix dernières années,[6] deux motifs ont retenu notre attention : un système pré-organisé tripodal de 
type N2O[vic,7] et un système pyridine triazole ou pyta,[8] comme illustré dans la Figure 1. 
 
Concernant le premier système, nous avons montré que ce motif tripodal était adapté à la 
complexation du technétium-99m. Le but de cette première partie est double : (i) d’une part essayer 
d’étendre notre famille de ligands en développant des structures tétradentes et en étudiant leur 
chimie de coordination vis-à-vis du rhénium/technétium à l’état d’oxydation +V et +I, (ii) d’autre part 
accéder rapidement à partir de notre entité tripodale modèle à des radiopharmaceutiques du 
technétium-99m capable de cibler les cellules hypoxiques. Pour ce faire, des groupements nitro seront 
greffés sur cette structure N2O.  
 
La seconde partie sera consacrée au fragment pyta dont les complexes de rhénium conduisent 
à des sondes luminescentes. Toutefois, la plupart de ces études photophysiques ont été uniquement 
réalisées en milieu dilués et très peu d’études ont été effectuées à l’état solide, ce qui peut paraitre 
surprenant quand on sait que certains complexes métalliques deviennent hautement luminescents à 
l’état solide ou à hautes concentrations grâce au phénomène AIE pour aggregation-induced emission. 
Dans cette partie, une structure pyta sera couplée à un motif phénylbenzoxazole (PBO) qui a des 
propriétés intrinsèques de fluorescence à l’état dilué. Le but de prendre ce fragment organique est aussi 
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pour voir si cela peut augmenter les propriétés photophysiques de notre système hybride (composé 
d’un complexe de coordination et d’un fragment purement organique). Différents systèmes seront 
développés qui différeront soit par la nature du cycle triazole (deux isomères structuraux seront 
étudiés : le 1,2,4-triazole et le 1,2,3-triazole), soit par la structure du fragment PBO ou soit par le point 
d’ancrage entre les fragment pyta et motif PBO. Une étude photophysique complète sera effectuée pour 
les différents composés préparés et les résultats et/ou mécanismes seront expliqués/confirmés par une 
étude théorique. Nous montrerons notamment que nos structures à base de rhénium(I) présentent un 
effet AIE, ce qui est rare pour ce type composé et qu’il est notamment gouverné par l’isomérisme de la 
structure triazole. 
 
 
Figure 1. Schéma général du travail présenté dans ce manuscrit avec quelques molécules représentatives de 
chaque chapitre. 
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Chapitre II : Développement d’une nouvelle famille de ligands pré-organisés 
polydentes pour la complexation du technéium-99m et du rhénium 
 
Comme expliqué précédemment, ce chapitre est consacré à la  préparation de ligands pré-
organisés polydentes adaptés à la complexation du technétium et du rhénium, à partir d’un ligand 
tripodal développé récemment ans notre groupe. 
 
La première étude a consisté à développer des ligands potentiellement tétradentes. Dans la 
première partie, différents chélatants ont été préparés. Les études de complexation vis-à-vis du 
rhénium/technétium ont démontré que suivant leur structures, les ligands complexaient les métaux de 
façon bidente ou tétradente (première partie du chapitre). .Durant cette étude, une réaction secondaire 
a conduit à l’obtention de dérivés benzoxazine qui ont conduit pour la première fois à la préparation de 
complexes dinucléaires hexacarbonylés de rhénium(I) dans lequel un cycle 1,2,3-triazole possède un 
caractère pontant (seconde partie du chapitre). 
 
La seconde étude a été d’introduire dans notre modèle tripodal de départ une entité nitro afin de 
développer les complexes de rhénium et surtout du technétium-99m correspondants, ces derniers 
pouvant être des composés intéressants pour cibler les cellules hypoxiques. Deux entités nitro ont été 
choisies : un groupement nitrophényle et un motif métronidazole. Cette étude sera détaillée dans la 
troisième partie de ce chapitre. 
 
Un schéma général ci-après résume les différentes stratégies développées dans ce chapitrevii 
  
 
vii Un schéma récapitulatif des molécules synthétisées est disponible dans le livret d’annexes 
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1. Design, synthèse et réactivité de nouveaux ligands polydentes vis-à-vis des coeurs 
technétiés et rhéniés 
 
Introduction 
La chimie de coordination du rhénium a été intensivement étudiée durant ses trente dernières 
années,[9] les complexes métalliques à base de rhénium(ou technétium-99m) pouvant conduire à de 
nombreuses applications notamment dans le domaine de la médecine nucléaire 
(radiopharmaceutique)[10] ou dans l’imagerie optique ou infra-rouge.[11]  
 
Récemment, nous avons publié la synthèse d’un ligand tripodal semi-rigide de type N2O ainsi 
que les premières évaluations biologiques du complexe de technétium-99m correspondant.[vi] 
L’originalité de ce ligand est qu’il est facilement synthétisable par une stratégie «Click-to-Chelate»[i] ou 
plus exactement Click, then Chelate et qu’il possède au sein de la cavité chélatante une entité 
aromatique introduisant une certaine pré-organisation du chélate. Les premiers résultats biologiques 
étant pertinents, nous avons décidé d’étendre la famille de ces composés en développant des ligands 
non plus tridentes mais tétradentes (Schéma 2). 
 
Schéma 2. Ligands tétradentes considérés dans cette étude.  
 
 
Synthèses et étude structurale des ligands et des complexes de rhénium correspondants 
Sur les deux voies considérées, la voie A (Schéma 3) a permis de conduire à des ligands 
potentiellement tétradentes L1 et L2, ces derniers possédant un bras complexant de type pyridine et 
se différenciant par leur fonctionnalisation (ester de méthyle pour L1 et groupement nitrophényle pour 
L2). Le rendement global de réaction est bon pour les deux composés. En revanche, les ligands 
analogues porteurs d’un bras méthylcarboxylate n’ont pu être obtenus. En effet, une réaction 
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secondaire a conduit à une cyclisation intramoléculaire, conduisant, quelques soit la voie de synthèse 
utilisée à des dérivés cycliques de type benzoxazine L3 et L4. Enfin, la voie B a conduit en peu d’étapes 
mais avec un bon rendement global au ligand L5 envisagé (Cf. Manuscrit en anglais pour la voie de 
synthèse des trois derniers composés). 
 
Schéma 3. Voie A 
 
Conditions : (i) (Boc)2O, THF, ta, nuit; (ii) chlorhydrate de 2-picolyl chloride, K2CO3, CH3CN, reflux, nuit; (iii) NaH, 
bromure de propargyle, DMF, 0ºC to ta, nuit; (iv) TFA, CH2Cl2, 0ºC, 2 h for 4a ou L2 et ta, 6 h, NH4OH pour 4b; (v) 
2-azidoacétate de méthyle et 4a pour L1 et l’azoture de 4-nitrophényle pour 5 et L2, Cu(OAc)2.H2O, NaAsc., t-
BuOH/H2O, ta, nuit. 
 
Une étude de complexation a été réalisée sur chaque ligand (Schéma 4). Celle concernant les 
composés L3 et L4 sera mentionné ultérieurement. Curieusement, seul le ligand L5 a conduit à un 
complexe oxorhénié stable, le rhénium étant au degré d’oxydation +V. Cela confirme que notre ligand 
a bien un caractère tétradente, comme attendu. A contrario, les essais de complexation dans des 
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conditions similaires à celles utilisées pour L5 n’ont pas permis d’obtenir des complexes oxorhéniés. 
Aucune réaction n’est observée ! Des réactions de complexation complémentaires ont été effectuées 
avec des cœurs à plus bas degré d’oxydation. Deux complexes de rhénium(I) ont pu être isolés et l’un 
deux a pu être caractérisé par RX.  
 
Scheme 4. Complexes à coeurs rhénium(V) (a) et rhenium(I) (b) 
 
 
 
 
L’étude structurale complète de ces composés (RMN, IR, MS) combinée à une étude DFT a pu 
indiquer que nos ligands L1 et L2 possédaient un caractère bidente, la complexation du cœur fac-
[Re(CO)3]+ se faisant vraisemblablement par les deux azotes des cycles aromatique et triazolyle. 
L’obtention de cristaux pour le complexe [Re(CO)3Cl(L2)] a définitivement confirmé ce fait (Figure 2). 
Les calculs théoriques démontrent également que ce composé est le plus stable de tous les isomères 
structuraux potentiellement envisageables (bidentes et tridentes). Ces mêmes calculs ont prouvé que 
l’isomère structural dans lequel le rhénium serait complexé par l’azote du cycle aromatique et l’azote 
du cycle pyridine ne peut exister qu’à l’état de trace. Ce résulte est très intéressant car généralement 
dans un composé polydente contenant un cycle pyridine et une entité triazole, le groupe de Benny a 
montré que la complexation du coeur fac-[Re(CO)3]+ se faisait préférentiellement par le cycle pyridine. 
[ii] 
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Figure 2. Schéma ORTEP du complexe [Re(CO)3Cl(L2)]. Ellipsoides dessinées avec une probabilité de 50%. 
 
Si Les résultats concernant L1 et L2 sont originaux et ont conduit récemment à une publication 
dans Eur. J. Inorg. Chem., les complexes de rhénium correspondants ne sont pas assez stables pour 
être utilisées à des fins médicales. De ce fait, l’étude préliminaire de radiomarquage au technétium-
99m (plus facile à réaliser que celle utilisant le 188Re) a été uniquement réalisée avec L5. En se basant 
et en optimisant un protocole rapporté en 2012 par l’équipe de Dugave,[12] nous avons pu obtenir le 
radiocomplexe [99mTcO(L5)] avec un rendement de 90% (Figure 3). 
 
 
Figure 3. Radiochromatogramme du complexe [99mTcO(L5)]. 
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Conclusion 
Cette première étude a permis d’agrandir notre famille de composés polydentes pré-organisés 
(ou semi-rigides) incorporant un motif triazole et un cycle aromatique au sein de la cavité chélatante. 
La stratégie Click, then Chelate a permis d’obtenir cette diversité de structures rapidement, sans 
purification fastidieuse et avec de bons rendements. Sur 5 ligands tétradentes envisagés, seulement 3 
ont été finalement obtenus. L1 et L2 bien que possédant quatre sites de coordination possèdent un 
caractère bidente vis-à-vis d’un cœur tricarbonylrhénium(I). En revanche, L5 a permis d’isoler avec un 
excellent rendement de radiomarquage un complexe oxotechnétié. Les perspectives à court termes 
seraient d’évaluer la stabilité de ce complexe de technétium in vitro (sérum, compétition avec la 
cystéine) et voire si il est possible de transférer cette approche au cœur fac-[188Re(CO)3]+. Si les 
résultats restent pertinents, une étude sur modèle animal pourra être envisagée. 
Concernant les deux composés L3 et L4, dérivés benzoxazines obtenus par cyclisation 
intramoléculaire lors de la synthèse des deux derniers composés tétradentes, ils n’ont évidemment 
aucun intérêt pour le développement de sondes d’imagerie/thérapie. Toutefois, ils ont permis 
d’obtenir pour la première fois un complexe dinucléaire de rhénium(I) dans lequel un cycle triazole 
agit comme un ligand pontant. Cette étude va être détaillée dans la seconde partie de ce chapitre. 
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2. Synthèse et caractérisation d’un complexe dinucléaire d’hexacarbonyldirhénium(I) 
possédant un cycle 1,2,3-triazole pontant  
 
Les complexes de tricarbonylrhénium(I) possédant un ligand de type D,D’-diimine présentent 
généralement une luminescence intense dans la région du visible et une durée de vie de luminescence 
rayonnante relativement longue. Récemment, une attention particulière s’est portée sur le 
développement de certaines espèces dirhéniées, la stratégie étant de relier deux ions de métaux lourds 
par un seul ligand pontant, afin d'exalter les propriétés photophysiques de ces espèces. Différents 
ligands bidentes du type pyridazine,[ 13 ] tétrazole[ 14 ] ou 1,3,4-oxadiazole[ 15 ] ont été liés au coeur 
dinucléaire [Re2(CO)6(μ-X)2] (X– = Cl–, Br–, I–, H–, OH–, OCH3–, OC6H5–, SC6H5–), comme illustré en Figure 
4. Il a été montré que les propriétés photophysiques dépendaient de la nature du ligand pontant. Ainsi, 
si les espèces dinucléaires de rhénium(I) à base de ligand pyridazine sont fortement luminescents, ceux 
basés sur un ligand tétrazole ou oxadiazoles  sont peu émissifs.  
 
Figure 4. Différents exemples de complexes dirhéniés contenant un ligand pontant du type: (a) pyridazine (1,2-
diazine), (b) tétrazole, (c) 1,3,4-oxadiazole. 
 
Curieusement, aucun travaux n’a été rapporté avec un motif triazole, ce qui peut paraitre 
surprenant vu que différentes études ont montré le caractère pontant du cycle triazole avec des 
métaux de type zinc(II), cadmium(II), cuivre(I/II/III) ou argent(I).[16] Nos composés L3 et L4, dérivés 
benzoxazines obtenus précédemment comme sous-produits de réaction, présentant un cycle 1,2,3-
triazole 1,4-disubstitués par des motifs non-coordinants, nous avons tester leur réactivité vis-à-vis d’un 
excès de cœur fac-[Re(CO)3]+. En faisant réagir nos composés avec un excès de [Re(CO)5Cl] (ratio 1/2) 
dans le méthanol en présence d’une base, un complexe dinucléaire, de formule [Re2(CO)6(μ-Cl)(μ-
OMe)(μ-L4)] a pu être isolé et caractérisé notamment par RMN et spectrométrie de masse (schéma 5). 
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La recristallisation de ce complexe dans un mélange éthanol/acétonitrile a conduit à un second 
complexe, [Re2(CO)6(μ-OEt)2(μ-L4)] pour lequel nous avons eu la chance d’obtenir une structure X. 
 
Schéma 5. Formation de complexes dinucléaires de rhénium(I) contenant un motif 1,2,3-triazole 
pontant. 
 
 
Conditions : (i) [Re(CO)5Cl], DIPEA, MeOH, 65°C, 16 h., (ii) cristallisation dans EtOH/CH3CN, (iii) 
[Re(CO)5Cl], DIPEA, toluène, 65°C, 16 h. 
 
Brièvement, la structure X du complexe [Re2(OEt)2] consiste en deux motifs A et B 
indépendants très similaires (Figure 5). Les deux rhéniums sont pontés par deux ligands éthoxo et le 
cycle triazole via ces deux atomes d’azote. Chaque atome de rhénium est dans un environnement 
pseudo-octaédral déformé.[17] La valeur Re•••Re′ (3.344(1) Å (molécule A) et 3.346(1) Å (molécule 
B)),est plus petite que celles indiquées pour des analogues structuraux de type [Re2(CO)6(P-X)2(P-N-N 
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ligand)] (X = Br, P-N-N ligand = oxadiazole; 3.58 Å; X = SPh, P-N-N ligand = pyridazine; 3.57 Å; X 
= Br, P-N-N ligand =  tétrazole; 3.70 Å). 
 
Figure 5. ORTEP de [Re2(OEt)2]. (Molécule A). Ellipsoides dessinées avec une probabilité de 30%. 
 
Les propriétés photophysiques de ces complexes ont été évaluées et, malheureusement, les 
complexes présentent des émissions très faibles. Si nous avons pu pour la première fois rapporter la 
synthèse et caractérisation d’un tel complexe, démontrant au passage le caractère pontant du triazole 
vis-à-vis d’un cœur Re(I), étude validée par une publication récente dans Inorg. Chim. Acta, 
l'amélioration des propriétés photophysiques de ces complexes binucléaires est nécessaire pour 
envisager un intérêt applicatif en tant que sondes luminescentes. Ce travail exigera donc des 
recherches théoriques et expérimentales supplémentaires pour essayer de comprendre le faible coté 
émissif de ces complexes et dans un second temps de l’améliorer.  
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3. Complexes de tricarbonylrhenium(I) fonctionnalisés par un groupement nitro 
comme sondes potentielles envers l’hypoxie 
 
L’hypoxie, qui résulte d’un manque d’oxygène dans la cellule est un marqueur 
caractéristique des tumeurs solides.[18] Sa détection est une cible prioritaire car sa 
présence dans la cellule a un impact sur le choix/efficacité du traitement donné. Parmi 
les traceurs de l’hypoxie, les composés contenant un groupement nitroimidazoles (NIs) 
sont les molécules les plus couramment utilisées pour le ciblage des cellules 
hypoxiques. Ces composés ont la propriété d’être retenus après réduction du 
groupement nitro uniquement dans les cellules hypoxiques, permettant ainsi leur 
détection sélective.[19,20,21] 
 
 
 
Figure 6. mécanisme de captation des NIs dans les cellules hypoxiques. (Figure tirée de la référence [xxia]). 
 
Les NIs les plus utilisées ou étudiées sont des radiotraceurs fluorés, en 
particulier le [18F]fluoromisonidazole (F-MISO). Ces composés présentant certaines 
limitations comme une courte période et un coût de production assez élevé, de 
nombreuses études se sont concentrées sur d’autres radiotraceurs comme ceux du 
technétium-99m. 
Disposant de ligands tripodaux ayant montré leur efficacité pour la 
complexation du 9mTc, nous avons décidé d’y incorporer un groupement nitro et de 
les évaluer en tant que marqueurs de l’hypoxie. Deux types de groupement nitro ont 
été testés : le nitrophényle et le métronidazole (Figure 6). 
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Différents composés ont été préparés. Toutefois, il ne nous a pas été possible 
de développer le composé porteur d’un bras métronidazole en position 2 (Cf. Figure 
7). Les différents ligands obtenus ont conduit aux complexes de rhénium 
correspondants. Une première étude d’électrochimie a permis de montrer que nos 
composés présentent des caractéristiques électrochimiques sensiblement similaires à 
des composés récemment rapportés dans la littérature. [22] 
 
 
 
Figure 7. Nitro and Mtz compounds considered in this study. 
 
Malheureusement, il ne nous a pas été possible d’obtenir les radiocomplexes 
de technétium-99m correspondants et donc d’évaluer leurs stabilités in vitro et de 
déterminer leur affinité vis-à-vis des cellules hypoxiques.  
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Chapitre III : Effet AIE (émission induite par l’agrégation) dans des complexes 
tricarbonylrhénium issus d’un ligand pyridine-triazole couplé à un motif 
benzoxazole 
 
1. Introduction 
Les luminophores qui de par leur l'agrégation permettent une exhaltation de leurs propriétés 
de luminescence ont fait l'objet de recherche intenses au cours des deux dernières décennies. Ils 
trouvent maintenant des applications croissantes en tant que biosondes et dans le domaine des 
matériaux fluorescents où ils présentent des performances supérieures à celles des produits 
conventionnels composés.[23] 
 
Le concept d'émission induite par l'agrégation (ou phénomène AIE) a d'abord été développé 
dans le domaine des composés organiques avant d'être étendu aux complexes de métaux de 
transition, où le phénomène est beaucoup plus rarement observé.[24] Cependant, comme récemment 
rapporté, un certain nombre de complexes ont démontré une activité AIE significative et des principes 
de conception pour l'émission efficace de composés métalliques commence à apparaître. Comme pour 
les composés organiques, la condition préalable au comportement AIE est la présence de groupes 
aromatiques reliés par une liaison simple C-C, C-N ou N-N. En solution, l'énergie d'excitation est perdue 
par les rotations et les vibrations, et le composé est faiblement luminescent. À l'état solide, la 
restriction de la rotation interne induit une amélioration des émissions. D'autres mécanismes peuvent 
être impliqués. Dans la plupart des cas, le processus d'émission prédominant dans les complexes 
métalliques est la phosphorescence, dont la longue durée de vie peut apporter des avantages en 
termes de détection. Certains de ces composés donnent des agrégats hautement luminescents et 
pourraient être des candidats idéaux pour les applications de haute technologie dans le domaine des 
biosondes, des nanomatériaux sensibles aux stimuli et des matériaux optoélectroniques. Cependant, 
de nombreux types de complexes n'ont guère été étudiés de ce point de vue et c'est notamment le cas 
des complexes de tricarbonylrhénium(I). 
 
En fait, les complexes de tricarbonylrhénium(I) ont été principalement étudiés en solution,[25-
37] et leurs propriétés d'émission à l'état solide n'ont guère intéressé, à l'exception des applications 
dans les domaines des diodes électroluminescentes organiques (OLED) et des cellules 
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électrochimiques émettrices de lumière (LEEC).[1313131313 38 ]131313131313 Seuls quelques rares 
exemples d'émission de phosphorescence induite par l'agrégation (AIPE) ont été signalés.[xxiv] 
 
À notre avis, l'effet AIE dans les complexes tricarbonylrhénium(I) mérite d'être plus étudié. 
L'association de l'effet AIE avec les propriétés intrinsèques des complexes Re(I) pourrait conduire à des 
composés très intéressants. En plus de permettre leur détection dans le visible, les complexes de Re(I) 
absorbent fortement dans l'infrarouge central où la pénétration de la lumière dans les tissus est 
optimale et peuvent ainsi permettre la bioimagerie multimodale. Leur analogie avec les complexes du 
[99mTc(CO)3]+ permet des corrélations avec les études de radioimagerie. Enfin, ces composés sont 
également photoactifs et peuvent être utilisés dans le cadre de la photothérapie et de la 
théranostique. Pour toutes ces raisons, les complexes de rhénium(I) AIE-actifs pourraient être une 
nouvelle génération de composés pour les matériaux sensibles à la lumière, la détection, l'imagerie et 
la thérapie. 
 
Dans le présent travail, quatre nouveaux complexes tricarbonylrhénium(I) ont été étudiés 
(schéma 6). Ils contiennent tous un ligand pyridyl-triazole (pyta) et un motif 2-phénylbenzoxazole 
(PBO) qui est introduit sur le ligand pyta dans le but d'améliorer le comportement spectroscopique. Ce 
colorant organique a été choisi pour son excellente stabilité et ses propriétés optiques. Les dérivés du 
PBO sont en effet largement utilisés dans le domaine des matériaux fluorescents, qu'ils soient dissous 
en solution ou dispersés dans une matrice appropriée. Beaucoup d'entre eux sont fortement émissifs 
à l'état solide et affichent parfois le comportement AIE. [39,40],[41] Il est à noter que dans nos composés, 
le motif PBO n'est pas directement impliqué dans la complexation contrairement à la plupart des 
complexes rapportés dans la littérature. Il est relié au groupe pyta par une seule liaison, ce qui permet 
sa rotation libre et cette conception devrait favoriser l'apparence d'un comportement AIE. Les quatre 
composés se distinguent par l'agencement des unités pyta et PBO les uns par rapport aux autres 
(Schéma 6).  
 
 
 
 
 
Schéma 6. Structures chimiques des 4 complexes. 
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2. Etude des complexes ReL8 et ReL9: influence de l’isomérisme structural du cycle 
triazole 
 
Les quatre composés ont été préparés en 3 ou 4 étapes en partant du 4-nitro-2-hydroxyaniline 
et de la pyridine-2-carbohydrazide (L8, ReL8) ou de la 2-ethynylpyridine (L9, ReL9). Comme attendu, 
la formation du cycle 1,2,3-triazole a été plus aisée que celle conduisant au cycle 1,2,4-triazole. Les 
complexes de rhénium correspondants ont été préparés par la même procédure que celle utilisée dans 
le chapitre précédent, i.e. en portant à reflux nos ligands avec le précurseur commercial [Re(CO5)Cl] 
dans le méthanol. Ils ont tous été obtenus avec des rendements aux alentours de 66%. 
 
Si les ligands et complexes ont été caractérisés par les techniques classiques de spectroscopies, 
nous avons eu la chance d’obtenir les monocristaux du ligand L9 et des complexes ReL8 et ReL9 par 
évaporation lente des solvants organiques. Dans l'analyse des structures cristallines, une attention 
particulière a été accordée à la conformation de chaque molécule, ainsi qu'aux interactions qui ont eu 
lieu entre les molécules les plus étroitement empilées, car ces caractéristiques régissent le 
comportement spectroscopique à l'état solide. Les vues moléculaires des deux composés métalliques 
sont données dans la figure 8. 
Résumé en Français 
265 
 
 
Figure 8. ORTEPs des complexes ReL8 (gauche) et ReL9 (droit). Ellipsoides dessinées avec une probabilité de 
50% et les atomes d’hydrogène ont été enlevés pour plus de clarté. 
Les deux complexes cristallins sont solvatés. Ils cristallisent dans le groupe spatial 
monoclinique P21/c, avec deux molécules cristallographiquement distinctes et une molécule 
d'acétonitrile dans l'unité asymétrique pour ReL8 et une molécule d'acétone dans l'unité asymétrique 
pour ReL9. La différence la plus frappante entre les complexes provient probablement de la 
conformation de leur système conjugué. Dans ReL9, l'ensemble du ligand organique Pyta-PBO est 
presque planaire (figure 9). L'angle entre le groupe benzoxazole et le groupe triazole est seulement de 
9,0(2)°, ce qui favorise une forte interaction entre ces fragments. Au contraire, dans le complexe ReL8, 
cet angle est de 64,0(2)° dans le type I et 69,3(3)°/82,0(6)° dans la molécule de type II. Cette forte 
flexion du ligand organique suggère que les systèmes π des fragments pyta et PBO ont peu 
d'interaction et devraient se comporter presque indépendamment dans ReL8. 
 
Figure 9. Crystal packing des complexes ReL8 and ReL9. De gauche à droite: structure cristallographique, 
arrangement et plan des molécules stackées. La couleur orange indique le recouvrement des systèmes aromatiques.  
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Faire une comparaison avec la structure cristalline des ligands libres aurait été instructif. 
Malheureusement, les monocristaux du ligand L8 convenant à l'analyse des rayons X n'ont pas été 
obtenus malgré nos efforts. Seuls, les cristaux de L9 ont pu être étudiés. Leur analyse a révélé que ces 
molécules sont presque planaires, à l'exception du groupe triazole qui décrit un angle d'environ 15° 
avec les groupes benzoxazole et pyridyle. La planarité du ligand a donc été améliorée après 
complexation. Les molécules de L9 sont dirigées le long du même axe, mais réparties selon deux plans 
distincts. Les molécules sont empilées tête à tête, avec un chevauchement important de leur système 
aromatique. L'arrangement est donc très différent de celui trouvé pour le ReL9 complexe 
correspondant. 
 
Les comportements électrochimiques des ligands et des complexes ont été étudiés par le Dr 
Béatrice Delavaux-Nicot (Laboratoire de Chimie de Coordination du CNRS, Toulouse) en voltamétrie 
cyclique (CV) et voltamétrie à ondes carrées Osteryoung (OSWV). De même, une étude théorique de nos 
ligands a été effectuée par le r Mariuz Wollf (Université de Silesia, Pologne). L’étude théorique sera peu 
développée dans ce résumé. Il faudra se référer au manuscrit pour plus de détails.  
 
Pour résumer ces deux études, lors de la comparaison des deux complexes, les deux 
caractéristiques caractéristiques principales sont un écart électrochimique significativement plus faible 
pour le composé ReL8 que pour le composé ReL9 et un comportement électrochimique différent pour le 
premier processus de réduction. Cette dernière propriété est probablement liée à la nature différente des 
deux composés. Pour le composé ReL9, les niveaux d'énergie LUMO et LUMO + 1 sont proches: 0,07 eV 
(environ 70 mV). Par conséquent, le premier potentiel de réduction détecté à -1.60 V provient 
probablement de la contribution des niveaux d'énergie LUMO et LUMO + 1 impliquant respectivement les 
orbitales π*(pyta) et π*(pyta) + π*(PBO). Contrairement à ReL8, la différence d'énergie entre ces niveaux 
est supérieure (0,41 eV) et permet une affectation électrochimique plus facile de ce processus de réduction 
résultant exclusivement de la fraction π*(pyta). 
 
Les propriétés spectroscopiques des quatre composés ont d'abord été étudiées en solution 
dans trois solvants organiques différents, à savoir le DCM, l'acétonitrile et le méthanol. Les résultats 
obtenus sont proches dans les trois solvants, indiquant que les composés dissous sont faiblement 
sensibles à la polarité et à la proticité de leur environnement. Avec une excitation d'environ 300 nm 
dans le dichlorométhane, le spectre d'émission de ReL8 a été détecté à environ 358 nm, légèrement 
décalé vers le bleu par rapport à celui du ligand correspondant L8. Le spectre d'émission de ReL9 a 
montré une bande centrée à 360 nm avec une faible résolution vibratoire, presque superposable à 
Résumé en Français 
267 
 
celle du ligand L9. On a constaté que les rendements quantiques de fluorescence étaient très faibles 
pour les deux complexes ReL8 et ReL9. Les valeurs étaient plus faibles par un et deux ordres de 
grandeur, respectivement, par rapport aux ligands libres.  
 
Des solutions très diluées de complexes émettent faiblement dans la gamme violette-bleue 
après illumination par une lampe UV à main. Cependant, avec une concentration légèrement 
croissante, de fortes émissions orange-rouge et vert ont été respectivement observées à l'œil nu pour 
ReL8 et ReL9 (Figure 10a). Les spectres correspondants ont montré la présence de bandes fortes 
atteignant environ 626 nm et 544 nm, respectivement, quelle que soit la longueur d'onde d'excitation. 
Leur intensité a été clairement améliorée avec l'augmentation de la concentration du composé, 
comme illustré pour ReL9 dans la Figure 10b. C’est beaucoup moins intense dans les solvants où les 
composés étaient plus solubles, c'est-à-dire le méthanol (figure 10c) et l'acétonitrile. La position des 
bandes aux longueurs d'ondes élevées est en accord avec les maxima de 645,1 et 553,2 nm prévus par 
les calculs TD-DFT pour les émissions provenant du premier état triplet (Cf. manuscrit en anglais pour 
les tableaux issus de l’étude DFT). De longues durées de vie de 73,5 ns et 192 ns ont été mesurées 
respectivement pour ReL8 et ReL9, confirmant ainsi que l'émission est due à la phosphorescence. Nos 
complexes émettent à la fois la fluorescence et la phosphorescence. La corrélation étroite de l'intensité 
de phosphorescence avec la concentration des complexes suggère fortement que cette émission 
provient d'agrégats qui pourraient être formés dans la gamme de concentration millimolaire. Dans ce 
cas, nous serions en présence d'un effet AIPE fort. 
 
 
Figure 10. (a) Photo des complexes en solutions concentrées sous lampe UV, λex = 365 nm. (b) Spectres d’émission 
normalisés pour les complexes ReL8 (rouge) et ReL9 (bleu) en solution concentrée dans le DCM, λex = 306 nm. 
Concentrations: ReL8 environ 4,2 × 10-6 M, concentration de ReL9 environ 6 × 10-7 M, 1,4 × 10-6 M et 3,5 × 10-6 
M en allant de bas en haut (c) Spectres d’émission (λex = 306 nm, BPem = 4 nm) pour le complexe ReL9 en méthanol 
à différentes concentrations (augmentant avec l’absorbance à 306 nm).  
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Après l'étude en solution, les quatre composés ont été étudiés à l'état solide. Les ligands L8 et L9 
ne sont pratiquement pas émissif à l'état solide. Même si mode de cristallisation de L8 est inconnu, 
l'empilement π-π fort et le chevauchement important du système aromatique observé pour L9 est 
totalement compatible avec l'absence de luminescence. En revanche, le complexe solide ReL8 émet 
fortement de la lumière jaune, tandis que le solide ReL9 émet dans le vert lorsqu'il est éclairé par une lampe 
UV portative (Figure 11a). Pour ReL8, le spectre d'émission a deux maxima à 584 et 622 nm. La bande 
d'émission à longueurs d'ondes élevées rappelle celle observée pour les solutions concentrées. Pour ReL9, 
le spectre est centré sur 542 nm (Figure 11b), également très proche de celui attribué aux agrégats. Par 
analogie, les émissions à l'état solide sont attribuées à la phosphorescence. Les rendements quantiques de 
photoluminescence (PLQY) sont respectivement de 0,065 et 0,016 pour ReL8 et ReL9. En comparant les 
rendements quantiques de fluorescence correspondants obtenus en solution, l'intensité des émissions a 
été multipliée par un facteur 8 pour ReL8 et 2,2 pour ReL9. La différence entre les complexes s'explique par 
la conformation pliée de ReL8 qui empêche l'empilement entre les cycles aromatiques et favorise l'émission 
de lumière. De plus, le fait que le niveau d'énergie de T1 soit légèrement plus faible pour ReL8 que pour 
ReL9 peut également favoriser une meilleure collecte d'énergie pour le premier complexe. 
 
La bande observée à 584 nm pour le complexe solide ReL8 peut être attribuée à un mélange de 
complexes amorphes et cristallins à l'état solide, le décalage de longueur d'onde résultant de diverses 
interactions intermoléculaires. Il faut garder à l'esprit que les caractéristiques d'état solide rapportées ici 
se réfèrent uniquement aux poudres étudiées. Très probablement, d'autres valeurs ont pu être trouvées 
avec des cristaux simples ainsi qu'avec des poudres préparées à partir de la recristallisation dans d'autres 
solvants, car l'agencement moléculaire et les défauts de surface jouent un rôle essentiel dans les propriétés 
à l'état solide. 
 
Figure 11. (a) Photo des complexes sous forme de poudre sous lampe UV, λex = 365 nm. (b) Spectres d’émission 
normalisés de ReL8 (λex = 380 nm, rouge) et ReL9 (λex = 340 nm, bleu). 
Pour conclure, ce travail a révélé que les écarts observés entre les propriétés électroniques des 
complexes issus de fragments 1,2,3 et 1,2,4-triazole étaient très spectaculaires. En particulier, avec un 
Solid state
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fragment 1,2,4-triazole comme dans ReL8, un encombrement stérique se produit en raison de la 
proximité du PBO avec le groupe pyridinyle. La fraction PBO est alors positionnée hors du plan et se 
comporte de manière plus indépendante du point de vue électronique. Par conséquent, les propriétés 
électrochimiques et spectroscopiques sont nettement modifiées, et un comportement photophysique 
inhabituel a été mis en évidence et rationalisé. En outre, il a été démontré que la fonctionnalisation du 
fragment triazole régit totalement la conformation du complexe à l'état solide et joue donc un rôle 
majeur pour la photoluminescence. L'isomérisme du triazole influe également fortement sur les 
propriétés biologiques comme la cytotoxicité et l'absorption cellulaire (non montré dans ce résumé). 
Finalement, ces composés ne sont pas de très bons agents d'imagerie, mais les conditions 
expérimentales peuvent certainement être améliorées. Ainsi, dans la section suivante, des 
modifications structurelles des complexes ont été introduites afin d'améliorer leurs propriétés 
spectroscopiques.  
 
3. Synthèse et étude spectroscopique de systèmes PBO-1,2,4-triazole et de leurs 
complexes de rhénium correspondants 
 
Nous avons décidé de développer deux nouveaux ligands hybrides à partir de 2-pyridyl-1,2,4-
triazole et de PBO ainsi que les complexes de rhénium(I) correspondants, avec de petites modifications 
par rapport aux structures précédentes (schéma 6). Le ligand L10 et le complexe ReL10 portent un 
groupe tert-butyle en position 4-phényle de la fraction PBO. Le système électronique étant semblable 
à celui de L8 et ReL8, respectivement, on peut s'attendre à ce que le même comportement soit en 
solution. Cependant, le groupe tert-butyle volumineux devrait introduire certaines variations dans 
l'arrangement à l'état solide, comme diminuer l'empilement π-π et améliorer ainsi les propriétés de 
photoluminescence. Le ligand L11 et le complexe ReL11 présentent une inversion de l'unité PBO, 
puisque ce dernier est maintenant lié par son groupe phényle au groupe pyta. Le système électronique 
conjugués est donc différent de celui de L8 et ReL8, respectivement, et différentes propriétés 
spectroscopiques en solution peuvent être attendues. En ce qui concerne l'agencement moléculaire à 
l'état solide et l'effet sur les propriétés de photoluminescence, les deux sont très difficiles à prédire. 
 
Les ligands L10 et L11 et leurs complexes de rhénium ReL10 et ReL11 ont été facilement (i) 
préparés avec de bons rendements en utilisant une stratégie de synthèse similaire à celle employée 
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pour les composés L8, L9 et leurs complexes de rhénium(I), (ii) caractérisés par les techniques 
spectroscopiques classiques.  
Les monocristaux du ligand L10 et les complexes ReL10 et ReL11 ont été obtenus et leurs 
structures cristallographiques résolues. Puisque nous n'avons pas obtenu la structure RX du ligand 
1,2,4-triazole L8, la structure du ligand L10 est particulièrement instructive. Cela nous donne une 
impression intuitive sur la conformation de l'unité Pyta et PBO dans le ligand libre, et les changements 
correspondants après complexation. Le ligand L10 (figure 12) cristallise dans le groupe spatial 
triclinique P-1. L'angle entre le groupe benzoxazole et 1,2,4-triazole est de 78,3q. Les molécules sont 
également tordues d'environ 20° entre les groupes benzoxazole et phényle. Dans le packing, tous les 
groupes de benzoxazole sont alignés dans le même plan, tandis que les cycles de phényle sont 
alternativement tordus dans un sens de l'autre par rapport au cycle benzoxazole. Les molécules sont 
affichées sous forme de dimères antiparallèles, dans lesquels les cycles phényle présentent un petit 
chevauchement mais sont distants de 4,3 Å. Cela suggère que l'interaction entre eux n'est pas très 
forte. Cette distance entre les molécules est probablement due à l’encombrement stérique du groupe 
tert-butyle. 
 
Le complexe ReL10 (Figure 12) cristallise également dans le groupe spatial triclinique P-1. Fait 
intéressant, le benzoxazole et le cycle phényle sont maintenant presque alignés dans le même plan. 
L'angle entre le groupe benzoxazole et le groupe 1,2,4-triazole de 69,6° est légèrement réduit par 
rapport au ligand libre et comparable au complexe ReL8 non substitué. Comme dans le complexe ReL8, 
la forte flexion des unités pyta et PBO suggère peu d'interaction des systèmes π respectifs.  
 
 
Figure 12. ORTEPs de L10, ReL10 (Type I) et ReL11. Ellipsoides dessinées avec une probabilité de 50% et les atomes 
d’hydrogène ont été enlevés pour plus de clarté. 
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La cellule cristalline et l'agencement de molécules empilées dans le réseau sont représentés 
sur la figure 13. Le groupe tert-butyle structure le réseau. Il implique des contacts courts 
intermoleculaires avec les atomes d'oxygène des groupes carbonyle, ainsi qu'avec les atomes de 
carbone des groupes pyridyle et phényle des molécules voisines. D'autres contacts courts se trouvent 
entre les hétéroatomes de benzoxazole et les atomes d'hydrogène phényle des molécules voisines. 
Aucun empilement des systèmes aromatiques, et donc aucun recouvrement, n'a été détecté entre les 
complexes, ce qui suggère que ce nouveau composé doit avoir de bonnes propriétés photophysiques 
à l'état solide.  
 
 
Figure 13. Crystal packing de L10 et du complexe ReL10. De gauche à droite: arrangement et plan des molécules 
stackées. La couleur orange indique le recouvrement des systèmes aromatiques.  
Le complexe ReL11 cristallise dans l'espace orthorhombique P212121. L'unité PBO est 
pratiquement plane (figure 14). Le groupe benzoxazole et 1,2,4-triazole sont presque orthogonaux, 
avec un angle de 83,11q. C'est le plus grand angle parmi les quatre complexes étudiés, ce qui suggère 
une interaction minimale des systèmes π. La géométrie de coordination du rhénium est la même que 
dans les autres complexes. Fait intéressant, les longueurs de liaison et les angles de ReL11 sont 
comparables à l'isomère ReL8, ce qui montre que l'inversion du groupe PBO par rapport au motif pyta 
n'a aucune influence sur la sphère de coordination. Les complexes sont agencés sous forme de dimères 
antiparallèles, avec un très faible recouvrement entre le groupe benzoxazole d'une molécule et le 
groupe pyridyle d’un voisin. À première vue, cet arrangement devrait favoriser l'émission de lumière à 
l'état solide. Les dimères sont eux-mêmes en épi, ce qui est sans précédent dans notre série de 
78.3q 4.32Å
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ReL10
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complexes. Les ligands inorganiques de la sphère de coordination participent à la structuration de 
l'ensemble du réseau. 
 
 
Figure 14. Crystal packing de ReL11. De gauche à droite: arrangement et plan des molécules stackées. La couleur 
orange indique le recouvrement des systèmes aromatiques.  
 
Seules les études spectroscopiques en solutions concentrées et à l’état solide seront reportées 
ci-dessous pour les deux complexes ReL10 et ReL11. Les deux complexes émettent faiblement dans la 
gamme violette-bleue après illumination par une lampe UV (365 nm). Cependant, lorsque la 
concentration est augmentée, une forte émission d'orange est observée à l'œil nu pour les deux 
complexes (figure 15). Son intensité est nettement augmentée avec une concentration plus élevée. 
Les spectres d'émission correspondants affichent deux bandes: une bande d'émission faible 
correspondant à la fluorescence et une bande intense qui a atteint 612 nm pour ReL10 et 617 nm pour 
ReL11, quelle que soit la longueur d'onde d'excitation. Cette bande d'émission est très probablement 
de la phosphorescence qui provient d'un état triplet 3MLCT, comme pour les complexes de 
tricarbonylrhénium(I). Il est intéressant de noter que cette bande est légèrement décalée à des 
longueurs d'onde plus courtes par rapport à celles de ReL8 (626 nm). Cette bande peut être liée à la 
formation d'agrégats, comme suggéré pour les complexes ReL8 et ReL9.  
 
Figure 15. (a) Photo des complexes en solutions concentrées (DCM) sous lampe UV, λex = 365 nm (b) Spectres 
d’émission normalisés pour les complexes ReL10 (noir) et ReL11 (rouge) en solution concentrée dans le DCM, λex 
= 306 nm. Concentrations: ReL10 à 8,5 × 10-6 M, concentration de ReL11 at 6,8 × 10-6 M.  
ReL11
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Après les études en solutions, les quatre composés ont été étudiés à l'état solide sous forme 
de poudres pures. Alors que les ligands L10 et L11 ne sont pratiquement pas émissifs à l'état solide, les 
complexes solides émettent fortement la lumière jaune. Les spectres d'émission correspondants 
possèdent une bande avec des maxima à 567 nm et 558 nm, respectivement pour Re10 et ReL11. Dans 
les deux cas, un épaulement est visible au-dessus de 610 nm (figure 16). L'émission est donc située à 
des longueurs d'ondes plus faibles que celle de ReL8, et la différence est particulièrement forte pour 
ReL11. Le rendement quantique de photoluminescence de ReL10 est de 0,21. L'encombrement 
stérique apporté par le groupe tert-butyle entraîne une augmentation marquée du PLQY par rapport 
au ReL8. L'effet AIE est très fort, puisque l'émission a été multipliée par 70 à l'état solide par rapport 
aux solutions de DCM. Pour ReL11, la valeur PLQY a atteint 0,31 et c'est la valeur la plus élevée obtenue 
dans cette série de complexes. L'intensité des émissions a été améliorée de 44 fois en passant à l'état 
solide. L'effet AIE a été fort, mais pas aussi fort que pour ReL10, car ReL11 est légèrement plus émissif 
en solution. 
 
 
Figure 16. (a) Photo des complexes sous forme de poudre sous lampe UV, λex = 365 nm. (b) Spectres d’émission 
normalisés de ReL10 (bleu) et ReL11 (rouge), λex = 380 nm. 
 
4. Conclusion et perspectives 
 
Si pendant longtemps, divers ligands triazole ont été utilisés pour introduire un groupe 
chélatant dans des complexes de coordination par chimie click, l'importance de la nature du groupe 
triazole dans les complexes n’a pas été explorée. Très récemment, une étude de Lo et al. a attiré 
l'attention sur ce point, par une comparaison entre les isomères réguliers et inverses des complexes 
2-pyridyl-1,2,3-triazole. Une autre étude traitant des complexes d'iridium contenant le ligand 2-
pyridyl-1,2,4-triazole a également montré que la modulation de la force du donneur / accepteur sur le 
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ligand était une stratégie intelligente pour régler les émissions induites par l'agrégation. Enfin, 
l'influence du régioisomérisme dans les chromophores à base de 1,2,3-triazole a également été 
rapportée.[42] 
 
Dans la première partie de ce chapitre, notre travail a montré que les écarts observés entre les 
propriétés électroniques des complexes issus de fragments 1,2,3 et 1,2,4-triazole étaient très 
spectaculaires. Pour rappel, avec un fragment 1,2,4-triazole comme dans ReL8, un encombrement 
stérique se produit en raison de la proximité du PBO avec le groupe pyridinyle. La fraction PBO est 
alors positionnée hors du plan et se comporte de manière plus indépendante du point de vue 
électronique. Par conséquent, les propriétés électrochimiques et spectroscopiques sont nettement 
modifiées, et un comportement photophysique inhabituel a été mis en évidence et rationalisé. En 
outre, il a été démontré que la fonctionnalisation du fragment triazole régit totalement la 
conformation du complexe à l'état solide et joue donc un rôle majeur pour la photoluminescence. Le 
ligand triazole doit donc être soigneusement choisi en fonction des applications envisagées.  
 
Dans la deuxième partie de ce chapitre, nous avons essayé d'optimiser les propriétés de 
photoluminescence des complexes. La stratégie qui consiste à accroître l’encombrement stérique de 
la molécule a «payé» en termes d'efficacité de photoluminescence. Nous avons également vu que la 
façon dont le groupe PBO est lié à pyta détermine l'agencement moléculaire et donc les propriétés 
photoluminescentes. Maintenant, nous savons que parmi les quatre complexes étudiés, le motif de 
substitution ReL11 doit être retenu si l'objectif est d'obtenir un composé fortement émissif à l'état 
solide. Si un effet AIE fort est souhaité, ReL10 devra être préféré.  
 
Ce travail a également confirmé l'intérêt de la fraction PBO pour accéder à des complexes de 
rhénium(I) qui présentent une luminescence importante à l'état solide. Ceci est particulièrement vrai 
pour les complexes neutres qui ne peuvent plus être « négligés » pour des applications 
spectroscopiques et/ou d'imagerie. Nos complexes seront prochainement testés en fonction de 
diverses applications, y compris sous forme de nanoparticules pour la coloration biologique. Des tests 
préliminaires sur ReL8 ont montré que ce composé a pénétré dans des cellules et qu’il a pu y être 
détecté, mais avec un signal assez faible. De meilleurs résultats devraient être obtenus avec les 
complexes ReL10 et ReL11, qui pourront être utilisés directement ou après incorporation dans des 
nanoparticules élaborées, car leurs propriétés d'émission à l'état solide sont vraiment intéressantes. 
Enfin, ce travail ouvre la voie à de nouvelles recherches. Différents colorants organiques pourront être 
introduits en utilisant la stratégie de synthèse développée ici, pour moduler les comportements 
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spectroscopique et photophysique d'une nouvelle génération de complexes. Toutes ces données 
seront utiles pour passer d'une approche empirique à une conception rationnelle de sondes 
luminescentes de rhénium(I) hautement émissives.  
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Conclusion générale et perspectives 
 
Comme mentionné dans l'introduction, les complexes de rhénium jouent un rôle important 
dans le domaine de la médecine nucléaire. Si pendant longtemps le rhénium a été utilisé comme 
modèle structural du technétium-99m, les caractéristiques physiques prometteuses des isotopes 186Re 
et 188Re (émetteurs E-), font des complexes de 186/188Re des candidats prometteurs en tant que 
radiopharmaceutiques thérapeutiques. De même, les propriétés intéressantes de photoluminescence 
des complexes de rhénium non-radioactifs en font d'excellents outils comme catalyseurs, matériaux 
luminescents et capteurs d'imagerie. Dans ce travail, notre objectif était (i) de développer, en utilisant 
une stratégie de chimie Click, des ligands multidentes pour la stabilisation de différents cœurs rhéniés 
de type [Re(CO)3]+ et [ReO]3+ (M = Re ou 188Re) ainsi que pour les coeurs analogues à base de 99mTc dans 
certains exemples, (ii) d’évaluer le potentiel des complexes de rhénium (technétium) en tant que 
sondes d’imagerie (Re naturel ou 99mTc) ou agents thérapeutiques (188Re). Pour ce faire, deux systèmes 
de chélatants spécifiques du rhénium (technétium) ont été utilisés: un système tripodal semi-rigide 
dans le deuxième chapitre et un fragment pyta au troisième chapitre, ces deux chélatants ayant été 
développés précédemment dans notre groupe. 
 
Ainsi, sur la base d'un ligand click tridente de type N2O, deux études différentes ont été 
réalisées dans le chapitre II. Dans la première étude, deux voies de synthèse ont permis de préparer 
une famille de ligands potentiellement tétradentes de type N3O, conçus pour coordonner les cœurs 
rhéniés aux états d'oxydation + I et + V. Les études de coordination envers ces différents noyaux de 
rhénium, ont également été étudiées. La première voie (voie A) a conduit à la formation de deux 
ligands tetradentes L1 et L2, ainsi que deux dérivés de benzoxazine L3 et L4 résultant d'une réaction 
secondaire inattendue. La synthèse des oxocomplexes de rhénium(V) a échoué avec L1 et L2. 
Cependant, de manière surprenante, ces ligands ont présenté un mode de coordination bidente 
inattendu avec le coeur de rhénium(I), [Re(CO)3]3+. L'analyse par rayons X et les études de DFT ont 
prouvé que les isomères des complexes fac-[Re(CO)3Cl(L)] (L = L1 ou L2) les plus stables, étaient ceux 
pour lesquels le rhénium est complexé par les deux atomes d'azote des cycles aniline et triazole. En 
revanche, par la deuxième voie de synthèse (voie B), nous avons réussi à obtenir un autre ligand 
tétradente L5 qui a conduit à l’oxocomplexe de rhénium(V), [ReO(L5)], correspondant. Mais aussi au 
radiocomplexe coeur [99mTcVO(L5)] après réaction du ligand avec le 99mTcO4- en présence de SnCl2 
comme réducteur. Rajoutons que cette étude préliminaire de radiomarquage a été réalisée en utilisant 
l'ion 99mTc au lieu du radionucléide 188Re, la réduction du 99mTcO4- étant plus aisée que celle de 
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l’analogue rhénié, 188ReO4-. Les premiers résultats de radiomarquage combinés aux récents travaux 
rapportés par l’équipe de Dugave[xii] sur des systèmes similaires indiquent que ce ligand pourrait être 
un chélatant prometteur pour le 99mTc…voire le 188Re. A court terme, l'extension du radiomarquage au 
coeur [188ReVO]3+ devra être effectuée et la stabilité in vitro du complexe radioactif testée dans des 
conditions physiologiques classiques, dans le plasma humain et par des expériences d'échange de 
cystéine (collaboration avec le Centre Eugene Marquis de Rennes) devra être estimée. Si les résultats 
sont prometteurs, la biodistribution sur modèle animal et/ou la bioconjugaison de ce complexe de 
188Re sur une biomolécule donnée pourra être considérée.  
En ce qui concerne L3 et L4, leur complexation avec le précurseur commercial [Re(CO)5Cl] a a 
permis de préparer pour la première fois des complexes dinucléaires hexacarbonylés. Ainsi, L4 conduit 
au complexe [Re2(CO)6(μ-OMe)(μ-Cl)(μ-L4)] ([Re2(Cl)(OMe)]) ou après recristallisation au complexe 
[Re2(CO)6(μ-OEt)2(μ-L4)] ([Re2(OEt)2]). La structure RX du dernier complexe a révélé que deux atomes 
de rhénium(I) étaient liés par deux groupes pontants éthoxo, et un ligand triazole également pontant. 
Les deux atomes de rhénium(I) présentent une configuration octaédrique déformée, avec deux atomes 
de carbones (issus des CO) et deux atomes d'oxygène (des groupes éthoxy) dans le plan équatorial et 
un atome de carbone (issu d’un CO) en trans d’un atome d’azote du triazole en position axiale.  
Les études théoriques ont permis de compléter cette étude et de comparer les caractéristiques 
de ce complexe de dirhénium(I) avec ceux issus d'autres ligands pontants similaires, tels que la 
pyridazine, le tétrazole ou l'oxadiazole. Bien que ses propriétés émissives soient très faibles, le 
complexe [Re2(OEt)2] représente le premier exemple d'espèces dinucléaires dans lequel un cycle 1,2,3-
triazole est lié à deux atomes de rhénium à faible état d'oxydation. Nous avons également montré que 
l'utilisation d'un groupe 1,2,3-triazole disubstitué contenant des substituants non chélatants semble 
être nécessaire pour la préparation de tels complexes de dirhénium(I). Bien que l'amélioration des 
propriétés photophysiques de ces complexes binucléaires soit intéressante, la poursuite de ce travail 
ne sera pas une priorité dans un proche avenir. 
 
La deuxième étude portait sur le développement de nouveaux radiopharmaceutiques du 99mTc 
sélectifs contre l'hypoxie. Notre ligand tripodal de départ a été décoré avec un groupe nitro (soit un 
groupe nitrobenzyle ou une entité métronidazole (Mtz)). Des positions différentes ont été considérées 
mais seulement deux ligands contenant du métronidazole (Mtz) et un ligand contenant un groupe nitro 
ainsi que les complexes correspondants de tricarbonylrhénium(I) ont été obtenus et caractérisés, 
notamment par électrochimie. Les potentiels de réduction du groupe NO2 dans les complexes 
[Re(CO)3Cl(L2)] et [Re(CO)3(L6)] sont similaires à ceux reportés dans la littérature pour des complexes 
de rhénium(I). Ces premiers résultats nous ont poussés à étudier davantage les autres propriétés de 
ces complexes. Malheureusement, aucun complexe correspondant du 99mTc n’a pu être obtenu avant 
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la fin de ce projet. Comme pour le complexe [ReO(L5)] (vide supra), la préparation de tels 
radiocomplexes, en particulier ceux contenant L6 (L6 devrait conduire du fait de sa structure tripodale, 
à un complexe de rhénium(I) plus stable), ainsi que la stabilité in vitro dans des conditions 
physiologiques devra être évaluées avant d'envisager des évaluations biologiques plus poussées. 
 
Le chapitre III est axé sur l'étude de l'effet AIE (émission induite par l'agrégation) dans les 
complexes tricarbonylrhénium(I), l'association de cet effet avec les propriétés intrinsèques des 
complexes de Re(I) pouvant conduire à des composés très attrayants. Pour ce faire, nous avons 
combiné un fluorophore organique (motif benzoxazole ou PBO) qui présente une excellente stabilité 
et des propriétés optiques intéressantes, avec un complexe tricarbonylrhénium(I) basé sur une unité 
pyta (soit le 2-pyridyl-1,2,3-triazole ou le 2-pyridyl-1,2,4-triazole). Quatre composés ont été étudiés. 
Les structures RX ont révélé des différences structurales spectaculaires entre les deux premiers 
complexes, ReL8 et ReL9. Dans le complexe ReL9, le ligand organique est quasiment planaire, alors 
qu’il est fortement plié dans ReL8, empêchant ainsi la délocalisation d'électrons. De même, leurs 
propriétés électrochimiques et spectroscopiques sont également différentes. Si l'effet AIE a été 
observé dans les deux complexes, cette étude a révélé que le fragment triazole régit totalement la 
conformation du complexe à l'état solide et joue donc un rôle majeur pour la photoluminescence, 
l’effet AIE étant plus important avec le complexe incluant le motif 1,2,4-triazole (ReL8). 
 
Suite à ces premiers résultats, deux structures optimisées basées uniquement sur un motif 2-
pyridyl-1,2,4-triazole ont été développées. Dans le premier composé, un groupement t-Bu volumineux 
a été ajouté sur le motif organique PBO (ReL10), afin d'augmenter l'encombrement stérique de la 
molécule. Dans le second composé, le complexe rhénié (motif pyta plus cœur [Re(CO)3]+) est situé de 
l'autre côté de l’entité PBO (ReL11), afin d'évaluer l'impact de cette modification structurale (ReL8 vs. 
ReL11) vis-à-vis des propriétés d'émission à l'état solide. Ces légères modifications chimiques ont eu 
un effet significatif sur les propriétés photophysiques des complexes. ReL10 a montré un effet AIE 
amélioré, tandis que le complexe ReL11 présente l'émission la plus intense à l'état solide parmi les 
quatre complexes étudiés.  
Concernant les perspectives à court et moyen termes, les complexes ReL8 à ReL11 seront 
testés en fonction de diverses applications, y compris après leur incorporation dans des 
nanoparticules. Cette étude étant une nouvelle orientation dans notre groupe, ce travail sera un 
excellent point de départ pour d'autres recherches. Divers colorants organiques et/ou des 
modifications structurales de la fraction organique seront bientôt pris en compte pour développer des 
sondes luminescentes de rhénium(I) hautement émissives. 
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